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T1 LYMPHOCYTIC BRONCHOALVEOLITIS IN IDIOPATHIC
CHRONIC COUGH
S.S. Birring, C.E. Brightling, F.A. Symon, S. Barlow, A.J. Wardlaw, I.D.
Pavord. Institute For Lung Health, Glenfield Hospital, Leicester
We have recently reported an excess of cases of organ specific auto-
immune diseases amongst patients with idiopathic chronic cough and
have suggested that the cough may be due to homing of activated
lymphocytes from the primary site of autoimmune inflammation to the
lung. We tested this hypothesis in comparative immunopathology
study of 19 patients with idiopathic chronic cough recruited over a
two year period (mean age 54y, 79% female, mean duration of
cough 2y), 11 healthy subjects and 14 patients with explained
chronic cough of similar severity. Organ specific autoimmune disease
was present in six of idiopathic cough patients (32%) but no normals/
explained cough subjects. All subjects had a bronchoscopy, broncho-
alveolar lavage (BAL) and bronchial biopsy using standard
techniques.
We obtained cytospins from the BAL for a differential cell count and
studied BAL T-cell status (CD4/8), activation (CD103, CD25, CD49a,
HLA-DR) and chemokine receptors (CCR3,5,6,11, CXCR3) using
3-colour flow cytometry. Bronchial biopsies were embedded in glycol-
methacrylate and immunohistochemistry for CD3,4,8 (lymphocytes),
CD14 (monocytes), CD45 (leukocytes), CD56 (NK cells), EG2
(eosinophils), Neutrophil Elastase (neutrophils), AA1 (mast cells),
Interferon-γ, IL5, 3H4(IL4) was performed. The mean (SEM) BAL differ-
ential lymphocyte count was 6.8 (1.3)% in normals, 15.1 (2.6)% in
idiopathic cough (mean difference from normals 8.3%; 95%
Confidence Interval 1.6 to 15.0; p<0.02) and 7.0(1.7)% in explained
cough. The proportion of BAL T-cells expressing CD4 was similar in all
three groups and there were no differences in activation status of
T-cells or chemokine receptor expression. CD56 and IFNγ expression
in biopsies (cells/mm2 submucosa) were reduced in subjects with idio-
pathic cough compared to normals and subjects with explained cough
(p=0.03 and 0.047: Kruskal-Wallis). EG2 and 3H4 expression were
raised in explained cough (p=0.02 & 0.03) but there were no differ-
ences in expression of CD3 and other markers between groups. In
conclusion, we have made a novel observation of lymphocytic
bronchoalveolar inflammation in patients with idiopathic chronic
cough. The association with organ specific autoimmune disease
suggests that this might be due to homing of activated lymphocytes
from primary sites of autoimmune inflammation or a hitherto unrecog-
nised autoimmune bronchitis. Further studies are required to
investigate the interaction between T-cells and the cough reflex.
T2 TGF-β ACTIVATION IS DIMINISHED FOLLOWING
BLEOMYCIN-INDUCED LUNG INJURY IN MICE LACKING
NEUTROPHIL ELASTASE
F. Chua1, S.E. Dunsmore1, A.W. Segal2, J. Roes2, G.J. Laurent1. 1Centre for
Respiratory Research; 2Department of Medicine, Royal Free and University
College London School of Medicine, London WC1E 6JJ
Transforming growth factor-beta (TGF-β) is widely implicated in the
pathogenesis of pulmonary fibrosis. We have previously reported that
mice lacking neutrophil elastase (NE-/-) are resistant to pulmonary
fibrosis induced by bleomycin instillation. We hypothesised that
decreased TGF-β activation may contribute to the resistance of these
null animals against fibrosis. Active TGF-β was quantitated in
bronchoalveolar lavage fluid (BALF) and lung tissue from wild type
(WT) and NE-/- mice seven days following instillation of 0.05 unit bleo-
mycin or saline. Levels of active TGF-β in bleomycin-treated WT BALF
averaged 0.36 ± 0.02 mg/ml, two-fold greater than in saline controls
(p<0.001). In contrast, active TGF-β levels in bleomycin-treated NE-/-
BALF (0.23 ± 0.01 mg/ml, p<0.001 v WT values) were not different
from saline controls. Conversely, a greater amount of TGF-β was
detected in lung tissue from bleomycin-treated NE-/- mice (p<0.05 v
WT). No differences in inflammatory cellularity, alveolar-capillary
leak, TGF-β1 or TGF-β3 mRNA expression were apparent between the
two genotypes at this time point. Furthermore, in bleomycin-treated
WT lungs, immunocytochemical staining for active TGF-β (LC1–30
antibody, Dr. K. Flanders, NIH) was widespread, with prominent
localization to areas of inflamed or damaged alveoli. In contrast,
staining for active TGF-β in bleomycin-treated NE-/- lungs was minimal,
and limited to peribronchial and perivascular locations. In conclusion,
TGF-β activation was diminished in alveolar fluid from bleomycin-
treated NE-/- mice and correlated with decreased staining for active
TGF-β in lung tissue. These data provide the first in vivo evidence that
neutrophil elastase may play a critical role in modulating TGF-β acti-
vation. In particular, this study suggests that neutrophil elastase inhibi-
tors may have a therapeutic potential in abrogating TGF-β-mediated
fibrotic lung disease.
Supported by the Wellcome Trust, MRC and the British Lung Foun-
dation.
T3 THE COST EFFECTIVENESS OF AN ASTHMA
MANAGEMENT STRATEGY DIRECTED AT NORMALISING
THE INDUCED SPUTUM EOSINOPHIL COUNT
R.H. Green, C.E. Brightling, S. McKenna, B. Hargadon, D. Parker, P.
Bradding, A.I. Wardlaw, I.D. Pavord. Institute for Lung Health, Glenfield
Hospital, Leicester, UK
We have recently shown that a management strategy directed at nor-
malising the induced sputum eosinophil count reduces asthma exacer-
bations and hospital admissions compared to a traditional approach.
We now report the results of a concurrent health economic evaluation
designed to determine the cost effectiveness of this sputum
management strategy. Seventy four subjects with moderate to severe
asthma recruited from hospital clinics were randomised into two
groups: one managed by standard British Thoracic Society asthma
guidelines (BTS management group) and one managed using an
algorithm aimed at normalising the induced sputum eosinophil count
as well as minimising symptoms (sputum management group). Patients
were seen nine times over 12 months and on each occasion sputum
was induced and processed, but the results were not disclosed in the
BTS guidelines group. Throughout the study patients completed daily
diary cards recording medication use, days off work, emergency GP
or hospital visits and hospital admissions. The overall cost of each
management strategy was calculated using our estimates of the cost of
sputum induction and processing, the 2001 Unit Costs of Health and
Social Care, the Department of Health 2001 reference costs and the
British National Formulary. Total costs for each patient were
calculated as the sum of the costs of hospital out-patient appointments,
primary care visits, hospital admissions and medication use
throughout the 12 months, with the addition of the costs of sputum
induction and processing for patients in the sputum management
group only. Patients in the sputum management group experienced
significantly fewer severe asthma exacerbations than patients in the
BTS management group (35 v 109, p=0.01) and significantly fewer
patients were admitted to hospital with asthma (1 v 6, p=0.047).
Amongst the 49 (24 v 25) patients in regular employment, the mean
(SEM) days off work was 2.2 (0.8) in the sputum management group
and 8.3 (2.1) in the BTS management group (p=0.01). The estimated
annual total mean (SEM) cost per patient was (£1755 (119) in the
sputum management group and £1954 (164) in the BTS management
group (p=0.30). A treatment strategy directed at normalising the
induced sputum eosinophil count reduces asthma exacerbations and
hospital admissions without incurring additional costs to the health
service. In addition, by reducing work days lost due to asthma, this
approach may result in significant cost savings to society.
T4 THE αVβ5 INTGERIN INDUCES ANOIKIS IN SQUAMOUS
CELL CARCINOMA (SCC) CELLS BY ACTIVATING THE
INTRINSIC AND EXTRINSIC DEATH PATHWAYS AND
INHIBITING AN AKT/PKB SURVIVAL SIGNAL
S.M. Janes, F.M. Watt. Cancer Research UK, 44 Lincoln’s Inn Fields, Lon-
don, WC2A 3PX, UK
Introduction: Focal or extensive loss of αvβ5 is a feature of the most
poorly differentiated SCCs, while an increase in αvβ6 is associated
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with invasiveness and metastatic spread (Watt. Dev Suppl 1993:185–
92). Epithelial cells normally undergo apoptosis on detachment from
their extracellular matrix (anoikis), but transformed cells do not. Hence
failure to express a particular integrin may render tumour cells “deaf”
to specific signals determining apoptosis. We hypothesised that
expression of αv on H357 cells (which completely lack αv) and SCC4
cells (which have low expression) would restore their ability to
undergo anoikis.
Methods: αv or α4 integrin subunits were transfected into H357
and SCC4 cells using the pBabepuro retroviral vector giving high
expressing polyclonal populations. Anoikis was assessed by FACS
analysis for sub-G1 cells and by TUNEL staining. Signalling pathways
were investigated using MEK, p38MAPK, and PI3K inhibitors, and a
constituitively active Akt construct. The apoptotic pathway was investi-
gated using specific caspase inhibitors, Western blotting for activated
pro and anti apoptotic molecules and a dominant negative FADD con-
struct. Anoikis activation was examined using a chimeric molecule
with the cytoplasmic domain of β5 attached to the extracellular
domain of β6.
Results: The αv subunit formed a functional heterodimer with β5 as
measured by FACS and adhesion to vitronectin. Anoikis was dramati-
cally increased in the αv infected cells (both H357s and SCC4s) com-
pared to the parental populations, empty vector controls and α4
infected cells at 48 and 72 hours (p<0.01). Anoikis was not increased
in αvβ6 expressing cells. The pathways involved in αvβ5 induced
anoikis include a suppression of activation of the survival factor Akt/
PKB, possibly via the cytoplasmic domain of β5 and both the intrinsic
(mitochondrial) and extrinsic (death receptor mediated) cell death
pathways.
Conclusion: Re-introduction of the αv integrin subunit increased
SCCs ability to undergo anoikis via the αvβ5 heterodimer. Both the
intrinsic and extrinsic apoptotic pathways are required, and a cell sur-
vival mechanism of activating Akt/PKB is suppressed.
T5 NASAL MUCOCILIARY CLEARANCE IS NORMAL IN
CHILDREN WITH CF: EVIDENCE AGAINST A PRIMARY
CFTR-RELATED MECHANISM IN THE UPPER AIRWAY
D. McShane, J.C. Davies, T. Wodehouse, A. Bush, D. Geddes, E. Alton.
Departments of Paediatrics and Gene Therapy, Royal Brompton Hospital,
London, UK
Studies in adult CF patients have reported impaired mucociliary clear-
ance (MCC) in both the nose and lungs, which has been implicated in
the pathogenesis of airway plugging and bacterial lung infection. We
studied young children to explore a primary versus secondary cause
of impaired nMCC. Saccharin clearance times were measured in 18
children with CF (median age 11y (9.5B15y)) and 21 non-CF children
(median age 12y (9.5B16y)). Eleven children with Primary Ciliary
Dyskinesia (PCD) served as positive controls (median age 12y (9 B
14.7y)). A 2 mm piece of saccharin was placed on the inferior
turbinate and the time taken to taste measured up to 30 mins. Nasal
lavage (NL) was performed from the other nostril with 4ml sterile PBS.
No difference was seen in nMCC times between the CF and non-CF
groups (CF median (IQR) 11(8;15) min; non-CF median 11 (9;16)
min), whereas those in the PCD group all had nMCC times of >30
minutes (p<0.05 for both CF & non-CF). There was no evidence of
excess inflammation in the CF NL samples as assessed by levels of the
neutrophil chemoattractant, IL-8 (CF 52 (3;75) pg/ml NLF;non-CF 37
(5; 108) pg/ml NLF). Interestingly,the children with PCD had
significantly raised levels of IL-8 (377 (244; 598) pg/ml NLF; p<0.01
compared with both CF & non-CF). We next measured nMCC in adult
CF patients with and without chronic sinus (CS) disease (CS+ or CS−).
CS+ CF patients had significantly longer clearance times than CS−
subjects (CS+ n=12:18 (11; 24) mins;CS− n=16: 14 (6; 16) mins;
p<0.05). IL-8 was significantly higher in the CF CS+ group than in the
healthy adult group (CF CS+45 (15; 76) pg/ml NLF; healthy adults:
10 (1; 64) pg/ml NLF; p=0.01) and there was a trend with regards to
the CF CS− group (15 (1; 39) pg/ml NLF; p=0.06). In conclusion, the
delayed MCC reported in the CF nose was not seen in a group of
young children,but became apparent in adult patients with chronic
sinus disease. This suggests a role for mucosal inflammation in the
aetiology of delayed MCC in the upper and proximal airways but not
distal airways where the ciliated epithelium is more sparse,and low
volume ASL may be more detrimental on the clearance process.
T6 PHOSPHODIESTERASE 4 ISOFORMS DIFFERENTIALLY
REGULATE LPS STIMULATED MACROPHAGE FUNCTION:
THE ROLE OF PDE4B2.
M.C. Shepherd1 2, N.C. Thomson2, M.D. Houslay1. 1Institute of Biological
and Life Sciences, University of Glasgow, Glasgow, UK; 2Department of
Asthma research, Medicine and Therapeutics, Gartnavel General Hospital
Glasgow UK
Phosphodiesterase4 (PDE4), a family of cAMP hydrolysing enzymes is
widely expressed in immune cells. Four genes encode PDE4A, PDE4B,
PDE4C, and PDE4D. Differential mRNA splicing produces variability
within these families. Structural differences between isoforms suggest
specific roles in cell regulation. I have shown PDE4 isoform expression
regulation with macrophage differentiation. Such monocytes lose
PDE4D expression, but gain PDE4A and PDE4B isoforms. I
hypothesised important roles for PDE4 isoforms in macrophage
behaviour.
Methods: RAW 264.7 cells were treated with 10ng/ml lps +/− the
PDE4 inhibitor rolipram, PDE3 inhibitor cilostamide or signal transduc-
tion inhibitors. Cyclo-oxygenase 2 (COX-2) and inducible nitric oxide
synthase (iNOS) expression, PDE4 isoform activity or ERK 1/2 activity
was measured. ERK activity was assessed by the phospho-ERK/Total
ERK ratio on western blot. Total PDE4, PDE3, and PDE4 isoform activ-
ity from immunoprecipitates were assessed, TNFα and prostaglandin
E2 (PGE2) production were measured in growth medium by ELISA.
RAP-1A G-protein activity mutants were used to investigate rolipram’s
action.
Results: Rolipram, not cilostamide caused indomethacin sensitive
increase in iNOS expression, but indomethacin resistant increase in
COX-2 expression in lps stimulated macrophages. PGE2 production
was dose dependently increased by rolipram while TNFα production
was inhibited in an indomethacin resistant fashion. Rolipram caused
an increased and early activation of ERK 2. Lps led to a MEK depend-
ent increase in PDE4 activity by 40% and PDE4B by 42%. Transfected
RAP-1A activity mutants did not influence inflammatory mediator pro-
duction.
Discussion: Rolipram increases the expression of COX-2, PGE2,
and iNOS while inhibiting TNFα. TNFα inhibition is not due to
increased PGE2 production. Complex crosstalk between the cAMP
and MAPKinase signal cascades suggests increased PDE4B activity
acts to regulate pro-inflammatory signal propagation. Rolipram alters
the response of ERK 2 to lps, promoting a “proliferative” response. The
G-protein Rap-1A did not mediate the interaction between cAMP and
MAPKinase.
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Lung cancer outcomes
S1 CARBOPLATIN AND VINORELBINE AS FIRST LINE
OUTPATIENT TREATMENT IN NSCLC
J. Maguire, N. Smith, V. Kelly, M. Ledson, M. Walshaw. Liverpool Lung
Cancer Unit, Cardiothoracic Centre, Thomas Drive, Liverpool, UK
Outpatient chemotherapy offers advantages for the Health Service in
terms of resource utilisation and expense compared to the patient
treatment, and is preferred by the vast majority of patients and their
families.
We have treated 130 patients (84 male, mean age 65.8 years, 46
female, mean age 62.2 years) with stage III or Stage IV NSCLC and
performance status 0–2 with outpatient chemotherapy using
Carboplatin and Vinorelbine using the following regimen:
Carboplatin AUC 5 day 1,
Vinorelbine 25 mg/m2 day 1, day 8
The intended duration of treatment was 3 or 4 courses of
chemotherapy using a 21 day treatment cycle. The mean number of
courses given was 3.2 (range 1–6).
With 102 patients so far having completed treatment, response
rates are as follows: Complete Responses 2%, Partial Responses
34.8%, Stable Disease 32%, and Progressive Disease 17.1%. Over-
all median survival is 9.1 months.
Treatment was generally tolerated. Toxicity included neutropenic
sepsis in 22% and anaemia requiring blood transfusion in 29%. There
were 8 (7.8%) treatment related deaths. Patients with performance
status 2 at commencement of treatment were at significantly greater
risk of serious morbidity and treatment related death compared to
patients with performance status 0–1. Patients aged >70 were more
likely to require blood transfusions but were not at increased risk of
neutropenic sepsis or treatment related death. We conclude that Car-
boplatin and Vinorelbine is a relatively safe and effective regimen for
the outpatient treatment of patients with NSCLC.
S2 A COMPARISON OF ACE AND CE CHEMOTHERAPY IN
SCLC
N. Diar Bakerley, N.P. Keaney, K. Sridharan, I.K. Taylor, H.W. Clague.
Chest Diseases Unit, Sunderland Royal Hospital, Sunderland SR4 7TP, UK
Background: Chemotherapy plays an important role in the treatment
of Small Cell Lung Cancer (SCLC). Several standard regimens are in
existence but there have been few direct comparisons with regard to
toxicity. In this retrospective audit we compare the toxicity of ACE
(Adriamycin, Cyclophosphamide and Etoposide) with CE (Carbopla-
tin and Etoposide).
Methods: Over a 12 month period from April 2000 28 patients
with SCLC received chemotherapy with either ACE or CE
chemotherapy. Toxicity was evaluated by a retrospective audit of case
notes looking in particular at neutropenia, neutropenic sepsis,
clinically significant anaemia, in hospital duration of stay and toxic
death.
Results: Eleven patients (39.2%) received ACE, 12 patients
(42.8%) received CE and five patients (17.8%) received both. In total
63 ACE and 80 CE chemotherapy cycles were given.
Severe neutropenia (neutrophils 0–0.5%) complicated 21 (33.3%)
ACE compared with 11 (13.7%) CE chemotherapy sessions
(p=0.005). Neutropenic sepsis occurred in 14 (22.2%) ACE sessions
compared with 2 (2.5%) CE sessions (p=0.0002). Thirty (46.8%) ACE
sessions were complicated with clinically significant anaemia
compared to 18 (22.5%) in the CE group (p=0.002). The average
in-hospital stay per patient was 19.3 days for patients receiving ACE
and 3.6 days for patients receiving CE. Toxic death happened in 1
patient in the ACE group and 1 patient in the CE group (p=0.9).
Conclusion: This retrospective audit indicates that in our
experience ACE chemotherapy for SCLC is associated with greater
toxicity than the CE regimen. This led to a greater use of resources in
terms of antibiotic therapy, blood transfusion, and hospital bed usage
and has led us to adopt the CE regimen as first choice chemotherapy
for this group of patients.
S3 PROLONGED SURVIVAL IN INOPERABLE NSCLC WITH
CONCURRENT CHEMO-RADIOTHERAPY
J. Maguire, R. Page, V. Kelly, N. Smith, M. Ledson, M. Walshaw. Liverpool
Lung Cancer Unit, Cardiothoracic Centre, Thomas Drive, Liverpool, UK
Synchronous chemotherapy and radiotherapy is a highly effective
treatment modality for a number of solid tumours including inoperable
Non-Small Cell Lung Cancer, and has been adopted as a standard
therapy for lung cancer in the United States. However, experience
with this form of treatment for lung cancer in the UK is limited.
We have treated 54 patients with locally advanced, inoperable
NSCLC (8 Stage IIB, 46 Stage IIIB) with concurrent cisplatinum and
radical radiotherapy using a tumour dose of 52.5 Gy given in 20
daily fractions over four weeks, together with cisplatinum 20 mg/m2
concurrent with fractions 1–5 and 16–20. Thirty four patients received
2–4 courses of chemotherapy after concurrent chemo-radiation. Toxic-
ity was acceptable, with three cases of severe but self-limiting oesoph-
agitis, a 70% incidence of mild to moderate oesophagitis and no
treatment related deaths.
One, two, and three year survival rates for patients with Stage IIIB
disease are 74%, 35%, and 32% respectively. Patients with Stage IIIB
disease treated with concurrent chemo-radiotherapy followed by sys-
temic chemotherapy have a median survival of 25 months, 3 year sur-
vival of 49%, and a local control rate of 89.5%.
Concurrent chemo-radiotherapy is a highly effective treatment
modality for patients with locally advanced inoperable NSCLC, but
this form of treatment is only suitable for patients who have good per-
formance status (PS 0–1), minimal co-morbidity and disease which
can be encompassed within a radical radiotherapy treatment volume.
S4 OUTCOME OF PATIENTS OVER SEVENTY YEARS OLD
WITH SMALL CELL LUNG CANCER TREATED WITH
CHEMOTHERAPY
P. Temblett1, J. Baker1, F. MacBeth2, A.P. Smith1. 1Section of Respiratory
Medicine, University of Wales College of Medicine, Llandough Hospital,
Cardiff, UK CF64 2XX, UK; 2Velindre Hospital, Whitchurch, Cardiff
CF14 2JL, UK
Introduction: Small cell lung cancer (SCLC) accounts for 25% of all
newly diagnosed cases of lung cancer over seventy years. No stand-
ard treatment is defined for elderly patients with SCLC, and prognosis
remains poor.
Methods: We performed a retrospective review of all SCLC cases
over 70 years treated with carboplatin and etoposide between
01/01/2000 and 31/12/2001. Prophylactic cranial irradiation
(PCI), chest and palliative radiotherapy were used when indicated.
Results: 29 patients were treated, median age 73.7 years, four
patients over 80 years. 52% had limited disease. 7% had
performance status (PS)=0, 41% PS=1, 35% PS=2, 17% PS=3. The
average number of cycles given was 3.27, 55% receiving a dose
reduction. PCI and chest radiotherapy was used in 4 patients, 5
patients received palliative radiotherapy. The overall response rate
was 65%. Actuarial median survival was 30 weeks (95% CI
22.1–37.9 ), 1 year survival = 23%, 18 month survival = 18%, 2 year
survival =10%. Four patients are still alive (range 33 B 121.4 weeks)
Febrile neutropenia occurred in 17% and neutropenic death in 10%.
21% of patients received blood transfusions. There were 5 (17%)
early deaths (<21 days), 3 of which were neutropenic.
Conclusions: This review confirms that the treatment of unselected
SCLC elderly patients with chemotherapy causes significant risks with
lower response rates and survival than previously reported. Despite
this palliation is achieved in a significant number with prolongation of
survival. Co-morbidity and quality of life issues should be carefully
considered when treating such patients.
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S5 WHAT PERCENTAGE OF PATIENTS WITH LUNG CANCER
PRESENT WITH POTENTIALLY CURABLE DISEASE?
P.M. Donnelly, W.J.A. Anderson on behalf of the Northern Board Lung
Cancer Group. Regional Cancer Center for the Northern Board, Antrim
Hospital, Bush Rd, Antrim BT41 2QB, UK
Background: Since 1995 there has been concern that the 5 year sur-
vival of patients suffering from lung cancer in the UK (6–7%) was sig-
nificantly less than that quoted for America and other western
countries (14–15%). This might represent differences in recording, dif-
ferences in disease or differences in treatment. The aim of this audit
was to define the number of patients with curable disease at presenta-
tion.
Method: We prospectively filled in audit sheets based on the diag-
nostic module of he RCP (London) lung cancer data sheets from 1/1/
2001–1/5/2002. At the end of the audit period we checked the
hospital databases in the catchment area for any additional patients
recorded as having lung cancer and retrospectively collected data for
these patients.
Results: 175 patients were identified. Patients had a mean age of
70 years (range 43–94). 133 had a pathological diagnosis—27 had
small cell tumours and 106 had non small cell tumours. 59 patients
were excluded from radical treatment by performance status, a further
62 by stage of disease, a further 15 by inadequate pulmonary func-
tion and 8 by other co-morbidity. Thirty-one (16%) remained and were
potentially suitable for radical treatment
Conclusion: In this study only 16% of patients were potentially cur-
able at presentation. On the basis of these figures targets for surgical
resection rates around 20% seem unrealistic, although with current
resection rates running around 10% in the UK there may be some sub-
jects who are suitable for surgery to whom it is not offered. Offering
surgery or radical radiotherapy to these patients might result in some
improvement in survival.
COPD: Cellular activation and
inflammation
S6 RELATIONSHIP BETWEEN BRONCHIAL BIOPSY
INFLAMMATORY CELL POPULATIONS AND
PHYSIOLOGICAL PARAMETERS IN COPD
I.S. Patel1, N.J. Roberts1, R.J. Sapsford1, M. Sheaff2, J.A. Wedzicha1. 1Aca-
demic Unit of Respiratory Medicine; 2Department of Morbid Anatomy,
Barts and the London NHS Trust, UK
This study was designed to evaluate the relationships between patterns
of bronchial biopsy inflammation and physiological parameters in
COPD. Bronchoscopic biopsies were taken from 36 patients with
COPD (mean (SD) age 69.5 (8.75) yrs, FEV1 1.36 (0.59) l, FVC 2.6
(0.88) l, FEV1% predicted 54.5 (16.2)%, PaO2 8.8 (1.2) kPa, PaCO2
5.4 (0.65) kPa, 46.2 (31.8) pack years of smoking, MRC dyspnoea
score 3.06 (1.24), daily inhaled steroid dosage 747 (810) µg, 16
current smokers). Samples were wax embedded and stained for CD3,
CD4, CD8, CD68, and EG2 positive inflammatory cells by
immunohistochemistry. Intraepithelial CD3 positive cells (per 100 epi-
thelial cells) were related to daily inhaled steroid dosage (rho=0.675,
p=0.046) and inversely related to the PaO2 (rho= −0.714, p=0.047).
Patients with symptoms of daily dyspnoea had significantly higher
numbers of intraepithelial CD3 cells than those without (median (IQR)
CD3 cells/100=17 (8.5) versus 9.5 (6.75), p=0.016). Numbers of
intraepithelial CD68 positive cells/100 were related to daily inhaled
steroid dosage (rho=0.731, p=0.016) and the MRC dyspnoea score
(rho=0.815, p=0.007). Patients with symptoms of daily dyspnoea
also had significantly higher numbers of intraepithelial CD68 cells
than those without (median (IQR) CD68 cells/100 = 9 (7) versus 4 (3),
p=0.027). Intraepithelial CD4 positive cells/100 were related to
inhaled steroid dosage (rho=0.850, p=0.032). An inverse relation-
ship was seen between numbers of intraepithelial EG2 positive cells/
100 and the FEV1% predicted (rho= −0.753, p=0.031). Numbers of
EG2 cells per high-powered field also increased with increasing daily
inhaled steroid dosage (rho=0.442, p=0.076). No effect on cell num-
bers was seen with current smoking.
Bronchial wall inflammation in COPD increases with increasing
indices of disease severity, as measured by PaO2, FEV1% predicted,
inhaled steroid dosage and the symptoms of daily dyspnoea.
Supported by the Joint Research Board, St. Bartholomew’s Hospital.
S7 NEUTROPHILS FROM PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE DEMONSTRATE
ENHANCED ENDOTHELIAL CELL INTERACTIONS
I.S. Woolhouse, N. Carrabino, D. Bayley, P.F. Lalor1, D.H. Adams1, R.A.
Stockley. Lung Investigation Unit; 1Liver Research Laboratories, Queen
Elizabeth Hospital, Birmingham B15 2TH, UK
Chronic obstructive pulmonary disease (COPD) is usually caused by
smoking, yet only 10–15% of smokers develop clinically significant
disease. Given that neutrophil (PMN) recruitment, and subsequent
inflammation, is central to the development of COPD, it is possible that
PMN from smokers who develop the disease are primed to migrated
from the bloodstream into the lung. The aim of this study was to com-
pare endothelial cell interactions, under flow conditions, and
adhesion molecule expression of PMN from non-smokers (NS), smok-
ers without COPD (HS) and patients with COPD.
PMN were isolated from 8 NS, 8 HS and 10 COPD patients. The
three groups were age and sex matched, and the mean (SD) FEV1 %
predicted were 101.8 (10.9), 97.4 (12.9), and 45.9 (20.9), respec-
tively. Pack year smoking history was similar in the HS and COPD
groups (32.1 (10.0) v 47.0 (19.3), p=ns). To assess endothelial
adhesion and migration, PMN were perfused at a physiological flow
rate over interleukin-1β stimulated human umbilical vein endothelial
cells cultured in microslides. Adherent and migrated PMN were
counted by phase contrast microscopy. CD11b/CD18 (Mac-1) and
CD62l (L-selectin) expression were assessed by flow cytometry. Mean
(SE) PMN-endothelial cell interaction results are tabulated in the table.
There were no significant differences in PMN expression of Mac-1
and L-selectin between the three groups.
The data suggest that PMN from smokers who develop COPD are
primed to adhere to, and migrate across, vascular endothelium. This
appears to be independent of Mac-1 or L-selectin expression. Further
work is needed to clarify the mechanism, but the PMN priming seen
here in COPD provides a potential target for new therapy.
S8 DIFFERENCES IN AIRWAY NEUTROPHIL NUMBERS,
ACTIVATION AND TLR-2 EXPRESSION IN SUBJECTS
WITH COPD AND AGE-MATCHED CONTROLS
M.I. Allenby, B. Sempasa, M.W. Lethbridge, J.C. Ratoff, M.W. Jensen, B.J.
O’Connor. Department of Respiratory Medicine and Allergy, King’s
College London, UK
Rationale: Subjects with COPD have higher numbers of airway neu-
trophils and these numbers correlate with airflow limitation (Lacoste, et
al 1993). The activation status of these neutrophils, and the effect of
smoking on this, is unknown. The toll-like receptor family is responsible
for innate immune responses against a wide variety of bacterial mol-
ecules. Their presence on airway neutrophils has not previously been
investigated.
Methods: 15 subjects with COPD and 18 healthy age-matched
controls underwent flexible bronchoscopy for collection of broncho-
alveolar lavage fluid (BALF). Both groups contained a mix of smokers
and ex/non-smokers. A BALF differential cell count was performed.
The neutrophils were labelled with fluorochrome-conjugated antibod-
ies against surface markers of activation (CD63, CD14) and the toll-
like receptor 2 (TLR-2), and analysed using flow cytometry. The
percentage of cells expressing the antibodies was calculated. Statisti-
cal analysis was performed using an unpaired t test.
Results: All data are expressed as means (SD). There was an
increase in the percentage of neutrophils within the BALF of subjects
with COPD when compared with controls (1.644 (1.717) v 0.343
(0.084); p=0.0037) irrespective of smoking status. However, the per-
centage of CD63+ve neutrophils was significantly lower in current
smokers when compared to ex/non-smokers (14.78 (17.06) v 45.64
(22.86); p<0.0001) regardless of airflow limitation. The same was
true for CD14+ve neutrophils (11.18 (15.65) v 40.98 (25.78);
Abstract S7 Mean (SE) PMN-endothelial cell interation
results
NS HS COPD
Adherent PMN 303.2 (22.7) 324 (26.7) 449 (70.8)
Transmigrated PMN 199.2 (33.8) 191.1 (32.1) 256 (52.0)
Total interacting PMN 502 (31.2) 515.8 (35.5) 706 (62.3)*
*p<0.05 v HS and NS.
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p=0.0002). Similarly, the percentage of TLR2 expression was reduced
in current smokers (10.57 (11.20) v 38.41 (23.80); p=0.0004).
Conclusions: Although airway neutrophils are increased in the
lungs of COPD subjects, their activation is related to the smoking sta-
tus of the subject. The fall in the level of neutrophil activation in smok-
ers may represent an immune suppression or increased recruitment of
neutrophils from the circulation.
Work supported by a grant from GKT School of Medicine.
S9 SPUTUM BACTERIAL COLONISATION IN STABLE COPD:
ITS INFLUENCE ON AIRWAY INFLAMMATION, HEALTH
STATUS, AND FIBRINOGEN
D. Banerjee1 2, D. Honeybourne2, O.A. Khair1. 1Department of Respiratory
Medicine, City Hospital NHS Trust, Dudley Road, Birmingham, UK;
2Department of Respiratory Medicine, Birmingham Heartlands Hospital,
Bordesley Green East, Birmingham, UK
Introduction and aims: It is unclear if the presence of potential
pathogenic micro-organisms (PPMs) in the sputum of patients with
moderate to severe COPD influences health status and blood fibrino-
gen levels during the stable clinical state. This study aimed to
determine if health status, fibrinogen and bronchial airway inflamma-
tion in those harbouring PPMs differ from those who do not
(Non-PPMs).
Methods: moderate to severe patients with no recent exacerba-
tions in the last 6 weeks were recruited. Saline sputum induction was
performed and markers of airway inflammation (total cell count, neu-
trophil count, IL-8, LTB4, TNF-α, neutrophil elastase (NE), and neutro-
phil chemotaxis (NC)—Boyden chamber technique), sputum bacterial
culture, health status (SGRQ and SF-36) and blood fibrinogen were
measured.
Results: 67 patients were recruited, 69% male, mean age (SD)
66.7 (7.9) years and 27 (40%) were current smokers. 27 (40%) of
patients grew PPMs, total number of bacterial isolates 38; H
influenzae (14), M catarrhalis (10), S pneumoniae (9) and others (5).
There was no significant difference in age, spirometry or smoking
pack years between the PPMs and Non-PPMs groups. Those with
PPMs had a worse health status score, mean (SD): Total SGRQ 58.7
(14.7) v 47.4 (15.7), p=0.004, SGRQ impact 46.1 (16.1) v 34.1
(17.3), p=0.005, SGRQ symptoms 70.3 (14.8) v 60.5 (21.4),
p=0.03, SGRQ activity 76.8 (17) v 63.2 (20.4), p=0.004. SF-36
vitality and physical role limitation were also worse in this group. The
PPMs group had an exaggerated airway inflammatory response,
mean (SD): sputum supernatant log IL-8 (nM) 0.01 (0.35) v −0.29
(0.47) p = 0.001, Log LTB4 (nM) 0.32 (0.33) v 0.01 (0.40),
p=0.008), Log TNF-α (pM) −0.15 (0.78) v −0.78 (0.56), p = 0.001,
NE (µM) −1.27 (1.01) v −2.04 (0.52), p = 0.001 and NC (% fMLP)
70.4 (17.1) v 54.6 (19.0), p=0.001. There were increased numbers
of sputum neutrophils (absolute count) but this was not statistically sig-
nificant (p=0.058). Fibrinogen level (g/l) was greater in the PPMs
group: 3.21 (0.87) v 2.85 (0.64), p=0.05.
Conclusion: clinically stable moderate to severe COPD patients
with sputum PPMs have a worse health status, exaggerated bronchial
airway inflammation and a higher blood fibrinogen level.
S10 RELATIONSHIP BETWEEN BRONCHIAL BIOPSY CELL
POPULATIONS, EXACERBATION FREQUENCY, AND
BACTERIAL COLONISATION IN COPD
I.S. Patel1, N.J. Roberts1, R.J. Sapsford1, M. Sheaff2, J.A. Wedzicha1. 1Aca-
demic Unit of Respiratory Medicine; 2Department of Morbid Anatomy,
Barts and the London NHS Trust, UK
The effect of exacerbation frequency on bronchial wall inflammation
in COPD, and the effect of bacterial colonisation in this context are
unknown. Bronchoscopic biopsies were taken from 36 patients with
COPD (mean (SD) age 69.5 (8.75) yrs, FEV1 1.36 (0.59) l, FVC 2.6
(0.88) l, FEV1% predicted 54.5 (16.2)%, PaO2 8.8 (1.2) kPa, PaCO2
5.4 (0.65) kPa, 46.2 (31.8) pack years of smoking, MRC dyspnoea
score 3.06 (1.24), daily inhaled steroid dosage 747 (810) µg, 16
current smokers, median (IQR) 2 (3) exacerbations per year). Samples
were wax embedded and stained for CD3, CD4, CD8, CD68, and
EG2 positive cells by immunohistochemistry. Lower airway bacterial
colonisation was quantitatively assessed by means of protected speci-
men brushings in 30 patients, of whom 14 were colonised by a poten-
tial pathogen. Patients were defined as frequent (>3 per year) or
infrequent (< 2 per year) exacerbators. Total numbers of CD3 positive
cells per section were related to exacerbation frequency (rho=0.512,
p=0.013) and the number of exacerbations in the previous year
(rho=0.459, p=0.011). Total CD8 positive cells per high-powered
field were related to exacerbation frequency (rho=0.454, p=0.03)
and number (rho=0.443, p=0.034). CD4 positive cells per
high-powered field also increased with exacerbation number
(rho=0.573, p=0.016). CD68 positive cells per high-powered field
were related to exacerbation frequency (rho=0.655, p=0.002) and
number (rho=0.584, p=0.007), as were numbers of activated
eosinophils (rho=0.623, p=0.003 and rho=0.555, p=0.009 respec-
tively). Exacerbation frequency was related to colonisation with a
potential pathogen (rho=0.383, p=0.041). The total bacterial count
was related to numbers of CD3 cells per high-powered field
(rho=0.443, p=0.06) and worsening MRC dyspnoea score
(rho=0.597, p=0.007).
Patients with frequent COPD exacerbations show increased
numbers of lymphocytes, macrophages and eosinophils in their bron-
chial biopsies when stable. These cells may contribute to the increased
airway inflammation seen in patients with frequent COPD exacerba-
tions, which may also be modulated by the presence of lower airway
bacterial colonisation.
Supported by the Joint Research Board, St. Bartholomew’s Hospital.
Smoking cessation, attitudes,
and examples
S11 A SURVEY OF PUBLISHED CURRICULUM CONTENT ON
SMOKING AND SMOKING CESSATION IN UK
MEDICAL SCHOOLS
E.L. Jones, P.J. Rubin, J. Britton. University of Nottingham, UK
Rationale: Cigarette smoking is the single most important avoidable
cause of respiratory disease in the UK, and smoking cessation
interventions are amongst the most cost-effective interventions
available in medicine. We have assessed the extent to which UK
medical schools recognise and address smoking as a medical
problem in their training programmes by a search of published data
on curriculum content.
Methods: We searched printed and electronic information on
course content published by UK medical schools for teaching on smok-
ing and smoking cessation, using the keywords “smoking”, “smoking
cessation”, “tobacco”, “tobacco control”, and “nicotine” in electronic
searches. Content was assessed according to previously defined crite-
ria.1
Results: Of 23 UK medical schools with current students, 9 (40%)
make no references to smoking or smoking cessation in their published
curriculum material. Most of the references made in the remaining 14
schools relate to the importance of taking a smoking history, and to the
occurrence of tobacco-related diseases. Four medical schools (17%)
offer optional modules in smoking related issues, four include
management of nicotine addiction as part of psychology or public
health modules, one included a module on smoking within respiratory
medicine, and one included a role-playing smoking cessation session
within a Primary Care module. No references were found to teaching
on the pharmacology of nicotine addiction.
Conclusions: This study suggests that teaching on the pharmacol-
ogy and determinants of nicotine addiction, and practical training in
the delivery of effective smoking cessation interventions, receive little
attention in UK undergraduate medical curricula.
The Department of Health funded this research.
1. Ferry LH, Grissino LM, Runfola PS. Tobacco dependence curricula
in US undergraduate medical education. JAMA 1999;282:825–9.
S12 ATTITUDES OF GENERAL PRACTITIONERS AND
PATIENTS TOWARDS SMOKING CESSATION ADVICE
IN PRIMARY CARE
J. Cleland, M. Thomas, H. Pinnock, T. Van der Molen. University of Aber-
deen, UK
Despite compelling evidence for the effectiveness of smoking cessation
advice from a GP, rates of provision of such advice remain persistently
sub-optimal (Freeth S. Smoking-related behaviour and attitudes, 1997:
a report on research using the ONS Omnibus Survey produced on
behalf of the Department of Health. London: The Stationery Office,
1998). Why are GPs not providing routine opportunistic smoking ces-
sation intervention? Previous research on provision of smoking cessa-
tion advice has focused mainly on the professional’s perspective. It
may be that smokers have quite clear ideas about what approach
and/or content they believe would be effective (Butler CC, et al. BMJ
1998;316:1878–81). Is there is an area of common ground between
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GP and patient attitudes where opportunistic interventions could be
based, thus maximising the chance of such an intervention being
received positively?
This qualitative study aimed to identify and explore barriers to the
routine provision of smoking cessation advice by GPs, GP and patient
attitudes towards such advice. Individual interviews and focus groups
were carried out separately with GPs, smokers, and ex-smokers.
Our results indicate that both GPs and patients think that primary
care smoking cessation interventions should be: (a) pertinent to the
consultation rather than population-based advice, (b) personalised,
linked to specific health benefits for that particular individual, and
linked to the individual’s personal timetable of change, (c) positive,
emphasising the positive benefits of quitting seems to be the preferred
approach, and (d) practical, which includes GPs prescribing NRT and
bupropion.
The importance and potential value of linking smoking to the
presenting complaint needs to be further researched. Ways of linking
information about the relationship of smoking to the patient’s own ill-
ness need to be explored. There needs to be rapid access at appropri-
ate times for individuals who may be at a window of opportunity in the
cycle of change. The recent development of problem-oriented
guidelines for smoking cessation in primary care may encourage GPs
to provide such advice and are likely to be more acceptable to
patients.
S13 “IF SOMEONE COULD WAVE A MAGIC WAND I’D
NEVER SMOKE AGAIN...”—BARRIERS AND
MOTIVATORS TO ACCESSING SMOKING CESSATION
SERVICES AMONGST SMOKERS IN DEPRIVED AREAS OF
NOTTINGHAM
E.L. Jones, A.W.P. Molyneux, M. Anotoniak, J.R. Britton, S.A. Lewis. Divi-
sion of Respiratory Medicine, City Hospital, University of Nottingham
Rationale: Smoking is the main factor responsible for inequalities in
health between rich and poor.1 Although smoking cessation services
have been developed in the UK as part of the Tobacco White Paper,2
these services have traditionally failed to reach many of the most
deprived smokers.3 Qualitative research methods are an appropriate
way to explore the views of smokers who live in deprived areas who
have made an attempt to stop smoking but who have not accessed the
local smoking cessation services.
Methods: We conducted a postal survey of the most deprived
households in Nottingham, and invited respondents who had made
an unsuccessful attempt to stop smoking in the last year without using
the Nottingham NHS Smoking Cessation Service, to attend focus
groups to explore attitudes, experiences, and knowledge of smoking
and stopping smoking, attitudes to smoking cessation services and
interventions, and barriers and motivators to the access of such serv-
ices. Group discussions were recorded and transcribed and a line-by-
line analysis was undertaken to allow themes and categories to
emerge from the data.
Results: Most participants started smoking in their teens and felt
highly addicted to nicotine. All were aware of the risks of smoking and
had tried to quit smoking, many on multiple occasions, but knowledge
of smoking cessation interventions and their effectiveness was poor.
Barriers to the access of smoking cessation services—such as cost, tim-
ing, childcare, lack of appropriate information, perceived ineffective-
ness, and negative publicity—were explored. Novel approaches to
the management of nicotine addiction were discussed, including par-
allels with drug and alcohol addiction treatments, brain surgery,
in-patient quit attempts, “staining” cigarettes and government subsidy
for complementary therapies.
Conclusions: Deprived smokers are highly addicted, have a poor
perception of the availability and efficacy of smoking cessation inter-
ventions and are unlikely to access services unless these barriers are
broken down.
Funded by the New Leaf, Nottingham NHS Smoking Cessation
Service.
1. Acheson D. Independent inquiry into inequalities in health. London:
The Stationery Office, 1998.
2. Department of Health. Smoking kills: a white paper on tobacco.
London, 1998.
3. Jarvis MJ. The tobacco epidemic. Basel: Karger, 1997:151–64.
S14 EXAMPLE OF AN EFFECTIVE SMOKING CESSATION
SERVICE WITHIN A PRIMARY AND SECONDARY CARE
TRUST
A. Burgoyne, A. Graham, M. Babores. East Cheshire NHS Trust, UK
Smoking is the nation’s single greatest cause of preventable illness
and early death. More than 120 000 people a year in the UK die
from smoking related diseases and it costs the NHS 1.7 billion each
year. In April 2000, funding was allocated from South Cheshire
Health Authority which supported the development of a locally based
smoking cessation service in east Cheshire for the following two
years—£9000 for year one and £18 500 for year two.
A multidisciplinary team was responsible for the co-ordination and
development of the smoking cessation service in east Cheshire with
representatives reporting to the Eastern Cheshire Primary Care Group
(Trust) and the NSF CHD Local Implementation Team. These services
were based in the Primary and Secondary health care settings deliver-
ing a standard rolling 6–8 weeks programme. This included one to
one or group support, counselling from a trained smoking cessation
adviser, provision of Nicotine Replacement Therapy and Bupropion
where appropriate.
Targets set were 650 smokers setting quit dates over two years.
Actual targets achieved doubled with 1190 smokers setting a quit
date. Of those 612 (52%) were not smoking at 4 weeks with CO vali-
dation, 244 (20%) relapsed and 334 were lost to follow up (28%).
Twelve months follow up rates are to be reported in August 2002.
Monitoring data supports the continuation of a smoking cessation
service in east Cheshire. Planning for long term funding needs to be
identified. Maintaining smoking cessation as a priority for health inter-
ventions is vital. Continued development and co-ordination of smoking
cessation services will be required to meet increasing public and
professional demand.
S15 12 MONTH QUIT RATES OF A “SPECIALISED”
HOSPITAL BASED SMOKING CESSATION SERVICE
S. Brown, R.M. Angus, I. Davies. Aintree Chest Centre, University Hospital
Aintree, Liverpool L9 7AL, UK
It is reported that intensive behavioural support plus Nicotine Replace-
ment Therapy (NRT) or Bupropion enables about 20% of smokers to
stop long term, compared to 5% from brief advice from a General
Practitioner.1 Quit rates in those with established smoking related dis-
eases are surprisingly lower than those in “healthy smokers”. We
established a hospital-based smoking cessation service for smokers
with respiratory disease. Patients are offered one-to-one counselling
with frequent structured advice and regular support. NRT and/or
Bupropion can be prescribed as required. All quit results were
validated by expired air CO (carbon monoxide). From April 2001 to
March 2002, 337 patients were referred into the service. Fifty nine
(16%) did not attend their first appointment and 40 (12%) were not
motivated to quit at the time of referral. Two hundred and thirty eight
(71%) set quit dates and the following are the results of these 238
patients. Mean (SD) age 57 (9) years, 135 (57%) female. Two
hundred and nine (88%) had previously tried to quit. Diagnoses were
as follows: COPD 107 (45%), asthma 58 (24%), bronchiectasis 14
(6%), lung cancer 13 (5%) and “other” 46 (19%). Patients used the
following pharmacological support: NRT patches 107 (45%),
Bupropion 41 (17%), NRT inhalator 37 (16%), NRT gum 10 (4%),
and NRT lozenge 7 (3%). Thirty six (15%) used willpower alone. Of
238 patients 147 (62%) reached a 4 week quit, 81 (55%) female.
Thirty nine (16%) patients were lost to follow up. Quit results at 6
months were 49/102 (48%), with 19 (19%) lost to follow up and at
12 months were 18/24 (75%) with 3 (13%) lost to follow up. Of the
18 patients that were continuously abstinent at 12 months, 11 (61%)
were female and products used were Bupropion 7 (39%), NRT
patches 7 (39%), and willpower alone 4 (22%). These results compare
favourably to recent Department of Health figures for smoking cessa-
tion services in the UK, where it was quoted that quit rates of around
20% at the 12 month follow up should be expected.2 This
demonstrates the value of targeting thoracic patients in specialist
smoking cessation services in the UK.
1. World Health Organisation. The case for commissioning smoking
cessation services. London, 2001.
2. Department of Health. New NHS Smoking Cessation Services. Lon-
don: Stationery Office, 1999.
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Sleep: New outlooks
S16 THE UPPER AIRWAY IN PREGNANCY AND
PRE-ECLAMPSIA
B. Izci1, R.L. Riha1, S.E. Martin1, M. Vennelle1, W.A. Liston2, K. Dundas2, A.
Calder2, N.J. Douglas1. 1Edinburgh Sleep Centre, University of Edinburgh,
UK; 2Department of Reproductive and Developmental Sciences, University
of Edinburgh, UK
Background: Snoring is common in pregnancy and snoring pregnant
women have increased rates of pre-eclampsia. Patients with
pre-eclampsia have an increased rate of upper airways (UA) narrow-
ing during sleep which may contribute to their blood pressure
elevation.
Aims: To compare upper airway dimensions in pregnant and non-
pregnant women and in patients with pre-eclampsia.
Method: 50 women in the 3rd trimester of pregnancy and 37
women with pre-eclampsia were recruited consecutively from the ante-
natal service and matched with 50 non-pregnant women. UA dimen-
sions were measured using acoustic reflection. Comparisons were by
analysis of variance and Student-Newman-Keuls tests.
Results: The pregnant, pre-eclamptic, and non-pregnant women
did not differ in terms of age or height, or in pre-pregnant weight or
body mass index. 14% of non-pregnant, 28% of pregnant, and 75%
of pre-eclamptic women reported they snored (p<0.001). Oropharyn-
geal junction area (OPJ) in the supine position was narrower in preg-
nant than non-pregnant women (1.0 SD 0.1, 1.1 SD 0.1cm2; p=0.05)
and smaller yet in pre-eclamptics (0.8 SD 0.1 cm2; p<0.05). Seated
OPJ was narrower (p<0.05) in the pre-eclamptics (1 SD 0.1cm2) than
either controls(1.2 SD 0.1cm2) or pregnant women (1.3 SD 0.1cm2).
Conclusions: Upper airways are narrower during the third trimes-
ter of pregnancy, and women with pre-eclampsia have further airway
narrowing. This could result from a combination of FRC reduction due
to the pregnancy and generalised oedema. These changes could con-
tribute to the increased snoring in pregnancy, and to the upper
airways resistance episodes during sleep in pre-eclampsia which may
further increase blood pressure.
Study supported by the Cunningham Trust.
S17 BRAIN fMRI ACTIVATION AND EVOKED POTENTIALS
DURING VISUAL STIMULATION AND VISUO-MOTOR
TRACKING IN NORMAL SUBJECTS BEFORE AND AFTER
SLEEP DEPRIVATION
G.V. Robinson1, R.C. Miall2, P.M. Matthews3, E.M. Jones1, J. Winter2, J.
Stein2, J.R. Stradling1, R.J.O. Davies1. 1Oxford Centre for Respiratory
Medicine, Churchill Hospital, Oxford, UK; 2University Laboratory of Physi-
ology, Oxford, UK; 3FMRIB Centre, John Radcliffe Hospital, Oxford, UK
Patients sleep deprived by obstructive sleep apnoea (OSA) have a
4–7 fold increased motor accident rate. This is associated with impair-
ment on tasks that test vision and tracking, including simulated steering
tests (Thorax 2001;56(Suppl 3):28). The neural explanation for this is
unknown.
Methods: Using a previously developed paradigm (Nature Neuro-
sci 2001;4:638), we have assessed the brain functional magnetic
resonance imaging (fMRI) activation patterns in normal subjects
during pure visual stimulation and during performance of coordinated
hand/eye tracking manoeuvres, before and after 28–32 hours total
sleep deprivation (TSD). Evoked potentials to a potent visual stimulus
were also recorded from the occipital cortex.
After pre-training, 10 normal subjects (7M, 3F, mean age 27)
underwent fMRI imaging, while looking at an alternating chequer-
board (pure visual stimulus) and while performing the visual tracking
paradigm (visuo-motor stimulus). Subjects were assessed at baseline
after normal sleep. Further assessments were performed, in random
order, after normal sleep and 28–32 hours of actigraphy monitored
TSD and stimulant abstinence. 4 subjects also had occipital visual
evoked potentials (VEPs) recorded.
Results: Following normal sleep, the expected brain areas were
activated on fMRI by both tasks. Tracking performance was
significantly impaired by TSD (mean tracking error 114.3 SD 49.1
after normal sleep, 219.7 SD 47.6 after TSD, p<0.0001, paired t
test). During the chequerboard (pure visual stimulus), TSD increased
brain activation in the primary visual cortex, precuneus and left
prefrontal areas, but decreased activation in the extra striate visual
cortex. The VEP studies confirmed a neural basis for this reduced brain
activation. During the tracking (visuo-motor) task, TSD lead to reduced
cerebellar and premotor activation, with unchanged primary motor
cortex activation.
Conclusion: TSD in normal subjects impairs tracking. This is asso-
ciated with activation of neural centres that may be associated with
vigilance maintenance (prefrontal cortex and precuneus) and depres-
sion of visual association areas and secondary motor centres.
S18 PLATELET ACTIVATION IS INCREASED IN
OBSTRUCTIVE SLEEP APNOEA AND DOES NOT FALL
WITH CPAP TREATMENT
G.V. Robinson1, J.C.T. Pepperell1, H. Segal2, B. Langford1, R.J.O. Davies1,
J.R. Stradling1. 1Oxford Centre for Respiratory Medicine, Churchill Hospi-
tal, Oxford, UK; 2Oxford Haemophilia and Thrombosis Unit, Churchill Hos-
pital, Oxford, UK
Obstructive sleep apnoea (OSA) is an independent risk factor for
hypertension and arterial thrombotic disease (Am J Resp Crit Care
Med 2002;166:159). The increased cardiovascular risk is probably
multifactorial, and related to insulin resistance and endothelial
dysfunction, in addition to hypertension (the increased incidence of
which in OSA is now well established). Platelets have a central role in
the pathogenesis of acute cardiovascular syndromes, and platelet
activation is associated with increased cardiovascular risk in normals
(Thromb Haemost 2001;85:584). The influence of OSA on platelet
function is not clear.
Methods: 94 male subjects mean (SD) age 48 (11) with OSA
defined as >10 oxygen saturation dips >4% per hour (actual dip rate
42.5 (23.0)) and an Epworth sleepiness score (ESS) >10 (actual ESS
15.7 (3.0)) were randomised to one month’s treatment with therapeu-
tic or sub-therapeutic (∼1cm water pressure) continuous positive
airways pressure (CPAP) treatment. Plasma levels of soluble P-selectin
(sP-sel), a marker of chronic platelet activation, were measured by
ELISA before and after treatment. 22 unmatched normal subjects were
used to establish a normal range.
Results: sP-sel was higher in the untreated OSA patients than in the
normal subjects (OSA patients 55.4 ng/ml (37.3), normal subjects
29.5 ng/ml (10.5), p<0.0001, unpaired t test). No significant fall in
sP-sel was seen following one month’s treatment with either therapeu-
tic or sub-therapeutic CPAP: therapeutic CPAP, pre treatment 58.3
ng/ml (41.9), post treatment 54.0 ng/ml (35.5), p>0.4, paired t test;
sub-therapeutic CPAP, pre treatment 52.5 ng/ml (32.1), post
treatment 45.4 ng/ml (22.7), p>0.1, paired t test.
Conclusion: OSA may cause increased platelet activation, which
does not fall with one month’s CPAP treatment. This is likely to be a
further contributor to the increased vascular morbidity of OSA, which
is not improved with one months standard OSA treatment.
Abstract S19 Table 1
Baseline Post CPAP p Value
Epworth Score 14 (0–20) 8 (0–20) <0.005
MFI-20, General Fatigue 17 (8–20) 12 (4–20) <0.005
MFI-20, Physical Fatigue 16 (4–20) 13 (4–20) <0.01
MFI-20, Reduced Activity 10 (4–17) 8 (4–20) <0.05
MFI-20, Mental Fatigue 13 (4–20) 7 (4–20) <0.005
SF-36, Physical Limitations 25 (0–100) 75 (0–100) <0.005
SF-36, Vitality 30 (0–85) 55 (0–100) <0.001
SF-36, Mental Health 68 (4–100) 84 (28–100) <0.005
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S19 THE MULTIDIMENSIONAL FATIGUE INVENTORY
(MFI-20) IN OBSTRUCTIVE SLEEP APNOEA (OSA):
EFFECTS OF NASAL CONTINUOUS POSITIVE AIRWAY
PRESSURE (CPAP)
N. Wiltshire, F. Buchanan, A. Harper, J.R. Catterall, A.H. Kendrick. Sleep
Unit, Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol,
UK
We have shown that the MFI-20 provides useful additional information
to the Epworth Score (ESS) and SF-36 in patients with OSA, and sepa-
rates sleepiness and fatigue (Kendrick et al. Thorax 2001;56(Suppl
III):46).
Aim: To assess the response of the MFI-20 in a CPAP naïve patients
and to compare this with data from the ESS and the dimensions of the
SF-36.
Methods: Patients were given the ESS, SF-36 and MFI-20 question-
naires before and at the end of a 4 week trial of CPAP as part of our
clinical management of patients with OSA. Data are given as median
(range).
Results: 50 patients (6F), age 54.5 yr (27–80) and Body Mass
Index 31.8 kg.m-2 (22.8 to 52.6) were studied. The results are summa-
rised in table 1.
At the end of the trial and using a cut-off of 10 for each MFI-20
dimension and for ESS, 16/50 had a MFI-20 GH >10, 17/50 had an
MFI-20 PH >10 and 20/50 had an MFI-20 RA >10 indicating signifi-
cant fatigue problems remain in the absence of daytime hypersomno-
lence. The relation between changes in ESS and MFI-20 are shown in
table 2.
Conclusion: The MFI-20 is a simple self-completion questionnaire
that provides useful additional information to that obtained from the
ESS and the SF-36 and separates out sleepiness and fatigue pre and
post CPAP.
S20 MODAFINIL IMPROVES WAKEFULNESS AND OVERALL
CLINICAL CONDITION AS ADJUNCTIVE THERAPY FOR
RESIDUAL EXCESSIVE SLEEPINESS IN OBSTRUCTIVE
SLEEP APNEA: A 12 WEEK RANDOMISED TRIAL
A. Williams and the Modafinil OSA study group. Sleep Disorders Centre,
St. Thomas’s Hospital NHS Trust, UK
Objective/Methods: A 12 week, randomised, double-blind,
placebo-controlled study was conducted to assess the efficacy and
safety of modafinil as adjunctive therapy for residual excessive sleepi-
ness in patients with obstructive sleep apnea (OSA) treated with nasal
continuous positive airway pressure (nCPAP). Patients were rand-
omized to receive placebo, modafinil 200 mg once daily, or
modafinil 400 mg once daily. Modafinil was initiated at 100 mg/d
and titrated to 200 or 400 mg/d within 1 week. Key outcomes
included changes from baseline in objective (Maintenance of Wake-
fulness Test [MWT]) and subjective (Epworth Sleepiness Scale [ESS])
measures of wakefulness and patients’ overall clinical condition (Clini-
cal Global Impression of Change [CGI-C]) at Week 12. Secondary
efficacy measures included changes from baseline in MWT, ESS, and
CGI-C at Weeks 4 and 8. nCPAP use and adverse events were moni-
tored.
Results: A total of 3 23 randomised patients received treatment
(placebo: n=108; modafinil 200 mg/d: n=109; modafinil 400 mg/d:
n=106). Modafinil significantly improved patients’ ability to sustain
wakefulness on the MWT at Week 12 (increases of 1.6 min for
modafinil 200 mg/d and 1.5 min for modafinil 400 mg/d) compared
with placebo (decrease of 1.1 min; p<0.0001). Modafinil treatment
also significantly improved wakefulness as measured by the ESS
scores: a 4.5-point decrease in ESS score was observed with
modafinil compared with a 1.9-point decrease with placebo at Week
12 (p<0.0001). Modafinil significantly improved patients’ overall
clinical condition at Week 12, as measured by the CGI-C
(p<0.0001). Modafinil had no effect on nCPAP use or nighttime sleep.
Modafinil was associated with significant improvements in wakeful-
ness and clinical condition at Weeks 4, 8, and 12. Headache (12%;
26%), nausea (2%; 11%), and anxiety (2%; 8%) were the most com-
mon adverse events occurring in the placebo and modafinil treatment
groups, respectively.
Conclusions: Adjunct modafinil therapy significantly improves
wakefulness and overall clinical condition and is well tolerated in
patients with OSA who have residual sleepiness despite treatment with
nCPAP.
Pulmonary hypertension:
Clinical issues
S21 PULSE PRESSURE PREDICTS MORTALITY IN
PULMONARY ARTERIAL HYPERTENSION
J.D. Chalmers1, R. Syyed2 , V. Impey1, A. Peacock2. 1University of Glasgow;
2Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK
Introduction: It is known that mean pulmonary artery pressure
predicts survival in pulmonary hypertension. Following the Framing-
ham heart study, it was shown that pulse pressure (PP) outperformed
mean arterial, systolic and diastolic pressures as predictors of
mortality in systemic hypertension. We wished to discover if this held
true for the pulmonary circulation.
Methods: We retrospectively reviewed all the patients with Pulmo-
nary hypertension who had been studied between 1996 and January
2002. 80 patients had Pulmonary hypertension (PHT). Of the 80
patients 19 (11 female, 8 male) had PPH, 18 (10 female, 8 male) had
thromboembolic disease, 17 (13 female, 4 male) had connective tis-
sue disease, 10 (8 female, 2 male) had COPD, 10 (8 female, 2 male)
had Eisenmengers, 3 (2 female, 1 male) had porto-pulmonary hyper-
tension, 2 (2 female) had valvular heart disease and 1 (1 female) had
Sarcoidosis. Haemodynamic variables as well as performance status
and medical history were examined. Kaplain Meier Survival curves
and regression analysis were used to determine correlation between
variables and survival.
Results: PP against survival produced a correlation coefficient (r) of
−0.76 (p<0.001) and Kaplain Meier survival curves revealed a 100%
probability of survival at 2 years for PP<30 mmHg compared to 85%
probability of survival for PP 30–40 and 46% for PP greater than 40.
No other variable predicted survival with this accuracy.
Conclusion: Pulse pressure is a powerful predictor of mortality in
all causes of pulmonary hypertension. No other variables proved
superior to pulse pressure, regardless of underlying diagnosis.
S22 LONG DURATION OF BREATHLESSNESS AT
DIAGNOSIS IS ASSOCIATED WITH LONGER SURVIVAL
IN PPH: A CLINICAL PARADOX
V. Impey, A. Peacock1. University of Glasgow, Glasgow G12 8QQ, UK;
1Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow G11 6NT,
UK
Introduction: Previous studies have shown that breathlessness
predicts survival. It is widely believed that a longer duration of breath-
lessness is related to a worse prognosis, probably due to slower time
to diagnosis. We expected to confirm this supposition in our data
Abstract S19 Table 2
∆MFI-20, GF = 1.59 + 0.5∆ESS r2 = 0.30 p<0.001
∆MFI-20, PF = 0.80 + 0.31∆ESS r2 = 0.13 p<0.01
∆MFI-20, RA = 0.40 + 0.27∆ESS r2 = 0.12 p<0.05
Abstract S21 (A) Pulse pressure and survival. (B) Kaplan Meier
survival curves, pulse pressure and survival.
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series but found the reality to be the opposite. We have previously
found cardiac index (CI) to be an important predictor of survival so we
correlated duration of breathlessness and CI.
Methods: We examined admission data in all our patients with
PPH. We included demographic variables (sex, age) medical history
(duration of breathlessness, NYHA class), haemodynamic data (mean
pulmonary artery pressure, cardiac index). Kaplan-Meier (KM)
survival curves and regression analysis were used to examine the cor-
relation between these variables and survival.
Results: For our 25 patients with PPH, the probability of survival at
12 months after diagnosis was 100% for those 8 patients with a his-
tory of breathlessness >3 years and 51% for those with breathlessness
<3 years (13 patients). There was also a positive correlation
coefficient of 0.6 between cardiac index and duration of
breathlessness (we excluded 2 patients with breathlessness longer
than 6 years as outliers).
Conclusion: A longer duration of symptoms at diagnosis may rep-
resent a slower progression of disease and better survival prospects,
reflected by the improved cardiac index.
S23 SCREENING FOR EARLY PULMONARY ARTERIAL
HYPERTENSION IN PATIENTS WITH SYSTEMIC
SCLEROSIS (SScPAH): RATIONALE FOR AN INVASIVE
APPROACH
D. Mukerjee, D. St George, J. Davar, C.M. Black, J.G. Coghlan. Depart-
ments of Rheumatology and Cardiology, Royal Free Hospital, Pond Street,
London NW3 2QG, UK
Aims: To document the accuracy of echocardiography to identify
early pulmonary hypertension (PHT) in a high-risk Systemic Sclerosis
(SSc) cohort, we identified 140 patients who have had echo and car-
diac catheter within ±3 months of either investigation. Previous studies
have documented under-estimation of echo-estimated tricuspid
gradient (TG) compared to catheter results, with only a few studies
reporting echo over-estimation of this parameter.
Method: Echo-estimated TGs and the catheter-measured TGs were
correlated and a linear regression was derived to predict
catheter-measured mean Pulmonary Artery Pressures (mPAPs) from
echo estimated TGs.
Results: N=140, (F:M=119:21), mean age=56 (7) years. Haemo-
dynamic parameters: mPA Systolic Pressure=47 mmHg, mPA diastolic
Pressure=18 mmHg, mPAP=34 mmHg, mRAP=4 mmHg, mean echo
estimated TG=42 mmHg. Echo-estimated TG showed a positive corre-
lation with catheter-measured TGs in 140 patients (r2=0.44,
p<0.005). By linear regression, echocardiography was sufficiently
accurate at moderate/ high pressures (echo TG >45 mmHg) identify-
ing >80 % of patients correctly. In contrast, at lower pressures where
early diagnosis is critical, echo was less accurate—it both
under-estimated the catheter-measured mPAPs in 30% and over-
estimated the catheter-measured mPAPs in 32% of cases. The latter
inaccuracy may lead to a potential for over-diagnosis in unaffected
patients.
Conclusions: Though echo accurately identified a poor prognostic
group of PHT patients (mPAP >35 mmHg on cardiac catheter),
reliance on the present technique to accurately identify early PHT in an
“at risk” SSc cohort is inadequate. In its current form, echo-estimated
TGs demonstrate a tendency to both under and over-estimation at the
lower end of the spectrum of pulmonary artery pressures—with the
subsequent risk of exposing a patient with either no or mildly elevated
pulmonary pressures to over-investigation. This latter finding is particu-
larly relevant when applied to low prevalence PHT populations where
the false positive rates are proportionately higher and in such
scenarios the accuracy of echo is further diminished.
S24 THE UTILITY OF D-DIMERS AND OTHER PREDICTORS
OF PULMONARY EMBOLI IN A LARGE SERIES FROM A
DISTRICT GENERAL HOSPITAL
S.A. Evans, S.C. Ward, M. Jarral, R.J. Clark, J. Langham-Brown, T. Fail, P.
Featherstone, P. Schmidt. Portsmouth Hospitals Trust, UK
Previous studies suggest that a negative D-dimer can have a negative
predictive value (NPV) for objectively diagnosed pulmonary emboli
(PE) of 99 % (Egermeyer et al. Thorax 1998;53:830–4). A pilot study
in our hospital comparing bed side and laboratory SimpliRED and a
ELISA D-dimer assays for DVT gave NPV=s of between 69% and
76 %.
We have used 4 parameters to assess the pre-test probability of PE:
(a) D-dimers (SimpliRED, performed on the ward), (b) Respiratory rate
(RR) > 20/minute (c) PaO2 on air of <10.7kPa, (d) Important risk fac-
tors from the history i.e. surgery/trauma, malignancy, cardiovascular
disease, previous PE/DVT, post-partum, immobilisation, and heredi-
tary thrombotic disorders.
These were prospectively evaluated in 521 patients who were
investigated for suspected PE. Assessment was incomplete in 101
cases, leaving 420 cases for analysis. Those with a normal CXR and
no chronic lung disease initially had a perfusion (Q) scan (n=297).
Leg dopplers (n=95) were performed on those with an abnormal CXR,
chronic lung disease or an indeterminate Q scan. CT pulmonary angi-
ograms were requested on those with negative or indeterminate leg
dopplers (n=51). 27 patients had features of a massive PE and were
investigated with urgent CT angiogram or an echocardiogram.
PE was confirmed in 131 patients, excluded in 289. The NPV of a
D-dimer was 83%, a RR <20 90%, a PaO2>10.7kPa 83%, and absent
clinical risk factor(s) 81%. Logistic regression gave RR high odds ratios
and suggested that PaO2 added little to the other 3 parameters. A com-
bination of no risk factor and a RR<20 gave a risk of objectively con-
firmed PE of <5% irrespective of the D-dimer result and the PaO2.
We conclude that negative D-dimer results are best used in conjunc-
tion with other predictors to exclude PE.
S25 OUTCOME AFTER PULMONARY
THROMBOENDARTERECTOMY FOR CHRONIC
THROMBOEMBOLIC PULMONARY HYPERTENSION
F. Reichenberger, J. Pepke Zaba, D. Hodgkins, A. Vuylsteke, K. McNeill,
J. Dunning. Papworth Hospital, Cambridge, UK
Pulmonary thromboendarterecomy (PTE) is the treatment of choice in
chronic thromboembolic pulmonary hypertension (CTEPH) with proxi-
mal vascular obstructions. However PTE is associated with a
significant perioperative risk. Over the last 5 years, 100 patients (50
male, 50 female, mean age 53 (18–81) years) underwent PTE at Pap-
worth Hospital. 71 patients survived the procedure, whereas 29 died
postoperatively: 10 due to reperfusion oedema, ARDS, or bronchop-
ulmonary infections despite significant improved haemodynamics, 12
had incomplete clearance of vascular obstruction with additional per-
ipheral vascular obstructions, 3 were misdiagnosed preoperatively
(PPH, peripheral CTEPH, advanced pulmonary artery sarcoma). Four
patients developed surgical complications. The quartile distribution of
the outcome is shown below. Evaluating preoperative factors that
influenced perioperative outcome, the surviving patients had a signifi-
cantly higher 6 minute walking distance (268 v 194 metres, p<0.01),
and higher cardiac index (1.8 v 1.5 l/min/qm, p<0.01) compared to
the non-survivors, whereas right atrial and pulmonary artery pressures
Abstract S22 (A) Breathlessness and cardiac index. (B)
Kaplan-Meier curve: breathlessnes.
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were similar in both groups. At our institution, experience within the
recently established PTE programme shows a learning curve
associated with a significant improvement in the postoperative
outcome in this high risk patient population.
Asthma therapeutics
S26 THE USE OF NEBULISED ISOTONIC MAGNESIUM
SULPHATE AS AN ADJUVANT TO SALBUTAMOL IN THE
TREATMENT OF SEVERE ASTHMA IN ADULTS
R.J. Hughes1 3, A.L. Goldkorn2, M. Masoli3, M. Weatherall2, C. Burgess2,
C.R.W. Beasley3. 1Greenlane Hospital; 2Wellington School of Medicine;
3Medical Research Institute of New Zealand, New Zealand
Background: Intravenous magnesium has been shown to cause
significant bronchodilation in the treatment of severe asthma, however
its effect by the nebulised route is uncertain. In this study we assessed
the efficacy of isotonic magnesium sulphate as an adjuvant to
nebulised salbutamol in severe asthma.
Methods: We enrolled 52 subjects with severe exacerbations of
asthma (FEV1 <50% predicted) presenting to the Emergency
Departments at two hospitals in New Zealand. In this randomised
double-blind placebo-controlled trial subjects received nebulised salb-
utamol (2.5 mg) mixed with either 2.5 mL of isotonic magnesium sul-
phate or isotonic saline on three occasions at 30 minute intervals. The
primary outcome measures were FEV1 at 90 minutes and requirement
for admission.
Results: The mean FEV1 in both groups at randomisation was simi-
lar (1.24 litres, 31.9% predicted v 1.20 litres, 31.8% predicted,
p=0.73). Subjects who received nebulised salbutamol with the
magnesium adjuvant achieved a greater improvement in FEV1 (0.72 v
0.35 litres, difference 0.37 litres, p=0.004) when compared with
nebulised salbutamol with the saline adjuvant. A corresponding
reduction in requirement for admission (relative risk 0.61, confidence
interval 0.37 to 0.99) was demonstrated. The greatest difference
between the two regimens occurred in those individuals presenting
with life-threatening exacerbations, defined by an FEV1 of less than
30% predicted (increase in FEV1 0.83 v 0.18 litres, difference 0.75
litres, p<0.0001).
Conclusions: The use of isotonic magnesium as an adjuvant to
nebulised salbutamol results in an enhanced bronchodilator response
in the treatment of severe asthma.
S27 GLUCOCORTICOID RECEPTOR ACTIVATION IN
INDUCED SPUTUM FOLLOWING INHALED
LONG-ACTING β2-AGONIST AND GLUCOCORTICOID
TREATMENT
O.S. Usmani, K. Maneechotesuwan, I.M. Adcock, P.J. Barnes. Department
of Thoracic Medicine, National Heart and Lung Institute, Imperial College
School of Medicine, London, UK
The clinical evidence is well established for the complementary effects
of inhaled long-acting β2-agonists (LABA) and glucocorticoids (GC) on
asthma control. Recent in vitro data suggest the molecular mechanisms
may involve enhanced glucocorticoid receptor (GR) nuclear transloca-
tion, as LABA have been shown to induce ligand-independent GR
translocation. GC activate GR which translocate to the nucleus and
bind to DNA to regulate the expression of GC-sensitive target genes,
or to coactivators to switch off inflammatory genes. The aim of our
research was to develop a model using cells relevant to airway
disease, to test the hypothesis that inhaled LABA were able to modu-
late the intracellular partitioning of GR in vivo.
We previously described a semi-quantitative method to identify GR
subcellular expression in induced sputum cells using immunocytochem-
istry, and showed ligand-induced GR activation in this model. Six
healthy subjects inhaled beclomethasone dipropionate (800µg) once,
and sputum was induced at 0, 30, 60,120mins post-inhalation. We
observed significant GR translocation (71%) at 60mins post GC inha-
lation compared to baseline (30%) (p<0.05). Using this information
on the optimal time point for GR activation, we describe here the
effects of LABA and GC in asthmatics.
Seven steroid-naïve asthmatics inhaled single doses of fluticasone
propionate (FP)-100µg, FP-500µg, salmeterol (SALM)-50µg & combi-
nation FP/SALM 100/50µg on separate visits. Dose dependent GR
activation was observed following FP; FP-100 (47%), FP-500 (61%)
where the higher dose was significant v placebo (31%) (p<0.05).
SALM alone achieved 43% GR translocation, but as combination
therapy, SALM was able to augment the action of FP on GR transloca-
tion (54%) (p<0.05).
We have shown it is possible to use induced sputum to investigate
the molecular effects of inhaled drug therapy. Our data support the
proposition that GR nuclear translocation may underlie the
complementary effects of LABA and GC. The precise signal transduc-
tion mechanisms remain unknown, but LABA may prime inactive GR
through phosphorylation, and subsequently GR may require less GC
for nuclear translocation. We now aim to research this hypothesis, as
it may identify biochemical targets for future therapeutic modulation.
S28 DOSE-RESPONSE RELATION OF INHALED
BUDESONIDE IN ADOLESCENTS AND ADULTS WITH
ASTHMA
M. Masoli, S. Holt, M. Weatherall, R. Hughes, R. Beasley. Medical
Research Institute of New Zealand.
Objective: To examine the dose-response relation of inhaled budeso-
nide in adolescents and adults with asthma.
Design: Meta-analysis of placebo controlled, randomised clinical
trials that presented data on at least one outcome measure of asthma
and that used at least two doses of budesonide, delivered by
turbuhaler twice daily.
Setting: Medline, Embase, and Astra-Zeneca’s internal clinical
study registers.
Main outcome measures: FEV1, morning and evening peak
expiratory flow, β-agonist use, withdrawals and exacerbations of
asthma leading to withdrawal.
Results: Three studies of 1013 adolescents and adults with moder-
ately severe asthma, met the inclusion criteria for the meta-analysis.
Only one study examined doses >800 µg/day and no studies exam-
ined doses >1600 µg/day. A negative exponential model for the
data, without meta-analysis, indicated that 80% of the benefit at 1600
µg/day was achieved at doses of 250–350 µg/day and 90% by
350–500 µg/day. A quadratic meta-regression showed that the
maximum effect was obtained with doses of around 1000 µg/day.
Comparison of the standardised difference in FEV1 for an inhaled dose
of 400 µg/day against higher doses showed a difference in FEV1 of
0.03 of a standard deviation (−0.153 to 0.213). It was not possible
to undertake a meaningful statistical analysis of withdrawals, however
examination of individual study data indicated that most of the benefit
with respect to reduction in asthma exacerbations leading to
withdrawal was achieved with a dose of 400 µg/day.
Conclusions: Determination of the dose-response relation of
budesonide was limited by the lack of individual patient data, the
paucity of studies reporting the effect of doses of >800 µg/day and
insufficient withdrawal data. However, utilising the available
published data, most of the therapeutic benefit of budesonide
delivered by the turbuhaler device was achieved with a total daily
dose of 250–500 µg/day, and the maximum effect at around 1000
µg/day, in adolescents and adults with asthma. These findings are
consistent with the recently determined dose-response relation of fluti-
casone propionate, assuming a potency ratio of 1:2. We recommend
that national and international consensus guidelines and formularies
are modified to ensure that they are consistent with the published data
from which the therapeutic dose-response range of inhaled
corticosteroids has been derived.
S29 DOSE-RESPONSE RELATION OF INHALED
FLUTICASONE PROPIONATE IN CHILDREN WITH
ASTHMA—A SYSTEMATIC REVIEW OF ITS EFFICACY
AND ADRENAL EFFECTS
M. Masoli, M. Weatherall, S. Hold, R. Beasley. Medical Research Institute
of New Zealand
Objective: To examine the dose-response relation of inhaled
fluticasone propionate for both efficacy and adrenal function in
children with asthma.
Design: Analysis of placebo-controlled randomised clinical trials of
fluticasone in children of at least 4 weeks duration, that used at least
one dose of fluticasone, and that presented data on at least one clini-
cal outcome measure of asthma or at least one sensitive measure of
adrenal function.
Setting: EMBASE and Medline.
Main outcome measures: FEV1, morning and evening peak
expiratory flow, night awakenings, β-agonist use, major exacerba-
tions leading to withdrawal, 12 or 24 hour urinary cortisol, peak
plasma cortisol post-stimulation.
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Results: Five studies of 1150 children with asthma met the
inclusion criteria for efficacy, with no studies examining doses
>200 µg per day. The dose-response curve for each outcome measure
suggested that the response began to plateau between a dose of 100
and 200 µg per day. The odds ratio for patients remaining in a study
at a dose of 100 µg, compared with 200 µg was 0.8 (95% CI 0.46
to 1.37).
Three studies of 523 children with asthma met the inclusion criteria
for assessment of adrenal function with no studies examining doses
>200 µg per day. A meta-analysis could not be undertaken as the
data was not presented in an appropriate format. The largest study of
437 children reported no difference in 24 hour urinary cortisol
between placebo and fluticasone at doses of 100 and 200 µg per
day. However, the two smaller studies demonstrated evidence of a
reduction in urinary cortisol at these doses.
Conclusions: There is insufficient data to determine the
dose-response relation of fluticasone in children at doses >200 µg per
day. The dose-response curve for fluticasone appears to plateau
between 100 and 200 µg per day for efficacy; there was weak
evidence of adrenal suppression at these doses. Pending formal stud-
ies which determine the dose-response relation of fluticasone in
greater detail, we recommend that fluticasone should be routinely pre-
scribed in children with asthma in doses of up to 200 µg per day.
S30 STEPPING DOWN INHALED CORTICOSTEROIDS IN
ASTHMA: A RANDOMISED CONTROLLED TRIAL
G. Hawkins1, A.D. McMahon2, S. Twaddle3, S.F. Wood1, I. Ford2, N.C.
Thomson4. 1Department of General Practice, University of Glasgow, UK;
2Robertson Centre for Biostatistics, University of Glasgow, UK; 3Stobhill
Hospital, Glasgow, UK; 4Department of Respiratory Medicine, University of
Glasgow, UK
Background: In an attempt to optimise the therapeutic action of
inhaled corticosteroids whilst minimising their side effects, asthma
management guidelines recommend that a reduction in the dose of
inhaled corticosteroid is undertaken when asthma is stable.1 We
aimed to determine whether a 50% reduction in the dose of inhaled
corticosteroid could be undertaken in patients with chronic stable
asthma, whilst maintaining control.
Methods: We recruited 259 adult asthmatics receiving regular
treatment with high-dose inhaled corticosteroids (mean daily dose =
1430 mcg beclomethasone dipropionate ) to a one-year, randomised,
double-blind, parallel group trial. Patients were allocated to receive
either no alteration to their inhaled corticosteroid dose (control) or a
50% reduction in their dose if they met criteria for stable asthma (step-
down). We compared asthma exacerbation rates, asthma related
general practice and hospital visits, quality of life measures and
corticosteroid dose between the two groups.
Findings: We found no significant difference in the asthma exacer-
bation rate between the two groups (step-down=31%, control=26%,
p=0.354). Similarly, there were no significant differences in the num-
bers of general practice or hospital visits, or in disease specific and
generic measures of health status over the one-year period. On aver-
age, the step-down group received 348 mcg (95% CI 202 to 494) of
beclomethasone dipropionate less per day than the controls with no
difference in the annual dose of oral corticosteroids between the two
treatment regimes.
Interpretation: Our study provides convincing evidence that it is
possible to step down high dose inhaled corticosteroids in patients
with chronic stable asthma, without compromising asthma control.
1. The British Guidelines on Asthma Management: 1995 Review and
Position Statement. Thorax 1997;52(suppl 1):S1–S21.
S31 A PLACEBO CONTROLLED COMPARISON OF
FORMOTEROL, MONTELUKAST OR HIGHER DOSE OF
INHALED CORTICOSTEROIDS IN SUBJECTS WITH
SYMPTOMATIC ASTHMA DESPITE TREATMENT WITH
LOW DOSE INHALED CORTICOSTEROIDS
R.H. Green, C.E. Brightling, S. McKenna, B. Hargadon, D. Parker, A.J.
Wardlaw, I.D. Pavord. Institute for Lung Health, Glenfield Hospital, Leices-
ter, UK
An important number of patients with asthma remain symptomatic
despite treatment with low dose inhaled corticosteroids. There is rela-
tively little data from placebo controlled studies directly comparing the
different treatment options for this group of patients. We have
performed a randomised, double blind, four way cross-over study
comparing the effects of one months treatment with higher dose
budesonide (400mcg bd), additional formoterol (12 mcg bd) and
additional montelukast (10 mg od) with placebo in patients with
asthma who remain symptomatic despite low dose inhaled
corticosteroids (budesonide 100mcg bd). Patients were seen before
and 12 hours after each treatment phase which was separated by a
one month washout period during which they took budesonide
100mcg bd and prn salbutamol only. At each visit exhaled nitric
oxide (NO), spirometry, methacholine PC20, visual analogue symptom
scores (VAS), the Juniper Asthma Quality of Life questionnaire and
induced sputum were performed. Patients recorded twice daily peak
expiratory flow (PEF) throughout and the mean morning PEF was cal-
culated for the final week of each treatment and washout period. 49
patients with symptoms consistent with asthma and objective evidence
of variable airflow obstruction despite low dose inhaled cortico-
steroids were recruited. High dose budesonide was the most
efficacious treatment resulting in significant improvements in global
VAS (−21.3 mm; 95% CI −40.4 to −2.3) morning PEF (16.5 l/min;
95% CI 2.3 to 30.7), FEV1 (0.14 l; 95% CI 0.0 to 0.28) and exhaled
NO (fold reduction 1.9; 95% CI 1.1 to 3.1) compared to placebo.
Formoterol was the next most efficacious treatment with similar
improvements in morning PEF (17.5 l/min, 95% CI 4.0 to 31.0).
However the change in sputum eosinophil count with formoterol (2.4%
to 3.8%; fold reduction 0.6, 95% CI 0.5 to 0.9) differed significantly
from the change seen with placebo (2.8% to 2.5%; fold reduction 1.1,
95% CI 0.7 to 1.6; p=0.03) and high dose inhaled corticosteroids
(2.7% to 1.6%; fold reduction 1.6, 95% CI 1.2 to 2.2; p<0.001). We
conclude that treatment given in addition to low dose inhaled cortico-
steroids results in modest benefits. Despite similar effects on morning
peak flow, long acting β2-agonists and high dose inhaled
corticosteroids differ in their effects on eosinophilic airway inflamma-
tion.
Paediatric airways disease
S32 THE BRAVELUNG STUDY: BRONCHIOLITIS RSV AUDIT
INTO VACCINATING FOR EARLY LUNGS
J. McCormick, M. Almaghrabi. Tayside Institute of Child Health, Ninewells
Hospital, Dundee, UK
Background: Each winter season there are pervasive outbreaks of
respiratory syncytial virus (RSV) bronchiolitis. Premature infants with
CLD who are re-admitted with RSV utilise greater health service
resources in the first two years of life after birth.1 Palivizumab, the
humanised RSV monoclonal antibody has been shown to cause a rela-
tive reduction in re-admission rates in infants born at <35 weeks group
by 55%.2
Objectives: To audit current protocols and practice into
Palivizumab prescribing and Palivizumab funding in Scotland and
Northern Ireland over the winter 2001—2002 season.
Design: Retrospective postal questionnaire.
Methods: Targeted questionnaire to lead neonatal or paediatric
consultants in 27 units in Scotland and Northern Ireland following the
end of the RSV season in late March/early April 2002.
Results: Response rate was 100% from units responsible for an
estimated 72 400 births. 200 babies received a course of
Palivizumab over the winter season (1 per 362 births) at an estimated
cost of £490 000. Important regional variations were demonstrated;
1 in 179 babies born in Northern Ireland compared to 1 in 538
babies born in Scotland receive RSV prophylaxis. Six units using
agreed guidelines prescribe 49% of the palivizumab in Scotland.
Only 63% of respondents had an agreed protocol for palivizumab
administration. Inclusion criteria for receiving palivizumab included;
chronic lung disease (76%), home oxygen (71%), congenital cardiac
abnormality (59%), specific gestation (53%), and consultant discretion
(35%). The source of funding was described as Trust (50%), Health
Board (32%), Directorate (14%) and 4 % from winter pressures
money. There were three reports of “breakthrough” RSV infection (3%
of treated babies) following immunisation.
Discussion: Palivizumab is prescribed 3 times more in Northern
Ireland than Scotland. Should UK guidelines for palivizumab adminis-
tration (like the US) now be the goal?
1. Greenough A, et al. Arch Dis Child 2001;85:463–8.
2. The IMpact-RSV Study Group. Pediatrics 1998;102:531–7.
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S33 THE COMPLEX RELATIONSHIP BETWEEN ASTHMA AND
AIRWAY RESPONSIVENESS THROUGHOUT
CHILDHOOD
S.W. Turner, L.J. Palmer, P.J. Rye, N.A. Gibson, P.K. Judge, S. Young, J.
Goldblatt, L.I. Landau, P.N. Le Souëf. Princess Margaret Hospital for Chil-
dren, Perth, Australia
Introduction: The relationship between childhood asthma and
increased airway responsiveness (AR) remains uncertain.
Aims: To investigate whether AR tracks from infancy through to
childhood; to determine which factors influence AR and assess
interactions with asthma.
Methods: From a cohort of 253 individuals, longitudinal
assessments of AR and atopy were made at one, six and 12 months
and at six and 11 years of age. AR was expressed as a dose response
slope (DRS) or graded on a scale of 0 to 2.
Results: DRS was measured in 203 individuals aged one month,
174 at six months, 147 at 12 months, 103 at six years and 176 at 11
years of age. There were 22 asthmatics at six and 27 at 11 years of
age. There was a positive relationship between the DRS in infants
aged one month and in children who were not atopic aged 11 years
(r=0.24, n=65, p=0.05). Atopy at six years of age was positively
associated with grade of AR χ22=6.2, n=93, p<0.05). Atopy at six
months and at 11 years of age was positively associated with the
grade of AR aged 11 years χ22=6.8, n=150, p=0.03 and χ22=18.7,
n=175, p<0.001, respectively). The DRS at six, but not 11, years of
age was positively related to the urinary cotinine concentration at 12
months of age (r=0.45, n=32, p<0.001) and also the number of ciga-
rettes currently smoked by parents (r=0.01, n=83, p=0.04). The DRS
at 11, but not six, years of age was increased in the presence of lower
respiratory tract infection (LRTI) in the first six months (n=79, p<0.001)
but not the second six months of life. Adjusting for the presence of
asthma, the DRS at six years of age was related to the urinary cotinine
concentration aged 12 months (p=0.001) and current atopy
(p=0.03); and the DRS at 11 years of age was related to atopy aged
six months (p=0.001) and LRTI before six months of age (p=0.001).
Conclusions: The data suggested that the level of AR in childhood
was determined in early infancy and then influenced in later infancy
by factors that included atopy, tobacco smoke exposure and lower
respiratory tract infections. Factors present in infancy are associated
with increased childhood AR and these appear to act independently
of asthma.
S34 TUMOUR NECROSIS FACTOR GENE POLYMORPHISMS
AND CHILDHOOD WHEEZING
H. Bilolikar1 2, A. Rodriguez Nam3, M. Rosenthal1, D.C. Henderson2, I.M.
Balfour-Lynn1 2. 1Dept. Paediatric Respiratory Medicine, Royal Brompton
Hospital; 2Depts. Paediatrics and Immunology, Chelsea & Westminster
Hospital; 3Dept. Clinical Immunology, Hammersmith Hospital, London, UK
Background: TNFα secretion is influenced by single nucleotide gene
polymorphisms within the TNF gene cluster. Higher constitutive and
inducible production of TNFα is associated with allele 2 of TNF-308
and allele 1 of an Nco1 polymorphism of the LTα gene. Since TNFα is
associated with infant wheezing and asthma, a genetic predisposition
to produce TNFα may be important. We compared the TNFα and LTα
polymorphisms in controls with a group of infant wheezers, and child-
hood asthmatics of differing severity. We also measured nasal TNFα
levels in the infants with acute wheezing to determine whether an
association between phenotype (in vivo production) and genotype
existed.
Methods: Asthmatic patients were identified in clinic with respira-
tory paediatrician-diagnosed asthma, which was defined as severe if
they were on inhaled steroids >800 mcg/day (budesonide
equivalent). Infant wheezers were inpatients with acute wheezing.
Controls were school children with no asthma. Nasal lavage was per-
formed in the infants using the inulin method to account for dilution,
and nasal TNFα was measured by commercial ELISA. Genomic DNA
was extracted from buccal smears using the Nucleon extraction kit.
After amplification by PCR, the DNA was sized by electrophoresis.
Results: There were 88 asthmatics (mean age 6.1 yrs, 52 boys),
27 severe asthmatics (mean age 12.8 years, 17 boys), 55 wheezy
infants (mean age 6.5 months, 35 boys) and 156 controls (mean age
10.2 years, 77 boys). All data were compared to the controls. In the
presence of TNF1 homozygosity, the risk (95% CI) of being a wheezy
infant was 3.2 (2–5) greater if they were also LTα AA than if one or
two LTα G genes were present. For all asthma the risk was 2.0 (1.2–
3.2) and for severe asthma risk was 2.4 (1.3–4.5). In the presence of
1 or 2 TNF2 genes, the co-presence of LTα AA gave a 12.6 (1.6–98)
risk of being a wheezy infant than if there was a LTα G gene present.
The risk for all asthma was 18 (2.4–128) and for severe asthma 13
(1.5–114). Although the positive predictive values were high, the sen-
sitivity of the testing was relatively low. The haplotype TNF12/ LTα AA
gives a positive predictive value for any wheezing of 96%, with sensi-
tivity of 17%.
In the wheezy infants, nasal TNFα levels were not influenced by
RSV status. Levels were significantly lower in the presence of a TNF2
gene (p=0.006), which was the opposite of that expected, and there
was a trend (p=0.08) to higher levels if the LTα A gene was present
(as expected).
Conclusions: The TNF2 allele is associated with wheezing
whereas the LTα G gene had a protective effect. Clearly the TNF
genotype influences the development of childhood wheezing. The
results of nasal TNFα needs further elucidation.
S35 DEVELOPMENTAL CHANGES IN VENTILATION
DISTRIBUTION IN HEALTH AND CF LUNG DISEASE
P. Aurora, H. Jungberg, C. Oliver, P. Gustafsson2, J. Stocks. 1Portex Respi-
ratory Unit, Institute of Child Health, London, UK; 2Queen Silvia Children’s
Hospital, Göteborg, Sweden
Longitudinal monitoring of airway function through childhood is often
complicated by the need to correct results for age and body size.
Aims: In this study we investigated the relationship between age
and lung clearance index (LCI), an index of ventilation inhomogeneity
derived from multiple breath inert gas washout (MBW) (Larsson et al.
J Appl Physiol 1988;65:2030–9), in cystic fibrosis (CF) and healthy
control children aged from 0 to 18 years.
Methods: 131 children (64 with CF) were tested. Infants were
measured whilst asleep, older children whilst awake. All performed 3
SF6 MBWs, and mean LCI was calculated for each child.
Results: LCI remained constant throughout childhood in healthy
controls, but became progressively elevated with increasing age
among those with CF. See table and figure.
Conclusion: The LCI can be used to assess airway function from
infancy to adulthood and has potential for monitoring CF lung
disease.
Abstract S35 LCI by age group expressed as mean
and (SD)
Infants
(0–2 yrs)
Pre-school
(3–5 yrs)
School-age
(6–18 yrs)
Healthy 6.47 (0.33) (n=23)6.49 (0.51) (n=22)6.50 (0.54) (n=22)
CF 8.05 (1.41) (n=24)8.92 (1.74) (n=19)11.48 (3.01) (n=21)
Abstract S35 Lung clearance index as a function of age in healthy
controls and CF.
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S36 CHEMOKINE PRODUCTION IN SEVERE RSV
BRONCHIOLITIS
P.S. McNamara, G. Jeffers, B.F. Flanagan, P. Newlands, P.C. Ritson, C.A.
Hart, R.L. Smyth. Institute of Child Health, Alder Hey Children’s Hospital,
Liverpool, UK
Introduction: Respiratory syncytial virus (RSV) bronchiolitis is one of
the most important causes of death and morbidity in infants
worldwide. Factors that predispose to severe disease include prematu-
rity. Neutrophils are the predominant cell-type within upper and lower
respiratory tract secretions from infants with bronchiolitis and reach
the airways along chemoattractant gradients. Our aim was to
compare the pulmonary chemoattractant protein response in term and
preterm infants ventilated with RSV bronchiolitis with that from a con-
trol group.
Subject/Methods: We collected non-bronchoscopic broncho-
alveolar lavage (BAL) samples from 48 infants (25 born at term (>37
weeks) and 23 born preterm (<37 weeks)) ventilated for RSV bronchi-
olitis. We also collected BAL samples from 13 “control” patients ven-
tilated for non-respiratory causes. All samples were collected within
24 hours of being intubated. BAL protein concentrations were
measured using ELISAs (R&D) according to the manufacturers instruc-
tions.
Results: Mean ages on admission were: term infants, 6.7 wks; pre-
term, 16.0 wks; control, 5.5 wks. Mean weights on admission were:
term, 4.3kg; preterm, 3.5kg; control, 4.2kg. Mean gestational ages
at birth were: term, 38.6 wks; preterm, 30.1 wks; control, 38.8 wks.
Preterm infants were ventilated for twice as long as term infants (4.4 v
9.0 days, p=0.02).
MIP-1α, RANTES and Eotaxin concentrations all differed signifi-
cantly between the three groups.
Conclusions: We have identified differences in the immunological
response in the lungs of infants ventilated for RSV bronchiolitis
compared to a control group. Our data also highlight for the first time
differences in this response between term and preterm infants with RSV
bronchiolitis which may relate to disease severity.
Study funded by Action Research
S37 SALMETEROL/FLUTICASONE COMBINATION (SFC) IS
ASSOCIATED WITH IMPROVED COMPLIANCE IN
CHILDREN COMPARED WITH INHALED
CORTICOSTEROID (ICS) ALONE, OR CONCURRENT
SALMETEROL + ICS
T.P. McCarthy, L. Rice, C.A. Blair. GlaxoSmithKline, Uxbridge UB11 1BT,
UK
Introduction: Paediatric compliance with regular asthma medication
is a concern, with levels of 55–58% being reported (Coutts J. Arch Dis
Child 1991; Milgrom H. J Allergy Clin Immunol 1996). It has been
suggested that a combination of a long-acting β2 agonist (LAB) and an
inhaled steroid in one inhaler—SFC (SeretideTM) may appeal to
children in terms of convenience; and the LAB, providing a rapid
improvement in lung function which will wear off after 24 hours, may
serve as a reminder that the medication should be taken.
Method: To evaluate compliance in children <16 using prescribing
data as a surrogate marker, DIN-LINK Data (CompuFile Ltd) were used
to analyse prescription collection/year (P) from 100 GP practices, for
SFC, fluticasone (F), salmeterol (S) and beclometasone (BDPI (dry
powder inhalers)).
Results: 1031 asthma patients identified who had been prescribed
SFC, F, S or BDPI over the 12 months January–December 2001. 99%
of patients prescribed S for asthma were prescribed an ICS. Accord-
ingly S may be taken to represent concurrent LAB (S) +ICS (p value
SFC v S unchanged).
Discussion: Although prescribing data are only a surrogate for
compliance, as patients may not collect or use all their prescriptions,
this study found compliance with F and S in keeping with other stud-
ies. In contrast SFC achieved compliance that was significantly greater
versus F, S, and BDPI. As 99% of patients on S are concurrently on
ICS, SFC achieved significantly greater compliance compared with
concurrent LAB and ICS therapy. In this study SFC was associated with
greater compliance with treatment than is usually found in children on
regular inhaled therapy for asthma.
Pulmonary rehabilitation
S38 CAN ALL COPD PATIENTS COPE WITH PULMONARY
REHABILITATION?
E. Roberts1, J. Goldman1, W.H. Williams2, D Egan1. 1Clinical Health
Psychology, Torbay Hospital, Torquay TQ2 7AA, UK; 2School of Psychol-
ogy, University of Exeter, Exeter EX4 4QG, UK
It has been suggested that hypoxemia may be responsible for intellec-
tual difficulties observed in COPD patients. Research to date is incon-
clusive as to the nature of these difficulties and at what stage of
disease they occur. This investigation aimed to establish what the dif-
ficulties are, which disease factors are involved and whether they are
mediated by emotional well-being. Forty patients participated.
Inclusion criteria were an established diagnosis of COPD; FEV1 <80%
predicted, and an FEV1/FVC ratio of <70%. Those who were receiv-
ing LTOT, had suffered a severe head injury in the past, who had a
learning disability or who had other medical conditions known to
affect intellectual functioning were excluded. A control group of 22
healthy volunteers was also recruited. Blood gases and lung function
measures were taken from the patients; oxygen saturation of haemo-
globin was measured for all participants. A range of intellectual
assessments measured verbal fluency, memory, attention processes
and other skills associated with the frontal lobes of the brain. The HAD
assessed anxiety and depression. Mean PaO2 was 8.6 (.97), mean
PaCO2 5.2 (.63). Oxygen saturation at rest was 93.4% (3.29) in
patients. Percentage of predicted FEV1/FVC ratio was 45.8% (12.4).
Independent t-tests showed that COPD patients performed significantly
worse than controls on speed of information processing (t = −2.99,
p<0.05), immediate memory (t =−3.24, p<0.01), divided attention (t
= 2.60, p<0.01) and verbal fluency (t = −2.58, p<0.05). Significant
correlations were obtained between these measures and some physio-
logical measures: speed of information processing and % of predicted
FEV1/FVC (r = −0.33, p<0.05); and immediate memory with PaO2 (r
= 0.33, p<0.05); divided attention with PaCO2 (r = −0.34, p<0.05)
and with FVC (r = −0.27, p<0.05). Independent t tests showed
patients scored significantly higher than controls on both anxiety and
depression (t =−3.89, p<0.001 and t = 4.63, p<0.001 respectively)
but were not correlated with any of the intellectual measures. These
findings suggest that mildly hypoxemic patients show impairments in
intellectual performance. There is some evidence for the contribution
of severity of illness, although other factors related to COPD or chronic
illness in general may be implicated. Future work could assess whether
severe hypoxemia is accompanied by more intellectual deterioration.
The presentation of rehabilitation programmes can be tailored to take
account of patients’ difficulties.
S39 RESPONDER ANALYSIS OF PULMONARY
REHABILITATION
R. Garrod1, K. Dix, C. Daly, M. Howard, P.W. Jones. 1School of
Physiotherapy St George’s Hospital and Kingston University; St George’s
Hospital NHS Trust, UK
Introduction: Research has shown improvements in exercise
tolerance (ET) and health related quality of life (HRQoL) after
Abstract S36
Term (SD) Preterm (SD) Control (SD)
MIP-1α (pg/ml) 409 (493) 208 (230) 74 (58)
RANTES (pg/ml) 243 (483) 407 (1268) 28 (69)
Eotaxin (pg/ml) 123 (249) 81 (148) 288 (312)
MCP-1 (pg/ml) 1268 (1779) 474 (679) 1134 (1189)
Abstract S37
SFC F S BDPI
No patients 80 662 242 47
Mean p (SD) 8.7 (4.9) 6.2 (4.7) 6.5 (4.1) 3.3 (2.2)
Compliance (%) 72.5 51 54 27.5
Treatment difference
(v SFC)
2.4 2.1 5.3
95% confidence interval 1.3 to 3.5 1.0 to 3.2 3.8 to 6.8
p Value (SFC v comparators) <0.0001 =0.0004 <0.0001
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pulmonary rehabilitation. However there are few reports of the effects
of “real life” rehabilitation, in particular descriptors of response and
non response behavior. This study reports on data from a 7 week, 2 ×
weekly exercise and education programme run at St George’s Hospi-
tal, London.
Methods: Outcome measures were spirometry, Shuttle walk test
(SWT), HRQoL using SGRQ and mood state using the Hospital Anxi-
ety and Depression Scale (HAD). 76 patients were admitted to the
programme, 67 were available for follow up.
Results: There was a statistically significant improvement in SWT
mean change; 52 m (84.4) (p = 0.0001) and in SGRQ; 5.2 (10.6)
(n = 67). Responder analysis, based on a change >30mt for SWT and
>4 points for SGRQ, showed that 37 patients were responders (R) for
ET and 33 for HRQoL. 18 patients were characterised as non
responders (NR) in both HRQoL and ET. 12 patients were NR for exer-
cise tolerance but R for HRQoL, 17 patients were classified as R for
SWT but NR for HRQoL and only 20 patients were classified as R in
both aspects. In these 20 patients the change in SWT and SGRQ was
large; 124 (71.4)m and 12 (6.2) respectively. There was a significant
difference for SGRQ between R and NR; 57 (14.6) and 47 (14.4), p
= 0.04 with Rs showing poorer QoL, similarly for depression 7.5
(3.2), 5.6 (2.4), p = 0.04. Rs showed a larger initial SWT compared
to NR; 270 (139.2) and 217 (94.6) m although the difference was
not significant (p =0.18). Baseline spirometry showed no significant
difference, R and NR, mean (SD): 1.1 (0.5)l (n = 17) and 1.1 (0.5)l
(n=15), respectively.
Conclusion: These data generate the testable hypothesis that
greater exercise tolerance and poor HRQoL are associated with better
improvements in pulmonary rehabilitation. Prospective randomised
trials are warranted.
S40 SYMPTOMS LIMITING EXHAUSTIVE WALKING AND
CYCLING EXERCISE IN COPD
J. Gearing, W.D-C. Man1, S.G. Radford, R.E. Atkins, A.J. Rossell, B.Gray1,
M.I. Polkey2, J. Moxham1. Department of Physiotherapy and 1Respiratory
Medicine, King’s College Hospital; 2Royal Brompton Hospital, London, UK
Background: Previous studies have shown that leg fatigue is a com-
mon symptom following exhaustive cycling in COPD patients.
However cycling is not familiar to many COPD patients, and walking
field tests may be more representative of everyday activities. We
hypothesised that the symptoms limiting exhaustive exercise in COPD
is dependent on the type of exercise performed.
Method: 50 stable patients with COPD (27M:23F, mean age 68.6
yrs, mean FEV1 0.95) were recruited. After an initial familiarisation
period, each patient performed to exhaustion an incremental shuttle
walk (ISW), an endurance shuttle walk (ESW), incremental cycle
ergometry (ICE), and endurance cycle ergometry (ECE), on four sepa-
rate visits. Patients were asked to name the predominant symptom lim-
iting further exercise: shortness of breath (SOB), leg fatigue (LF), an
equal combination of SOB and LF, or other symptoms.
Results: See table.
Discussion: SOB is by far the most common limiting symptom fol-
lowing exhaustive walking exercise, but is less important following
exhaustive cycling exercise when LF becomes more prominent. It may
be more appropriate to use walking tests to assess the effects of thera-
peutic interventions on exercise-induced dyspnoea.
WDCM is a Clinical Research Training Fellow of the MRC (UK).
S41 ASSESSING THE DETERMINANTS OF INCREMENTAL
SHUTTLE WALKING DISTANCE
S. Dogan1, B. Watson2, W. Cochrane1 2, G. Dovey-Pearce1, G. Afolabi1,
M. Heatley1, C. McAlpine1, G. Oliver1. 1Northumbria Healthcare NHS
Trust, UK; 2Northumbria University, UK
Introduction: The shuttle test is a widely used outcome measure for
pulmonary rehabilitation to assess a person’s exercise tolerance. To
better understand what this outcome means we examined the relation-
ship between incremental shuttle test walking distance and biomedical
and psychological dimensions in people with COPD. These findings
derive from the baseline data of a trial comparing pulmonary rehabili-
tation with solely exercise and psychological interventions.
Participants: All 218 participants had stable COPD. 60% reported
MRC Dyspnoea grade 3, 29% grade 4, and 11% grade 5. 44% were
male and mean (95% CI) age was 68.8 (67.8–69.7) years.
Methods: Incremental shuttle walking test was carried out.
Spirometric and anthropometric measurements were recorded includ-
ing Forced Expiratory Volume (FEV-1), weight, and four site skinfold
thickness. Perceived health status, personal cognitions of illness and
affect were assessed using the Chronic Respiratory Disease Question-
naire (CRDQ), the Illness Perceptions Questionnaire (IPQ) and the
Hospital Anxiety and Depression Scale (HADS) respectively. Stepwise
multiple linear regression was carried out with incremental shuttle
walking test distance as the dependent variable.
Results: Mean (SD) incremental shuttle walking distance = 202.5
(111.3) meters. Independent variables included: predicted FEV-1
(mean (SD) = 52.7 (15.6)); fat free mass index (mean (SD) 17.6
(2.6)); CRDQ (mastery (median (IQR) = 19.0 (9.0)), fatigue (median
(IQR) = 14.0 (8.0)), emotional function (median (IQR) = 32.0 (12.8)),
dyspnoea (median (IQR) = 14.0 (7.8)); IPQ (timeline (median (IQR) =
21.0 (3.0)), consequences (median (IQR) = 19.5 (5.0)), personal con-
trol (median (IQR) = 20.0 (5.0)), treatment control (median (IQR) =
16.0 (4.0)), illness coherence (median (IQR) = 12.0 (6.0)); and HADS
(anxiety (median (IQR) = 18.0 (5.0)), depression (median (IQR) =
15.0 (3.0)). In a model controlling for participant age and gender,
and explaining 27.7% (p<0.001) of the variance in the dependent
variable, fatigue (beta = 4.6 (p=0.004)) and mastery (beta = 3.5
(p=0.02)), as measured by the CRDQ, were the only significant vari-
ables entered.
Conclusion: In this population, these findings demonstrate that a
person’s perception of their fatigue and their degree of control and
confidence in managing their condition, play an important and inde-
pendent role in promoting exercise performance. This suggests it is
important to directly address these factors when providing pulmonary
rehabilitation.
S42 EVALUATION OF MAINTENANCE PROGRAMMES
AFTER PULMONARY REHABILITATION IN THE
COMMUNITY SETTING
K. Dix, C. Daly, M. Howard, E. Porter, C.F.J. Rayner. St George’s Hospital
NHS Trust, Tooting, London, UK
Introduction: The role of maintenance programmes (MP) in pulmonary
rehabilitation is at present unknown. This data reports on the outcomes
of a community based MP provided after a 7 week 2 × weekly out
patient programme (OP) as part of “real life” clinical service.
Methods: After the 7 week out patient programme, patients self
selected to either attend a 6 month MP (n = 10) or not (n= 15). The MP
was provided once weekly in a local leisure centre. Assessments of
Shuttle Walk Test (SWT) and St George’s Hospital Respiratory Disease
Questionnaire (SGRQ) were made at the end of the 7 week out patient
and after the 6 month period (n= 25).
Results: Descriptive data are provided, based on an improvement
in SWT >30mt and >4 points for SGRQ. Of those who attended, 4
improved SWT, 5 stayed the same and 1 deteriorated; mean change
post OP rehabilitation, 17m. Of those who did not, 7 improved, 6
stayed the same and 2 got worse, mean change 45m. For SGRQ in
group attendees, 1 improved, 5 stayed the same and 4 got worse. In
the non attendees, 6 improved SGRQ, 6 stayed the same and 4 got
worse. There were no significant differences between the groups for
SWT or SGRQ.
Conclusion: This early report of a clinical community MP suggests
that patients who choose to attend the MP do as well as those who do
not attend for exercise and health related quality of life. It is unknown
whether these patients would maintain improvements without the
opportunity of a maintenance programme. Long term studies are indi-
cated.
S43 A FOCUS GROUP STUDY ON THE IMPACT OF THE
DIFFERENT COMPONENTS OF PULMONARY
REHABILITATION
M. Gray1, R.C.M. Jones1, M. Hyland2, J. Goldman3. 1Respiratory Research
Unit, University of Plymouth, Devon; 2Department of Psychology, University
of Plymouth, Devon, UK; 3The Heart and Lung Unit, Torquay Hospital,
Torquay, Devon, UK
Background: Multi-professional pulmonary rehabilitation (PR) has
been shown to improve exercise tolerance and quality of life. It is not
Abstract S40
Test
% Total number of patients
SOB LF SOB/LF Other
ISW 84 6 4 6
ESW 62 12 14 12
ICE 36 40 22 2
ECE 30 40 30 0
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known which aspects of PR (e.g. exercise versus education versus
social support) are found to be most helpful by patients, and existing
quality of life tools do not explore this issue.
Methods: Six focus groups were held 3 months after PR with
patients recruited from 2 programmes. One being a typical intensive,
hospital-based scheme, (Torquay), the other a short, once weekly pro-
gramme based in various locations in the community (Plymouth).
Results: Perceived effects of education included reduced fear of
dyspnoea, improved use of benefit system and improved drug compli-
ance; perceived effects of social context included encouragement dur-
ing exercise and smoking cessation, and new social activities amongst
group members; exercise in a safe environment increased confidence
in activity and also reduced fear of dyspnoea, leading to new activi-
ties (e.g. holidays, shopping trips etc.) Patients judged PR to be more
helpful then medical interventions. There appeared to be more extra-
curricula social contact in the community group.
Conclusions: Patients reported benefits of PR can be attributed to
exercise, education, social context, supporting the use of multi-
professional, multi-component PR programmes. Peer group support in
both programmes appears to be an important factor in behavioral
change.
Interstitial lung disease: From
diagnosis to treatment
S44 AN ASSESSMENT OF REPRODUCIBILITY OF DIAGNOSIS
IN DIFFUSE PARENCHYMAL LUNG DISEASES
A.G. Nicholson, A.R. Gibbs, B.J. Addis, S. Stewart, C.A. Clelland, N.B.
Ibrahim, W.A. Wallace, P.S. Hasleton, B. Corrin, H. Bharucha, K.M. Kerr
(UK-ILD panel), A.U. Wells. Departments of Histopathology, Royal Bromp-
ton, Llandough, Southampton, Papworth, John Radcliffe, Frenchay,
Edinburgh, Wythenshawe, Royal Victoria Hospital, Belfast, Aberdeen
Royal Hospitals, and Department Of Medicine, Royal Brompton Hospital,
UK
There are very few inter-observer studies of histologic patterns of
diffuse parenchymal lung disease (DPLD), and the reproducibility of
the consensus ATS/ERS classification for interstitial pneumonias has
not yet been tested. This study assesses inter-observer variation in the
diagnosis of DPLDs, both for interstitial pneumonias and orphan lung
diseases (OLDs). Cases referred for clinical assessment of DPLD
between Jan 1996 and Dec 1997, in which a surgical lung biopsy
was taken, were retrieved and H&E slides were circulated to 7 review-
ers, with knowledge only of age and sex of patient and site of biopsy.
As well as histologic patterns in the consensus classification, follicular
bronchiolitis (FB), extrinsic allergic alveolitis (EAA), sarcoidosis,
end-stage lung, normal, non-diagnostic, unclassifiable and “other” for
OLDs were permitted. Reviewers provided a first choice diagnosis
with a confidence rating of 1 (>95%), 2 (70–95%) or 3 (30–65%) for
each lobe (n=133). The differential diagnosis for each lobe was also
recorded along with its percentage likelihood, censored at 5%. The
same procedure was applied for the gestalt diagnosis if patients
(n=83) had more than one biopsy. Statistical analysis was performed
using STATA software (CA, USA). A confidence level of >95% for
diagnosis was made in 37% (range 22–47) of cases and >70% in
64% of cases (range 54–73). The overall kappa coefficient for first
choice lobar diagnoses was 0.35. Examples for more commonly
found patterns of interstitial pneumonias were UIP, 0.43; NSIP, 0.24;
DIP, 0.51; OP, 0.53; DAD, 0.52; EAA, 0.32; sarcoidosis, 0.70. In
cases with a high degree of confidence (n=79), the overall kappa
value was 0.49, whilst for low confidence diagnoses (n=54) this was
only 0.19. For UIP, the weighted kappa for lobar diagnosis was 0.55
rising to 0.59 for the gestalt diagnoses. Selected examples of
weighted kappas for gestalt diagnosis were NSIP, 0.34; OP, 0.58;
EAA, 0.50. These data suggest that the ATS/ERS consensus
classification is sufficiently reproducible when used by pathologists
with a specialist interest in pulmonary pathology.
S45 INCREASED SERUM LEVELS OF MUCIN KL-6,
SURFACTANT PROTEIN-D(SP-D) AND ANTIBODY TO
DIETRY ANTIGENS SUGGEST ALTERED MUCOSAL
PERMEABILITY AMONG PIGEON FANCIERS
C. McSharry, K. Anderson, T. Ismail, F. Boyd, J. Burgon, K.B.M. Reid, G.
Boyd. Department of Respiratory Medicine and Immunology, North Glas-
gow University Hospitals NHS Trust
Background: Increased clearance of inhaled 99mTc-DTPA in pigeon
fanciers has been observed irrespective of symptoms. The aim of this
study was to use serum levels of lung-epithelium-derived KL-6 and SP-D
to assess lung epithelial permeability and antibody to dietary antigens
to assess gut epithelial permeability in pigeon fanciers.
Methods: Serum KL-6, SP-D, antibody to inhaled avian antigens
and to common dietary antigens was quantified by enzyme immuno-
assay in 60 pigeon fanciers.
Results: The serum KL-6 levels in pigeon fanciers was (median, I-q
range) = 422 (244–616) units/ml and the serum SP-D level was
(mean (SD) = 201 (141) ng/ml). Both of these were significantly
higher than normal. These levels were not significantly higher in those
with EAA, but there was a significant correlation between the KL-6 lev-
els and the IgG antibody to inhaled avian antigen (r=0.435,
p=0.001) and between SP-D level and the IgG antibody (p=0.005).
There were significantly higher than normal titres of IgG antibody to
common dietary antigens among the pigeon fanciers suggesting
increased gut permeability, but these did not correlate with either
symptom category or antibody titre to avian antigens.
Conclusion: Increased lung mucosal permeability reflects local
inflammation which could be the cause or the effect of antibody-
associated events. The increased gut permeability in pigeon fanciers
suggests either an inflammatory reaction in the gut to avian antigens
in the diet or a pre-existing generalised increase in mucosal
permeability.
S46 MACROPHAGE MIGRATION INHIBITORY FACTOR
INDUCES PROLIFERATION AND HAS PRO-FIBROTIC
EFFECTS IN PRIMARY HUMAN PULMONARY
FIBROBLASTS
K.M.A. O’Reilly1, J.A. Baugh1, B.J. Plant1, M.X. Fitzgerald1, R. Bucala2,
S.C. Donnelly1. 1Department of Medicine and Therapeutics, University Col-
lege Dublin, Ireland; 2School of Medicine, Yale University, USA
Macrophage Migration Inhibitory Factor (MIF) is an important
pro-inflammaory cytokine which has been linked to the development of
fibro-proliferative or “chronic” acute respiratory distress syndrome
(ARDS).1 This finding lead you to postulate that MIF might have direct
pro-fibrogenic effects on fibroblasts, and therefore be an important
effector in the development of pulmonary fibrosis from a variety of
causes.
Primary human pulmonary fibroblasts (CCD-19Lu) were transiently
transfected with MIF, RNA extracted and an RNase protection assay
(RPA) performed. Levels of transforming growth factor (TGF)-β, a cyto-
kine known to be highly pro-fibrogenic, were found to be significantly
up-regulated (336% above control levels (n=3)). Similarly, when the
fibroblasts were stimulated with recombinant MIF, levels of secreted
TGF-β (measured by ELISA) were increased by 295% compared to
controls (n=3). In order to assess whether MIF had any direct effects on
fibroblast proliferation, MIF was co-incubated with the primary pulmo-
nary fibroblasts and cellular proliferation assessed by (H3)-thymidine
incorporation. Fibroblast proliferation was increased by 210% over
controls (n=9).
These data identify MIF as a cytokine which has the capacity to
both significantly up-regulate TGF-β production and induce fibroblast
proliferation; both key parameters which have the capacity to drive an
exaggerated pathological fibro-proliferative response.
This work is supported by the Wellcome Trust.
S47 COLLAGENASE 1 (MATRIX METALLOPROTEINASE 1,
MMP1) IS INVOLVED IN THE DEVELOPMENT OF
CRYPTOGENIC FIBROSING ALVEOLITIS
A. Walne, P. Lympany, K. Welsh, R. du Bois. National Heart and Lung
Institute, Imperial College of Science, Technology and Medicine, London
Cryptogenic Fibrosing Alveolitis (CFA) is a relentlessly progressive dif-
fuse lung disease of unknown aetiology, characterised by fibroblast
proliferation and extracellular matrix (ECM) accumulation. It is the
most common of the diffuse lung diseases, affecting up to 10 adults
per 100 000 in the UK and has a median survival time of only 3 years
from diagnosis. Even though the existence of familial CFA suggests
there may be a genetic component, there have been few large scale
studies showing an association between any genetic marker and the
development of CFA. The genetic component of CFA is likely to be
complex, involving several genes each with a variable effect, acting in
combination to determine the predisposition to lung fibrosis. In CFA,
the pathological process is characterised by ECM accumulation and
abnormal remodeling that may be due to a relative deficit in proteo-
lysis.
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In this study we fine mapped across collagenase-1, the gene coding
for the main enzyme involved in type I collagen degradation. We
examined 12 single nucleotide polymorphisms (four promoter, two
3=UTR, one intron 1/exon 1 boundary and five intronic) in 50 CFA
patients and 225 Caucasian controls. The genotype, allele and allele
carriage frequencies for the intron/exon boundary polymorphism
(C/T) were significantly different between patients and controls (geno-
type pc= 0.01, allele pc=0.03, allele carriage for C pc=0.006). There
were differences in the T allele carriage for the intron/exon polymor-
phism (p=0.016); in genotype frequency for one of the intronic poly-
morphisms (MMP1–3 p=0.036) and in allele carriage for one of the
3=UTR polymorphisms (G, p=0.045), but these differences became
trends when corrected for the total number of polymorphisms studied.
The finding of an association between collagenase-1 polymor-
phisms and CFA may indicate a role for this enzyme in the pathogen-
esis of this disease, but at present, the functional consequences of
these polymorphisms are unknown. They may affect mRNA splicing or
stability; alternatively, they may be markers for other unidentified
polymorphisms in this or other genes in the MMP cluster on
chromosome 11q23. We conclude that a susceptibility marker for
CFA maps to this MMP region.
S48 THE DEVELOPMENT OF LUNG FIBROSIS IN
TRANSGENIC TGFβ1 MICE
Y. Haider, M.W.J. Ferguson, J. Egan. CID, Stopford Building, University of
Manchester, Oxford Road, UK
TGFβ1 has been shown to be an important growth factor in the patho-
genesis of lung fibrosis. It has been hypothesised that human genetic
predisposition mediated via TGFβ1 may place some individuals at risk
of developing lung fibrosis (Anscher et al. NEJM 1993;328:1593–8).
We previously studied the natural history of a transgenic mouse
colony that expressed high circulating plasma levels of active TGFβ1
and found that lung fibrosis was not present irrespective of the age of
the mouse. This was despite histological evidence of liver fibrosis.
We proceeded to study the potential susceptibility of these mice to
the development of lung fibrosis using a known chemical injury (bleo-
mycin) and a suspected environmental pathogen (a herpes virus).
We bred two lines of transgenic mouse and confirmed their pheno-
type (Tr+) qualitatively (by tail DNA analysis) and quantitatively (by
plasma TGFβ1 bioassay). We then analysed their lungs histologically
after bleomycin injection (3000 IU intraperitoneal)(n=8), and after
administration of herpesvirus (4 × 105 pfu of Murine
gammaherpesvirus-68 intranasal)(n=8). Mice were killed after 6
weeks. A control population received the same treatment (n=8). Lung
fibrosis was graded 0–3, based on a previously published grading
system (Ashcroft et al. J Clin Pathol 1988;41:467–70).
The Tr+ mice were confirmed to have higher circulating levels of
active TGFβ1 compared to controls (p<0.05). Prior to bleomycin
exposure, the lungs of the Tr+ and control mice were histologically
normal. After bleomycin, control lung showed fibrosis (mean score
1.4) and Tr+ lung showed more severe and extensive fibrosis (mean
score 2.7)(p<0.05). Prior to herpesvirus innoculation, the lungs of the
Tr+ and control mice were normal. After herpesvirus, there was no
evidence of lung fibrosis in either group. In conclusion plasma TGFβ1,
while not causing de novo lung fibrosis, appears to predispose to lung
fibrosis when exposed to an exogenous injury (e.g bleomycin). This
may be a consequence of a compartmental disruption allowing
passage of circulating TGFβ1 into lung tissue. Therefore lung injury
may be of primary importance and individual susceptibility a second-
ary phenomenon.
S49 A DOUBLE BLIND RANDOMISED PLACEBO
CONTROLLED PILOT STUDY OF SEPTRIN IN THE
TREATMENT OF CRYPTOGENIC FIBROSING ALVEOLITIS
V. Varney, H. Parnell, D. Salisbury, S. Ratneepan, R. Tayar. Department of
Respiratory Medicine, St Helier Hospital, Wrythe Lane, Carshalton, Surrey
SM5 1AA, UK
Background: 14 patients with end stage pulmonary fibrosis were
openly treated with oral Septrin. All made a dramatic clinical recovery
and were discharged home. This prompted a double blind
randomised placebo controlled pilot study in earlier stages of the dis-
ease when cough, dyspnoea and oxygen desaturations on exercise
were present.
Method: 20 patients with pulmonary fibrosis (aged 49–84 years)
underwent a detailed assessment of arterial blood gases, lung
function, progressive shuttle walking tests with oxygen saturation
monitoring, quality of life and diary cards etc. Randomisation was to
Septrin or identical placebo for 3 months followed by 6 weeks of pul-
monary rehabilitation (rehab) before decoding. 2 weekly reassess-
ments of shuttle walk (etc) were made throughout the study.
Results: The first 16 cases have been decoded (8 Septrin, 8
placebo). The remaining patients will complete by September 2002.
Conclusion: Septrin produced a significant improvement in shuttle
walking distance with improved arterial oxygen values, lung volumes
and quality of life assessments. A fully decoded study by October
2002.
Acute respiratory distress
syndrome
S50 CHARACTERISATION OF A MURINE MODEL OF OLEIC
ACID-INDUCED ACUTE LUNG INJURY
K. Ulrich1, M. Stern1, M. Goddard2, D. Geddes1, M. Takata2 E. Alton1.
1Department of Gene Therapy, Faculty of Medicine at the National Heart
and Lung Institute, Imperial College, London, UK; 2Department of
Anaesthetics and Intensive Care, Faculty of Medicine at the Chelsea and
Westminster Hospital, Imperial College, London, UK
We are developing a programme of gene therapy for acute respira-
tory distress syndrome (ARDS). Oleic acid-induced lung injury has
been suggested as the optimal animal model, but has not been char-
acterised in mice. Current gene therapy studies focus on this species,
and we have therefore developed a mouse model of oleic
acid-induced lung injury. BalbC mice were anaesthetised, ventilated
and injected with either oleic acid (OA, 0.2 or 0.4 ml/kg body
weight) or saline. One hour after OA administration (0.2 ml/kg),
mouse lungs had significantly (p<0.01) higher wet-to-dry weight ratios
(6.9 (0.3) compared to 4.9 (0.04)). Analysis of BAL fluid from treated
animals demonstrated significant (p<0.005) increases in total protein
(2.9 (0.4) and 5.9 (0.6) µg/µl respectively for 0.2 and 0.4 ml/kg OA
compared to 0.2 (0.03) in the PBS control group). Albumin was also
detected in BALF from all OA-treated animals (0.2 (0.0) µg/µl). Total
cell numbers (1.4 (0.3) ×106 and 1.9 (0.3) × 106/ml for the two doses
compared to 0.4 (0.1) ×106/ml in control) and the marker of cell
damage, lactate dehydrogenase (LDH) activity (156 (40) and 446
(117) U/l compared to control 4.9 (1.3) U/l) were also significantly
increased. MIP-2, isolated from lung homogenates, revealed a signifi-
cant (p=0.005) increase in mice treated with the lower dose of OA
Abstract S49
Test
Placebo median (SD) Septrin median (SD)
Pre 3 mths Post rehab Pre 3 mths Post rehab
Shuttle (m) 200 (57) 210 (48) 220 (85) 200 (56) 360 (73)* 350 (86)*
PO2 (kPa) 9.7 (1.7) 8.9 (1.4) 9.9 (1.2) 11.3 (1.5)
FVC (L) 1.8 (0.6) 1.8 (0.7) 1.8 (0.6) 1.8 (0.6) 2.0 (0.8) 2.3 (1.0)
TLC 3.75 3.51 3.73 4.22
DLCO 4.81 4.18 4.78 5.13
MRC 5 Pt 3 3 3 3 2 2
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compared to control. OA treatment resulted in substantial hypoxemia
(PaO2 at FIO2 1.0 decreased from 425 (28) to 68 (6) mmHg) with
decreased respiratory system compliance (69.7 (5.6) %, n=4).
Electron microscopy demonstrated the presence of intra-alveolar fibrin
and haemorrhage, type I alveolar epithelial cell necrosis and destruc-
tion of alveolar architecture. Histological quantification of the above
lung damage parameters revealed a dose dependent increase in
patchy lung damage with treated mice having 34.7 (7) and 48.9
(3.6) % damage compared to 14.9 (2.9) % in control animals,
p=0.05 and 0.005 respectively). Correlation of these physiological,
histological and clinically relevant parameters in the OA mouse
provides a model for further investigation of treatments for ARDS.
S51 REGULATION OF NEUTROPHIL FATE BY HYPOXIA
S.R. Walmsley, A. Cowburn, J. Deighton, K.I. Mecklenburgh, E.R. Chilvers.
Respiratory Medicine Division, Department of Medicine, University of
Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth
Hospitals, Cambridge CB2 2QQ, UK
Introduction: Neutrophil apoptosis represents a major mechanism
involved in the resolution of acute inflammation. In contrast to many
other cell types, we have previously shown that hypoxia (0–3.5 kPa
O2) has the ability to inhibit apoptotic cell death in neutrophils when
aged in vitro. This may be of physiological importance given the sig-
nificant drop in local oxygen tension at sites of inflammation. We
therefore sought to elucidate the oxygen sensing pathways involved in
this regulation of neutrophil apoptosis.
Methods: Human neutrophils were purified from the peripheral
blood of healthy volunteers by dextran sedimentation followed by cen-
trifugation through discontinuous plasma-Percoll gradients. Cells were
cultured in supplemented MDM +/- test reagents in normoxic (19 kPa),
hypoxic (3 kPa) or anoxic (0 kPa) environments. Apoptosis was
assessed by cell morphology and flow cytometry with annexin V and
propidium iodide. Cytokine release was measured by ELISA, and
cytosolic and nuclear protein expression by western blotting.
Results: Oxygen deprivation profoundly inhibited constitutive
apoptosis in human neutrophils from 59% to 29% (p=0.0025). Con-
ditioned medium from oxygen deprived neutrophils also induced cell
survival in normoxia but this was independent of GM-CSF, IL-1β, IL-6
and TNFα. Furthermore, the hypoxic inhibition of neutrophil apoptosis
was unaffected by the PI3 kinase inhibitors LY294002 (10 µM) or
wortmannin (100 nM). The hypoxic survival of neutrophils previously
shown to be mimicked by the iron chelators desferrioxamine and
hydroxypyridone (Mecklenburgh KI et al. Blood 2002; in press) was
replicated with the novel prolyl hydroxylase inhibitor dimethyl
oxaloylglycine at HIF stabilising concentrations (1 mM).
Conclusion: Our results indicate that neutrophils have a
ferro-protein oxygen sensing mechanism involving prolyl hydroxylase
domain (PHD) containing proteins which can regulate the hypoxic
inhibition of neutrophil apoptosis. This survival effect is independent of
the PI3-kinase pathway. Moreover neutrophils cultured under hypoxic
conditions secrete an apparently novel factor that has a profound sur-
vival effect on neutrophils cultured in normoxic conditions.
Research funded by the MRC, and Sackler studentship.
S52 TOLL-LIKE RECEPTOR EXPRESSION IN ACUTE
RESPIRATORY DISTRESS SYNDROME (ARDS): A ROLE
FOR TLR-2?
L. Armstrong, A.R.L. Medford, K.M. Uppington, A.B. Millar. Lung Research
Group, University of Bristol Division of Medicine, UK
ARDS is a condition commonly associated with sepsis. Recently the
toll-like receptor family has been identified on the basis of homology
with the type I IL-1 receptor. 10 members have been described, but
only 3 of them have a known function: TLR-4 is a component of the LPS
receptor and is essential for gram negative responses, TLR-2 is a
receptor for gram positive lipoproteins but may also cross-signal in
response to LPS with TLR-4. TLR-9 recognises CpG bacterial motifs. We
have looked at the expression of TLR-2 and TLR-4 on monocytes from
patients with gram negative (n=20) and gram positive sepsis (n=20),
compared to non-septic ITU controls (n=15). TLR expression was also
determined on alveolar neutrophils and macrophages. We also
looked at the relationship between TLR expression and the
development of ARDS. Monocytes were isolated from whole blood by
density gradient centrifugation and adherence. Total RNA was
isolated after 2 hours in culture and RT-PCR was performed for TLR-2,
TLR-4 and GAPDH transcripts. TLR protein expression was determined
by flow cytometry on whole blood, dual stained with CD14-FITC and
specific TLR-2 and TLR-4 monoclonal antibodies, or on ungated macro-
phages and neutrophils. Expression of both TLR-2 and TLR-4 mRNA (%
GAPDH) was significantly increased in sepsis (126 and 87.5 %
respectively) versus non-sepsis controls (96 and 68% respectively)
(p<0.05). This was reflected at the protein level; TLR-2 expression
(above isotype control) on monocytes was 15.44 versus 0.13 for non-
sepsis controls (p<0.05). TLR-4 expression was 3.77 versus 0.59 non-
sepsis controls. Both TLR mRNAs significantly correlated with TNF-α
mRNA suggesting increased function. In ARDS subjects there was no
significant differences in TLR-4 expression. However, monocytes from
ARDS subjects had significantly lower levels of TLR-2 mRNA (83% of
GAPDH for ARDS subjects vs 126% for non-ARDS subjects, p<0.001).
Similarly TLR-2 mRNA was lower in patients who died (103%) versus
survivors (144%). In the lung, alveolar neutrophils and macrophages
both express high levels of TLR-2 and TLR-4. We hypothesise that
reduced levels of TLR-2 may influence development of ARDS in sepsis
populations by increasing the availability of LPS for TLR-4 receptor
ligation and signalling.
S53 ELEVATION OF THIOREDOXIN CONCENTRATIONS IN
PLASMA AND BRONCHO-ALVEOLAR LAVAGE FLUID
FROM PATIENTS WITH THE ACUTE RESPIRATORY
DISTRESS SYNDROME
M.E.J. Callister1, A. Burke-Gaffney1, G.J. Quinlan1, H. Nakamura2, J.
Yodoi2, T.W. Evans1. 1Unit of Critical Care, National Heart and Lung Insti-
tute, Imperial College Faculty of Medicine, Royal Brompton Hospital, Lon-
don, UK; 2Department of Biological Responses, Institute of Virus Research,
University of Kyoto, Japan
Introduction: The acute respiratory distress syndrome (ARDS) is char-
acterised by refractory hypoxaemia secondary to alveolar derecruit-
ment and disordered ventilation-perfusion matching. Oxidative stress
and inflammation are key features that contribute to the pathogenesis
of ARDS. Thioredoxin (Trx) is an intracellular redox active protein
involved in maintaining cellular redox balance, and is actively
secreted into the extracellular space in response to clinical conditions
associated with oxidative stress and inflammation. Extracellular Trx
may have profound implications for the inflammatory response by vir-
tue of its reported chemokine/cytokine properties. We therefore
measured Trx levels in plasma and broncho-alveolar lavage fluid
(BALF) from 30 patients with ARDS and 18 healthy controls.
Results: Trx levels were significantly elevated in ARDS patients v
controls in plasma (45.9 (27.9) ng/ml v 23.6 (13.4) ng/ml,
p<0.002) and BALF (103.8 (116.0) ng/ml v 17.4 (9.6) ng/ml,
p<0.0001). There were significant positive correlations between Trx
concentration and IL-8 concentrations (p<0.001, r=0.631) and IL-1β
concentrations (p<0.05, r=0.448) in BALF from the ARDS population.
BALF Trx concentrations were higher in patients with ARDS of pulmo-
nary compared to extrapulmonary aetiology (132.3 (129.2) ng/ml v
39.7 (26.9) ng/ml, p<0.01). BALF from patients with pulmonary
ARDS also had significantly higher concentrations of IL-8 (p<0.05)
and a greater percentage neutrophil count (p<0.05) compared to
BALF from patients with extrapulmonary ARDS. Plasma and BALF Trx
levels were not significantly different between surviving and
non-surviving patients and there was no relationship between Trx lev-
els and the sequential organ failure assessment (SOFA) score when all
patients were considered. However, in cases of pulmonary ARDS,
there was a significant association between SOFA score and plasma
Trx levels (p<0.05, r=0.482).
Discussion: These results demonstrate that concentrations of Trx
are increased in BALF and plasma in patients with ARDS. Trx has been
shown to have profound effects on the inflammatory response and the
correlation between levels of Trx and pro-inflammatory cytokines
suggests a link between Trx and the inflammatory response in this con-
dition, although the exact nature of the role of increased extracellular
Trx in ARDS remains to be evaluated.
Research Funded by the Wellcome Trust.
S54 PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR
(VEGF) LEVELS AND THE VEGF +936 C/T
POLYMORPHISM IN ACUTE RESPIRATORY DISTRESS
SYNDROME (ARDS)
A.R.L. Medford1, L.J. Keen2, D.R. Thickett1, K.J. Hunter1, A.B. Millar1. 1Lung
Research Group, University of Bristol Division of Medicine, Southmead
Hospital, Bristol, UK; 2Department of Pathology and Microbiology, Univer-
sity of Bristol, Homeopathic Hospital Site, Bristol, UK
Previous work in our laboratory suggested a role for VEGF in the
pathogenesis of ARDS (Thickett DR et al. Am J Resp Crit Care Med
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2001;164:1601–5). There is considerable interindividual variation in
plasma VEGF levels and the +936 C/T polymorphism (CT or TT geno-
types) is associated with low plasma VEGF levels (Renner W et al.
J Vasc Res 2000;37:443–8). Because of the possible functional role
of VEGF, we hypothesised that the frequency of this polymorphism
would be altered in ARDS. DNA was extracted from healthy subjects
(n=50) as well as ARDS patients (n=45) and ventilated at risk patients
in intensive care (n=38). A 120 base pair fragment of the VEGF gene
containing the polymorphism was amplified and cross-matched with
an internal heteroduplex generator containing a polyA insert adjacent
to the polymorphism. Artificial heteroduplex formation was analysed
on a 15% polyacrylamide gel. ELISA was performed to measure VEGF
levels in matched plasma samples from the ARDS and at risk groups.
The abnormal (CT or TT) genotypes occurred in 31.3% of at risk
patients, 28.9% of ARDS patients and 24% of normal subjects. In
ARDS patients, those with an abnormal genotype had a significantly
higher 30 day mortality than those with a normal genotype. In the at
risk groups, plasma VEGF levels were lower in those with abnormal
genotypes compared to normal genotype (129 pg/ml versus 305
pg/ml) but this was not observed in ARDS (337 pg/ml versus 309
pg/ml). The +936C/T polymorphism occurs more frequently in at risk
and ARDS patients than normal subjects indicating a possible
functional significance in intensive care patients. The normal relation-
ship between plasma VEGF level and genotype appears to be
disrupted in ARDS suggesting additional regulatory mechanisms may
be important in these patients.
Asthma mechanisms I
S55 EXPRESSION OF TRANSFORMING GROWTH FACTOR
ISOFORMS IN HUMAN AIRWAY SMOOTH MUSCLE
AND NORMAL LUNG TISSUE
B. Islam, D. Bradbury, L. Corbett, I. Soomro, J. Ronan, A. Knox. 1Division
of Respiratory Medicine; 2Histopathology, Nottingham City Hospital,
Hucknall Road, Nottingham NG5 1PB, UK
Introduction: transforming growth factor beta (TGF-β) is an
immunomodulatory cytokine regulating the proliferation and differen-
tiation of various cell types. It also contribute to the maintenance of tis-
sue architecture by influencing the production of extracellular matrix
components. In this study we examined the expression of TGF-β
isoforms in human airway smooth muscle cells (HASMC) and normal
lung tissues by rt-PCR, bioassay and immunohistochemical staining.
Methods: HASMC were obtained from post-mortem samples of
human lung and studied at passage 6. Normal lung tissues were
obtained from lung biopsy samples and thoracic surgery. Mink lung
epithelial cells (Mv1Lu) were obtained commercially. Recombinant
TGF-β-1 and neutralising antibodies to TGF-β-1,-2,-3 were obtained
from R&D Systems. TGFβ isoforms mRNA were measured by rt-PCR
using primers designed from the human sequences of TGFβ-1,-2,-3
genes and GAPDH as control. The presence of bioactive TGF-β in
HASM-conditioned medium was determined using a bioassay that is
based on the ability of TGF-β to inhibit proliferation of the Mv1LU cells.
Immunohistochemical localisation of TGF-β-1,-2,-3 in normal lung sec-
tions was assessed using avidin-biotin-peroxidase and antibody to the
TGFβ Bisoforms.
Results: Messenger RNA transcripts for TGF-β-1,-2,-3 were all
expressed in the HASMC. The conditioned medium shows presence of
bioactive TGF-β in the acid treated sample and by using the neutralis-
ing antibodies it demonstrated that all three isoforms are present in the
conditioned medium. Very little TGFβ was present in the non-acid
treated medium, implying that majority of the TGFβ secreted by the
HASMC is in the biologically non-active form. The TGF-β bioactivity
was significantly abrogated by panspecific antibody to TGF-β. Immu-
nohistochemistry showed that all three isoforms of TGFβ were detected
in the epithelial cells, smooth muscle cells, and macrophages.
Conclusion: This study demonstrates the expression of TGF-β
isoforms in the lung, and suggest that autocrine/paracrine release of
TGF-β by HASMC could play an important role in the remodelling of
airway smooth muscle in asthma.
S56 IL-4 EXPRESSION IS INCREASED AND CO-LOCALISED
TO MAST CELLS WITHIN THE AIRWAY SMOOTH
MUSCLE IN ASTHMA
C.E. Brightling, F.A. Symon, S.T. Holgate1, A.J. Wardlaw, I.D. Pavord,
P. Bradding. Division of Respiratory Medicine, Institute for Lung Health,
Leicester, UK; 1University of Southampton, Southampton General Hospital,
UK
Airway smooth muscle infiltration by mast cells is a key feature of
asthma and not eosinophilic bronchitis (Brightling CE, et al. NEJM
2002;346:1699–705). In asthma Th2 cytokines have been impli-
cated as playing a critical role in the development of airway
inflammation, but whether inflammatory cells within the airway smooth
muscle release these cytokines is unknown.
We have undertaken a comparative immunohistochemical study in
bronchial biopsies from 14 subjects with asthma, 10 with eosinophilic
bronchitis and 8 normal controls recruited from two centres.
The median cells/mm2 smooth muscle were significantly higher in
the subjects with asthma than eosinophilic bronchitis and normal con-
trols for IL-4 (3H4)+ cells (2.4, 0, 0 respectively; p=0.001), and IL-4
(4D9)+ cells (1.6, 0, 0 respectively; p=0.02). There were significant
differences in the median (range) cells/mm2 smooth muscle IL-5+ cells
in the subjects with asthma 0 (0–1.7), eosinophilic bronchitis 0
(0–1.4) and normal controls 0 (0–0.3) (p=0.31). 94% of the cells
expressing IL-4 (3H4) and 92% of those expressing IL-4+ (4D9) in the
airway smooth muscle were mast cells. 55% of the mast cells within the
airway smooth muscle co-localised to IL-4 (3H4) and 29% to IL-4
(4D9).
In asthma mast cells localised within the airway smooth muscle
express IL-4 but not IL-5, suggesting that IL-4 may play an important
role in mast cell-airway smooth muscle interactions.
Supported by the National Asthma Campaign.
S57 EFFECTS OF LONG ACTING β AGONISTS AND
STEROIDS ON CYTOKINE EXPRESSION
H. Yanagawao, I.M. Adcock1, A.L. Hewitt2, H. Buck2
1
National Heart and
Lung Institute, Imperial College London, UK; 2Innovata Biomed Ltd, St
Albans, UK
Rationale: In bronchial asthma treatment, combination therapy with
inhaled corticosteroids and long acting β agonists (LAβA) can improve
disease control. Since research suggests that ligand-independent acti-
vation of the glucocorticoid receptor (GR) by LAβA may aid steroid
anti-inflammatory action, the functional consequence of GR nuclear
translocation was examined via the effect of LAβA and steroids on
cytokine production.
Methods: U937 cells were incubated with fluticasone, budeso-
nide, formoterol and salmeterol, alone and in combination
(10-6B10-11M), for 1 hour prior to lipopolysaccharide (LPS) stimulation.
Secreted cytokines (GM-CSF, TNF-α, IL-1ra and IL-10) were quantified
by ELISA.
Results: Addition of formoterol or salmeterol to steroid gave
greater suppression of LPS-induced GM-CSF and TNF-α release com-
pared with that observed with budesonide or fluticasone alone,
although neither LAβA altered the steroid concentration-response
curve. Additionally, both LAβA prevented steroid-induced repression
of IL-1ra release. The actions of the LAβA differed with IL-10, where
formoterol, in combination with fluticasone, enhanced production,
whilst salmeterol did not increase LPS-induced IL-10 production
compared with fluticasone alone.
Conclusions: These data indicate that the added benefit of formot-
erol may relate to the anti-inflammatory gene-inducing action of
steroids rather than in enhancing the repressive functions of steroids
towards inflammatory cytokines.
This study was sponsored by Innovata Biomed Ltd.
S58 LEUKOTRIENE RECEPTORS ON HUMAN EOSINOPHILS
H. Rupani, I. Hao, A.P. Sampson. Respiratory Cell and Molecular Biology
Division University of Southampton School of Medicine
Cysteinyl-leukotrienes are potent bronchoconstrictor mediators and
eosinophilotaxins released by mast cells and eosinophils within the
asthmatic airway. These actions are thought to be mediated by CysLT1
receptors, with vascular effects mediated by CysLT2 receptors. CysLT1
expression on human eosinophils may be regulated by cytokines, but
the effects of asthma therapies including corticosteroids and methylx-
anthines are unknown. Recently, eosinophils were reported to
transcribe larger amounts of mRNA for CysLT2 than for CysLT1 (Mita, et
al. Clin Exp Allergy 2001;31:1714–23). We investigated firstly
whether CysLT1 on eosinophils is modulated by dexamethasone or
theophylline, and secondly whether eosinophils also express CysLT2
receptors on their cell surface. Immunomagnetically-purified human
blood eosinophils of normal and mild atopic volunteers were cultured
in HEPES-buffered RPMI 1640 with 10% FCS for 22 hours in the pres-
ence or absence of dexamethasone (0.01–10µM) or theophylline
(0.01–1mM). Basal expression of CysLT1 mRNA and protein was con-
firmed by RT-PCR, flow cytometry, immunocytochemistry, and immuno-
blotting. Flow cytometric expression of cell-surface CysLT1 declined
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during 22 hours culture from a median fluorescence intensity (MFI) of
4.96 (0.50) to 2.87 (0.23) arbitrary units (p<0.009; n=9). This
decline was not observed in the presence of dexamethasone (1µM),
with an MFI value of 4.01 (0.36) at 22 hours (p=0.044 v untreated).
Theophylline (0.1mM) provided similar protection but this did not
achieve statistical significance (p=0.056). In contrast to CysLT1, no
CysLT2 expression was detectable by flow cytometry on the surface of
live eosinophils, although these cells transcribed mRNA for CysLT2.
Flow cytometry readily detected surface expression of CysLT1 and the
chemokine receptor CCR-3 on eosinophils, while CysLT2 surface
expression was detected on autologous blood monocytes and T-cells.
We conclude firstly that dexamethasone may upregulate eosinophil
expression of CysLT1 receptors, a paradoxical effect also observed for
the LT-synthesising enzymes (Cowburn, et al. J Immunol
1999;163:456–65). Secondly, while CysLT2 mRNA may be
transcribed, the receptor protein does not appear to be expressed on
the surface of blood eosinophils from healthy donors.
S59 CAT-213, AN ANTI-EOTAXIN (CCL11) ANTIBODY,
REVEALS A ROLE FOR EOTAXIN IN THE EOSINOPHIL
CHEMOTACTIC ACTIVITY OF ASTHMATIC SPUTUM
G. Dent1, C. Hadjicharalambous1, J. Ward1, T. Yoshikawa1, G. Angco,
D.E. Davies1, R. Louis2, R.L.C. Handy3, J. Powell3, I.K. Anderson3, R.
Dukanovic´1. 1Respiratory Cell & Molecular Biology, University of
Southampton School of Medicine, Southampton; 2Department of Pneumon-
ology, University of Liège, Liège, Belgium; 3Cambridge Antibody Technol-
ogy, Melbourn, Cambridgeshire, UK
To understand the mechanisms underlying eosinophilic airways
inflammation in asthma, it is necessary to characterise the
chemoattractants mediating eosinophil recruitment. The CC chemok-
ines eotaxin (CCL11), eotaxin-2 (CCL24), RANTES (CCL5) and mono-
cyte chemotactic proteins 2, 3 and 4 (CCL8, CCL7, CCL13) are potent
eosinophil chemoattractants and are believed to play an important
role in eosinophilic inflammation (Kita & Gleich. J Exp Med
1996;183:2421). Of these, eotaxin and eotaxin-2 act exclusively via
the CC chemokine receptor CCR3 upon a restricted set of cells:
namely eosinophils, basophils and Th2 lymphocytes. We have inves-
tigated the role of eotaxin in the eosinophil chemotactic activity of
asthmatic airway secretions using a specific anti-eotaxin antibody,
CAT-213.
Sputum samples were collected from 60 volunteers: 11 healthy con-
trols, 12 mild asthmatics, 12 stable moderate asthmatics, 12 unstable
moderate asthmatics and 13 severe asthmatics. Sputum was
processed by thorough mixing with 4 volumes of phosphate-buffered
saline (PBS) containing protease inhibitors. Cells and mucus were pre-
cipitated by centrifugation and supernatants were assayed for immu-
noreactive eotaxin by ELISA and for eosinophil chemotactic activity in
a fluorescence-based modified Boyden chamber assay.
Sputum eotaxin concentration differed significantly among the sub-
ject groups (p=0.0096, ANOVA); group mean eotaxin concentration
showed a significant linear trend v group number when groups were
sorted by disease severity (P=0.0006), rising from 3.71 (1.07) pmoll-1
(mean (SEM)) in healthy controls to 35.9 (11.4) pmol l-1 in severe asth-
matics. Eosinophil chemotactic activity also differed among groups
(P=0.0073, Kruskal-Wallis) and showed a significant increase over
healthy control in both moderate groups (P<0.05, Dunn=s test) and
the severe asthmatic group (P<0.01). There was a significant linear
correlation between chemotactic index and eotaxin concentration
(P=0.008). CAT-213 (100 nM) caused significant inhibition of sputum
chemotactic activity in the unstable moderate and severe asthmatic
groups (P<0.001, paired ANOVA and Dunnett’s test), with a mean
inhibition of 80 (13) % in the severe asthmatic group.
We conclude that eotaxin contributes significantly to the eosinophil
chemotactic activity of asthmatic sputum. This contribution increases
with disease severity. CAT-213 may provide therapeutic benefit in the
treatment of severe asthma.
S60 DIFFERENTIAL ACTIONS OF PHOSPHATIDYINOSITOL
3-KINASE INHIBITORS ON HUMAN EOSINOPHIL
CHEMOTACTIC RESPONSES TO PLATELET-ACTIVATING
FACTOR AND EOTAXIN (CCL11)
R. Mishra, B.C. Gray, R. Djukanovic´, G. Dent. Respiratory Cell & Molecu-
lar Biology, University of Southampton School of Medicine, Southampton,
UK
The signal transduction pathways that lead to chemotaxis of human
eosinophils are incompletely understood but are believed to involve
protein tyrosine kinase(s) and MAP kinase(s) but not protein kinase C
(Schweizer et al. J Leukoc Biol 1996;59:347; Kampen et al. Blood
2000;95:1911). As MAP kinase activation by eotaxin in human eosi-
nophils has been shown to occur downstream of phosphatidylinositol
3-kinase (PI-3K) activation (Miike et al. J Leukoc Biol 2000;67:117),
we investigated a possible role for PI-3K in the induction of eosinophil
chemotaxis using the inhibitors wortmannin and LY294002 in human
eosinophils stimulated with platelet-activating factor (PAF) or eotaxin
(CCL11).
Eosinophils were isolated from the blood of atopic, non-asthmatic
donors and chemotaxis was evaluated in a fluorescence-based
96-well blind-chamber assay. Calcein-labelled eosinophils (2H105)
were pre-incubated for 30 min at 37EC in the absence and presence
of wortmannin (0.1–100 nM) or LY294002 (0.1–100 µM) and
placed in the upper wells of the chemotaxis chamber. Migration
through 8-µm pore-size PVP-coated polycarbonate filters in response to
PAF or eotaxin (both at 30 nM in the lower wells) was measured after
1 h as cell-associated fluorescence (λem=485 nm, λex=530 nm) in the
lower wells.
PAF and eotaxin caused chemotaxis of eosinophils (geometric
mean 19,140 (14,060–26,060) and 27,010 (15,310–47,640) cells
well-1, respectively, above the background level of migration; n=12).
Wortmannin caused concentration-dependent inhibition of PAF-
induced eosinophil chemotaxis (IC50=1.24 nM (0.092–16.6 nM);
n=6), with significant inhibition observed at 1 nM (P<0.0001), while
responses to eotaxin were inhibited substantially less potently
(IC50=17.6 nM (1.06–292 nM); n=6), with significant inhibition
observed only at 100 nM (P<0.05). LY294002 also inhibited
PAF-induced chemotaxis (IC50=0.76 µM (0.026–22.1 µM); n=6) but
had no effect on responses to eotaxin (<50% inhibition at 100 µM;
n=6).
We conclude that, although PAF and eotaxin both induce MAP
kinase activation and chemotaxis in human eosinophils, PAF-induced
chemotaxis is dependent upon the activation of PI-3K while the
response to eotaxin involves PI-3K to a much lesser extent. This may
indicate alternative pathways of activation of MAP kinases and
chemotactic responses.
Ongoing management issues
in cystic fibrosis
S61 STENOTROPHOMONAS MALTOPHILIA ACQUISITION
IN CYSTIC FIBROSIS; A COMPLICATION OF
ASPERGILLUS FUMIGATUS?
A. Equi, V. Marchac, C. Le Bihan-Benjamin, M. Hodson, A. Bush. Depart-
ment of Respiratory Paediatrics and Department of Cystic Fibrosis Royal
Brompton Hospital, London, UK; Service de Pneumologie et D’Allergologie
et Bio-statistique et Informatique Medicale, Hopital Necker- Enfants
Malades, Paris, France
Stenotrophomonas maltophilia (SM) is a Gram negative bacillus
which is resistant to many antibiotics. Its role as a pulmonary
pathogen in CF is still being defined.
Methods: The aim of this study was to use a case control design to
describe the characteristics of CF patients isolating SM in sputum, to
assess risk factor for acquisition of SM and to assess clinical outcomes.
Data were collected on patients and controls between 1991 and
1999. A control patient had never isolated SM in sputum and was
matched for age, sex and FEV1 (±10%). The following data were col-
lected: FEV1, FVC; height and weight; sputum culture and antibiotic
sensitivity; antibiotic use; oral steroid use.
Results: 63 patients isolated SM at least once. Controls were found
for 52 patients. Prevalence of SM rose from 3.3 to 15% by 1999. Iso-
lation of Aspergillus fumigatus (AF) was much more frequent in SM
patients than controls, 51% v 8.9% (p=0.001, OR 5.9 (95% CI 2.0–
17.8). The effect of AF was independent of steroid use. Post acquisi-
tion there was no difference between the two groups in mortality,
antibiotic use, lung function or nutritional status. Antibiotic treatment
had no impact on future isolation of SM.
Conclusions: This is the first documentation of an association of
SM with AF isolation. We also can reassure patients that SM acquisi-
tion is unlikely to cause accelerated decline in clinical status.
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S62 GENOTYPING PSEUDOMONAS AERUGINOSA IN CYSTIC
FIBROSIS CLINICS: IMPLICATIONS FOR SEGREGATION
F.P. Edenborough, H.R. Stone, S.J. Kelly, P. Zadik1, J.R.W. Govan2. Adult
Cystic Fibrosis Unit and 1Public Health Laboratory, Northern General Hos-
pital, Sheffield, UK; 2Department of Medical Microbiology, University of
Edinburgh, UK
We were concerned that the antiobiograms from patients harbouring
Pseudomonas aeruginosa appeared to show increasing resistance,
despite segregation policies initiated early in 1999. Genomic finger
printing was performed on P aeruginosa isolates from 40 patients
attending the clinic.
Twenty three (57%) had unique strains, 10 (25%) had strains indis-
tinguishable from the “Liverpool” epidemic strain and 7 (17%) shared
a common strain not previously seen, henceforth referred to as the
“Sheffield” epidemic strain. 4/10 patients with the Liverpool strain
had multiresistant (MR) organisms, compared to all 7 patients with
Sheffield strain and only 1 patient (4%) out of the 23 with a unique
strain. One patient harboured both Sheffield and Liverpool MR strains.
Those with the Sheffield MR strain were younger with poorer FEV1
and weight together with a higher proportion of ˆF/ˆF genotype, pan-
creatic insufficiency, diabetes mellitus and liver disease vs unique
strains. Consequently numbers of clinic visits, days in hospital and
time on intravenous antibiotics were increased. Comparison of
Liverpool MR with Liverpool non-MR showed a similar pattern.
9/10 with Liverpool strains had been transferred from the paediat-
ric unit since July 2000. MR strains being detected on the sputum sam-
ple taken when or in some cases before the patient first attended the
CF Unit. Four of 7 Sheffield MR patients had also been transferred but
all have been inpatients in the adult centre at the same time as subjects
who were found to have Sheffield MR strains already (including 1 sib-
ling pair). We suspect we have “imported” the Liverpool strain, which
is known to become multiresistant from the paediatric unit, but the
Sheffield strain is our own and is transmissible. If MR confers poor
prognosis we believe these groups should be segregated from each
other and those with unique strains, both as inpatients and in the out-
patient clinic and have acted accordingly.
S63 RE-AUDIT OF THE SCREENING PROTOCOL FOR CYSTIC
FIBROSIS RELATED DIABETES (CFRD) IN AN ADULT
CENTRE
A. Verma, A. Claridge, T. Havelock, J. Biesty, D. McMenna, A.K. Webb.
Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital,
Manchester M23 9LT, UK
Introduction: The average age of onset of CFRD is 18–21 years and
is associated with a 6-fold increase in mortality and associated
co-morbidity.1 Yung et al described annual oral glucose tolerance test-
ing (OGTT) as being time and resource consuming for patients and
staff.2 An earlier audit at our centre, using these selective screening
criteria for OGT testing found that, the identified incidence of 1.9%
was significantly less than the expected (4–6%) and concluded that
only 52% of patients with CFRD would have been identified.3 Hence
all patients were offered routine annual OGT testing.
Aims: To assess whether all patients received annual OGTT
between 3.00–3.01. To assess the true incidence of CFRD at the Cen-
tre. To identify the CFRD patients who would have been “missed” if the
old screening protocol were still in place. To calculate the sensitivity
and specificity of the selection criteria in our population
Method: A retrospective review of case notes using the OGTT and
HbA1c databases. 242 patients were identified but 91 patients
excluded due to pre-existing CFRD at 01/03/2000 (n= 52), referred
after 01/03/00 (n=13), care transferred to other centre (n=18), post-
transplant (n=7), not CF (n=1).
Results: 89 OGTT were performed on 151 patients. The incidence
was found to be 4.4% and the prevalence 26.9%. Using the previous
selective screening protocol, 6 patients with CFRD and 10 patients
with impaired glucose tolerance would have been missed. The total
sensitivity and specificity of the screening criteria would only have
been 70% and 51% respectively.
Conclusions: In view of the need for early diagnosis and treatment
of CFRD, annual OGT testing is essential for all CF centres especially
for adult patients. Selective screening does not identify all patients
who need to be tested.
1. Moran et al. Diabetes Res Clin Pract 1999;45:61–73.
2. Yung et al. J R Soc Med 1999;92:35–40.
3. Verma et al. J of CF 2001;PS138.
S64 LUNG TRANSPLANTATION OUTCOME IN CYSTIC
FIBROSIS PATIENTS WITH PREVIOUS PLEURAL
PROCEDURES
H.J. Curtis, S.J. Bourke, P.A. Corris, J.H. Dark. Cardiothoracic Centre,
Freeman Hospital, University of Newcastle upon Tyne, UK
Background: High post-operative mortality secondary to haemor-
rhage from pleural adhesions as a consequence of previous invasive
pleural procedures (IPP) was reported in the early experience of lung
transplantation. This observation led to IPP becoming a relative/
absolute contra-indication to transplantation in some centres.
Aim: Comparison of post-operative outcome in patients with and
without previous IPP, undergoing single sequential lung transplant
(SSLT).
Method: Retrospective review of 3 groups of patients undergoing
SSLT at this centre from 1989–2002. Group A: 17 cystic fibrosis (CF)
patients with a history of previous pneumothorax (PTX) +/- IPP. Group
B: 17 CF patients with no history of PTX. Group C: 17
non-CF/non-bronchiectatic (emphysema, fibrosing alveolitis or oblit-
erative bronchiolitis) patients with no history of PTX. Patients were
matched for year of transplantation to allow for changes in surgical
technique. Measured outcomes included: pre- and post-operative
haemoglobin; blood products given intra-operatively; operation and
cardiopulmonary bypass times; post-op haemorrhage; times to
extubation, ITU discharge and hospital discharge; FEV1 at 6 months;
30 day mortality; and adhesions scored descriptively via pathology
reports.
Conclusion: Patients with CF and previous PTX +/- IPP undergoing
SSLT have more dense pleural adhesions and increased requirement
for blood transfusion. However this does not significantly affect surgi-
cal outcome. Patients with emphysema, fibrosing alveolitis or oblitera-
tive bronchiolitis were significantly more likely to be free of pleural
adhesions at operation B suggesting that the inflammatory/chronic
infective component of CF independently contributes to the increased
pleural adhesions. Previous IPP for PTX should not be considered a
contra-indication in the assessment of suitability for lung transplanta-
tion.
Abstract S64
Results: n=17 in all groups
Group A Group B Group C
p Value A v
B, & Cmean SD mean SD mean SD
Packed red cells (units) 5.8 4.9 3.6 1.7 4.5 3.3 p<0.05
Platelets (pools) 0.9 1.2 0.6 0.9 0.3 0.5 NS
Fresh frozen plasma (units) 2.7 2.5 1.9 2 1.6 1.5 NS
number number number
Re-exploration for bleed 2 0 1 NS
30 day mortality 0 0 0 NS
Dense adhesions 8 0 0 p<0.01
No adhesions 1 7 13 p<0.01
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S65 PULMONARY ARTERY PRESSURE AND RIGHT
VENTRICULAR FUNCTION IN CYSTIC FIBROSIS ADULTS
R.J. Bright-Thomas1, M.I. Burgess2, M.E. Dodd1, S.G. Ray2 , A.K. Webb1.
1Adult Cystic Fibrosis Centre; 2Department of Cardiology, Wythenshawe
Hospital, Manchester, UK
Introduction: Pulmonary hypertension has been reported as a poor
prognostic marker in adult CF patients with severe disease. We
evaluated the association between clinical status, oxygen status,
pulmonary artery pressure and right ventricular (RV) function in a
cross-section of CF adults.
Methods: CF adults and healthy volunteers were studied.
Demographic and clinical data collected. Patients were stable at the
time of study. All subjects underwent echocardiographic examination
by a trained operator (RBT). Pulmonary artery systolic pressure (sPAP)
was measured from the peak velocity of tricuspid regurgitant jets.
Systolic function of the RV assessed via measurement of RV dimensions
and tricuspid long axis motion (TLAM) and diastolic function via meas-
urements of transtricuspid flow profile.
Results: 65 CF adults age, mean (SD), 26.1(7.1) years and 25
healthy controls age 27.7 (8.8) years were studied. Partial pressure of
oxygen (PO2)(mmHg) 68.8 (12.2) v 90.1 (9.7) (p<0.001) and FEV1
percentage predicted (FEV1%) 47.0 (21.7) v 98.1 (9.8) (p=<0.001)
respectively. sPAP(mmHg) was 35.8 (9.7) in CF patients and
21.6(3.2) in controls (p<0.001). 36 patients and 0 controls had
sPAP>30mmHg. There was no significant difference in RV dimensions
between groups. TLAM(cm) was reduced in CF patients compared to
controls 2.1 (0.4) v 2.5 (0.3) (p<0.001). There was a significant dif-
ference in the diastolic variables A wave velocity and E/A ratio
between patients and controls; values (CF v control): Avel(cm/sec) 45
(13) v 29 (6) (p<0.001), E/A ratio 1.4 (0.5) v 1.8 (0.3) (p<0.001).
Pearson correlation of CF patient data identified significant
correlations between both PO2 and FEV1% with sPAP (r=-0.516,
p<0.001; r=−0.432, p=0.001) and TLAM (r=0.459, p<0.001;
r=0.620, p<0.001) respectively. An association was also found
between diastolic variables and PO2 and FEV1%: Avel (r=−0.311,
p=0.012; r=−0.420, p=0.001), E/A ratio (r=0.302, p=0.015;
r=0.412, p=0.001) respectively.
Conclusion: Pulmonary artery pressure is raised in adult CF
patients. RV dimensions are normal in CF but there is evidence of
deranged RV systolic and diastolic function. Both PO2 and FEV1% cor-
relate with sPAP and measures of RV function. Whether the abnormal
RV function is due to the effect of hypoxia on the RV or due to pulmo-
nary hypertension is unclear.
S66 INCREASED ENERGY COSTS DURING UPPER AND
LOWER LIMB ACTIVITIES IN ADULTS WITH CYSTIC
FIBROSIS
A.A. Jonescu, T.D. Mickleborough1, K. Chatham, M. Lindley1, R.
Colasanti2, I.S. Nixon, C.E. Bolton, D.J. Shale. 1Section of Respiratory
Medicine, School of Sports Science, University of Wales Institute Cardiff
and School of Applied Sciences; 2University of Glamorgan, University of
Wales College of Medicine, Cardiff, UK
Patients with Cystic Fibrosis (CF) have increased resting energy
expenditure, which may be associated with altered body composition.
We hypothesised that adults with CF have increased energy costs dur-
ing skeletal muscle work. Twelve patients were studied after 2 weeks
treatment for an exacerbation (to assess them with their best lung func-
tion); mean (95%CI) age 24.6 (21.4, 27.8) years, FEV1 51.3 (36.3,
66.2) % predicted, body mass index 21.5 (20.8, 22.2) kg/m2. Fat
free mass index (FFMI, kg/m2) was assessed by anthropometrics. Ten
healthy subjects were studied, age 32.1 (27.9, 36.1) years. Energy
expenditure (EE, kJoule (kJ)/kg/min) was calculated from breath by
breath O2 uptake and CO2 output measured with a mask (K4b, Cos-
med). Subjects completed the following: 10 handgrips (HG, force in
cm H2O), 1/second; 10 steps (20 cm high), 1/second, and 10 lifts of
a 1 kg weight through 80 cm height, 1every 2 seconds. EE ratio to the
work performed and the recovery time after each activity were calcu-
lated.
EE ratio to the work performed during HG and stepping, but not
during lifting were greater in patients (table). The recovery time was
greater for patients than healthy subjects for HG (46.4 (29.9 to 62.9)
and 21.6 (10.9 to 32.3) seconds, p=0.02) and stepping (70.7 (47.2
to 94.2) and 28.9 (16.6 to 41.2), p=0.002), but not lifting (35.9
(26.7 to 45.1) and 28.6 (17.7 to 39.4), p=0.3). FFMI was inversely
related to EE during HG, (r=−0.75, p=0.005).
Adults with CF have greater energy expenditure for upper and
lower limb muscle work. This excess energy expended for tasks simi-
lar to those of daily living suggests physical activity in such patients
adds to the potential for negative energy balance and weight loss.
Supported by the Cystic Fibrosis Trust UK.
Issues in paediatric lung
disease
S67 EFFECT OF β-2 ADRENOCEPTOR (β2-AR)
POLYMORPHISMS ON NEONATAL LUNG FUNCTION
AND ASTHMA IN SCHOOL CHILDREN
N.M. Wilson1, J.C.W. Mak2, J. Lamprill, H. Bilolikar, J.R. Clarke, A. Bush,
M. Silverman3. 1Department of Paediatrics and 2Respiratory Medicine,
Royal Brompton Hospital, Imperial School of Medicine, London, UK;
3Department of Child Health, University of Leicester, Leicester, UK
An association between neonatal bronchial responsiveness (BR) and
lung function at 11 yr, related to β-2AR gene influence, has been
reported (Turner, et al. ERJ 2001;18(suppl 33);2S). Polymorphisms of
β2-AR at amino-acid (aa) 27 and aa16 have also been shown to be
related to bronchial BR and childhood asthma. To assess the effect of
these polymorphisms on the development of wheeze, lung function
and BR, we genotyped from blood or buccal cells 41 children at risk
of atopy, in whom maximal flows at FRC (VmaxFRC) and BR had been
measured in the first month of life using the “squeeze” technique. They
were followed prospectively and reviewed at age 10 yr (SD 0.8),
when lung function (FEV1) and BR were repeated. We also genotyped
166 local school children from buccal cells
Neonatal BR correlated significantly with FEV1 (p=0.03) but not BR
at 10 yr. VmaxFRC varied according to aa27 genotype (ANOVA
p=0.023); it was significantly increased in those homozygous for
glutamate at aa27 (p=0.01), but had no effect on history of wheeze.
No effect of aa16 was found on lung function or BR at either age, but
homozygous glycine at aa16 was seen more frequently in those
wheezing beyond 4 years, when compared to local school children
(Fischer’s exact test p=0.05).
We have shown for the first time an effect of β2-AR polymorphism
at aa27 on neonatal lung function, and confirmed the association of
β2-AR polymorphism at aa16 with childhood asthma, as wheeze
beyond 4 years was strongly related to atopy and increased BR at
10 yr.
S68 PNEUMOCOCCAL SEROTYPES IN CHILDREN WITH
CULTURE NEGATIVE EMPYEMA
K.M. Eastham1, R. Freeman2, A. Kearns2, G. Eltringham2, J.P. Leeming3,
J. Clark4, D.A. Spencer1 . 1Freeman Hospital, Newcastle Upon Tyne,
2Newcastle Public Health Laboratory , 3Bristol Public Health Laboratory,
4Newcastle General Hospital, Newcastle Upon Tyne, UK
Background: Streptococcus pneumoniae serotype 1 accounts for up
to 50% of pneumococcus culture positive childhood empyema in the
USA.1 This organism has been a relatively uncommon cause of
invasive pneumococcal disease in the under 5 age group in England
and Wales.2
Aim: To describe the pneumococcal serotype distribution and peni-
cillin susceptibility of consecutive cases of parapneumonic effusion
and empyema presenting to a Tertiary Referral Centre over a 4.5 year
period.
Method: 43 pleural fluid specimens, negative for pneumococcus
on routine culture, were analysed for pneumococccal DNA by
real-time polymerase chain reaction (PCR). Penicillin susceptibility was
determined by a complementary PCR assay. Capsular serotype
specific antigen detection was by Enzyme Immuno-Assay (EIA) using
monoclonal antibodies to types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F, and 23F.
Abstract S66 Energy expenditure (kJ/kg/min) for kJ
work performed (means, 95% CI)
Stepping Lifting Handgrip (×10)
Patients 0.55
(0.45 to 0.65)**
3.27
(2.61 to 3.92)
0.13
(0.11 to 0.17)*
Healthy 0.37 (0.31 to 0.44) 2.99
(1.94 to 4.04)
0.09
(0.07 to 0.11)
*p<0.05; **p<0.01
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Results: The median age was 5.6 years (0.6–16.9 years). All
pneumococcal DNA positive specimens were penicillin sensitive.
Conclusions: Pneumococcus is the major pathogen in childhood
empyema, accounting for 75% of culture negative cases. Capsular
antigen detection indicates that 63% of are serotype 1, paralleling
culture-based studies.1 These data have implications for vaccine devel-
opment strategy, as the new 7-valent pneumococcal vaccine does not
protect against serotype 1. Penicillin resistance does not appear to be
a problem in our population.
1. Byington CL, et al. CID 2002;34:434–40.
2. George AC, Melegaro A. CDR Weekly 2001;11:21.
S69 RESPIRATORY DISEASE IN CHRONIC
GRANULOMATOUS DISEASE
L. Jones1, T.J. Flood2, P. McGrogan1, L. Morton3, L. Parker1, D. Goldblatt3,
A. Thrasher3, A.J. Cant2.1Department of Child Health, University of
Newcastle; 2Department of Paediatric Immunology, Newcastle General
Hospital; 3Institute of Child Health, Great Ormond Street Hospital, Univer-
sity College London, UK
Chronic Granulomatous Disease (CGD) is a rare primary immuno-
deficiency due to defective phagocytic cell oxidative burst, rendering
patients susceptible to severe recurrent bacterial and fungal infections.
Recurrent respiratory infection is a common presenting feature.
Objectives: To describe the common pathogens causing pneumo-
nia in these patients in the UK and review their lung function.
Methods: The first national survey of CGD patients was started in
2000 and aimed to characterise the epidemiological and clinical fea-
tures of CGD.
Results: Of 82 patients analysed to date, aged 0–60 years, 39
(48%) have suffered from pneumonia and 7 (9%) from lung abscesses.
85 episodes of probable pneumonia were recorded with x ray
changes documented in 65 (77%) of these. Organisms were isolated
in 37 cases (44%). However Staphylococcus aureus and Burkholde-
ria, respiratory pathogens previously reported in other series,1 only
accounted for 5 cases. Aspergillus was isolated in 10 and suspected
in a further 12 cases. Of the 11 documented cases of lung abscess,
Staphylococcus species and Aspergillus species were isolated in 4
cases, however Streptococcus milleri was also isolated from 2
patients. 4 patients suffered from their first episode of pneumonia
before the age of 1 year, a further 5 before the age of 5 years and a
further 14 before the age of 15. Lung function is documented in 15
patients who had pneumonia (39%) and in an additional 7 patients.
Of the 16 patients for whom heights are available, 3 demonstrated a
restrictive pattern, 3 an obstructive pattern and 10 had normal lung
function.
Conclusion: Pneumonia is the most common infection encountered
in patients with CGD across all age groups and is typically caused by
Staphylococcus aureus, Burkholderia cepacia, and Aspergillus
species. Surprisingly Burkholderia accounted for only 2 cases in this
series. Monitoring lung function is essential in CGD and further
prospective studies to delineate the extent of occult pulmonary morbid-
ity are indicated.
1.Winkelstein JA, et al. Medicine 2000,79:155–69.
S70 EXERCISE LIMITATION IN CF AND NON-CF
BRONCHIECTASIS
I. Narang, E. Edwards, A. Li, D. Hansell, M. Rosenthal, A. Bush. Depart-
ment of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney
Street, London SW3 6NP, UK
Non-CF bronchiectasis (Bx) is an orphan disease; little is known about
exercise physiology.
Aims: (1) To compare factors limiting exercise in CF and non-CF Bx
compared to normals; (2) To establish whether chest CT is a useful
indicator of functional capacity in either disease.
Methods: Clinical assessment, spirometry, chest CT and incremen-
tal exercise test using cycle ergometry and respiratory mass spectrom-
eter were performed at a time of disease stability. We measured
effective pulmonary blood flow (Qeff), oxygen consumption (VO2),
effective stroke volume (SV), alveolar ventilation (VA), transfer factor
(DLCO), and functional residual capacity (FRC). Heart rate (HR) and
oxygen saturations (SaO2) were measured by continuous pulse oxime-
try. The CT scans were scored using a modification of the Bhalla sys-
tem.
Results: We compared 18 children with CF (7 males; median age
13 years (range 10.7–17) median FEV1 76% predicted (range
40–95%), and 17 children with non-CF Bx (7 males; median age 13
years (range 10.6–17.1) median FEV1 74% predicted (range
47–90%). Data are expressed as mean z scores derived from normal
values at rest and at maximum exercise (MEX) in 106 normal children:
Conclusions: In both groups Qeff was abnormally low at rest and
did not increase normally during exercise in spite of an increased
heart rate, due to SV limitation during exercise. A low Qeff with a high
VA and a low FRC is evidence of significant mismatching during exer-
cise. There was no correlation between CT and any exercise param-
eter in either group. Since the haemodynamic and functional
impairment is similar in non CF BX as in CF. More attention should be
paid to this neglected disease.
S71 RESPIRATORY SYMPTOMS IN CHILDREN WITH
DOWN’S SYNDROME
N. John1, K. Williams2, I.J.M. Doull1. 1Cystic Fibrosis/Respiratory Unit,
Department of Child Health, University Hospital of Wales, Cardiff, UK;
2University of Leeds, UK
Background: Children with Down’s syndrome (DS) are at increased
risk of hospitalisation due to respiratory disorders. Although anecdo-
tally they report frequent respiratory symptoms, objective evidence is
lacking.
Aims: To compare parental reported respiratory symptoms of chil-
dren with DS with normal controls.
Methods: Questionnaire survey of all children with DS under 12
years of age in the Bro Tâf Health Authority. Families completed ques-
tionnaires for any unaffected sibling(s) as controls. The questionnaire
was based on the ISAAC core questions, with additional sections on
upper airway and cardiac disease.
Results: Questionnaires were received on 65 children with DS (38
male) and 35 controls (24 male). There was no significant difference
in mean age between the 2 groups: DS mean (SD) 6.5 (2.8) years
(range 1.4–11.1); controls 5.6 (2.9) years (range 0.3–10.8).
Children with DS had significantly greater ever wheeze (OR 10.1;
95% CI 3.8–26.6); wheeze in the preceding 12 months (OR 10.2;
95% CI 3.5–29.9); wheeze during exercise (OR 4.2; 95% CI
1.1–15.6); use of anti asthma medication (OR 3.5; 95% CI 1.3–9.6),
but were no more likely to be labelled asthmatic. Children with DS had
significantly greater chest congestion or phlegm with (OR4.1; 95% CI
1.7–10.0) or without (OR 18.3; 95% CI 2.3–143) a cold, were
receiving nasal medications (OR 8.3; 95% CI 2.6–26) but were no
more likely to be labelled rhinitic. Twenty-one DS and 1 control
reported a cardiac condition. After excluding these cases, most rela-
tionships with wheeze, chest congestion, and coughing up phlegm
with or without a cold persisted.
Conclusions: Children with DS have significantly greater
respiratory symptoms than normal—wheeze, chest congestion, and
coughing up phlegm with or without a cold. The aetiology of
symptoms is unclear, but do not appear related to cardiac conditions.
Abstract S68
Pneumococcal DNA
+ve (32)
Pneumococcal DNA
−ve (11)
Serotype 1 17 0
Serotype 3 3 0
Serotype 14 4 1
Negative 3 7
Insufficient 5 3
Abstract S70
Parameter CF rest CF MEX Bx rest Bx MEX
Qeff −0.11 −1.08* −0.1 −0.95*
SV −0.6* −1.0* −0.71* −0.94
HR 1.1* 0.85* 0.9* 1.29*
VA 0.15 1.33* 0.08 1.0*
DLCO −0.11 −0.82* 0.64 −0.32
FRC 0.4 −1.11* 1.12* −0.6
*Statistically significant (p<0.05) compared to normal.
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S72 ESTIMATES OF PLETHYSMOGRAPHIC FRC EXCEED
THOSE BY GAS DILUTION IN INFANTS WITH CYSTIC
FIBROSIS (CF) BUT NOT IN HEALTHY CONTROLS
H. Ljungberg2, G Hulskamp2, A.-F. Hoo2, J. Pillow2, S. Lum2, P. Gustafsson2,
J. Stocks1. 1Portex Respiratory Unit, Institute of Child Health, London, UK;
2Queen Silvia Children’s Hospital, Göteborg, Sweden
Involvement of the peripheral airways is an early feature of CF lung
disease and may result in pathological gas trapping. This is reflected
by the difference between plethysmographic and gas dilution
estimates of functional residual capacity (FRC) in older children and
adults.
Aim: To compare paired measures of FRC using plethysmography
(FRCp) and multiple breath inert gas washout (FRCmbw) in infants with
recently diagnosed CF and healthy control infants.
Methods: 21 infants with CF, median age (range) 36 (10–83)w,
and 20 healthy control (HC) infants 42 (5–91)w were studied during
quiet sleep. FRCmbw was measured using a respiratory mass
spectro-meter with SF6 as the tracer gas, and determined from
the cumulative volume of expired gas divided by the difference
between end-tidal gas concentration at start and at the end of the
washout. FRCp was measured immediately afterwards according to
ERS/ATS guidelines (ERJ 2001;17:302–12) using commercially avail-
able equipment (Jaeger MasterScreen BabyBodyplethysmograph).
Results: The mean within-subject coefficient of variation for FRCmbw
and FRCp was 3.0% and 2.9% respectively.
Summary: In healthy infants, there was no difference in FRC as
measured by plethysmography and inert gas washout, and there was
no difference in FRCmbw when comparing HC and CF. In infants with
CF, however, the FRCp was significantly elevated not only compared
to HC (p=0.001), but also compared to FRCmbw in the CF group itself
(p=0.01).
These findings may be explained by pathological gas trapping.
Paired measurements of FRC using these two techniques may provide
a sensitive and useful method for early detection of pulmonary
changes in CF.
Henrik Ljungberg is supported by an ERS Long Term Research Fel-
lowship.
Mechanisms of cough
S73 RELATIONSHIP BETWEEN CAPSAICIN COUGH
SENSITIVITY AND QUALITY OF LIFE IN PATIENTS WITH
CHRONIC COUGH
S.S. Birring, B. Prudon, I.D. Pavord. Institute for Lung Health, Respiratory
Medicine, Glenfield Hospital, Leicester, UK
Most patients with a chronic cough have a heightened cough reflex.
Little is known about how this relates to patients perception of cough
severity or the degree to which the cough impacts on quality of life.
We have assessed the relationship between capsaicin cough sensitiv-
ity, cough visual analogue score and quality of life in 26 patients with
chronic cough presenting to our outpatient clinic. All patients had (1)
capsaicin cough reflex sensitivity measured using a dosimeter with the
results expressed as the concentration of capsaicin (ìmol/L) causing 2
(C2) and 5 (C5) coughs, (2) cough visual analogue score (VAS;
0–100mm), (3) cough specific quality of life measurement using the
Leicester Cough Questionnaire (LCQ). The LCQ is a 19-item
self-administered health related quality of life questionnaire for
patients with chronic cough that has 3 domains (physical, psychologi-
cal and social; domain score range 1–7, total score 3–21; higher
score indicated better quality of life) and a 7-point Likert response
scale. We have previously shown that the LCQ is a fully validated,
reliable, repeatable and responsive instrument that is brief and easy to
administer. The patients were 62% female, mean (SEM) age 57 (3)
years and had a mean (SEM) cough duration of 69 (23) months. The
mean (SEM) cough VAS score was 53 (6) mm; logC2: 0.57 (0.08);
logC5 1.41 (0.18) µmol/L; physical domain score: 4.7 (0.3); psycho-
logical domain score: 4.8 (0.3); social domain score: 4.8 (0.3); LCQ
total score: 14.4 (0.8). There was no correlation between logC2 and
logC5 and the LCQ total score (r=0.19 and 0.23 respectively), the
individual LCQ domain scores or the cough VAS score (r = −0.32 and
B0.34 respectively). In conclusion, we found no relationship between
quality of life or symptom scores and capsaicin cough reflex sensitivity
in patients with chronic cough. Our results suggest factors other than a
heightened cough reflex are important in how a patient perceives the
severity of their cough, or how it impacts on their quality of life. These
measures assess different aspects of cough and therefore may provide
complimentary information.
Supported by the British Lung Foundation and University Hospitals
of Leicester NHS Trust.
S74 REPEATABILTY OF CAPSAICIN COUGH REFLEX
SENSITIVITY MEASUREMENT
B. Prudon, S.S. Birring, D.D. Vara, I.D. Pavord. Institute for Lung Health,
Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK
Although widely used in clinical practice and research, little is known
about the validity and repeatability of capsaicin cough sensitivity in
healthy adults and patients with chronic cough. We measured capsai-
cin cough reflex sensitivity in 134 healthy subjects and 85 patients
with an isolated chronic cough using a KoKo Digidoser with an
inspiratory flow regulator valve (0.5L/s). Two-week repeatability was
assessed in 15 healthy subjects and 15 patients with chronic cough.
Healthy subjects (mean age 42 years (range 20–78), female 62%)
had a wide variation of capsaicin cough sensitivity (mean log capsai-
cin concentration that causes 2 coughs C2 (SD) 1.2 (0.8) and 5
coughs (C5) 2.7 (1.8) µmol/L). There was no correlation between age
and logC2 (r=−0.1) or logC5 (r=−0.1). Females had significantly
raised capsaicin cough sensitivity compared to males (logC2: 1.0 v
1.4; mean difference 0.4; 95% confidence interval 0.1 to 0.8;
p=0.01 and logC5: 2.3 v 3.3; mean difference 1.0; 95% CI 0.2 to
1.8 µmol/L; p=0.01). Patients with chronic cough were significantly
more sensitive than healthy subjects (mean age 59 (range 27–83),
female 64%; logC2: 0.5 v 1.2; mean difference 0.7; 95% CI 0.5 to
0.9; p<0.001 and log C5: 1.3 v 2.7; mean difference 1.4; 95% CI
0.9 to 1.8; p<0.001). The capsaicin cough reflex sensitivity measure-
ment was repeatable over 2 weeks in both healthy subjects (mean of
difference (within subject SD): logC2 −0.2 (0.2), logC5 −0.4 (0.5)
µmol/L; intraclass correlation coefficients 0.9 and 0.9 respectively),
and patients with chronic cough (mean of difference (within subject
SD): logC2 B0.1 (0.2), logC5 B0.3 (0.5); intraclass correlation coef-
ficients 0.6 and 0.7 respectively). We have shown a wide variation of
capsaicin cough reflex sensitivity in health which potentially limits the
use of this method as a discriminatory test. We have also
demonstrated an effect of gender but not age on capsaicin cough
reflex sensitivity measurement highlighting the importance of matching
subjects when making comparisons using this test. Capsaicin cough
reflex sensitivity measurement is a repeatable test over 2 weeks (C2
more than C5) in both healthy subjects and patients with chronic dry
cough. These data would be useful for powering clinical studies of
antitussive drugs.
Supported by BLF and PPP Healthcare Trust.
S75 UPPER AIRWAY SENSITIVITY IN SUBJECTS WITH A
CHRONIC NON-PRODUCTIVE COUGH
B. Prudon1, S.S. Birring1, A.P. Hall2, J.P. Thompson2, I.D. Pavord1. 1Institute
for Lung Health, Respiratory Medicine, Glenfield Hospital, Leicester, UK;
2Department of Anaesthesia, Leicester Royal Infirmary, Leicester, UK
Subjects suffering from a chronic non-productive cough usually have a
heightened cough reflex compared to healthy subjects. Whether this
phenomenon is confined to the cough reflex, or whether other upper
airway reflexes are also abnormal is unknown. We measured the sen-
sitivity of the “Glottic-stop reflex” (a reflex closure of the vocal cords in
response to inhaled irritants), and the capsaicin cough reflex sensitiv-
ity in 16 healthy subjects and 14 subjects with a chronic cough (cough
subjects were predominantly female (81%) and the causes of cough
were idiopathic chronic cough (11), cough variant asthma (1), rhinitis
(1) and rhinitis and gastro-oesophageal reflux (1). Glottic stop sensitiv-
ity was measured using a previously validated non-invasive technique1
in which subjects inhaled single breaths of increasing concentrations
of ammonia and adduction of the vocal cords was detected using a
S72 Table of results
HC (n=20) CF (n=21) 95% CI: CF-HC
FRCmbw mean (SD) 19.4 (3.5) 20.3 (4.4) −1.6;3.5
FRCp mean (SD) 19.2 (3.1) 25.4 (7.4) 2.6;9.8
95% CI: FRCp-FRCmbw −0.8;0.4 2.3;7.9
All values expressed as mL/kg body weight.
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pneumotachograph. Cough sensitivity was measured at the same time
of day on a different occasion greater than 1 week apart with a
single-breath dosimeter method, using capsaicin as the tussive agent
and results expressed as the log of concentration (µmol/L) required to
cause 2 coughs (C2). Cough subjects had a significantly more sensi-
tive glottic stop reflex and capsaicin cough reflex sensitivity compared
to age and sex matched healthy subjects (mean glottic reflex sensitiv-
ity threshold: 483 v 1029 ppm; mean difference 546ppm, (95% Con-
fidence Interval 137 to 954], p=0.01; logC2: 0.3 v 1.1; mean
difference 0.7, (95% CI 0.4 to 1.1), p<0.001). Glottic stop reflex sen-
sitivity correlated significantly with cough reflex sensitivity (r=0.5,
p=0.006). These results suggest that the cough reflex and the glottic
stop reflex share a common pathway, or that subjects who have a
chronic cough have a global abnormality of upper airway reflexes.
Further investigation of possible common mechanisms sensitising these
two reflexes may lead to a greater understanding of chronic cough,
and lead to new targets for antitussive medications.
1. Langton JA, et al. Br J Anaesth 1993;70:126–30.
S76 ASSOCIATION BETWEEN COUGH AND REFLUX
EVENTS IN PATIENTS WITH CHRONIC COUGH WITH
AND WITHOUT GASTRO-OESOPHAGEAL REFLUX
J.A. Kasterlik, I.P.A. McGarvey, S.A. Mulrennan, B. Johnston, J.C. Ojoo1,
A.E. Redington1, A.H. Morice1. 1Academic Department of Medicine,
University of Hull, Castle Hill Hospital, Cottingham, UK; 2Department of
Medicine, Queen’s University Belfast, UK
Background: Gastro-oesophageal reflux (GOR) is a common cause
of chronic cough, but the mechanisms of GOR related cough are not
fully understood.
Aim: To determine the association between cough and reflux
events in patients with chronic cough due to GOR and due to causes
other than GOR.
Methods: 60 patients with undiagnosed chronic cough aged mean
(IQR) 55 (49–62) yr with cough duration 8 (1.5–10) yr underwent
24-h pH monitoring during which cough and reflux events were
recorded. GOR related cough was diagnosed when pH<4 was
recorded for >4% of total time and when cough improved with subse-
quent antireflux therapy. A reflux event was defined as a drop of
pH<4 for >12 sec. Cough was considered associated with reflux
when it occurred within 5 min from reflux.
Results: 29 patients had GOR related cough. The other 31 patients
had normal 24-pH monitoring, and cough was either due to asthma or
rhinosinusitis or was idiopathic. The total number of coughs did not
differ significantly (p=0.85) between patients with GOR (9 (5–17)/24
hr) and without GOR (8 (6–16)/24hr). Patients with GOR related
cough had 20 (10–31)% of coughs associated with reflux, compared
with 0(0–7)% in patients without GOR (p<0.001). In patients with
GOR related cough, 7 (1–10)% of total reflux events occurred within
5 minutes before cough, compared with 1 (0–2)% in patients without
GOR (p<0.001). In patients with GOR related cough 6 (4–6)% of
reflux events occurred within 5 min after cough, compared with 3
(0–2)% in patients without GOR (p=0.002).
Conclusions: In GOR related chronic cough, reflux and cough
events are frequently associated. In patients with other causes of
chronic cough, in contrast, this association is infrequent.
S77 SMOKING, SALBUTAMOL, AND THE COUGH REFLEX
S.A. Mulrennan1, J.C. Ojoo1, J.A. Kastelik1, C. Wright1, R.H. Thompson1,
A.E. Redington1, P. Goustas2, A.H. Morice1. 1Academic Department of
Medicine, University of Hull, Castle Hill Hospital, Cottingham, UK; 2Glaxo-
SmithKline, Stockley Park West, Uxbridge, Middlesex, UK
Background: Smokers have an increased prevalence of chronic
cough. Patients frequently complain of exacerbation of cough when
attempting smoking cessation.
Hypothesis: Do cigarettes affect cough in smokers and does
salbutamol have antitussive properties in smoking related cough?
Methods: A randomised double blinded crossover study to
determine the efficacy of 400 µg salbutamol via MDI plus spacer ver-
sus placebo on cough before and after the first cigarette of the day in
healthy adult smokers. Medication was given at time 0 minutes.
Number of coughs were recorded from 0–10 and 10–20 min using a
voice activated analogue tape recorder. Coughs following a cigarette
at 20 minutes were observed at 20–40 and 40–60 min. Citric acid
cough challenge was performed at 60 minutes after medication.
Results: 44 healthy smoking subjects (13 females), mean age 34
(range 20–61) were recruited. Cigarettes significantly reduced cough
in those on placebo. Mean cough frequency per minute 20 minutes
pre cigarette was 0.3 compared to 0.2 post cigarette (p=0.02).
Cough frequency did not reduce significantly pre and post cigarette in
those taking salbutamol. Mean 0.23 versus 0.19 respectively
(p=0.116). The citric acid concentration causing two coughs (C2) at
60 minutes increased on salbutamol. Geometric mean 278.8
compared to 190.4 mM on placebo (p=0.03).
Conclusions: Cough is reduced by the morning cigarette and this
corroborates smokers observations of increased cough on smoking
cessation and the “beneficial” effect of smoking on that symptom. The
absence of a significant difference in cough before and after smoking
a cigarette and the increase in C2 suggests that β agonists may be
useful in cough associated with cigarette abstinence. The effect of
salbutamol is however small and other more potent and longer acting
agents may prove more effective.
Funded by GlaxoSmithKline.
S78 CHOCOLATE, CHILLI PEPPER, AND COUGH
O.S. Usmani, H.J. Patel, M.G. Belvisi, P.J. Barnes. Department of Thoracic
Medicine, National Heart and Lung Institute, Imperial College School of
Medicine, London, UK
Cough is the most common respiratory symptom for which medical
attention is sought. It may become debilitating and socially distressing,
and a recent meta-analysis showed that most OTC remedies were
ineffective against cough. Opiods are often used, but have unpredict-
able efficacy and side-effects. There is great need for effective thera-
pies. Capsaicin, derived from chilli peppers, is a well-established,
reproducible, tussive stimulant widely used in clinical research to test
the efficacy of new cough treatments. We describe theobromine, a
methylxanthine derivative present in cocoa and chocolate, as an
effective anti-tussive agent able to elevate the capsaicin induced
cough threshold in healthy volunteers.
Ten healthy non-smoking subjects participated in a randomised
double blind cross-over study. The anti-tussive effect of a single-dose of
theobromine (1000mg) was compared to codeine phosphate (60mg)
and placebo. The main outcome measure was the capsaicin concen-
tration required to induce five coughs (C5). Subjects had their screen-
ing C5 value established, and at each treatment visit their C5
threshold was determined 2 hours post-dosing. The mean C5 values
between treatments were compared using two-way ANOVA.
Theobromine was markedly able to increase the cough threshold
when compared to codeine phosphate (p=0.07) and placebo
(p<0.01). There was no significant difference between codeine and
placebo (p=0.25). The C5 variability was similar between the
placebo and screening values, supporting the reproducibility of the
capsaicin challenge in this subject group. No adverse effects, particu-
larly CVS or CNS, were observed.
Although the anti-tussive mechanisms remain unknown, preliminary
data have shown direct inhibition of sensory nerve depolarisation in
isolated guinea-pig vagus. Theobromine has been shown to possess
anti-angiogenic properties through its action on adenosine (A2)
receptors, and it also has weak phosphodiesterase inhibiting activity.
It may act on the capsaicin vanilloid receptor (VR1). Elucidation of the
molecular targets using in vitro and animal models, will help develop-
ment of novel therapeutic entities.
In conclusion, the data suggest a significant anti-tussive effect of
theobromine in healthy subjects when compared to placebo. Further
studies are needed in select patient categories to see whether these
phase I effects are borne out.
Issues in non-invasive
ventilation
S79 A SURVEY OF HOME MECHANICAL VENTILATION IN
THE UK
S.J. Lloyd-Owen1, M.W. Elliott2, A.K. Simonds3, J.A. Wedzicha1. European
Union Concerted Action on Home Respiratory Ventilation, 1St Bartholom-
ew’s Hospital, London; 2St James’s University Hospital, Leeds; 3Royal
Brompton Hospital, London
As part of a European-wide Project, a survey of custom and practice
in Home Mechanical Ventilation (HMV) was carried out in the UK. 80
known and possible HMV centres were targeted with initial requests,
of which 65 responded. 13 of these did not have any HMV users. Full
surveys were received from 47 centres (at least 70% response rate). 7
of these were paediatric centres. The answers reflected the situation on
the 1st July 2001. A total of 2842 HMV users were identified in the
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UK by the 47 centres. The median size of the units was 18 users (IQR
6.5 to 46.5), with 7 centres having more than 100 users. 96% of the
users had their HMV initiated at that centre with 13% having some
form of shared care between units. 27 centres described themselves as
University hospitals (57%) with 18 non-University hospitals (38%) and
1 Outpatient facility (no data for 1 centre). 26 of the centres took
referrals, either regional only (18) or regional and national (8). The
median year of each centre starting HMV was 1992 (IQR 1987 to
1996). The users’ characteristics were: 55% male, 45% female; ages:
16 years or less: 7%, 17 to 25 years: 7%, 26 to 65 years: 59%, 66
years or more: 27%. 21% had been on HMV for less than 1 year,
52% for 1 to 5 years, 23% for 6 to 10 years and 4% for more than
10 years. The conditions requiring ventilation were categorised into 3
groups with lung and airways diseases (LA) in 26%, thoracic cage
(TC) problems in 35% and 39% neuromuscular (NM). Pressure preset
positive pressure ventilators (PP) were used most often (92% overall)
with relatively more volume preset ones (VP) in the TC and NM groups
(LA: 95% PP, 5% VP; TC: 91% PP, 9% VP; NM: 89% PP, 11% VP).
Nasal (N) and facial (F) masks were predominant in all groups with
tracheostomy (T) used more frequently in the NM group (LA: 77% N,
22% F, 1% T; TC: 86% N, 13% F, 1% T; NM: 65% N, 18% F, 17%
T). 24 hour ventilation was also commoner in the NM group (12%
compared to 1% for LA and TC). Concomitant oxygen use was more
frequent in the LA group (LA: 61%; TC: 16%; NM: 8%). Indications for
ventilation and tracheostomy use and investigations were consistent
across centres, but there was variability in the provision of follow up,
training and homecare.
Funded by the European Commission.
S80 RESPIRATORY FAILURE: EARLY NON-INVASIVE
VENTILATION (NIV) USE IN A DISTRICT GENERAL
R. Rabanni, W. Heberlein, J. Wilson, R. Hayton1, M. Al-Jibry, H. Moudgil.
Departments of Respiratory Medicine and 1Clinical Audit, Princess Royal
Hospital NHS Trust, Telford, UK
Severe respiratory acidosis ([H+] >55 mmol, pH<7.26) predicts
mortality in exacerbation of chronic obstructive pulmonary disease
(COPD). Non-invasive ventilation (NIV) is an effective alternative to
intubation and mechanical ventilation and is justified in milder respira-
tory acidosis (pH 7.35 to 7.26) associated with exacerbation of
COPD. To assess our use in the first year since introduction (to Decem-
ber 2001) we have retrospectively audited our management of
patients with hospital discharge codes for COPD or respiratory failure.
Where results from arterial blood gas (ABG) samples were available
(n=239, 46%), 60 had type 2 respiratory failure complicated by aci-
dosis. Of the others, 74 had type 1 respiratory failure, 48 had com-
pensated type 2 respiratory failure, 10 had metabolic acidosis, 2 had
hyperventilation, and 45 had no respiratory failure. Of those with res-
piratory acidosis (n=60), 15 were excluded from NIV; reasons
included post-arrest, respiratory depression with drugs, pneumotho-
rax, brainstem stroke, and immediate self-correction of acidosis. Of
the remaining 45, 24 had a review by the anesthetists (ITU) who fur-
ther excluded four as inappropriate, offered NIV to 17 patients and
intubation with mechanical ventilation to three. Of those initiated on
NIV, 11 satisfied criteria for mild acidosis with six others more
acidotic (range 7.0 to 7.24). Of the 17 offered NIV, 10 had success-
ful correction of acidosis with mean duration of assisted therapy over
3.3 days (range 1 to 9 days); one subsequently required re-ventilation
and one died. Of the seven who failed a trial of NIV, length of time on
NIV was at a mean of 0.7 days (range 0 to 2 days); three had been
intubated within two hours and three died. Of the original group with
respiratory acidosis (n=45) but not given additional ventilatory
support (n=25), no ITU input was requested for 21 and only one set of
ABGs had been requested on 15 (with 14/15 patients within the mild
category for acidosis); five in this group had contraindications to NIV,
and in total five died. We find that (1) not all patients are being
assessed by formal ABGs, (2) not all patients satisfying the criteria for
NIV were being offered that provision, and (3) there has been
inappropriate use of NIV in some patients with more severe acidosis
who possibly should have been intubated as a first measure.
S81 TITRATION OF NON-INVASIVE VENTILATION IN COPD
J.M. Tuggey, M.W. Elliott. St James’s University Hospital, Leeds, UK
Introduction: The settings used in establishing a patient on NIV are
often somewhat arbitrary, often defined by patient comfort and
improvement in arterial blood gas settings. There is contention that
higher levels of IPAP simply result in greater leak with no improvement
in minute ventilation. The aim of this study was to identify the relation-
ship between set pressure, delivered minute ventilation (MVe) and
mask interface leak.
Method: We measured the effects of varying IPAP levels in 9
patients (mean age 60, mean FVC 1.7 l) with COPD already using
NIV at home. Using a pneumotachometer connected adjacent to the
nasal mask, measurements of delivered tidal volume (Vti), expired
tidal volume (Vte) and respiratory rate (fR) were made once Vte was
stable for each pressure setting. Minute leak (Min leak) was measured
as the difference between inspiratory and expiratory tidal volume mul-
tiplied fR. Recordings were repeated at least three times for each com-
bination of settings.
Results: MVe is expressed as percentage of spontaneous
ventilation. Leak varies considerably from patient to patient depending
on mask fit. To allow for this, leak is expressed as change from that
measured at 15cmH2O in each subject. The data from 9 subjects is
presented in the figure.
Conclusion: Whilst minute ventilation increases linearly with set
pressure, minute leak increases exponentially, particularly above
20cmH2O. Some patients will benefit from increased minute
ventilation at higher pressures, but may suffer intolerable leak.
JT is funded by NHS Northern & Yorkshire Executive.
S82 FACTORS WHICH MIGHT INFLUENCE MEDIUM TERM
PROGNOSIS IN SUBJECTS WITH ACUTE VENTILATORY
FAILURE TREATED WITH NON-INVASIVE VENTILATION
S. Nadeem, P. George, M. Healy, M.J. Doherty. Dudley Group Of Hospi-
tals, Dudley, West Midlands, UK
Subjects treated with NIV for acute ventilatory failure have been
shown to have a reasonable medium term prognosis. We examined if
any easily attainable data help to suggest a good medium term prog-
nosis. Survival data were obtained on a group of 47 consecutive
patients treated with NIV (Mean age 72 (7) years, 24 males, 38 main
diagnosis COPD, mean pre NIV arterial blood gases pH 7.23 (0.09),
PaO2 8.2 (2.4), PaCO2 11.8 (2.5), bic 35 (8). This was collected 2 to
3 years after the initial illness by review of the case notes and contact
with the relevant GP. Data on severity of ventilatory failure, stable %
predicted FEV1, reported exercise tolerance, diagnosis, etc were com-
pared between those still alive and those dead at two time points, 2–3
years post treatment and one year post treatment, using Wilcox an
and χ2. Survival at one year was 60%. There was no difference
between survivors and non-survivors in terms of age 71 (8) v 73 (7)
p=0.3, sex (53 v 54% males), mean % predicted FEV1 45 (21) v 35
(16) p=0.08 or severity of initial ventilatory failure pH 7.24 (0.1) v
7.23 (0.08) p=0.22 or by diagnosis (33 of those still alive v 66% of
dead subjects did not have COPD as the cause of their ventilatory fail-
ure, p=0.08). The only factor which significantly varied between the
two groups was reported exercise tolerance 150 (230) v 54 (79)
metres, p=0.016. At the end of a mean follow up of 26 months 45%
of subjects were still alive. There was no difference between those who
survived and those that did not in terms of sex or initial blood gases
pH (p=0.22), PaCO2 (p=0.14), bic (p=0.5). However the difference
almost reached significance in terms of age 70(6.7) v 73.5 (7) p =
0.057 and % predicted FEV 1 45 (17) v 39 (7) p=0.058. There were
significant differences in terms of reported exercise tolerance 180
(255) v 57 (84) metres, p=0.022 and diagnosis, all patients who did
not have COPD being dead at the end of follow up compared to 45%
of patients with COPD being dead. In summary in the medium term
survival in this group was related to the subjects usual chronic state
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rather than the severity of ventilatory failure at presentation. Reported
exercise tolerance was the only factor which varied between survivors
and non survivors at both time points.
S83 PREDICTORS OF BENEFIT FROM, AND COMPLIANCE
WITH, NON-INVASIVE VENTILATION IN MOTOR
NEURONE DISEASE
S.C. Bourke, G.J. Gibson. University Of Newcastle, UK
Background: In motor neurone disease (MND), there is considerable
variation in the reported tolerance of, and benefit from, non-invasive
ventilation (NIV).
Methods: NIV was initiated in 11 subjects with MND and orthop-
noea due to respiratory muscle weakness. Maximum inspiratory pres-
sure (PImax), PaCO2, bulbar score (amyotrophic lateral sclerosis
functional rating scale), limb and axial muscle score and quality of life
(QoL; SF-36) were assessed at baseline. Subsequently, the SF-36 was
completed every two months until death in all subjects. Relations
between 1) survival, and 2) the duration the SF-36 mental component
summary (SF-36 MCS) was maintained above baseline, and each of:
NIV compliance, age, gender, PImax, PaCO2, bulbar score, and limb
and axial muscle score were evaluated by univariate and multivariate
analysis. Relations between compliance and subject characteristics at
initiation of NIV were also assessed. Variables were included in the
multivariate analysis only if they showed a relation with the dependent
variable on univariate analysis (p<0.1).
Results: Duration of survival correlated with NIV compliance
(r=0.70 p=0.016) only. In univariate analysis, duration of QoL benefit
(SF-36 MCS) correlated with NIV compliance (r=0.86, p<0.001) and
age (r= −0.61, p=0.048), however in multivariate analysis, NIV com-
pliance was the only independent predictor of QoL benefit. In univari-
ate analysis, NIV compliance correlated with age (r = −0.62 p =
0.042) and upper limb muscle score (r=0.67 p<0.05), and showed a
trend towards correlation with ALSFRS bulbar score (r=0.58 p=0.06)
and PImax (r= −0.56 p=0.07). In multivariate analysis the only inde-
pendent predictors of compliance were age and upper limb muscle
score (adjusted r2 = 0.76).
Conclusions: In MND subjects with symptomatic respiratory com-
promise, NIV compliance was the sole independent predictor of
survival and duration of QoL benefit. Younger patients with relatively
preserved upper limb function (more likely to be able to fit and remove
their mask independently), were more likely to comply with, and ben-
efit from, NIV.
S84 AN AUDIT OF NON-INVASIVE VENTILATION
DELIVERED BY A CRITICAL CARE OUTREACH TEAM IN
A DISTRICT GENERAL HOSPITAL
C.D. Shee, M. Green, H. Hackwood, A. Cook. Queen Mary’s Sidcup NHS
Trust, Sidcup, Kent DA14 6LT, UK
In March the British Thoracic Society published guidelines on
non-invasive ventilation (NIV) in acute respiratory failure (Thorax
2002;57:192–211) and recommended regular audit. We have
audited NIV used in medical patients in our hospital in the three
months prior to publication of the guidelines. We have excluded
patients where NIV was started on the intensive care unit (ICU) or on
surgical wards. The NIV service is available 24 hours per day and is
supervised by a critical care outreach team led by a nurse consultant
who is supported by five clinical nurse specialists, ICU senior house
officers and the senior respiratory physiotherapist. Patients at risk are
notified to the team by the accident and emergency department (A&E),
ward nurses, doctors or physiotherapists.
In the three months, 35 patients (18 male) received NIV. The mean
age was 72 years (range 18–86) with 13 (37%) over 80 years. Geri-
atricians looked after 17 patients (49%), chest physicians 7, and other
physicians 11. Only 14 patients (40%) were treated for an exacerba-
tion of COPD (mean arterial pH 7.25; mean PaCO2 11.2 kPa). The
other groups were: pulmonary oedema, n=10 (pH 7.22, PaCO2 9.0);
neuromuscular, n=4 (pH 7.34, PaCO2 6.2); bronchopneumonia, n=7
(pH 7.26, PaCO2 6.3). NIV was started on admission in 17 patients,
and in 18 on a mean of nine days post-admission. NIV was started in
A&E in five patients and on general wards in 30 patients. Most
patients were documented as not for intubation/ventilation (n=26;
74%), of whom 12 (46%) survived. Seven of nine patients (78%) for
full active resuscitation survived. The overall survival figures for COPD
were 8/14 (57%); for pulmonary oedema 7/10 (70%); for
neuromuscular problems 3/4 (75%), but for bronchopneumonia
(including three patients with lymphoma) only 1/7 (14%).
Although NIV was probably life-saving in some patients, in many it
could be considered a “palliative” intervention to help symptoms. Pro-
vision of a comprehensive hospital-wide NIV service is feasible when
run by a critical care outreach team. However, patients referred to
such a team are likely to be older and frailer and with a wider range
of diagnoses, and less likely to be for intubation/resuscitation than the
usual patients treated by a respiratory-led NIV team.
Neutrophil and epithelial cell
biology
S85 EFFECT OF NEUTROPHIL PRIMING AND ACTIVATION
ON 18F-DEOXYGLUCOSE (18FDG) UPTAKE IN VITRO
J.F. White, J.R. Ballinger, K.C. Cadwallader, H.A. Jones, A.M. Peters, E.R.
Chilvers. Departments of Medicine and Nuclear Medicine, University of
Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth
Hospitals, Cambridge CB2 2QQ, UK
Priming describes up-regulation of the neutrophils response to a secre-
togogue agonist following prior exposure to a priming agent. 18FDG is
used in PET to identify areas of infection and inflammation. This study
addresses the mechanisms underlying 18FDG accumulation in vitro in
human neutrophils and monocytes. Time courses of 18FDG accumula-
tion for both reversible priming agent platelet activation factor (PAF)
and priming/activating agents GM-CSF and fMLP were undertaken.
18FDG uptake by neutrophils and monocytes was compared.
Methods: Isolated human neutrophils and monocytes were
resuspended in PBS with calcium and magnesium and incubated with
0.1 MBq 18FDG and 200U/ml TNF-α, 100 ng/ml GM-CSF, 100 nM
fMLP and 1 nM PAF. Reactions were terminated by addition of
iodoacetic acid and cold PBS. Differential counts in the cell pellet and
supernatant were compared.
Results: Neutrophils took up more 18FDG than monocytes. In
neutrophils incubated for 35 mins 18FDG accumulation increased from
20.2 (3.7) % (mean (SEM)) in control conditions to 49.3 (3.1) % when
primed with TNF-α (p<0.05) and 48.2 (4.9) % when fully activated
with TNF-α followed by fMLP (p<0.05). Uptake by monocytes
increased from 2.8 (1.0) % at basal conditions to 13.5 (4.3) % when
fully activated. 18FDG uptake in cells treated with either GM-CSF or
fMLP peaked at 60 mins with accumulations of 60.6 (1.9) % and 59.9
(3.5) % respectively. Neutrophils incubated with PAF showed faster
initial uptake of 18FDG although the final uptake was less at only 13.3
(2.7) %.
Conclusions: Our data correlate well with in vivo autoradiography
studies where neutrophils rather than monocytes take up 18FDG at sites
of inflammation/infection (Jones et al. Am J Respir Crit Care Med
1994;149:1635–9). Time courses of 18FDG uptake mirror previously
documented shape change responses and priming of the oxidative
burst. Priming, in isolation from superoxide anion release or degranu-
lation, requires glucose uptake. Furthermore agents vary in the rate
and amount of 18FDG accumulation in line with their demonstrated
priming efficacy.
S86 DIMINISHED NEUTROPHIL RESPONSES IN MICE
LACKING THE REGULATORY SUBUNIT OF
PHOSPHOINOSITIDE 3-HYDROXYKINASE γ (PI3Kγ)
A.M. Condliffe1,2, G.J. Ferguson1,2, E.R. Chilvers2, P.T. Hawkins1, L.R.
Stephens1. 1Babraham Institute, Babraham, Cambridge CB2 4AT, UK;
2Department of Medicine, Addenbrookes’ Hospital, Cambridge
CB2 2QQ, UK
Protection from infection is conferred by the coordinated and
regulated response of the non-specific and specific arms of the
immune response. Excessive or dysregulated immune responses may
cause tissue injury. Neutrophils, recruited rapidly and in large
numbers to inflammatory foci, have been implicated in the pathogen-
esis of a number of diseases, including the acute respiratory distress
syndrome (ARDS) and bronchiectasis. Neutrophil-mediated tissue
injury is produced by release of reactive oxygen species e.g. superox-
ide (O2-) and histotoxic enzymes (e.g. elastase), both processes requir-
ing the enzyme phosphoinositide 3-hydroxykinase (PI3K). The isoform
PI3Kγ, activated by G-protein linked agonists such as activated
complement (C5a) and bacterial formylated peptides (fMLP), is
thought to mediate aspects of neutrophil activation, with a possible
role for its unique regulatory subunit, p101.
To clarify these issues, we have engineered mice lacking p101
(p101-/- mice). These mice are healthy and fertile, with normal expres-
sion of the p110γ catalytic subunit of PI3Kγ. Analysis of
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β-galactosidase (introduced by the targeting process) confirmed that
p101 is expressed predominantly by cells of the myeloid lineage.
Bone marrow-derived neutrophils displayed reduced formation of
phosphatidylinositol 3,4,5-trisphosphate (the second messenger prod-
uct of PI3K) when stimulated by C5a (36±3% and 52±6% of wild type
values for 5 and 100 nM C5a respectively, n=3 at 10 seconds). Acti-
vation of protein kinase B was also substantially reduced (27±5% and
23±8% of wild type values for 5 and 100 nM C5a, n=4 at 5 minutes),
but activation of mitogen-activated protein kinase and c-jun N-terminal
kinase were unaffected. p101-/- neutrophils exhibited reduced chemo-
taxis towards several G-protein coupled agonists, but equivalent
formation of reactive oxygen species compared to wild type controls.
Baseline rates of apoptosis were unaffected, but C5a, which did not
affect apoptosis in wild-type bone marrow-derived neutrophils, was
pro-apoptotic when applied to p101-/- cells. We conclude that p101
enhances the catalytic activity of PI3Kγ in vivo, and that this reaction is
important in fundamental neutrophil responses.
S87 THE EFFECT OF SALBUTAMOL ON NEUTROPHIL
ADHESION MOLECULE EXPRESSION
G.D. Perkins1, W. Rea2, F. Gao1 , D.R. Thickett2. 1Birmingham Heartlands
Hospital, Birmingham B9 5SS, UK; 2Queen Elizabeth Hospital, Birming-
ham B15 2TH, UK
Background: Neutrophil activation and recruitment to the alveolar
space are important steps in the development of the Acute Respiratory
Distress Syndrome (ARDS). Neutrophil emigration from the pulmonary
circulation has been shown to occur by CD11/18 dependent and
independent pathways. Furthermore blockade of the CD11/18 path-
way can reduce lung injury and improve survival in animal models of
ARDS. β-Agonists have already been proposed as a potential therapy
for ARDS through their ability to accelerate alveolar fluid clearance.
These drugs also affect a variety of neutrophil functions including
chemotaxis. The aim of this study was to investigate the effects of in
vitro incubation of whole blood with physiological doses of salbutamol
on neutrophil adhesion molecule expression.
Methods: Whole blood from 10 healthy volunteers was incubated
with RPMI or salbutamol (10-5M or 10-9M) at room temperature for 15
minutes. Unstimulated or FMLP (10-6M) stimulated samples were then
stained with CD 11b, CD18, CD 62(L) or Mab 24 (an activation
dependent epitope of LFA-1). Samples were analysed by flow
cytometry and data collected as median flouresence intensity and
analysed using Wilcoxon signed rank test.
Results: See table.
Conclusions: The effects of β-agonists on neutrophil chemotaxis
and adhesion may be unrelated to changes in the adhesion molecule
expression (CD 11b, CD18, Mab 24). L-selectin expression. which
falls with neutrophil activation, was significantly reduced by
salbutamol only at the higher end of the physiological dose range,
suggesting that these agents may have some role in reducing neutro-
phil activation.
S88 CO-LOCALISATION OF MMP-9 WITH NEUTROPHILS IN
STABLE LUNG TRANSPLANT RECIPIENTS—A
POTENTIAL ROLE IN BRONCHIOLITIS OBLITERANS
I.A. Forrest1, C. Ward1, G. Pritchard1, A.D. Rowan2, T.E. Cawston2, P.A.
Corris1. 1 Lung Biology and Transplantation Group; 2 Department of Rheu-
matology, University of Newcastle-upon-Tyne and The Freeman Hospital,
Newcastle-upon-Tyne NE7 7DN, UK
Background: Chronic rejection of lung allografts is manifest by
Bronchiolitis Obliterans Syndrome (BOS), occurring in up to 50% of
lung transplant recipients by 2 years. This is an inflammatory/fibrotic
process resulting in collagen deposition, luminal obliteration of
airways and resultant fall in lung function. Increased airway
neutrophilia is recognised as a predictive feature of those at risk of
BOS. Matrix Metalloproteinases (MMPs) and their inhibitors (TIMPs)
tightly regulate the turnover of the extracellular matrix. There has been
recent interest in the role of MMPs in airway diseases characterised by
remodelling, such as asthma. The MMP/TIMP system may offer novel
therapeutic targets.
Hypothesis: MMPs are effector mechanisms in the remodelling of
the airway associated with BOS and other airway diseases.
Methods: Stable lung transplant recipients (n=27), more than three
months post transplant and without evidence of acute rejection, infec-
tion or BOS underwent standardised bronchoalveolar lavage (BAL
3×60mls) and large airway endobronchial biopsy.
Results: BAL showed a significant neutrophilia (4%±0.8) com-
pared to normal controls (n=34) (1.6%±0.2) (Mean±SEM, p<0.005)
Immunohistochemistry (Mouse anti-human MMP-9) of endobronchial
biopsies demonstrated apparent cellular localisation of MMP9 to neu-
trophils. Migrating neutrophils were demonstrable within bronchial
epithelium as well as the sub basement membrane area. Gelatin
zymography performed on lavage supernatant confirmed the
presence of significant activity at 92kDa with lesser activity at 72 kDA,
suggesting pro-MMP-9 to be the predominant gelatinase. In addition
a 125kDa mw band was apparent, likely relating to a complex of
MMP9 and Neutrophil Gelatinase Associated Lipocalin.
Conclusions: Neutrophils are present in significant numbers in
apparently stable lung transplant recipients and are the primary
source of MMP-9. The local balance of MMPs/TIMPs in the pericellu-
lar space is likely integral to airway remodelling. An ongoing
prospective longitudinal study relating architectural changes of the air-
way and clinical outcomes will help clarify the role of MMPs in BOS.
S89 DETERMINANTS OF CYTOTOXICITY OF RESIDUAL OIL
FLY ASH (ROFA) ON BRONCHIAL EPITHELIAL CELLS
P.A.B. Wark, S.M. Puddicombe, A.J. Frew, S.T. Holgate, D.E. Davies.
Brooke Laboratories, School of Medicine, University of Southampton, UK
Rationale: Epidemiologic studies have demonstrated associations
between particulate air pollution and increased asthma symptoms.
Epithelial damage is a pathological feature of asthma and is
associated with pro-inflammatory responses. Residual oil fly ash
(ROFA) is an emission particle with in vitro toxicity to epithelial cells.1
We hypothesised that less confluent epithelial cell cultures would be
more prone to injury by ROFA.
Methods: 16 HBE bronchial epithelial cells were cultured and
treated for up to 48 hours with concentrations of ROFA 10 and
100µg/mL at 80% confluence or at 60% culture confluence. Cells
were exposed in the absence or presence of TNF-α 10ng/ml. Cells
were photographed using phase contrast microscopy, cultures were
then fixed and the supernatant removed. Cell biomass was measured
using a methylene blue assay, cell necrosis by lactate dehydrogenase
(LDH) activity and interleukin (IL)-8 release by ELISA.
Results: Cells treated with either dose of ROFA showed a
significant increase in IL-8 secretion by 8 hours, peaking at 24 hours.
Cells at 80% confluence treated with high dose ROFA showed a 40%
reduction in cell number as compared with controls (p=0.03), while
those treated at 60% confluence had a 70% reduction compared to
controls (p=0.004). An increase in LDH activity was seen at both 80%
and 60% confluence by 24 hours. In contrast confluent cells treated
with low dose ROFA showed reduced LDH activity even at 48 hours
while those also treated with TNF had an increase in cell biomass of
16% above controls (p=0.03). This effect was not seen in cells treated
with ROFA 10µ/ml at 60% confluence.
Conclusion: Exposure of 16 HBE cells to ROFA leads to an early
dose dependent inflammatory response with IL-8 release and dose
and time dependent cell necrosis which is more pronounced in less
confluent cell cultures, suggesting damage to cells is cumulative and
related to pre-existing cell numbers. The addition of TNF to confluent
cells exposed to low dose ROFA appears to be partially protective to
the cytotoxic effects of ROFA and appears to be associated with cell
proliferation.
NHMRC (Australia) and British Medical Association.
1. Jiang, et al. Toxical Appl Pharmacol 2000;163:221–30.
Abstract S87
Median
(IQR) Unstim FMLP
FMLP/Salb
(10−9 M)
FMLP/Salb
(10−5 M)
CD 11b 25 (14–31) 42 (27–72)* 42 (30–81)* 45 (28–75)*
CD 18 36 (23–47) 57 (42–70)* 48 (31–69)* 50 (45–71)*
CD 62(L) 49 (22–57) 16 (4–26)* 14 (4–31)* 26 (6–37)†
MAb 24 15 (5–33) 40 (36–54)* 48 (28–57)* 43 (31–55)
*p<0.05 compared to unstimulated; †p<0.05 compared to FMLP
stimulated.
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S90 DOXYCYCLINE INHIBITS CIGARETTE SMOKE
STIMULATED IL-8 RELEASE FROM NCI-H292 CELLS
T. Howell, A. Richter, S.T. Holgate, D.E. Davies. Division of Infection,
Inflammation and Repair, Brooke Laboratory, Level F, South Block (888),
Southampton General Hospital, Southampton SO16 6YD, UK
Cigarette smoke (CS) has been shown to cause phosphorylation and
activation of the epidermal growth factor receptor (EGFR) leading to
upregulation of mucin expression in bronchial epithelial cells. It has
been suggested that this occurs via an oxidant-mediated, ligand-
independent mechanism (Takeyama, et al. Am J Physiol Lung Cell Mol
Physiol 2001;280:L165–L172). However, we have shown recently
that CS stimulated the transcription and release of EGFR ligands from
NCI-H292 bronchial epithelial cells (Richter, et al. Am J Resp Cell Mol
Biol 2002;27:85–90). Moreover, CS also induced the production of
IL-8 from H292 cells and this response was mediated via the EGFR.
Therefore upregulation of EGFR signalling may underlie some of the
long-term effects of CS on bronchial epithelium such as chronic inflam-
mation and goblet cell hyperplasia.
EGFR ligands are cleaved from transmembrane precursors by Zn2+-
dependent metalloproteinases (MP) of the A-Disintegrin and Metallo-
protease (ADAM) family to generate active soluble peptides. The
antibiotic doxycycline has been reported to inhibit MP activity
independently of its antimicrobial properties (Golub, et al. Crit Rev
Oral Biol 1991;2:297–322). Therefore we tested its ability to reduce
EGFR ligand shedding and inhibit IL-8 production in NCI-H292 cells
exposed to CS. Firstly, we determined the toxicity of doxycycline to in
vitro cultures of H292 cells. We then exposed the cells to an aqueous
extract of cigarette smoke (CSE) in the presence or absence of
sub-toxic doses of doxycycline. We used enzyme-linked immunoassay
to determine the concentration of EGFR ligands and IL-8 in the culture
medium 6 and 24 hr post exposure. We measured their level of
mRNA expression 6 hr post exposure by quantitative real-time PCR.
CSE stimulated the release of EGFR ligands and IL-8 and these
responses were inhibited by doxycycline in a dose dependent
manner. Doxycycline also blocked CSE-induced ligand and IL-8
mRNA transcription. We propose that CSE acts initially by promoting
the shedding of EGFR ligands. This causes autocrine activation of the
EGFR and, subsequently, increases the gene transcription of EGFR lig-
ands and IL-8. Doxycycline, by acting as an MP inhibitor, prevents the
shedding of EGFR ligands hence and blocks EGFR activation by CSE.
Infections: From bench to
bedside
S91 THE MAIN SITE OF iNOS ACTIVITY INDUCED BY GRAM
POSTIVE STAPHYLOCOCCUS AUREUS MAY BE BLOOD
VESSELS AND NOT MACROPHAGES: COMPARISONS
WITH GRAM NEGATIVE ESCHERICHIA COLI
E. Belcher, T.W. Evans, S. Sriskandan, J.A. Mitchell. Unit of Critical Care
Medicine, Royal Brompton Hospital, NHLI Imperial College School of
Medicine, Dovehouse Street, London SW3 6LY, UK
Sepsis and septic shock caused by either Gram positive or Gram
negative bacteria is associated with a mortality rate of 40–70%. We,
and others have hypothesised that such adverse outcomes result from
an unchecked immune response mounted initially by neutrophils and
macrophages in order to kill the invading pathogen. As sepsis devel-
ops, endothelium and vascular smooth muscle become activated to
express inducible (i) inflammatory genes such as that encoding for
nitric oxide synthase (iNOS), leading to the production of large
amounts of NO, rendering the vessel hyporesponsive to constrictor
agents. This contributes significantly to the profound decline in blood
pressure that typifies septic shock. However, the ability of bacteria to
induce iNOS activity in immune cells (e.g. macrophages) versus vas-
cular tissue remains unclear. Secondly, a comparison between the
ability of Gram positive and Gram negative bacteria to induce iNOS
in these tissues has not been made. We therefore assessed the ability
of heat killed S aureus or E coli to induce iNOS (indexed by the abil-
ity of tissue to release nitrite, measured by Griess assay) in murine
macrophages (J774.2) versus murine blood vessel (aorta) in cell and
organ culture respectively. E coli induced concentration-dependent
increases in NO release in J774 macrophages, to a maximum of
24FM. By contrast, S aureus induced only low levels of NO release
(2FM). E coli induced significant NO release from aorta, but similar in
magnitude to that produced by S aureus (figure).
E coli induced NO release from both immune modulating cells
(macrophages) and vascular tissue. By contrast, S aureus caused NO
release only in aorta. The inflammatory response to bacterial infection
may be dictated by the inflammatory stimulus.
Work supported by the MRC.
S92 THE PRESENCE OF QUORUM SENSING SIGNAL
MOLECULES IN CLINICALLY STABLE LUNG ALLOGRAFT
RECIPIENTS SUGGESTS BACTERIAL BIOFILM BIOLOGY
C. Ward, M. Cámara1, I. Forrest, B. Rutherford, G. Pritchard, M. Daykin1,
A. De Soyza, A.J. Fisher, P. Williams1 2, P.A. Corris. Lung Biology and
Transplantation Group, University of Newcastle upon Tyne and The Free-
man Hospital, 1School of Pharmaceutical Sciences; 2Institute of Infections
and Immunity, University Park, University of Nottingham, UK
Introduction: Infection with bacteria such as Pseudomonas is
common in lung allograft recipients, particularly during chronic rejec-
tion. Analysis of sputum samples from CF patients infected with Pseudo-
monas aeruginosa or Burkholderia cepacia have indicated the
presence of the bacterial N-acylhomoserine lactones (AHLs) quorum
sensing signaling molecules. AHLs not only control the expression of
bacterial virulence genes but are also involved in stimulating the matu-
ration of antibiotic resistant biofilms.
Hypothesis: AHL activity may be detected even in clinically stable
lung transplant recipients free of clinical infection or rejection.
Methods: A standardised 3×60mL Bronchoalveolar lavage (BAL)
taken from 9 stable, non smoking lung transplant recipients, 3 B12
months post transplant. Detection of AHLs was carried out on dichlo-
romethane extracted supernatants, using the bioluminescence-based
AHL reporter plasmid pSB1075. This responds to AHLs with long acyl
chains (10–14C), generating light. Synthetic AHLs were included as
+ve controls.
Results: From the 9 BAL supernatants, 5 exhibited AHL activity,
suggesting the presence of long chain AHLs. There was no correlation
between the levels of AHLs detected (+,++,+++), or their absence, BAL
microbiology or pre transplant diagnosis.
Discussion: We provide the first evidence of AHL quorum sensing
signals in human lung allograft recipients, with activity even in subjects
with no rejection or infection. Longitudinal studies are required of AHL
levels, to elucidate potential links with infection, rejection, and
allograft deterioration.
Abstract S91 Effects of heat killed S aureus and E coli on NO
release by (A) segments (2–3 mm) of intact mouse aorta (n=4) and
(B) J774.2 macrophages (n=6) incubated in 96 well plates
containing 200 µl medium for 24 hours.
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S93 HEME OXYGENASE INDUCTION IN ISOLATED
NEUTROPHILS STIMULATED WITH LPS, OR FROM
PATIENTS WITH SEPSIS DUE TO NOSOCOMIAL
PNEUMONIA
R.L. Upton, J.H. Cranshaw, G.J. Quinlan, T.W. Evans. Unit Of Critical
Care, National Heart And Lung Institute, Dovehouse Street, London
SW3 6LY, UK
Rationale: Evidence suggests that macrophages are a source of
Heme Oxygenase (HO) protein and activity during inflammatory
processes. HO enzymes have anti oxidant potential and may confer
anti-inflammatory protection. However, few data relate to the
induction of this enzyme in other inflammatory cell types, such as neu-
trophils, which are recruited initially to sites of infection or injury. We
therefore evaluated the potential for human neutrophils to produce HO
under contrasting inflammatory conditions.
Methods: Neutrophils were isolated from whole human blood and
stimulated with LPS (10µg/ml) in 6 well plates at a concentration of 5
× 106 cells/well for 8, 16 and 24 hours, harvested and lysed. HO-1
and HO-2 protein expression was measured by Western blot. Stimu-
lated cells were compared to un-stimulated neutrophils at time zero, 8,
16 and 24 hours. Blood (with cycloheximide 1mg/ml) was also taken
from patients with Gram-negative septic shock (n=6) and from healthy
volunteers (n=5). In four of the six patients with septic shock microbio-
logical culture identified the lung as a site of infection. Neutrophils
were isolated and 5 × 106 cells were harvested and lysed. HO-1 and
HO-2 protein expression was measured as before.
Results: In vitro, HO-1 levels were elevated 8 hours after LPS by
comparison to baseline and unstimulated cells (199.2% ± 42%, n=9,
p<0.05). HO-1 levels in cells 16 and 24 hours after LPS were not sig-
nificantly different from levels in untreated cells because of
non-specific induction of HO-1 in the unstimulated cells (115.8
(21.19), n=9 and 94.94 (12.58), n=9 respectively). HO-2 levels were
not significantly altered at any of the timepoints between the LPS stimu-
lated and non-stimulated cells.
By contrast, in vivo, HO-1 protein was lower in septic patients com-
pared to normal controls (60.97 (24.5), n=6 and 125.7 (34.4), n=5
respectively). HO-2 levels were not changed between the two groups.
Conclusion: HO-1 production can be induced by LPS in
neutrophils, and is also present in neutrophils from patients with sep-
sis. However, HO-1 levels in septic patients are lower than controls.
The anti oxidant potential of HO-1 may therefore be reduced in the
neutrophils of these patients, which has implications for neutrophil
mediated tissue damage in this population.
This work was supported by The British Lung Foundation and The
Dunhill Trust.
S94 THE EFFECT OF AIRWAY BACTERIAL LOAD ON
EXACERBATION SEVERITY IN PATIENTS WITH COPD
T.M.A. Wilkinson, I.S. Patel, A.C. Whiley, M. Wilks, J.A. Wedzicha. Aca-
demic Unit of Respiratory Medicine, St Bartholomew’s and the Royal Lon-
don School of Medicine and Dentistry, London, UK
COPD exacerbations are an important cause of morbidity and
mortality. In the majority of these episodes infective agents including
both bacteria and viruses can be identified. However bacteria can
also be isolated from the lower airway of many stable COPD patients
and the type and number of these bacteria affects the level of airway
inflammation in these colonised patients in the stable state. The
changes between bacterial load and type seen at exacerbation and at
baseline and how these changes may affect the deterioration in lung
function seen at exacerbation are poorly described.
75 patients (mean (SD) FEV1 1.00 (0.38) l, FEV1 % predicted 38
(16.8), FVC 2.57 (0.93) l, PaO2 10.2 (1.1) kPa, PaCO2 6.22 (0.9) kPa,
age 67.4 (11.8) yrs, m 40, 28 current smokers) completed daily diary
cards of respiratory symptoms were followed up for 12 months and
reported symptoms of exacerbation to our study team. Sputum was ini-
tially sampled in the stable state and later within 48 hours of the onset
of exacerbation (before antibiotic treatment was commenced) and
analysed for quantitative and qualitative bacteriology. Contempora-
neous lung function measurement was performed by spirometry. 55
satisfactory paired samples were obtained, the relative frequency of
bacterial isolates being: Haemophilus influenzae in 12% of stable
samples (1) and 31% of exacerbation samples (2), Streptococcus
pneumoniae ((1) 9%, (2) 11%), Haemophilus parainfluenzae ((1)
12.5%, (2) 2%), Branhamella catarrhalis ((1) 7%, (2) 13%) and Pseu-
domonas aeruginosa ((1) 5%, (2) 5%) with Non specific growth in (1)
48% and (2) 25%. The mean (SD) stable bacterial load was 107.49
(101.26) log cfu ml-1 rising to 108.00 (101.02) cfu ml-1 at exacerbation
p=0.0001. The mean (SD) stable FEV1 was 0.99(0.38) l falling to
0.90 (0.31) l at exacerbation. The percentage fall in FEV1 at exacer-
bation was related to the rise in airway bacterial load rho=0.411
p=0.018. Linear regression analysis confirmed that a rise in bacterial
load contributed to a fall in FEV1 p=0.034, 95% CI (0.006–0.141).
Both airway bacterial load and the prevalence of potentially
pathogenic organisms increase at exacerbation. Exacerbation
severity as measured by the acute deterioration in FEV1 is directly
related to the rise in airway bacterial load seen at exacerbation.
Supported by The Joint Research Board, St Bartholomew’s Hospital.
S95 HOW USEFUL ARE THE BTS COMMUNITY ACQUIRED
PNEUMONIA (CAP) GUIDELINES IN MANAGING
URBAN ELDERLY PATIENTS
J. Harbison, R. Shepherd, S.K. Bansal. Dept of Geriatric Medicine,
Sunderland Royal Hospital, UK
Introduction: In 2001 the BTS published guidelines for the
recognition and management of adult community acquired pneumo-
nia (CAP) in which it is stated that elderly patients “more frequently
present with non-specific symptoms” and “are less likely to have a
fever specific symptoms and pyrexia” with CAP. However both pres-
ence of specific symptoms and pyrexia are included in the clinical
diagnostic criteria in the guidelines. SRH has an age related
admissions policy, patients >70 years being admitted under Geriatric
physicians and the BTS guidelines being used in their care.
Purpose of study: We sought to determine the utility of the BTS
CAP guidelines in the management of consecutive admissions with a
primary diagnosis of lower respiratory tract infection. Subjects with
carcinoma, tuberculosis or non-CAP were excluded.
Results: 81 subjects (average age 78yrs, 39 F) were admitted over
the 6-week study period. 55 (68%) had a previous diagnosis of COPD
or Asthma. 17 subjects (21% (CI 12–30%)) had CAP according to the
guidelines’ clinical diagnostic criteria. In contrast, 48 (59%, 95% CI
54–64%) had pneumonia identified on admission radiograph. Radio-
graphic and clinical diagnoses agreed in only 38 cases (Pneumonia
agreed present in 11, absent in 27. Kappa 0.041, very poor agree-
ment).
Core adverse prognostic features used for severity assessment in the
guidelines (new confusion, Urea >7mmol/l, respiratory rate >30,
Systolic BP <90mmHg or diastolic <60mmHg) were recorded in the
48 subjects with radiographic evidence of CAP. 13 subjects had no
features, 31 had one and 3 had two. As guideline advice for those
>50 years of age with no or one feature is to “Use Clinical
Judgement” with regard to admission and specific management, the
guidelines directed management in only 3 patients (6% CI 0–13%).
Of note 26% (54%) of subjects had an elevated Urea and 7 (15%)
had evidence of hypotension, the causes of which were multifactorial.
Conclusions: The clinical diagnostic criteria for community
acquired pneumonia in the BTS guidelines are unsuitable for use in an
urban elderly population. This could be expressed more explicitly in
the text. The severity assessment flow chart in the guidelines is of lim-
ited use in the majority of elderly subjects with community acquired
pneumonia. Consideration should be given to the development of spe-
cific guidelines for the management of lower respiratory tract infection
and pneumonia in the elderly.
Procedures in respiratory
medicine
S96 BTS GUIDELINES FOR BRONCHOSCOPY: PHYSICIANS
APPROACH TO THE NON-EVIDENCE BASED
RECOMMENDATIONS
A. Mirakhur, M. Al-Aloul, D. Russell, M.J. Ledson, M.J. Walshaw, C.
Smyth. Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool,
UK
In March 2001 the BTS published guidelines for the practice of diag-
nostic flexible bronchoscopy. However, it was apparent that many of
the recommendations were not evidence based (27 of 68 (40%) were
SIGN Grade C), and we had the impression that they were not
routinely practiced by chest physicians within the UK. We therefore
compared the SIGN Grade C recommendations in these guidelines
with the routine practice of chest physicians as described by a postal
questionnaire sent to 548 UK chest physicians in 2000. Three
hundred and twenty eight questionnaires (60%) were returned. Based
on these, prior to bronchoscopy 227 physicians (69%) routinely
measured spirometry and 117 (37%) pulse oximetry. Whilst only 7
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physicians (2%) measured blood gases in all patients, 70 (21%) did
so depending upon spirometry, 48 (15%) upon the patient’s clinical
status, and 35 (11%) when the SpO2 < 93%. Overall, 122 physicians
(37%) did not measure blood gases prior to bronchoscopy under any
circumstances. For patients theoretically at risk from bacteraemia dur-
ing bronchoscopy, only 192 physicians (59%) routinely gave prophy-
lactic antibiotics. Prior to transbronchial biopsy, 281 physicians (86%)
checked the platelet count, but only 273 (83%) checked clotting
parameters. Two hundred and eighty operators (85%) always used
prophylactic venous access, and 26 (8%) occasionally. Thus, 14 phy-
sicians (7%) carried out bronchoscopy with no routine venous access.
Nearly all physicians (324, 99%) monitored pulse oximetry during
bronchoscopy, but 180 (56%) did not monitor ECG or blood pressure.
In 19 centres (6%), the physician carried out bronchoscopy with only
1 endoscopy assistant and in 2 (1%) no trained nurse was present. In
terms of operator safety, for routine bronchoscopy, (315, 96%) wore
gloves, but only 197 (60%) wore gowns and very few goggles (45,
14%) or a facemask (80, 24%). However, for “high risk”
bronchoscopy, these figures improved to 321 (98%), 290 (88%), 228
(69%), and 290 (88%), respectively. Thus, based upon this postal sur-
vey, it is apparent that there are wide discrepancies between current
practice and the guideline recommendations for diagnostic flexible
bronchoscopy that are not evidence based.
S97 PROSPECTIVE RANDOMISED TRIAL OF ABRAM’S
PLEURAL BIOPSIES VERSUS CT GUIDED CUTTING
NEEDLE BIOPSIES IN UNDIAGNOSED PLEURAL
EFFUSIONS
N.A. Maskell, F.V. Gleeson, R.J.O. Davies. Oxford Centre for Respiratory
Medicine, Churchill Hospital, Oxford, UK
Introduction: Approximately 180 000 people in the U.K., develop a
pleural effusion each year, of which 40 000 will turn out to be due to
malignancy. Unfortunately, cytological examination alone has a sen-
sitivity for malignancy of only 60%, necessitating further more invasive
investigations in many cytology negative pleural effusions. With the
rising incidence of mesothelioma (where track invasion by tumour is
common), the minimum number of invasive investigations to obtain a
diagnosis is desirable. We have assessed whether CT guided pleural
biopsy is more sensitive than blind Abram’s biopsy in these patients.
Methods: 50 consecutive patients with undiagnosed exudative
effusions, negative pleural fluid cytology, but possible pleural
malignancy, were recruited. All received a contrast enhanced CT tho-
rax, with the degree of pleural thickening recorded. Patients were ran-
domised to blind Abram’s pleural biopsy or CT guided cutting needle
biopsy. The Abram’s pleural biopsy was performed by NAM without
knowledge of the CT findings. The CT guided biopsy was performed
by FVG.
Results: Of the 50 patients, 3 did not have a biopsy (1 withdrew
consent, 1 pleural effusion resolved and 1 had deranged blood clot-
ting). There was one chest wall haemtoma in the Abram’s group. The
median age was 72 (range 25–88) in the CT group and 73 (41–85)
in the Abram’s group. The maximal pleural thickening on CT was
<5mm in 17/25 patients in the radiology group and in 17/25 of the
Abram’s group. The final diagnosis was confirmed with a minimum
follow up of 1 year. Abram’s blind biopsy gave the true positive (TP)
diagnosis of malignancy in 8/17 cases, Sensitivity 47%, Specificity
100% and Negative predicted value (NPV) 44%. In the CT group, TP
rate for malignancy was higher at 13/15 (p=0.02, χ2), Sensitivity
87%, Specificity 100%, NPV 80%. 7 of the 8 cases of mesothelioma
in the radiology group were established by biopsy, Sensitivity 88%,
Specificity 100%, NPV 94%. This compared with only 6 of the 11
cases in the Abram’s group, Sensitivity 55%, Specificity 100%, NPV
72%.
Conclusion: In cytology negative pleural effusions CT guided pleu-
ral biopsy has a significantly higher sensitivity for malignancy and
should be the biopsy method of choice in patients unable to tolerate
thoracoscopy.
S98 THE COMPLICATION RATE OF PERCUTANEOUS
IMAGE-GUIDED CHEST DRAIN INSERTION
J.C. Hillier1, C.L. Davies2, R.J.O. Davies2, Z.C. Traill2, F.V. Gleeson2.
1Department of Radiology, Chelsea and Westminster Hospital, 369 Fulham
Road, London SW10 9NH, UK; 2Department of Radiology, Churchill Hos-
pital, Oxford Radcliffe Hospitals, Old Road Headington, Oxford OX3 7IJ,
UK
Purpose: The aim of this study was to assess prospectively the success
and complication rate associated with image-guided percutaneous
pleural drainage.
Materials/Methods: A prospective single institution study of all
image-guided chest drains placed over a 36-month period was
carried out. All drains were inserted using the Seldinger technique.
Data collected included, indication for drain insertion, size of drain,
type of image-guidance used (CT or ultrasound), demographic data,
nature and amount of fluid aspirated, success rate, duration of drain-
age and complications.
Results: 352 drains were inserted into 273 patients. 121 patients
were male and 152 female. 149 were inserted on the left and 203 on
the right. The majority of drains were 12 French, (256), other drain
sizes were 8 French (90), 10 French (2) to 14 French (3) 16 French
(1). 333 drains were placed under ultrasonic guidance and 19 under
CT. Indications included 236 malignant effusions 94 empyemas and
22 benign non-infective effusions. 350 drains were successfully
inserted. Two patients suffered significant immediate complications of
haemorrhage during drain placement due to intercostal artery lacera-
tion. Both drains were inserted posteriorly. Both patients underwent
percutaneous artery embolisation. One procedure was successful;
unfortunately one procedure was unsuccessful and the patient died
within 24 hours of drain insertion of intrathoracic haemorrhage. Both
of these patients had drain insertion for a current empyema, had a his-
tory of chronic renal failure and a prior empyema.
Conclusion: Percutaneous image-guided drain placement is
successful in the majority of patients (99%). Posteriorly inserted drains
may have a higher and more significant complication rate compared
to other drain position. Patients with renal impairment appear at
greater risk.
S99 TALC BUT NOT TETRACYCLINE PLEURODESIS INDUCES
HYPOXIA AND INCREASED DTPA CLEARANCE OF THE
CONTRA-LATERAL LUNG
N.A. Maskell, Y.C.G. Lee, E. Jones, F.V. Gleeson, R.J.O. Davies. Oxford
Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK
Introduction: Talc slurry is the most commonly used and effective
pleurodesis agent in the UK. There are concerns about its safety and it
is associated with at least 34 reported cases of severe lung inflamma-
tion leading to Adult Respiratory Distress Syndrome (ARDS). It is not
known if milder generalised lung inflammation is a consistent feature
of talc pleurodesis. 99mTc-DTPA lung clearance is a very sensitive
marker of lung inflammation. This study assesses whether DTPA clear-
ance from the lung contra-lateral to a pleural effusion is changed by
talc or tetracycline pleurodesis used to control the effusion.
Methods: 31 patients with recurrent symptomatic effusion
consented to the study. 11 were excluded (5 with trapped lung, 3
unable to perform baseline DPTA , 1 M.I. pre pleurodesis, 2 chest tube
displacements). 20 were randomised to 4g talc slurry (10) or
20mg/Kg tetracycline (10) balanced by type of malignancy and pleu-
ral pH. Oxygen saturation breathing air, serum C-reactive protein
(CRP), limited HRCT and DTPA scan were performed before and 48
hours after pleurodesis. Pleural fluid IL-8 was measured at before and
24 hours after pleurodesis.
Results: DTPA t1/2 of the contra-lateral lung fell significantly after talc
but rose after tetracycline. Talc 64.4 minutes (90% range 40–111.1)
to 59.5 (35.3–84.8) difference B8.95 (-35.2–12.4), tetracycline 60.1
(26.1–119) to 83.6 (27.8–189.2) difference 2.85 (-16.3–75.1),
p<0.03 Mann-Whitney. No changes were detected on limited HRCT.
CRP rise was significantly higher in the talc than tetracycline group.
Talc 198 (SD 79) v Tetracycline 74 (SD 79) p=0.004. SaO2 also fell
significantly more in the talc group. Talc 95.5 (2.3) to 92.2 (2.6) dif-
ference 3.2 (SD 1.6) , tetracycline 94.0 (4.7) to 93.3 (4.9) diff 0.7
(SD 1.5) p=0.003. There was also a trend towards a greater increase
in pleural fluid IL-8 levels in the talc group: Talc 12618 (258–29911)
vs Tetracycline 50 (-1657–29919) p=0.13.
Conclusion: Talc pleurodesis induces a greater systemic inflamma-
tory response than tetracycline quantified by CRP. Increased aerosol
DTPA clearance from the contra-lateral lung and greater hypoxaemia
are induced by talc but not by tetracycline. This suggests that
occasional severe ARDS induced by talc is the severe extreme of a
spectrum and not an idiosyncratic adverse reaction.
S100 TRANSBRONCHIAL NEEDLE ASPIRATION (TBNA)—AN
ADDITIONAL TOOL TO INCREASE THE DIAGNOSTIC
YIELD OF BRONCHOSCOPY
J. Mills, P. Nuttall, S. Kearney, J. Edwards, M. Munavvar. Royal Preston
Hospital, Preston, Lancashire, UK
Introduction: In patients with essentially extrinsic or submucosal dis-
ease on Bronchoscopy, the positive diagnostic rate of conventional
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sampling with endobronchial biopsy, brush and wash (CS) remains
relatively low (Dasgupta, et al. Chest 1999;115). TBNA is reported to
increase the pick up rate in this group, and also in necrotic endobron-
chial tumours, but is not widely used (Mehta. Clin Chest Med
1999;20:39–51).
Methods: We prospectively recorded the results of TBNA in addi-
tion to appropriate conventional sampling in 23 patients over a 12
month period. All the sampling was done by a single operator, and
during regular bronchoscopy lists. 22G Olympus and Millrose-Wang
needles were used.
12 patients had submucosal/ extrinsic disease and 7 had necrotic
endobronchial lesions. Bronchoscopy was normal in 4 patients. CT
scans were performed prior to the bronchoscopy in 13 patients.
Results: TBNA was positive in 21/23 patients (91%), whereas
conventional samples were positive in 16/22 patients (73%). Biopsy
was positive in 13/15, Brush in 12/15 and wash in 9/22 patients
respectively. TBNA was the only positive diagnostic test in 5 patients
(22%). The diagnosis was non-small cell malignancy in 15 and small
cell carcinoma in 5 patients. One patient presented with isolated sub-
carinal adenopathy, and acid fast bacilli were demonstrated on the
FNA sample. There were no significant complications during or after
the procedure.
In short, with the addition of TBNA, the diagnostic yield of
bronchoscopy went up from 73% to 91%.
Conclusions: TBNA is a cost-effective and safe technique to
improve the diagnostic yield of bronchoscopy, particularly in patients
with (a)extrinsic/submucosal disease (b) normal bronchoscopy but CT
scan evidence of peribronchial disease or medistinal abnormality and
(c) necrotic, haemorrhagic endobronchial lesions. It can also be used
to diagnose benign disease. TBNA can be performed during a stand-
ard flexible bronchoscopy list, and could potentially reduce the need
for a surgical biopsy.
S101 FLUORESCENCE BRONCHOSCOPY IN CLINICAL
PRACTICE
A.K. Banerjee,1 P.H. Rabbitts1, P.J.M. George2. 1Molecular Oncology
Group, University of Cambridge, UK; 2The Middlesex Hospital, London, UK
Introduction: Autofluorescence bronchoscopy (AFL) uses the fluores-
cence properties of bronchial mucosa to enhance the real-time detec-
tion of abnormal endobronchial lesions. This study assesses the
efficacy of the Storz bronchoscope in a UK population of patients.
Methods: Patients with suspected lung cancer attending for
diagnostic bronchoscopy underwent AFL during the same procedure.
Conventional white light followed by AFL was performed. Biopsies of
all abnormal areas and control biopsies from bronchoscopically nor-
mal areas were obtained. The bronchoscopic and histological
findings were compared.
Results: 53 patients have undergone AFL (41 male), mean age
63.8 yrs (range 35–79 yrs). Controls: 106 areas were biopsied as
controls. 3.7% showed high grade pre-invasive lesions (carcinoma-in-
situ & severe dysplasia). The remaining areas showed no abnormality
or low-grade pre-invasive lesions. Bronchoscopically abnormal areas:
The table shows the histology and bronchoscopic findings of the 133
areas biopsied. Compared toconventional white light bronchoscopy,
autofluorescence improved the detection of high-grade pre-invasive
lesions. 7 early-stage microinvasive carcinomas were detected by AFL
alone. The false negative rate for AFL detection of high-grade
pre-invasive lesions was 3.7% and the false positive rate 38.3%.
Conclusions: The addition of AFL to conventional bronchoscopy
improves the sensitivity of high-grade pre-invasive lesion and
importantly invasive carcinoma detection. Detection of microinvasive
carcinoma at a radiologically occult stage allows intervention with
potentially a 90% 5 year survival. The dilemma of pre-invasive lesion
management is also raised. Not all pre-invasive lesions become inva-
sive carcinomas, and so intervention is not justified for all lesions. Fur-
ther information on the natural history of such lesions is needed. The
high false positive rate is similar to that found in other studies and
suggests that abnormal findings must be confirmed histologically and
that approaches to improve specificity are required.
Lung cancer targets
S102 AUDIT IMPROVES DIAGNOSTIC DELAYS IN LUNG
CANCER MANAGEMENT
J. Walker, J.S. Sarvesvaran, M. Patel, A. Coote, K.R. Patel. Department of
Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK
Aim: Delays in diagnosis are often causes of distress to patients, and
may have a detrimental effect on therapeutic options and overall
prognosis. The aim was to prospectively audit the time taken to diag-
nose patients with suspected lung cancer in a large teaching hospital
with reference to established national guidelines of best practice.
Method: From January 1999, all available data required for the
Scottish Intercollegiate Guidelines Network (SIGN) and Royal College
of Physicians (RCP) minimum dataset for lung cancer, was collected
from case notes of patients managed by the lung cancer team at
Gartnavel hospital. This was prospectively entered into Microsoft
access and SPSS databases.
Results: 518 patients were identified between 1999 and 2001.
Histological evidence of lung or other malignancy was obtained in
474 (91.5%) patients. The time taken to see a respiratory physician,
for the investigations to be performed and to obtain a definitive diag-
nosis is presented below, with the p-values for differences between the
time taken in 1999 and 2001.
Conclusion: Simple organisational changes following clinical audit
have significantly reduced the time taken for CT imaging of thorax,
and have improved diagnostic delays, in patients with lung cancer.
Abstract S101
Biopsy result
No areas +ve
white-light
No areas +ve
AFL
Normal\inflammation 13 35
Low grade pre-invasive 10 16
High grade pre-invasive 35 48
Squamous carcinoma 27 34
Abstract S102
Time taken (days): 1999 2000 2001
t test 1999
to 2001
To see respiratory physician from referral n=155 n=213 n=150
mean=8.3 Mean=6.6 Mean=7.3 NS
SD=13.3 SD=8.6 SD=10.8
For bronchoscopy from clinic review n=116 n=163 n=125
Mean=9.9 Mean=11 Mean=9.3 NS
SD=24.2 SD=22.8 SD=25.8
For CT scan of thorax from clinic review n=122 n=170 n=131
Mean=28.8 Mean=21.0 Mean=18.2 p=0.03
SD=45.9 SD=38 SD=30.0
For definitive diagnosis from clinic review n=155 n=211 n=150
Mean=33.1 Mean=29.3 Mean=16.4 p=0.06
SD=90.6 SD=57.1 SD=59.7
NS, not significant.
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S103 THERAPEUTIC DELAYS IN LUNG CANCER
MANAGEMENT
A. Coote, K.R. Patel, J.S. Sarvesvaran, J. Walker, M. Patel. Department of
Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK
Aim: As lung cancer is such an aggressive disease with poor progno-
sis, following the diagnosis, an appropriate member of the multidisci-
plinary team should initiate treatment quickly. To identify any
therapeutic delays in lung cancer management, a prospective audit
was set up in Jan 1999.
Method: A SPSS database was constructed and all available data
required for the Scottish Intercollegiate Guidelines Network(SIGN)
and Royal College of Physicians (RCP) minimum dataset entered pro-
spectively by a part time data manager.
Results: During the period Jan 1999 to Dec 2001, the lung cancer
team at Gartnavel General hospital managed 518 patients. 96
(18.5%) patients were diagnosed with small cell lung cancer (SCLC),
335 (64.7%) were non-small cell lung cancer (NSCLC). The times
taken for patients to receive the different modalities of lung cancer
treatment are shown in the table.
Conclusion: Chemotherapy for SCLC is prescribed primarily by
respiratory physicians and is administered promptly. Similarly patients
with NSCLC who are fit for surgery have the procedure within the rec-
ommended period. Although oncology review of patients is rapid,
patients receiving chemotherapy for NSCLC, face a slight delay. This
may be due in part to patients requiring time to consider therapeutic
options but administrative delays due to treatment being administered
at another hospital site cannot be excluded. The significant delay par-
ticularly for radical radiotherapy is of concern as it may have a detri-
mental effect on overall survival.
S104 MEETING GOVERNMENT LUNG CANCER TARGETS:
DOES LUNG CANCER PRESENTATION HAVE A
SEASONAL VARIATION?
A. Bastin, A.G. Davison, D. Eraut, A. Hutchings, A.S. Haque, A. Lamont,
C. Trask. Southend Associate University Teaching Hospital, Southend on
Sea, Essex SS0 0RY, UK
Currently the Government target for seeing a patient with suspected
lung cancer is within 2 weeks of referral and from 2005 the target
time for starting treatment is to be within one month of diagnosis. It is
known that exacerbations of COPD vary seasonally and are more
common in winter months. COPD is very common in patients with lung
cancer. The knowledge of any seasonal variation in lung cancer pres-
entation is important for service planning and to allow Government
targets to be met.
We have analysed the 2127 new cancer cases presenting over a
ten year period from 1990 to 1999 from the Southend Lung Cancer
Study. This includes every case in a well defined population of
325 000. Winter (W) months are defined as December, January, and
February, and Summer (S) months are June, July, and August. The
number presenting in S (561) was slightly higher than W (494). There
was a lack of evidence that presence of cough at diagnosis differed by
season (66% had a cough in W, compared to 70% in S) (p=0.14).
There was a lack of evidence that dyspnoea at diagnosis differed by
season (59% in W, compared to 63% in S) (p=0.25). There was a
lack of evidence that the presence of COPD in those presenting with
lung cancer (using the BTS COPD Guidelines criteria for diagnosis
and severity) differed by season (74% in W compared to 71% in S),
nor that there was any difference in the severity of COPD at presenta-
tion according to season (p= 0.6). Similar results were found when
those presenting in the 6 months of October through to March were
compared to those presenting in the 6 months of April through to Sep-
tember.
Conclusion: There is no increase, unlike COPD, in the presentation
of lung cancer in the W months. Even patients with severe COPD and
lung cancer do not present more commonly in W. There is no
difference in the respiratory symptoms in lung cancer patients present-
ing in the W or S. These results have important implications for the
planning of lung cancer services. Diagnostic services, e.g. outpatient
2 week lung cancer slots, MDTs, bronchoscopy, CT scanning,
histology etc, and treatment services, surgery, radiotherapy, and
chemotherapy need to be provided on a continual basis throughout
the year. In particular in order to meet Government targets they will
need to be maintained in the summer, the traditional holiday period
for staff.
S105 LUNG CANCER: ARE THE NSF TARGETS FOR
RESECTION AND RADICAL RADIOTHERAPY
ACHIEVABLE?
N.J. Ali1, G.A. Cox1, A. Hastings1, S. Brauer1, C. Butcher1, D. Fyfe2, D.
Beggs2, M. Curtis1, J. Morley1. 1Kings Mill Hospital, Sutton in Ashfield, UK;
2Nottingham City Hospital, UK
The NSF for Lung Cancer has set targets for histology and resection
rates for lung cancer against which services can be judged. One
report from a tertiary referral centre suggested that resection rates of
25% were achievable (Laroche, et al. Thorax 1999;53:445–9). We
set out to review the demographics and staging of lung cancer
patients diagnosed at our DGH (Kings Mill Hospital) to examine the
reasons for not obtaining a pathological diagnosis and not operating
on patients with stage I and II disease. We have prospectively
collected the full BTS/RCP audit data set on all patients diagnosed
with lung cancer at our hospital since April 1999. These results are
presented.
Over three years between 04/99 and 03/02 we diagnosed 441
cases of lung cancer. The rate of histological confirmation overall was
83.5%. More than 85% had their management discussed at the
weekly Multi Disciplinary Meeting, which included respiratory
physicians, a thoracic surgeon and an oncologist.
Small cell lung cancer (SCLC) accounted for 14% of all cases.
Of the 379 remaining patients 310 had confirmed Non Small Cell
Lung Cancer (NSCLC). 299 of these (96%) were formally staged. The
stage distributions are shown below and compared with those
reported by Mountain (Mountain. Chest 1997;111:1710–17).
Of those with stages I and II, the surgical resection rate was 42%
and radical radiotherapy rate 28%. Co-morbidity prevented the
remaining 30% from receiving potentially curative treatment. The
resection rate for pathologically confirmed NSCLC was 32/
310=10.3% or 32/379=8.4% if those without pathologically
confirmed disease are included. Our results show that at our hospital
patients with lung cancer present with later stage disease than those
reported from tertiary referral centers. Selection bias may explain the
differences between our results and those previously reported (see
above). Even if all those with stage I and II disease underwent surgery
we would barely achieve 15% resection rate.
S106 SURGICAL REFERRAL AND RESECTION RATE FOR
NSCLC AT QUEEN ELIZABETH HOSPITAL OVER A 5
YEAR PERIOD: WHY IS IT SO LOW?
J.I. Whitehouse, N. Jahan, J.R. Webb, T.C. Stokes. Department of Respira-
tory Medicine, Queen Elizabeth Hospital, Stadium Road, Woolwich,
London SE18 4QH, UK
Aim: to analyse the referral rate for surgery in stage I and II NSCLC in
Queen Elizabeth Hospital Woolwich, from September 1997 up to
April 2002.
A total of 746 patients were diagnosed with lung cancer between
1997 and 2002. Of these, 458 had histologically proven non-small
Abstract S103
Time taken in days from
referral for treatment during
Jan 1999–Dec 2001
SCLC chemotherapy n=88 median=6
NSCLC chemotherapy n=47 median=23
NSCLC surgery n=55 median=18
Oncology review n=338 median=6
Radical XRT n=29 median=49
High dose palliative XRT n=38 median=32
Palliative XRT n=150 median=18
Abstract S105
Stage Ia Ib IIa IIb IIIa IIIb IV
% 5.1% 13.2% 0.3% 7.7% 13.9% 21.3% 39%
Mountain 13% 23% 1% 7% 10% 20% 27%
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cell lung cancer (NSCLC). All were staged and discussed at a multidis-
ciplinary meeting, which does not have the input of a surgeon.
Reasons for non-referral of stage I and II patients included poor lung
function (13), age (10), WHO health status (5) patient refusal (5) other
diseases (3) or a combination of the above (11). The median age for
those referred relative to those not referred was 66 and 76,
respectively (p<0.0001, Wilcoxon rank sum). Of the 60 stage I and II
patients referred for surgery, 40% were deemed to be inoperable.
Reasons were upstaging by PET scanning (9), age/lung function (3),
upstaging at mediastinoscopy/thoracoscopy (5) and surgical
opinion (7).
Conclusions: the surgical referral and resection rates for patients
with operable cancer on staging criteria remains low. Despite the ini-
tiation of multidisciplinary meetings in 1997, fewer than half of the
potentially operable patients (stages I, II and IIIA) were referred for
surgery. However, nearly half of all stage I and II patients referred for
a surgical opinion were refused, predominantly after upstaging. The
introduction of a telemedicine link with cardiothoracic surgeons may
improve referral rates.
S107 WHAT’S IN I.T. FOR US? USE OF AN I.T. SYSTEM TO
INFORM AND IMPROVE A LUNG CANCER SERVICE
J.M. Hill, A. Lally, P.B. Anderson, B.J. Hutchcroft, P.M. Fisher, B. Entwistle.
Chest Clinic, Northern General Hospital, Herries Road, Sheffield S5 7AU,
UK
Background: An audit of 100 lung cancer case records in our institu-
tion in 1999 demonstrated that only 18% of cases had an MDT
discussion and decision recorded in the medical records, and no
regular outcome data were available.
Process: During 2 timeout sessions in 1999 and 2000 lead
clinicians in the lung cancer services (diagnostics, thoracic surgery,
oncology) mapped the lung cancer care pathway and clinical
processes, and identified key stages of the patients care journey. This
work was influenced by the need for performance target data and
clinical minimum data sets.
In 2000 the Infoflex™ system was chosen to support the lung cancer
services. The implementation required clinicians to define information
requirements and outputs.
Outcome: The use of the Infoflex system coincided with the devel-
opment of a weekly combined lung cancer clinic (Respiratory
Medicine, Clinical Oncology and Palliative Care). Prior to the weekly
Lung Cancer clinic (t=0 days) a first visit proforma and faxable imme-
diate GP letter are printed, incorporating patient demographics from
the hospital PAS system. Data from the proforma are entered on to the
Infoflex system immediately after the clinic. Bronchoscopy findings are
entered live onto the Infoflex system by clinicians and a bronchoscopy
report, GP letter, and histopathology request form are printed. Prior to
the MDT meeting (t=10 days) the results of investigations are entered
onto the system and an MDT summary sheet is produced. The
summary sheet aids decision making in the MDT meeting and serves
as a referral letter between specialities. A second clinic visit proforma
and immediate faxable GP letter are prepared for the second clinic
visit (t=14 days).
The initial 12 months of complete data demonstate that 92% of
patients diagnosed with lung cancer have an MDT discussion and
decision recorded. Reports for any time frame are readily accessible,
and present a realtime position of all suspected lung cancer referrals,
their progress and outcome. Future plans include the use of projection
equipment in the MDT meeting to view the discussion sheet and record
decisions realtime, and the use of Infoflex for comparison of data with
other units, primarily to ascertain reasons for differences in resection
rate.
The genetics of respiratory
disease
S108 AGE-SPECIFIC EFFECT OF THE CYSTIC FIBROSIS
MODIFIER GENE, MBL-2
J.C. Davies1 2, M. Johnson3, C. Booth3, K. Fidler3, A. Bush1, D.M. Geddes2,
E.W.F.W. Alton2, M.W. Turner3, N. Klein3. 1Department of Paediatric Res-
piratory Medicine, Royal Brompton Hospital, UK; 2Dept of Gene Therapy,
Imperial College, UK; 3Immunobiology Unit, Institute of Child Health, Uni-
versity College, London, UK
The variable severity of cystic fibrosis lung disease, even in subjects
with identical CFTR mutations, has led to the search for non-CFTR
modifier genes. Mannose-binding lectin (MBL) is involved in innate
defence, both through direct opsonic activity and complement activa-
tion. Low-expressing MBL-2 haplotypes were reported in two studies of
older CF children and adults to lead to a poor outcome. We have
looked for correlations with clinical status in 260 paediatric CF
patients. Genomic DNA was analysed for structural mutations (desig-
nated 0; wild-type A) and the low (X) or high (Y) expressing promoter
polymorphisms. Patients were grouped based on haplotype which
correlated closely with MBL levels (measured by ELISA) into group 1
(A/A, 62.9%), group 2 (YA/O, 24%) and group 3 (XA/O or O/O,
13.1%). At the earliest time point available (7.0 (6.9–7.4) years),
children in group 3 had a significantly (p<0.05) higher FEV1 than
those in either of the other groups (gp 3: median [IQR] 105.5
(83;113)%; gp 2: 85.5 (78;103)%; gp1: 91 (76;105)%). At the age
of 9, a similar trend was seen (p=0.055). At approximate ages of 11,
13 and 15 years, no difference was seen in either parameter between
groups. Annual rate of decline was not affected by MBL status (gp 3:
−3.4 (−6.7; 0.3)%; gp 2: −3.5 (−5.9; −0.8 % gp 1: −3.0 (−6.4;
0.7)%). Infection with P aeruginosa increased the rate of decline, but
affected each group equally. In contrast to adult studies, low MBL is
not detrimental in childhood CF. The surprising finding that children
with the lowest MBL levels in fact have higher lung function early in life
may relate to the complex role of this protein in the inflammatory
response. The loss of effect later is likely due to the increased protease
activity on the airway surface with advanced disease. The most obvi-
ous difference between our group and those previously reported
relates to year of birth, other groups having been born up to 20 years
earlier. Over this time, CF treatment has progressed rapidly, possibly
reducing the importance of certain host factors. These results highlight
the importance of considering such environmental and treatment fac-
tors when studying modifier genes in CF.
S109 POLYMORPHISMS IN THE HYDROPHILIC
SURFACTANT PROTEINS A AND D ARE MODIFIERS
OF LIVER INVOLVEMENT BUT NOT LUNG DISEASE IN
CHILDREN WITH CYSTIC FIBROSIS
J.C. Davies1 3, P. Pantelidis2, A. Lagan2, R. Du Bois2, K. Welsh2, D.M. Ged-
des3, E.W.F.W. Alton3. 1Dept of Gene Therapy and 2Clinical Genomics
Unit, Imperial College, UK; 3Dept of Paediatric Respiratory Medicine, Royal
Brompton Hospital, London, UK
The surfactant proteins A and D are members of the collectin family
involved in the innate immune system. Polymorphisms within SP-A
have been associated with infant respiratory distress syndrome and
severe RSV bronchiolitis. We have explored a modifying effect of
these proteins on disease phenotype in children with CF. A sequence
specific primer-PCR methodology was employed which enabled the
identification of all known allelic variants on SP-A1, SP-A2 and SP-D
genes directly from genomic DNA samples. Clinical data collected
included lung function at defined ages, infection with common CF
pathogens, and the presence of liver disease on ultrasound. Data
were avaliable on 241 children at a mean (SEM) age of 8.5 (0.3)
years. No correlation was seen between any haplotype and lung
function at any age, risk of infection, use of IV antibiotics or age at
diagnosis. However, in children with liver disease (n=19) both the
SPA-1 allele 6A2, and the SP-A2 allele, 1A0, were significantly
overrepresented (6A2/6A2 68% v 33%, 6A2/non-6A2 32% v 47%,
non6A2/non6A2 0% vs 19%, p<0.01; 1A0/1A0 63% v 34%,
Abstract S106
Stage Not referredReferred
Resection (% of stage
group)
Stage I 19 33 23 (44%)52
Stage II 28 27 13 (24%)55
Stage IIIA 34 16 1 (2%)50
Total 81 76 37/458 (8%)157/458 (34.3%)
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1A0/non1A0 32% v 47%, non1A0/non1A0 5% v 18%, p<0.05). A
significant but less pronounced relationship was seen with the SP-D
group possessing both the 11T and 160A polymorphisms (p<0.05).
The lack of an association between these proteins and lung disease
may either reflect redundancy in the host defence system, or
enzymatic destruction of these proteins after release. The association
with liver disease was unexpected and is interesting. Inflammation has
been described in CF liver disease, although whether this is primary or
secondary remains uncertain. The surfactant proteins have recently
been identified in many extra-pulmonary sites including the the gastro-
intestinal tract, to date, only SP-D has been found in the biliary tree.
These data suggest a role for inflammation and host defence proteins
in the development of CF liver disease, and if further work is confirma-
tory, may allow identification of a subgroup at risk of this
complication.
S110 PRELIMINARY IDENTIFICATION OF GENETIC LOCI
ASSOCIATED WITH HIGH ALTITUDE PULMONARY
HYPERTENSION BY ASSOCIATION MAPPING
L. Long, A.A. Aldashev, A. Hensiek, S. Eddahibi, S. Adnot, R.C. Trembath,
M.R. Wilkins, N.W. Morrell. University of Cambridge School of Clinical
Medicine, Department of Medicine, Addenbrookes’ and Papworth Hospi-
tals, Cambridge CB2 2QQ, UK
Hypoxia-induced pulmonary hypertension is observed in residents at
high altitudes and in patients with hypoxic lung diseases, such as
chronic obstructive pulmonary disease. Well documented differences
between individuals, and between high altitude populations, in
susceptibility to pulmonary hypertension in low oxygen environments,
suggest that genetic factors may play a role. To identify genes confer-
ring susceptibility to hypoxia-induced pulmonary hypertension in
native highlanders, we performed an ECG survey of the inhabitants
(age 16 to 75, n=741) of 3 villages in Kyrgyzstan, at an altitude of
2800 to 3100m above sea level. Subjects with and without ECG signs
of cor pulmonale underwent echocardiography to define groups of
highlanders with and without pulmonary hypertension (defined by
mean pulmonary arterial pressure >25mmHg). DNA samples were
obtained from 30 cases and 30 controls. We used a DNA pooling
technique and performed a whole genome screen using 811 micros-
atellite markers (Applied Biosystems high density linkage mapping set
LMS-HD5), allowing a resolution of 5–10cM across the genome.
Association mapping identified alleles that occured with significantly
different frequency between cases and controls. Fifteen markers
showed significantly different frequencies (p<0.05) on chromosomes
1,3,5,6,7,8,15,17, and 20. An initial search for candidate genes
identified the locus for the serotonin transporter (5HTT) lying in close
proximity (2mB) to the marker on chromosome 17. A polymorphism in
the promoter of the 5HTT gene (L/S) is known to alter the expression
of 5HTT and is associated with primary pulmonary hypertension. The
frequency of the LL genotype, which increases 5HTT expression and
activity, was 24% in the group with high altitude pulmonary
hypertension compared with 12% in the controls. These results require
confirmation in a larger cohort of cases and controls, and refinement
of the chromosomal loci to aid in the identification of further candidate
genes. Nevertheless, this study provides a novel approach to the iden-
tification of genes that confer susceptibility to hypoxia-induced pulmo-
nary hypertension.
Funding: Wellcome Trust and British Heart Foundation.
S111 SMOKING RELATED EMPHYSEMA AND SMALL
AIRWAYS DISEASE HAVE INDEPENDENT GENETIC
RISK FACTORS IN COPD
B.D. Patel, A. Tasker, N. Screaton, W. Anderson, S. Sharma, E.K. Silver-
man, D.A. Lomas. Departments of Medicine and Radiology, University of
Cambridge, UK; GlaxoSmithKline, North Carolina, USA; Channing Labo-
ratory, Brigham and Women’s Hospital, Boston, USA
We previously have shown that COPD clusters within families suggest-
ing that shared genetic factors predispose some smokers to airflow
obstruction. It is unknown whether these genetic factors contribute to
the airway disease and/or emphysema components of COPD. This
has been addressed as part of the GSK COPD Genetic International
Network designed to identify the genes that predispose smokers to
COPD. The network has recruited probands aged 45–65 with an FEV1
<60% predicted and >5 pack years smoking history in the absence of
PiZ α1–antitrypsin deficiency. Siblings of the proband with a >5 pack
year smoking history were screened by spirometry for airflow obstruc-
tion. An HRCT scan was conducted on all consenting probands and
siblings and the extent and distribution of emphysema was quantified
by two independent radiologists. To date the network has recruited
approximately 2400 individuals from over 800 families. 350
individuals have been recruited from 105 families by the Cambridge
centre and this cohort has been used to define the familial risk of air-
ways disease and emphysema. Family phenotype was determined by
the extent of airways disease or emphysema in the proband. A
stronger correlation was found between pack years smoked and
FEV1% (r=−0.62, p=0.003) in the 20 siblings from families in whom
the proband had predominantly airways disease (<5% emphysema)
than in the 84 sibs from families where the proband had significant
emphysema (r=−0.32, p=0.0001). The familial risk for emphysema
was assessed in 89 sibs (47 men and 42 women) from 49 families in
whom the proband and at least 1 sibling had an HRCT. The siblings
of probands with 10–25% emphysema had an increased risk for sig-
nificant (>5%) emphysema (unadjusted OR 4.64, p=0.05) when com-
pared to siblings of probands with <10% emphysema. This risk was
independent of pack years smoked but was significantly greater in
women (OR 3.58, p=0.03). In conclusion, our data show that
individuals with COPD have a genetic susceptibility to airways
disease that is dependent on the pack years smoked. However
emphysema develops in genetically susceptible individuals who
smoke in a manner that is less dose dependent than airways disease.
Finally women may be more susceptible to emphysema than men if
they smoke.
S112 IMMUNOGENETICS OF LABORATORY ANIMAL
ALLERGY
H. Jeal, A. Draper, M. Jones, J. Harris, K. Welsh1, A. Newman Taylor, P.
Cullinan. Department of Occupational and Environmental Medicine and
1Interstitial Lung Disease Unit, Imperial College (NHLI), London, UK
Laboratory animal allergy is a common occupational health problem
affecting approximately 30% of the exposed population. Allergic
reactions to rats or mice are most common, probably because these
animals are most frequently used in experimental studies. HLA class II
molecules are involved in the presentation of allergen to the T cell and
are therefore likely candidates for controlling the immune response.
We hypothesised that HLA class II molecules might be associated with
sensitisation to rat urinary protein among individuals exposed to labo-
ratory animals.
We undertook a cross sectional study of 741 employees in contact,
at work, with laboratory rats at 6 pharmaceutical sites across the UK.
109 cases (defined as having a skin prick test wheal >3mm to rat
urine and/or a rat urine RAST >2%binding) and 397 non-sensitised
referents were HLA typed for DRB1 and DQB1 loci. Participants were
asked to complete a questionnaire enquiring into symptoms,
exposure, and job history.
After adjustment for independent risk factors, HLA-DR7 was found to
be associated with sensitisation (OR 1.99 CI 1.91–3.27), work-
related chest symptoms (OR 2.98 CI 1.66–5.36) and sensitisation
with symptoms (OR 4.81 CI 2.29–10.13). HLA-DR3 was protective
against sensitisation (OR 0.55 CI 0.31–0.98). Atopy and exposure
proved to be more strongly associated with sensitisation and sensitisa-
tion with symptoms than HLA.
Amino acid analysis of the associated HLA molecules provides a
biologically plausible explanation for these associations.
S113 MATERNAL BUT NOT PATERNAL GENETIC
VARIATION IN GSTP1 IS ASSOCIATED WITH ASTHMA
PHENOTYPES IN CHILDREN
F. Child1, W. Lenney1, S. Clayton1, S. Davies1, P.W. Jones2, J. Alldersea3,
R.C. Strange3, A.A. Fryer3. 1Academic Department of Paediatrics, North
Staffordshire Hospital, Stoke on Trent, UK; 2Department of Statistics,
University of Keele, UK; 3School of Medicine, Keele University, North Staf-
fordshire Hospital, Stoke on Trent, UK
Background: Maternal factors including atopy and smoking during
pregnancy are associated with the risk of developing asthma in child-
hood. Suggested mechanisms include transmission of specific
maternal alleles to the child and maternal influences on the intrauterine
environment. We have previously shown that polymorphism in gluta-
thione S-transferase, GSTP1 is associated with asthma, airway hyper-
responsiveness (AHR) and atopy in adults. We now hypothesise that
GSTP1 genotypes in the both mother and child, but not the father,
mediate asthma phenotypes in the child.
Methods: 145 Caucasian families were recruited via an asthmatic
proband aged 7–18 years. Atopy and asthma were assessed using a
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questionnaire, skin prick testing, total serum IgE, spirometry and
methacholine challenge testing. Phenotypic data were analysed as
continuous and categorical variables. Bronchial challenge data were
corrected for age, gender, height and baseline lung function. GSTP1
genotyping was determined using PCR.
Results: GSTP1 Val105/Val105 genotype in the child was weakly
associated with a reduced risk of atopy (p=0.038) and AHR
(p=0.069). In mothers (p=0.026) but not fathers (p=0.407), GSTP1
Val105/Val105 was associated with a reduced risk of AHR in the child.
This was independent of the child’s genotype, maternal and child
atopic status, maternal smoking during pregnancy, and transmission
of parental GSTP1 alleles.
Conclusion: For the first time, we have shown an association
between maternal genotype and the child’s asthma phenotype that is
not due to transmission of specific maternal alleles to the child. This
suggests an in utero effect of maternal genotype on the child and adds
new insights into the mechanisms by which maternal factors may influ-
ence the development of asthma in childhood.
Asbestos and the pleura
S114 DIFFUSE ASBESTOS-RELATED PLEURAL FIBROSIS; A
POOR GUIDE TO HEAVY DUST EXPOSURE?
C McGavin, K Smith, L Sykes. Derriford Hospital, Plymouth, UK
There has been an assumption that diffuse pleural fibrosis (DPF) is an
indicator of heavy dust exposure.1This has considerable implications
in the decision as to whether a given lung cancer has been caused by
asbestos. The UK Industrial Injuries Advisory Council2 consider that
lung cancer in the presence of DPF is an industrial tumour, but not in
the presence of pleural plaque (PP).
Method: We have tested the hypothesis that DPF is a marker of
heavy exposure by comparing estimated asbestos burden in 192
workers from the Devonport Dockyard, 96 with PP and 96 with DPF
(43 bilateral). Dust burden was calculated from previously published
data of exposure to asbestos by individual trades within the Yard mul-
tiplied by years spent in that trade prior to 1972. Detailed
occupational histories were taken by one experienced observer who
had also read all the radiographs (C McG).
Results: There were no differences between the groups in terms of
age or time since first exposure. There were no differences in
estimated dust burden between men with PP and DPF (independent
samples t test, DF adjusted for unequal variances, t=1.045, DF=179,
p=0.3), nor between PP and unilateral and bilateral DPF analysed
separately, using logs of asbestos burden because of unequal
variances (F2, 189=2.56, p=0.08). However there was evidence that
men with bilateral DPF had had more exposure than those with unilat-
eral (t=2.86, DF=88, p=0.004, t-test adjusted for unequal variances).
Conclusion: We found no evidence that men with DPF have had a
greater exposure to asbestos than men with PP, and conclude that
there is no justification for using the presence of DPF as an indicator of
heavy exposure, for example in qualifying a lung cancer for industrial
status. Bilateral DPF suggests a heavier dust burden than unilateral.
1. International Expert Meeting on Asbestos, Asbestosis & Cancer: the
Helsinki Critera. Scand J Work Environ & Health 1997;23:311–16.
2. IIAC. Asbestos-related disease without Asbestosis. HMSO 1984,
C9184.
S115 TRANSFORMING GROWTH FACTOR BETA (TGFβ)
INDUCES MITOGEN-ACTIVATED PROTEIN KINASE
(MAPK) SIGNALLING IN MALIGNANT
MESOTHELIOMA CELLS
M.K. Wood, K.S. Abayasiriwardana, G.J. Laurent, S.E. Mutsaers, R.J.
McAnulty. Centre for Respiratory Research, University College London,
London WC1E 6JJ, UK
Malignant Mesotheliomas (MM) are fibrous tumours containing abun-
dant collagen. MM cells produce collagen as well as TGFβ, which is
a potent inducer of collagen synthesis. We have shown that antibody
neutralisation of TGFβ or inhibition of collagen synthesis using a pro-
line analogue inhibits collagen production in MM cells and reduces
tumour growth. TGFβ signals predominantly via the Smad pathway,
but also through the MAPKs. Over-expression of Smad7, the natural
inhibitor of the Smad pathway, blocks collagen production in
fibroblasts. However, in MM cells, we demonstrated enhanced colla-
gen production and tumour growth following transfection with Smad7.
From these findings we hypothesised that TGFβ-induced collagen pro-
duction by MM cells occurs via MAPK signalling. To assess this
hypothesis we performed Western blotting to determine if TGFβ stimu-
lated activation of two components of the MAPK pathway, ERK1/2
and p38 kinase, in MM cells. The effect of blocking these pathways,
using specific inhibitors UO126 (10µM) and SB203580 (10µM)
respectively, on collagen production was assessed by measuring
hydroxyproline levels using HPLC (nmol hydroxyproline/105
cells±SEM).
Results: Exogenous TGFβ1 activated both ERK1/2 and p38 kinase
in MM cells within 5min. Blocking ERK1/2 activity increased procolla-
gen production basally (control 0.26±0.01, UO126 0.49±0.02,
p<0.01) and after TGFβ1 stimulation (control 0.58±0.004, UO126
0.72±0.02, p<0.01). However the fold increase in collagen produc-
tion in response to TGFβ1 was 2.3 and 1.5 times basal levels in con-
trol and UO126 treated groups respectively, suggesting a decrease in
the response to TGFβ1. Blocking p38 kinase activity had a small inhibi-
tory effect on collagen production basally (control 0.48±0.02,
SB203508 0.39±0.02, p<0.01) and after TGFβ1 (control 0.59±0.01,
SB203508 0.47±0.04, p<0.02).
Conclusions: (1) the ERK1/2 and p38 kinase MAPK pathways are
rapidly activated by TGFβ1 in these cells, which may be important in
MM tumorigenesis; (2) MAPKs appears to have a role in TGFβ stimu-
lated collagen production by MM cells but do not appear to be the
major route of signalling in this response. Further elucidation of the
TGFβ signalling pathways involved in the regulation of collagen syn-
thesis and the specific roles of the MAPKs in MM may identify unique
pathways in this tumour, which might be exploited as potential thera-
peutic targets.
This work was funded by Cancer Research UK and British Lung
Foundation.
S116 IMMUNOHISTOCHEMICAL PROGNOSTIC MARKERS
IN MALIGNANT MESOTHELIOMA
N. Chaudhuri, I. Cawkwell, M.E. Cowen, A.P. Campbell, M.J. Lind. Aca-
demic Depts. of Oncology and Surgery, Castle Hill Hospital, Cottingham,
UK
Objective: A nihilistic attitude exists towards malignant mesothelioma
of the pleura (MMP) as most people die within a year of diagnosis
regardless of treatment or palliation. Some patients do survive longer,
multimodality treatment has increased survival in some centres and
there are promising novel therapies on the horizon. Immunohisto-
chemical markers have shown promise in predicting survival in other
solid tumours and they could be used to select patients for further treat-
ment in MMP.
Methods: Archival specimens were identified from a pathological
database. Immunostaining was carried out with p53, proliferative
markers—MIB1 and PCNA and apoptotic markers—Bcl2 and BAX.
Up to 90 blocks analysed from 74 patients (M:F—66:8, median age
67.7 years) diagnosed with malignant mesothelioma between 1997
and January 2001.
Results: Median and mean survivals were 218 and 314 (SD331)
days respectively. Patients were divided into two groups. See table.
Abstract S116
Survival
> 10 mths
Mean (SD)
Survival
< 10 mths
Mean (SD) p Value
Age (years) 64.1 (10.2) 68.5 (9.8) 0.021
MIB +ve stain 43.8 (14.9) 78.3 (12.2) <0.001
PCNA +ve stain 79.4 (14.4) 75.5 (14.4) NS
BAX score 4.7 (1.6) 4.7 (1.1) NS
Bcl2 score 0.9 (1.4) 1.2 (1.3) NS
P53 score 3.8 (1.3) 4.0 (1.3) NS
P53 stain 57.0 (18.3) 51.8 (19.4) NS
Histological
subtype
Mean Survival
(days) SD p Value
Epithelial 425.8 277.2 <0.001
Biphasic 212.3 162.5
Sarcomatous 127.8 113.2
Spoken sessions iii35
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
Conclusions: Age and histological subtype influence survival in
malignant mesothelioma as has been shown in other studies. In our
study we found MIB1 could predict long-term survival in patients with
MMP.
S117 SURVIVAL IN SURGICALLY DIAGNOSED PATIENTS
WITH MALIGNANT MESOTHELIOMA IN CURRENT
PRACTICE
C. Tan1, S. Swift2, C. Gilham3, S. Shaefi1, W. Fountain2, J. Peto3, T. Treas-
ure1. 1Thoracic Unit, Guy’s Hospital, London, UK; 2Thoracic Unit, Harefield
Hospital, Harefield, UK; 3Institute of Cancer Research, London, UK
Objective: There is an epidemic of malignant mesothelioma in Europe
that presents a challenge to thoracic surgeons. The median survival is
quoted as five months (150 days) but reports are from ten or more
years ago. To evaluate results of new treatments we set out to estab-
lish survival statistics for current practice.
Methods: We searched back five years in the pathology database
of our two hospitals for all pleural biopsies in which mesothelioma was
diagnosed.
Results: We found a total of 426 cases and report on 409 where
we know vital status (table). Survival was 174 days (82%) longer at
one hospital than the other. This difference is not explained by histo-
logical type, sex, or age. Epithelioid type and age (younger) were
associated with better survival as is consistently shown.
Conclusion: Claims for improved treatments are made with refer-
ence to historical data for the natural history of the disease. Not only
are survival times (from diagnosis) longer than those quoted but the
difference between two hospitals is far greater than the likely gain
from any novel or more radical therapy. The possible explanations
include lead time bias due to earlier referral in Harefield as opposed
to Guy’s or differences in histological diagnostic threshold. Whatever
the explanation it illustrates the need for a contemporaneous control
group and our data emphasise the case for a randomised controlled
trial.
S118 ACTIVATION OF PROTEASE ACTIVATED RECEPTOR-2
IN MESOTHELIAL CELLS: A NOVEL MECHANISM OF
PLEURAL INFLAMMATION
Y.C.G. Lee, D.A. Knight, K.B. Lane, D.S. Cheng, M.A. Koay, I.R. Teixeira,
P.J. Thompson, R.W. Light. Vanderbilt University and St. Thomas Hospital,
Nashville, TN, USA; Wellcome Trust Centre for Human Genetics, Oxford
University, UK; University of Sao Paulo, Brazil; Asthma and Allergy
Research Institute and University of Western Australia, Australia.
Pleural inflammation underlies a vast range of pleural diseases, but its
mechanism remains poorly understood. Protease activated receptor
(PAR)-2 is a novel seven-transmembrane G protein-coupled receptor.
We recently showed that PAR-2 are present in abundance on human
pleural mesothelial cells, and stimulation of PAR-2 in vitro resulted in
significant release of inflammatory cytokines (AJRCCM
2002;165:A606).
We hypothesised that PAR-2 in mesothelial cells has a functional
role in pleural inflammation in vivo.
C57BL/6 mice were given a single intrapleural injection of
10mg/kg of SLIGRL-NH2 (a specific PAR-2 activating peptide), or
10mg/kg of LSIGRL-NH2 (control peptide), or the vehicle, phosphate-
buffered saline (PBS). At 4 hours, the mice were sacrificed. Cytokines
were measured with ELISA. Neutrophils were counted on cytospin
slides (Geimsa stains).
Pleural fluid MIP-2 levels were significantly higher in mice injected
with SLIGRL-NH2 (2710±165pg/mL) than in those given control pep-
tide (880±357pg/mL) or PBS (88±46pg/mL), p<0.001. Similarly,
pleural fluid TNFα was significantly higher in the SLIGRL-NH2 group.
In the SLIGRL group, the neutrophil counts in the pleural fluid were sig-
nificantly higher than the control peptide (by 40 fold) and the PBS
groups (by 26 fold). The MIP-2 and TNFα levels were 15- and 4-fold
higher in the pleural fluid than in serum, consistent of local pleural pro-
duction. There were no differences in the serum levels of these
cytokines among the three groups. The MIP-2 and TNFα levels were
strongly correlated in the pleural fluids (r=0.92, p<0.00001) and in
serum (r=0.76, p<0.01). There were no differences in the pleural fluid
volume or in its VEGF concentrations among the three groups.
This study is the first to show a functional role for PAR-2 in the
pleura. Our results confirmed that activation of PAR-2 in mesothelial
cells in vivo resulted in significant production of pro-inflammatory cyto-
kines with resultant neutrophil recruitment into the pleural cavity.
Asthma mechanisms II
S119 INCREASED SUB-EPITHELIAL PROTEOGLYCANS IN
THE AIRWAYS OF MICE FOLLOWING OVALBUMIN
SENSITISATION AND CHALLENGE
A.K. Reinhardt, S.E. Bottoms, G.J. Laurent, R.J. McAnulty. Centre for Respi-
ratory Research, University College London, London WC1E 6JJ, UK
The sub-epithelial thickening of asthmatic airways is manifested by
increased fibroblast/myofibroblast proliferation and deposition of
extra-cellular matrix components including collagens and proteogly-
cans. The degree of proteoglycan deposition has been correlated with
airway responsiveness. Existing murine models of asthma, including
our own, have demonstrated increased amounts of airway
sub-epithelial collagen following ovalbumin sensitisation and chal-
lenge. However, we are not aware of any studies examining altered
airway proteoglycan deposition in an asthma model. In this study we
have investigated changes in proteoglycan deposition in sections of
murine lung using a selective histological stain and computer-assisted
image analysis.
Wild-type SV129/C57BL/6 mice were sensitised by intra-
peritoneal injection of 10µg of ovalbumin in 0.1ml saline on two
occasions 10 days apart. 21 days after the second sensitisation mice
were challenged with 400µg of ovalbumin in 50µl saline by
intra-tracheal instillation daily for 6 days. Control mice were sham
sensitised/sham challenged. 12 days after the final challenge mice
were killed. Lungs were inflated with a 1:3 embedding matrix:saline
mixture at a pressure of 25cm water, set in embedding matrix and fro-
zen in liquid nitrogen for histological analysis. 7µm frozen sections
were stained overnight using cupromeronic blue and a critical electro-
lyte concentration of 250mM magnesium chloride. Sub-epithelial pro-
teoglycan staining was quantitated using a computer-assisted image
analysis system. Airways were selected using pre-defined criteria and
each airway was examined using separate colour thresholding for
lumen and sub-epithelial proteoglycans. Results were expressed as
amount of proteoglycan per unit airway lumen perimeter.
Lung sections from a total of 19 animals were examined (10 oval-
bumin sensitised/challenged and 9 controls). A total of 52 ovalbumin
sensitised/challenged and 32 control airways were analysed. The
mean area of proteoglycan/µm airway perimeter was 5.46±0.39µm2
in the ovalbumin sensitised and challenged group and 4.13±0.44µm2
in the sham sensitised/sham challenged group (p=0.03). This
represents a mean increase of 32% in sub-epithelial proteoglycan
deposition following ovalbumin sensitisation and challenge. Interest-
ingly, in view of the association between proteoglycans and collagen
fibril assembly, sub-epithelial collagen is increased by 33% using the
same sensitisation/challenge protocol. We conclude that the increase
in sub-epithelial proteoglycan and collagen deposition found in the
airways of asthmatics can be reproduced in mice following ovalbumin
sensitisation and challenge and that this may be a useful model to
assess the mechanisms regulating sub-epithelial airway remodelling.
Work funded by the Wellcome Trust.
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Hospital
Number of
cases
Median
survival
(days)
Days to
25% dead
Days to
75% dead
Age median
(IQR) Males
Epithelioid
histology
Guy’s Hospital 175 213 93 478 67 (59–74) 80% 54%
Harefield Hospital 234 387 162 – 68 (62–74) 83.4% 58%
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S120 WNT SIGNAL TRANSDUCTION IN ADULT
BRONCHIAL EPITHELIAL CELLS
M.D. Steel, D.E. Davies, S.M. Puddicombe, S.T. Holgate, J.E. Collins. Divi-
sion of Inflammation, Infection and Repair, School of Medicine, University
of Southampton, Southampton, SO16 6YD, UK
Wnts are a highly conserved family of secreted glycoproteins that play
a fundamental role in cell fate determination and tissue morphogen-
esis during embryonic development.1 Through binding to members of
the Frizzled (Fzd) receptor family, class-1 Wnts induce the accumula-
tion of hypophosphorylated β-catenin by inhibiting the GSK-3β/axin/
APC destruction complex. Consequent translocation of β-catenin to the
nucleus gives rise to activation of TCF/LEF-1 transcription factors,
leading to expression of genes involved in cell migration (CD44,
MMP7) and proliferation (c-myc, cyclin-D1). In mammalian embryonic
lung, activation of this “canonical” pathway in airway epithelial cells
has been implicated in the process of branching morphogenesis, and
Wnt secretion by underlying mesenchymal cells is thought to play a
key role.2 Despite reports that several WNT and FZD genes are
expressed in adult human lung tissue, very little is known about which
cells are involved, and their functional significance remains unclear.
Using an RNAse protection assay, we have identified expression of
FZD-2, -3, -5 and -6 in both H292 and primary bronchial epithelial
cells. In addition, these cells also express the gene encoding secreted
Frizzled receptor protein-1 (SFRP1), the product of which is capable of
modulating Wnt signals in the extracellular compartment. Postulating
that human airway epithelial cells retain the ability to transduce a
canonical Wnt signal in adult life, we employed RT-PCR and observed
expression of TCF-4 mRNA in primary cells, with weaker expression of
TCF-3, but no detectable message for TCF-1 or LEF-1. Using a TCF
reporter construct (TOPFLASH) in H292 cells, we demonstrate repres-
sion of TCF transcription at baseline, with activation induced by stimu-
lation with lithium, an inhibitor of GSK-3β and mimicker of class-1 Wnt
activity. Our data supports our hypothesis, and we speculate that
reactivation of this morphogenetic pathway in adult human lung may
play an important role in airway epithelial regeneration, as well as
remodelling in airways disease.
This study is funded by: Medical Research Council (UK)
G84/5708.
1. Wodarz, et al. Ann Rev Cell Dev Biol 1998;14:59–88.
2. Tebar, et al. Mech Dev 2001;109:437–40.
S121 FACTORS INFLUENCING CROSS SECTIONAL AND
LONGITUDINAL ASSOCIATIONS BETWEEN EXHALED
NITRIC OXIDE AND INDUCED SPUTUM EOSINOPHIL
COUNT IN ADULTS WITH ASTHMA
M.A. Berry, R.H. Green, A.J. Wardlaw, I.D. Pavord. Glenfield Hospital,
Groby Road, Leicester LE3 9QP, UK
There is increasing evidence that a management approach that
includes monitoring airway inflammation in asthma leads to an
improved outcome. Induced sputum eosinophil count and exhaled
nitric oxide (NO) concentration are both potential non-invasive meas-
ures of airway inflammation, although exhaled NO is more suited to
serial measurements. Little is known about the relationship between
these two measurements and the factors which influence it. We have
investigated the relationship in 246 non-smoking and 75 smoking
adults with stable asthma of variable severity who had both exhaled
NO and induced sputum eosinophil counts measured on the same
visit. We have also examined the relationship between change in spu-
tum eosinophil count and exhaled NO in 75 patients with moderately
severe asthma who were participating in a prospective longitudinal
study and had 9 paired measurements over the period of one year.
We found a significant positive correlation between exhaled NO and
sputum eosinophil count in non-smokers (r=0.461, p<0.001) and
between change in the variables (r=0.262, p<0.001). There was no
significant correlation between the two measurements in smokers.
Within the non-smoking group the correlation was stronger in: males
(r=0.637, p<0001) than females (r=0.387, p<0.001), in those not on
inhaled steroids (r=0.497, p<0.001) compared to those who were
(r=0.385, p<0.001) and in atopic (r=0.605, p<0.001) compared to
non-atopic patients (r=0.366, p<0.001). The relationship between
change in sputum eosinophil count and exhaled NO was also stronger
in males (r=0.303, p<0.001) than females (r=0.183, p=0.016).
Smoking, gender, atopy and inhaled steroid use have a significant
impact on the relationship between exhaled NO and sputum eosino-
phil counts in cross sectional analysis. In both cross sectional and lon-
gitudinal analysis there is a marked difference in the relationship
between exhaled NO and sputum eosinophil count in males and
females. This could be due to the effect of female sex hormones on
NO-synthase. The relationship between the variables is much closer in
cross sectional study than between change in the variables,
suggesting that they identify a common airway abnormality but are
regulated differently by factors that alter airway inflammation.
S122 SIMVASTATIN HAS AN ANTI-INFLAMMATORY EFFECT
IN A MURINE MODEL OF ALLERGIC ASTHMA
A. McKay1 2, B.P. Leung1, I.B. McInnes1, S. Culshaw1, N.C. Thomson2, F.Y.
Liew1. 1Departments of immunology and 2Respiratory Medicine, Western
Infirmary and University of Glasgow, UK
Introduction: Asthma is an eosinophilic inflammatory airways
disease. There is increasing evidence that statins, such as simvastatin,
have anti-inflammatory properties which are unrelated to their
lipid-lowering activity. We therefore wished to study the effect of sim-
vastatin in a murine model of asthma.
Methods: BALB/c mice primed with ovalbumin (OVA) were
re-challenged with OVA on three consecutive days. Simvastatin
40mg/kg or 4mg/kg or vehicle control were given intraperitoneally
(i.p.) at the time of these challenges. Analysis was done one day after
the last challenge.
Results: Simvastatin treatment at a dose of 40mg/kg i.p. resulted
in a significant reduction in bronchoalveolar lavage (BAL) total cellu-
larity (mean \” SD: simvastatin 17.9 \” 5.53 × 104/ml v vehicle con-
trol 39.4 (15.2) x 104/ml, p < 0.01) and eosinophilia (simvastatin
5.59 (3.17) × 104/ml v vehicle control 19.4 (9.92) × 104/ml, p <
0.01). Both high and low dose i.p. simvastatin treatment were associ-
ated with a reduction in BAL interleukin (IL)-4 and IL-5 levels and also
in OVA-induced IL-4 and IL-5 production in thoracic lymph node (LN)
cultures. See table.
Reduced inflammation was observed in lung histology in the
simvastatin-treated mice. Serum OVA-specific IgG1, IgG2a, and total
IgE levels were unaltered by simvastatin treatment.
Conclusion: These results demonstrate that simvastatin has
anti-inflammatory effects in this murine model of allergic asthma.
S123 A CASE-CONTROL STUDY OF MEMBRANE FATTY
ACIDS IN ASTHMA
E. Broadfield, A. Whitehead, N. Lawson, J. Britton, A. Fogarty. University
of Nottingham, UK
Rationale: As substrates for eicosanoid production, it is hypothesised
that omega-6 polyunsaturated fatty acids (PUFA) may increase the
prevalence and/or severity of asthma. Furthermore as competitive
antagonists of this process, omega-3 fatty acids may have a protective
role. This study was designed primarily to explore whether asthmatics
have increased levels of erythrocyte membrane omega-6 PUFA
compared to non-asthmatics, and secondarily whether there are differ-
ences in the levels of the other main fatty acids between asthmatics
and controls.
Method: Fasting blood samples were taken from 89 asthmatics on
inhaled steroids and 89 community controls, matched for age, sex,
and area of residence. Percentage levels of the 8 most abundant
erythrocyte membrane fatty acids were measured using gas
chromatography, and the levels in cases and controls compared using
the paired t test.
Results: The levels of two PUFA (palmitoleic and eicosapentaenoic
acids) were too small to be measured and were therefore excluded
from the analysis. Cases were found to have significantly lower eryth-
rocyte membrane levels of the omega-6 fatty acid linoleic acid and
higher levels of the saturated fatty acid stearic acid. See table.
Abstract S122
Mean (SD)
Simvastatin
40mg/kg i.p.
Simvastatin
4mg/kg i.p. Vehicle control
BAL
IL-4 (pg/ml) 13.2 (21.9)** 26.0 (20.2)* 52.6 (32.2)
IL-5 (pg/ml) 57.8 (30.2)** 90.2 (34.5)** 219.3 (52.2)
LN
IL-4 (pg/ml) 55.1 (15.1)** 99.8 (18.3)* 160.9 (11.8)
IL-5 (pg/ml) 510 (40)** 1096 (76.5)** 1747 (239)
i.p., intraperitoneally.
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Conclusion: These findings are consistent with the hypothesis that
dietary omega-6 PUFA may be involved in the aetiology of asthma,
but not with a protective role for omega-3 fatty acids. The unexpected
finding of increased levels of the erythrocyte membrane saturated fatty
acid stearic acid warrants further investigation.
Drug therapy in cystic fibrosis
S124 SERUM AND SPUTUM CONCENTRATIONS
FOLLOWING THE ORAL ADMINISTRATION OF
LINEZOLID IN ADULT PATIENTS WITH CYSTIC
FIBROSIS
D. Saralaya, D. Peckham, B. Hulme, C. Tobin, S. Conway. Regional Adult
Cystic Fibrosis Unit, Seacroft Hospital, Leeds LS14 6UH, UK
Introduction: Linezolid is a new antibiotic with efficacy against
methicillin resistant Staphylococcal aureus (MRSA). Although licensed
for the treatment of respiratory tract infections, there are, as yet, no
published trials of its use in cystic fibrosis (CF).
Aim: The objective of the study was to evaluate the absorption and
sputum penetration of oral Linezolid in with CF patients.
Methods: 10 (5 male & 5 female) adult CF patients were recruited
over a 3 month period. The mean (range) age, BMI and % predicted
FEV1 were 25.4 years (19–36), 20 (2.2) and 47.8% (22–90) respec-
tively. Inclusion criteria included the absence of MRSA infection or sig-
nificant liver disease. Treatment was administered under nursing
supervision. Subjects received 600mg of Linezolid orally every 12
hours for 6 doses. Serum and sputum drug levels were measured
before and at 2 hours after the final dose of Linezolid. A further serum
level was measured at 4 hours. Serum and sputum levels were
measured by High Performance Liquid Chromatography.
Results: Mean (SD) serum Linezolid levels were 2.3mg/l (1.5) at
12 hours following the 5th dose and 13.5 mg/l (4.3) and 8.1 mg/l
(3.3) at 2 and 4 hours following the 6th dose. High sputum concentra-
tions were obtained with mean (SD) levels of 3.6 mg/l (2.1) and 17.3
(6.9) at 2 and 4 hours following drug administration. Good sputum
penetration was observed with mean sputum to plasma ratio of 1.4 at
2 hours. There was a significant variation in peak serum levels within
the studied population. However, even the lowest peak concentration
exceeded the MIC 90 for MRSA (2–4 mg/l). Serum levels in this study
are slightly lower than levels obtained in non-CF historical controls.
Conclusion: The administration of 12 hourly ,600mg oral
Linezolid to CF patients results in sputum levels that exceed the MIC90
of MRSA for almost the whole dosing period. Further clinical trials are
needed to assess the efficacy of Linezolid against MRSA in this patient
group.
S125 A PROSPECTIVE, DOUBLE-BLIND, RANDOMISED,
PLACEBO CONTROLLED, CROSSOVER TRIAL OF
AZITHROMYCIN IN PAEDIATRIC CYSTIC FIBROSIS
A. Equi, A. Bush, I.M. Balfour-Lynn, M. Rosenthal. Royal Brompton and
Harefield NHS Trust, London, UK
Following significant improvements in lung function in a pilot study of
seven patients with cystic fibrosis who received azithromycin daily for
at least three months,1 we now report a prospective, double blind, pla-
cebo controlled, double blind, crossover trial of AZM in paediatric CF
patients.2
Methods: 41 CF children aged 8 to 18 years, median expired vol-
ume in one second (FEV1) 61% (range 33 to 80%) participated in a 15
month randomised double-blind placebo controlled crossover trial
receiving either Azithromycin (body weight <40kg: 250mg daily,
>40kg: 500mg daily) or placebo for 6 months. Following 2 months
washout, the treatments were crossed over. Spirometry, sputum
cultures, sputum interleukin 8 and neutrophil elastase, exercise testing,
quality of life, antibiotic usage and pulmonary exacerbation rates
were outcome measures. Side effects were assessed by pure tone
audiometry and liver function tests.
Results: The median relative difference in FEV1 between azithromy-
cin and placebo was +5.4% (95% CI 0.8 to 10.5 %). 13/41 subjects
improved by >13% and 5/41 deteriorated by >13% (p=0.059). The
median relative difference between azithromycin and placebo was
+11.5% (5.3 to 16.5) when not receiving concurrent rhDNAse (n=26)
and −3.6% (−22 to +3.9) for the 15 receiving rhDNAse (Mann Whit-
ney p=0.003). There was no significant overall change in forced vital
capacity or mid expiratory flow rates but the effect of rhDNAse usage
was similar for these measurements. Overall, 17/41 subjects had 24
fewer oral antibiotic courses when on azithromycin compared with
placebo and 5 subjects had 6 extra courses (p<0.005). Of the 12/15
children on rhDNase, 11/15 needed intravenous antibiotics whilst on
azithromycin compared with 6/15 when on placebo (p<0.05). There
were no changes in sputum bacterial densities, inflammatory markers
exercise tolerance or subjective well-being. There were no significant
side effects.
Conclusions: A four to six month trial of azithramycin is justified in
children with CF not responding to conventional therapy.
1. Jaffe A, et al. Long-term azithromycin may improve lung function in
children with cystic fibrosis. Lancet 1998;351:420.
2. Equi A, Balfour-Lynn I, Bush A, et al. Long term azithromycin in chil-
dren with cystic fibrosis: a randomised, placebo-controlled crossover
trial. Lancet 2002;360:978.
S126 A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL
TRIAL TO DETERMINE THE SAFETY OF ICODEXTRIN
AND ITS EFFECT ON MUCOCILIARY CLEARANCE IN
CYSTIC FIBROSIS
M. Stern1 4, T. Wodehouse1 4, A. Hasani2 , J. Davies1 4, D. Hansell1, M.
Parry-Billings3, E. Peers3, M. Shott3, J. Agnew2, D.M. Geddes1 4, E.W.F.W.
Alton1 4. 1Dept Gene Therapy, Imperial College at the NHLI; 2Dept Medical
Physics, Royal Free Hospital & Medical School; 3Innovata Biomed Ltd, St
Albans, Hertfordshire, UK; 4UK Gene Therapy Consortium
Cystic fibrosis (CF) may best be managed by therapy directed at
restoring the volume of airway surface liquid (ASL). We tested a strat-
egy to increase ASL, and hence mucociliary clearance, by providing
an osmotic stimulus to the lower airways using icodextrin, a high
molecular weight glucose polymer used in peritoneal dialysis to
produce colloidal osmosis but never tested in the human lung. In a
double-blind, placebo-controlled crossover study, 10 CF patients
(>18 yr, FEV1>60% predicted) were randomised to receive either
nebulised (Pari LC-65) icodextrin (10 ml, 200 mg/ml in normal saline)
or placebo (10 ml normal saline). The second treatment was adminis-
tered one week later. Following each treatment, measurements of lung
function (spirometry and oximetry) made daily for 7 days as well as 2
serial high resolution CT scans of the lungs showed no evidence of
icodextrin-associated pulmonary toxicity. There were no significant
changes detected in serial full blood counts, ESR, CRP, renal and liver
function tests, serum IL-6 and IL-8, supporting systemic safety. Baseline
mucociliary clearance (MCC) was determined for a 4hour period
using a radioaerosol/gamma camera technique and 5 m
99mTcpolystyrene particles. The same scanning protocol was repeated
after each treatment. Compared to baseline (443.5±7.8 %/hour), ico-
dextrin (401.5±11.8 %/hour), but not placebo (417.8±10.2
Abstract S123
% composition
Mean difference Standard error p ValueAsthmatic Controls
Palmitic acid 38.2 37.5 0.678 1.003 0.50
Stearic acid 20.1 18.0 2.090 0.478 0.00
Oleic acid 13.1 13.0 0.060 0.443 0.89
Linoleic acid 7.4 8.6 −1.197 0.347 0.00
Arachidonic acid15.4 16.3 −0.936 0.533 0.08
Docosahexcae
noic acid
5.8 6.3 −0.535 0.612 0.38
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%/hour), was associated with a significant (p=0.01) increase in MCC
as expressed by the area under the whole lung radioaerosol retention
curve. The effect of icodextrin was most marked on tracheobronchial
clearance rate after 150 and 180 minutes respectively when
significantly (p=0.03) less radioaerosol (26.4±2.4% and 21.8±2.0%)
was retained compared to baseline (43.2±4.8% and 34.2±4.1%).
Whilst compared to placebo, icodextrin was associated with
increased tracheobronchial radioaerosol clearance, the difference
between icodextrin and placebo did not reach statistical significance
at any time point measured. In conclusion, nebulised icodextrin
appears to improve MCC in CF patients but further optimisation of
dose and delivery may still be required to determine whether it offers
any significant advantage over nebulised saline.
S127 INTERACTION BETWEEN AEROSOL DELIVERY SYSTEM
AND BRONCHODILATORS IN CF PATIENTS TAKING
COLISTIN
M.E. Dodd1, S. Conway2, R.J. Marsden3, P.H. Weller4. 1Wythenshawe
Hospital, Manchester, UK; 2St. James’s Hospital, Leeds, UK; 3Profile Thera-
peutics, UK; 4The Birmingham Children’s Hospital, Birmingham, UK
Chest tightness is a recognised side effect of nebulised antibiotics
(AB). We describe a sub group of patients who nebulised colistin in a
clinical trial. Patients using nebulised AB and DNase for >90 days
were randomised to use the HaloLite AAD system (AAD) or a conven-
tional high output nebuliser (NEB) over a 182 day period (study MAL
25–70). All patients used bronchodilators, some of the patients in
each nebuliser group used a pMDI or DPI (INHL) others used a solution
(SLN) form through the study device. This abstract reports preliminary
analysis of % predicted FEV1 mean change from baseline to day 28,
and to day 182 for each combination of nebuliser (AAD or NEB) and
bronchodilator (SLN or INHL).
Results: 189 of 259 patients used colistin. See table.
Two way anaysis of variance demonstrated a significant interaction
between device type and bronchodilator type for change in FEV1
(p=0.001).
Conclusions: The use of a bronchodilator prior to nebulising anti-
biotics is recommended practice to prevent inhaled antibiotic induced
chest tightness in adult and paediatric patients. These data suggest
that the use of a bronchodilator solution with colistin in patients using
AAD has a positive effect on maintaining both short and long-term
FEV1. This effect was not seen in the NEB group, nor was it evident in
patients using INHL.
This study was sponsored by Profile Therapeutics, UK.
S128 THE UTILITY OF SALIVARY LEVELS FOR MONITORING
ONCE DAILY INTRAVENOUS AMINOGLYCOSIDES IN
CHILDREN WITH CYSTIC FIBROSIS
H. Spencer, P. Webber, M. Chadwick, S. Makhechas, J. Kerr, J.C. Davies.
The Royal Brompton Hospital, London, UK
First line intravenous antibiotic treatment for children with pulmonary
exacerbations of cystic fibrosis (CF) includes an aminoglycoside (AG)
such as gentamicin or tobramycin. The nephro and ototoxic side effect
of these drugs make monitoring of levels mandatory. Two previous
studies have reported the use of salivary trough levels to monitor once
daily AGs in patients without CF. Although a correlation was shown
between saliva and serum values, there was no confirmation that the
method could reliably detect toxic levels. In view of this, and the fact
that CF saliva is known to be abnormal, we have assessed the utility
of this approach in children with CF. CF children prescribed once
daily AGs (10–12 mg/kg) were eligible for inclusion if they were old
enough to produce saliva, and if they and their parent consented to
the study. 28 patients (21 gentamicin, 7 tobramycin, median (range)
age9.97 years(3.89 to 16.75) had simultaneous serum and saliva
samples immediately prior to the 3rd dose of drug. In the majority
(n=25), a few crystals of citric acid were placed on the tongue to
stimulate saliva production, up to 2 mls of which was collected into a
sterile polystyrene container. Blood samples were taken by peripheral
venepuncture. Saliva collection was well tolerated in all cases. 27/28
patients had a serum level of <1 (mg/L). In 24 of these (89%), the sali-
vary level was also <1, but in 3 patients higher levels were obtained
(8.96,4.98,4.3). Only one patient had a toxic serum level of 1.6; this
patient also had a high salivary level (7.7).
This study demonstrates that both gentamicin and tobramycin can
be detected in saliva. The salivary measure confirmed a safe serum
level (<1mg/L) in 89% of children, but in a minority, salivary levels
were spuriously high. With regards to safety of salivary monitoring,
only one patient had a serum trough level that was considered toxic at
>1 (mg/L). In this child, the saliva sample detected this and was also
abnormally high. Although these data are promising, confirmation of
safety will require evidence from further children that salivary levels
are consistently raised in the presence of toxic serum levels.
S129 ALTERED TISSUE DISTRIBUTION IN ADULTS WITH
CYSTIC FIBROSIS
C.E. Bolton, A.A. Ionescu, W.D. Evans, R. Pettit, D.J. Shale. Sections of
Respiratory Medicine and Medical Physics, University of Wales College of
Medicine, Llandough Hospital, Penarth, Cardiff CF64 2XX, UK
We studied the distribution of altered body composition in 51 adults
with cystic fibrosis (CF) colonised with Pseudomonas aeruginosa and
18 age and sex matched healthy subjects. Using DEXA scanning we
derived height indices for total fat mass (FMI), fat free mass (FFMI) and
bone mineral content (BMCI) of the right arm, leg and trunk.
Spirometry, height, weight, and physical activity (METS) data were
determined.
In patients, FFMI of the arm and leg were less (p<0.05).The truncal
FFMI difference was not significant (possibly due to group diversity or
that viscera are classed as FFM). Amongst the patients, there was a
greater deficit (compared with the mean control) of FFMI in the leg
than arm than the trunk (18.19%, 14.86%, +0.09%, p<0.02).
For patients, FFMI for arm, leg and trunk were less (p<0.05) in the
severe (FEV1 <45%) than the mild (FEV1 >65%) disease group.
Amongst the severe group, there was (p<0.02) greater deficit of FFMI
in leg (28.68%) than arm (23.76%) than trunk (3.93%). See table.
Patients with a normal BMI, low total FFM (n=10) had a lower
(p<0.01) arm, leg and trunk FFMI than those with a normal BMI, nor-
mal total FFM (n=13).
The BMCI of the arm, leg, and trunk of patients were less (all
p<0.001) than the controls. There was a lesser BMCI in the severe
than the mild (p<0.03) disease. Patients with a normal BMI, low total
FFM had a lower (p<0.03) arm, leg, and trunk BMCI than those with
a normal BMI, normal total FFM. In all cases, there was no significant
difference in the deficit of BMCI between arm, leg, and trunk. Fat mass
in patients was not reduced.
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Device
bronchodilator
combination n
Baseline age
median (IQR)
Baseline FEV1
% predicted
mean (CI)
% Change in FEV1 %
predicted at 28 days
mean (CI)
% Change in FEV1 %
predicted at 182 days
mean (CI)
AAD SLN 51 19 50 6.6 0.5 (n=48)
(13 to 26) (44 to 56) (1.0 to 12.1) (−6.6 to 7.7)
NEB SLN 43 19 53 −3.9 −3.7 (n=41)
(14 to 28) (47 to 60) (−8.6 to 0.8) (−11.7 to 4.3)
AAD INHL 43 13 65 −7.3 −7.0 (n=39)
(10 to 18) (59 to 70) (−12.5 to −2.1) (−12.1 to −2.0)
NEB INHL 41 15 64 −0.8 −5.1 (n=38)
(13 to 18) (57 to 72) (−4.7 to 3.2) (−11.3 to 1.1)
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Preferential loss of FFM occurs in adults with CF. Such loss is related
to severity of lung disease and physical activity. It can occur in the
presence of a normal weight/height ratio. A similar loss of BMC
occurs with preservation of FM. A hierarchical pattern of FFM loss of
legs > arms > trunk was demonstrated whilst bone mineral loss
occurred generally.
Sponsored by the CF Trust, UK and the British Lung Foundation.
TNFα: Its role in respiratory
disease
S130 GENETIC SUSCEPTIBILITY TO OZONE EXPOSURE
I.A. Yang1, O. Holz2, R.A. Jorres2, H. Magnussen2, S.J. Barton1, J.A. Cake-
bread1, J.W. Holloway1, S.T. Holgate1. 1Asthma Genetics Laboratory, Divi-
sions ofHuman Genetics & IIR (Respiratory, Cell and Molecular Biology),
University of Southampton, UK; 2Hospital Grosshansdorf, Center for Pneu-
mology and Thoracic Surgery, Grosshansdorf, Germany
Ozone is a major air pollutant with adverse health effects, yet there is
variability in response between individuals. Genetic determinants that
modulate ozone-induced lung inflammation have been found in mice
specifically inbred to be prone or resistant to ozone exposure.1 We
hypothesised that polymorphisms in homologous human genes would
influence response to ozone.
Methods: 37 participants (12 asthmatic, 25 healthy) who had
undergone ozone challenge (intermittent exercise during inhalation of
ozone >200 ppb) were genotyped using ARMS-PCR for tumour
necrosis factor-α (TNF), glutathione peroxidase (GPX1), manganese
superoxide dismutase (SOD2) and toll-like receptor 4 (TLR4) polymor-
phisms.
Results: There was no difference in lung function response between
asthmatics and healthy participants. Mean change in FEV1 with ozone
challenge was −9.0% baseline in TNF -308G/G individuals,
compared to −0.6% baseline in TNF -308G/A or A/A individuals
(95% CI for difference between means −14.5 to −2.3, p=0.008, t
test). This difference remained significant even when only including
250 ppb exposures for 3h (p=0.007, Mann-Whitney U test, n=32).
No significant differences were detected with GPX1 or SOD2,
whereas the TLR4 polymorphism was too infrequent to analyse. No
significant interactions between genotypes were observed (General
Linear Model, SPSS V11).
Conclusions: This is the first study to extend the genetic linkage
findings of ozone exposure in mice to clinical ozone challenges. These
results suggest that the TNF locus is a genetic factor for susceptibility
to ozone exposure, as it is in the mouse.1 TNF haplotyping of larger
cohorts and functional analysis of cellular models are required to con-
firm these findings.
Supported by: Allen+Hanburys/Thoracic Society of Australia and
New Zealand Respiratory Research Fellowship
1. Kleeberger SR, et al. Linkage analysis of susceptibility to
ozone-induced lung inflammation in inbred mice. Nat Genet
1997;17:475–8.
S131 POLYMORPHISMS IN THE PROMOTER OF TUMOR
NECROSIS FACTOR (TNF) ALPHA GENE IN PATIENTS
WITH SILICOSIS AND THE DEVELOPMENT OF
PROGRESSIVE MASSIVE FIBROSIS
Y. Ohtsuka, X. Wang, K. Kimura1, T. Ishida, J. Saito, M. Munakata.
Department of Pulmonary Medicine, School of Medicine, Fukushima Medi-
cal University, Fukushinma, Japan; 1Iwamizawa Rousai Hospital,
Hokkaido, Japan
It is well known that there was pronounced individual variation in the
severity of silicosis even in the same exposure environments. To
explain this, we made our hypothesis that there might be an
association between genetic polymorphisms of TNF-α promotor region
and lung responses to silica particles in silicotic patients. To examine
our hypothesis, we studied the association of TNFα promoter polymor-
phisms (−308, −238 and −376 ) with the roentgenological severity of
silicosis in 124 sex-, smoking-, and exposure history - matched Japa-
nese silicotic patients. Silicotic patients were divided into three groups,
Pr (profusion rate) 1 (1/0–1/1, n=47), Pr3 (2/0–2/2, n=36), and
PMF (progressive massive fibrosis) (4c, n=43) according to the ILO
classification. We also examined 122 healthy controls within the
same regional district. TNF-α promoter polymorphisms were
determined using PCR-RFLP method. Results showed that frequency of
A-308 (GA/AA) genotype is significantly higher in Pr 1 and Pr3
patients, (17% and 22%) as compared with PMF and controls (0%
and 4%)(p<0.005). There were no significant differences at the −238
and −376 loci among the groups and controls. There are no linkage
disequilibilium among these regions. From these results, the TNF pro-
moter single nucleotide polymorphism (SNP) −308 might affect the
development of silicosis.
S132 TNF PROMOTER REGION SINGLE NUCLEOTIDE
POLYMORPHISM IN ARDS
A.L. Lagan, E. Beddow, S. Mumby, G.J. Quinlan, P. Goldstraw, J.D. Chris-
tie, P.N. Lanken, A.B. Fisher, R.M. Du Bois, K.I. Welsh, T.W. Evans. Unit
of Critical Care, Dept Thoracic Surgery & Clinical Genomics Group, ILDU
Imperial College Faculty of Medicine. Division of Pulmonary Medicine,
Department of Medicine, University of Pennsylvania Medical School, Phila-
delphia, USA
Critical illness in adults frequently predisposes to, or is accompanied
by acute lung injury (ALI), which in its most severe manifestation is
termed the acute respiratory distress syndrome (ARDS). Therapy for
ALI/ARDS is supportive and mortality rates remain high (30–70%).
The incidence of ALI/ARDS in a given patient population is dependent
in part upon the nature of the precipitating insult, and by inference
upon individual susceptibility. Genetic variation may therefore
contribute to the onset of ARDS in at risk populations. Acute inflamma-
tion is a major contributing factor to ARDS and TNF is a major media-
tor of the inflammatory response. We therefore performed a case
control study to test the association of a TNF promoter region polymor-
phism (−857) with ARDS. Patients were consented and DNA extracted
from whole blood and stored until time of analysis in sterile water at
−20°C. Archived controls were used for comparison. The genotype of
the biallelic single nucleotide polymorphism was determined by
polymerase chain reaction in association with sequence-specific prim-
ers incorporating mismatches at the 3’ end.
Patients with established ARDS (15 UK patients, 28 USA patients)
were typed for the TNF −857 promoter region polymorphism and
compared with a normal control population (347 UK controls) and an
at risk group of surgical lung resection patients (26 UK patients). A
significant increase in the rarer −857 T allele was observed in the
ARDS group when compared to controls (31% v 14%, p=0.01) and
the at risk group (31% v 4%, p=0.006). These preliminary results indi-
cate that variation in the expression of TNF a major pro-inflammatory
cytokine may contribute to the onset of ARDS. However increased
patient numbers and functionality studies will be required before firm
conclusions can be drawn.
Work in part funded by the Dunhill Medical Trust and The British
Lung Foundation.
S133 AUGMENTATION OF TNFα-INDUCED APOPTOSIS OF
HUMAN NEUTROPHILS BY THE AMINOPEPTIDASE
INHIBITORS BESTATIN AND ACTINONIN
A. Sobolewski, B.J. Reed, E.R. Chilvers. Department of Respiratory
Medicine, University of Cambridge, School of Clinical Medicine,
Addenbrookes’ and Papworth Hospitals, Hills Road, Cambridge,
CB2 2QQ, UK
Neutrophil apoptosis plays an important role in the control of lung
inflammation, resulting in cell clearance without a pro-inflammatory
response. Therapeutic enhancement of this process therefore
represents a major experimental goal. TNF is unique in its ability to
induce both neutrophil apoptosis and priming. Aminopeptidase
enzymes (AP) are involved in both protein maturation and
degradation, and their inhibition has been shown to induce apoptosis
in leukaemic cell lines. The aim of this study was to investigate the
effect of aminopeptidase inhibition on TNFα-induced apoptosis in
human neutrophils. Neutrophils were isolated from human blood using
Abstract S129
Leg FFMI Arm FFMI Trunk FFMI
FEV1 0.556 (p<0.001) 0.429 (p=0.002) 0.418 (p=0.003)
METS 0.652 (p<0.001) 0.555 (p<0.001) 0.507 (p<0.001)
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a Percoll separation. Cells were pre-incubated with AP inhibitors
actinonin and bestatin (0.001–1mM,30min) in RPMI (10% autologous
serum), prior to the addition of TNFα (100U/ml, 6h), and apoptosis
assessed by morphology. FACS analysis was used to assess
membrane TNFR55/75 following TNFα exposure (100U/ml,15min)
+/- actinonin/bestatin (1mM). Shape change and superoxide assays
were performed to study neutrophil priming and activation. To
elucidate the nature of neutrophil APs, colorimetric enzyme-substrate
assays were conducted on cell lysates in the presence of
actinonin/bestatin. TNFα alone enhanced the rate of apoptosis
(12±2%) compared to control levels (5±2%). Actinonin or bestatin
alone had no effect, but in conjunction with TNFα, increased apopto-
sis to 21±3% and 20±2% respectively. Actinonin and bestatin did not
affect neutrophil TNFR55/75 expression, shape change, or agonist
induced superoxide anion generation. Enzyme-substrate inhibition
profiles suggested the involvement of a basic AP. In conclusion, the AP
inhibitors, actinonin and bestatin, augment TNFα-induced neutrophil
apoptosis, independent of neutrophil priming, activation or altered
TNFR55/75 expression. This effect is likely to be via inhibition of a
specific aminopeptidase involved in maturation/degradation of a pro-
tein in the TNFα signalling cascade.
S134 TREATMENT OF CHRONIC SEVERE ASTHMA WITH A
SOLUBLE TNF ALPHA RECEPTOR (ETANERCEPT)
K.S. Babu1, S.H. Arshad1, E.J. Bell1, S.D. McLoughlin1, P.H. Howarth1, A.J.
Chauhan2, S.T. Holgate1. 1Respiratory Cell & Molecular Biology,
Southampton General Hospital, Southampton, UK; 2Department of Respira-
tory Medicine, St. Mary’s Hospital, Portsmouth, UK
Tumor Necrosis Factor Alpha (TNF-α) is a pro-inflammatory cytokine
implicated in the pathogenesis of asthma. TNF-α is increased in the
airways of asthmatics and is involved in the production of IL-8,
RANTES and GM-CSF by airway epithelial cells. Therefore there is a
good case for blocking TNF-α as a therapeutic strategy in asthma. This
open labelled study evaluated the efficacy of etanercept- a soluble
TNF-α receptor (p75) linked to the Fc portion of human IgG1 in the
treatment of chronic severe asthma.
Methods: 10 patients (18–65 years) with chronic severe asthma
on regular oral corticosteroids (13 ± 10.1mg/day), high dose inhaled
steroids, long acting inhaled β2 agonists and/or oral theophyllines
were enrolled. They had an FEV1 of at least 50% of their predicted and
demonstrated a reversibility of at least 9% with inhaled salbutamol.
The study involved administration of 25mg of etanercept twice weekly
for 12 weeks. Lung function measurements, methacholine response,
and asthma control questionnaire were completed before and after the
study.
Results: Treatment with etanercept resulted in clinically significant
improvements in the lung function. FEV1 improved from 2.21L/sec
(1.81–2.52), median (IQR) to 2.68 L/sec (1.77–2.75, p= 0.037) and
the FEV1/FVC ratio improved from 75.63% (68.03–81.27) to
82.39% (69.64–88.75, p= 0.028). The mean asthma control symp-
tom score improved from 26 (18.25–28.5) to 11.5 (4–16, p=0.005).
Airway hyper-responsiveness as measured by methacholine dose
response improved from 234.44 ml/mg to 9.21ml/mg (p=0.021). All
patients successfully withdrew their nebulised β2 agonist medication
from a mean dose of salbutamol 8.25 mg/day.
Conclusions: Etanercept improves FEV1, FEV1/FVC ratio, asthma
control symptom scores, airway hyperresponsiveness and the use of
rescue nebulised bronchodilator medication in patients with chronic
severe asthma. Blocking the effects of TNF-α could prove to be an
effective and novel therapeutic strategy for the treatment of patients
with chronic severe corticosteroid dependent asthma.
This abstract was supported by Wyeth Laboratories, Berks, UK.
Epidemiology and ethnicity in
respiratory disease
S135 DO VARIATIONS IN CHEST WALL DIMENSIONS
EXPLAIN ETHNICITY-RELATED DIFFERENCES IN LUNG
FUNCTION?
A.L. Whittaker1, A.J. Sutton2, C.S. Beardsmore1. 1Departments of Child
Health1 and 2Epidemiology and Public Health, University of Leicester, UK
Introduction: Differences in lung function between people of varying
ethnic origins may affect interpretation of individual results if inappro-
priate predicted values are used. Our aim was to characterise differ-
ences in spirometry in Asian (ethnic origins in the Indian Subcontinent)
and white children and relate these to differences in chest dimensions.
We hypothesised that Asian children would have smaller values for
lung function and the differences would be explained by variations in
chest size.
Methods: Children were seen in primary schools for measurements
of FVC, FEV1, PEF, MMEF, FEF50, and FEF25, using a spirometer. Chest
circumference, chest height, transverse diameter and A-P diameter
were measured using an anthropometric tape measure and
anthropometer. Relationships between standing height, lung function,
chest dimensions, gender, and ethnicity were assessed using multiple
linear regression analysis.
Results: Ninety-three white and 201 Asian children were included
in the study. The final models explained 78% of the variability in FVC,
72% in FEV1 and 45% in PEF (adjusted R2 values). Standing height
was the single most important predictor, however height squared,
chest height, gender, and chest volume were also useful predictors for
some outcomes. Ethnicity also remained an important predictor for all
three measures, particularly FVC and FEV1, having adjusted for all
other variables. FVC and FEV1 were smaller on average in the Asian
children by 0.23L (95% CI 0.17 to 0.28) and 0.18L (95% CI 0.13 to
0.23) respectively. The average decrement in PEF in Asian children
was 10L.min-1 (95% CI −0.2 to 20.6). The influence of chest
dimensions (both singly and in combinations to represent the chest vol-
ume as a cylinder or a box) on the prediction was examined to see if
they explained the ethnic differences in lung function. Only small dif-
ferences in the regression coefficients for ethnicity were observed
when variables related to chest volume were included in the model.
Conclusions: Equations taking account of ethnicity have been gen-
erated and can be used for the accurate prediction of spirometry. The
influence of ethnicity on lung volumes is not explained by differences
in chest dimensions. Further research in genetic and socio-economic
factors is required in order to determine what factors are responsible
for the ethnic differences in lung function reported here.
S136 NORMATIVE DATA FOR TOTAL SERUM
IMMUNOGLOBULIN E MEASUREMENTS IN CHILDREN
OF 3 ETHNICITIES
E.Y. Chan, S.A. McKenzie. Department of Paediatric Respiratory
Medicine, Barts and the London NHS Trust, UK
Background: It is about 20 years since total immunoglobulin E (IgE)
measurements were published for children without atopic disease. It is
possible that the recent increase in atopic disease1 is reflected in
altered measurement in subjects who have no clinical expression of
atopy. If the measurement of IgE is to be used as a clinical test of
atopy, contemporary normative data must be available.
Aim: To measure total serum IgE in healthy children of three ethnici-
ties born and living in an inner city environment.
Method: Subjects were aged 1–12 years of Afro-Caribbean,
Bangladeshi, and white British ethnicities with no personal history of
atopic disease (asthma, eczema, hayfever, or food allergy). Extra
blood (1ml) for the measurement of total IgE was collected when blood
was taken for other purposes or when a surgical procedure was being
undertaken.
Results: Measurements from 151 boys (median age 5.4 years)
and 106 girls (median age 6.0 years) included 127 Bangladeshis, 58
Afro-Caribbeans, and 72 white British children. Log10 total IgE
increased with age (Log10 IgE = 1.291+0.077*age; p<0.001) but
was not related to gender or ethnicity. The data were significantly
(6-fold) higher than previously published measurements.2
Conclusion: These contemporary normative data can be used to
determine how useful IgE measurements are in separating healthy chil-
dren from children with atopic illnesses.
1. Von Mutius E. Clin Exp Allergy 1998;28(Suppl 5):45–9.
2. Kjellman N. Clin Allergy 1976;6:51–9.
S137 EFFECT OF ETHNICITY ON ASTHMA PREVALENCE
AND HEALTH SERVICE UTILISATION IN THE UK: A
SYSTEMATIC REVIEW
G. Netuveli1, A. Sheikh1, B. Hurwitz3, M. Barnes4, M. Fletcher5, M. Levy6,
S.R. Durham2. 1Dept of Primary Health Care; 2NHLI, ICSTM, London; 3Dept
of English King’s College, London; 4 National asthma Campaign; 5National
Respiratory Training Centre, Warwick; 6UK Kenton Bridge Medical Centre,
London
Background: Healthcare providers perceive asthma prevalence to be
higher in some ethnic minorities than in the white majority UK popula-
tion but epidemiological studies to date have reached conflicting con-
clusions.
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Objective: To review systematically the effect of minority ethnic sta-
tus on asthma prevalence and service utilisation in Britain.
Methods: A systematic review of studies reporting prevalence of
and/or hospitalisation for asthma were identified using the standard
search strategies. Outcome variables were self reported asthma or
wheeze. Only studies on populations living in the UK, reporting data
on at least one minority ethnic group and the white majority and on
children (below 16 years) were included. Differences in proportions
and odds ratios, if reported, were pooled using both fixed and
random effects models.
Results: Of the 36 studies identified, five studies reporting data on
prevalence and two studies on hospital admission met the inclusion
criteria. Meta-analysis of prevalence data was performed on the out-
come measures and ethnicity separately using a random effects
model. We found no significant difference in asthma or wheeze
prevalence between whites and minority ethnic groups in the UK. The
two studies reporting hospital admission rates could not be
synthesized. Nevertheless, one group (5 to 14 years old) in one of the
studies showed a greater odds ratio for Asians for hospitalisation for
asthma (OR 2.03, 1.32 to 3.12).
Conclusions: There is no difference in the prevalence of asthma or
wheeze between minority ethnic groups and the white majority in the
UK. The dearth of data currently available does not allow conclusions
to be reliably drawn regarding hospital admission rates for asthma.
Acknowledgments: A NHS R&D National Primary Care Fellowship
supports AS. This work has been supported by a grant from the
National Asthma Campaign, UK.
S138 MIND THE GAP! AGE AND SEX RELATED CHANGES
IN THE EXPRESSION OF ASTHMA, ECZEMA, AND
HAYFEVER
M. Osmano, P.J. Helmso, C. Simpson, M. Taylor1. Depts of Child
Health and General Practice and 1Primary Care, University of Aberdeen,
UK
Backgroun d: Asthma prevalence is higher in males during childhood
reversing to a female predominance during adolescence. The timing
of this “gender switch” and its relation to other atopic diseases in
whole populations is less clear.
Methods: Prevalences of currently active asthma, eczema, and
hayfever were identified from individuals who consulted their GP at
least once for one or more of the above in the year April 1998–99.
Records were extracted from 47 Scottish Morbidity Recording
General Practices (population 252 538).
Results: Changes in the sex distribution were apparent during the
adolescent period such that hayfever and asthma became more
prominent in females. Females also had a higher prevalence of
eczema in childhood that became more prominent in early adulthood.
The gender switch for eczema precedes hayfever which in turn
precedes that for asthma. See figure.
Conclusion: The similar, although differently phased, patterns in
the adolescent gender switch suggests a shared underlying
mechanism. Further studies on the relative contributions of sex
hormones and socio-cultural influences seem justified.
S139 DO HOUSING IMPROVEMENTS IMPROVE
RESPIRATORY HEALTH?
M Somerville1, M Basham1, C Foy2, A Barton1 for the Torbay Healthy Hous-
ing Group. 1Plymouth and South Devon Research and Development
Support Unit, University of Plymouth, Tamar Science Park, Plymouth, UK;
2Gloucestershire Research and Development Support Unit, UK
Cold, damp housing has been associated with poor respiratory
health, but few studies have tried to evaluate the effect of improving
housing on the occupants’ health.1 During a community development
project in a deprived area of Torquay, local residents surveyed their
council-owned homes and reported high levels of damp, mould, and
respiratory illness. Torbay Council agreed to improve the houses over
a two year period and funding was obtained for evaluation. Of the
142 houses on the estate, 119 agreed to randomisation, which was
carried out at a public meeting; 50 houses were selected for improve-
ment in the first year. Measurements of the indoor environment, gen-
eral and respiratory health were taken at baseline and annually for the
next two years in all houses and for all occupants.
At baseline, there were 480 people living in 119 houses. The
population profile was young, with 58% aged 20 and under and 10%
aged 50 and over. Bedroom and living room temperatures improved
after renovation (central heating and insulation), but only bedroom
temperatures showed a significant difference (p=0.002) between
improved and unimproved houses at the end of the first year.
Self-reported asthma prevalence in those aged under 18 years
declined from 24% at baseline to 14% at the end of the study.
Frequency of asthma symptoms2 reported in the month before each
survey also reduced. The difference between those living in improved
and unimproved houses at the end of the first year was not significant.
Severity, as estimated by BTS asthma steps, remained unchanged in
those continuing to report asthma. The study demonstrates the feasibil-
ity of evaluating the health effects of housing improvements. Further
work is in progress to evaluate the social and economic impact of the
renovations.
1. Thompson H, et al. Health effects of housing improvement: system-
atic review of intervention studies. BMJ 2001;323:187–90.
2. Steen N, et al. Development of a symptom-based outcome measure
for asthma. BMJ 1994;309:1065–8.
S140 FACTORS ASSOCIATED WITH QUALITY OF LIFE IN A
COMMUNITY BASED SAMPLE OF YOUNG ADULTS
WITH ASTHMA
W. Chaudhri1, J. Knox1, D. Jarvis1, B.D.W. Harrison2, R. Hall3, D. Seaton3,
P. Burney1, S. Chinn1, C. Luczynska1. 1Dept of Public Health Sciences, Kings
College, London, UK; 2Norfolk and Norwich Hospital, Brunswick Rd, Nor-
wich, UK; 3Ipswich Hospital, Heath Road, Ipswich, UK
Quality of life (QOL) in asthma patients provides a measure of the
effect of the disease on an individual’s everyday life but there is little
information on factors associated with QOL in asthmatics in the UK. In
1997/1998 a short questionnaire was sent to 1140 subjects who
took part in the East Anglia Respiratory Health Survey I (EARHS I) in
1991. Responders with symptoms suggestive of asthma (waking with
shortness of breath OR having an asthma attack in last twelve months
OR current use of asthma medication) completed the Marks’ QOL
Questionnaire (4 domains—breathlessness, mood, social, and
concerns). Regression analyses were conducted on the square root
transformed QOL score to determine the difference in mean adjusted
QOL score (MEAN DIFF) by gender, age-group, (<35, 35–44.9,
>45), social class group, smoking status, and whether symptoms were
present in EARHS I. To examine associations within each domain
Mann Whitney tests were performed. Of the 983 who responded,
242 subjects aged between 27 and 53 years had symptoms of
asthma and information on QOL. Worse QOL was reported by
women (MEAN DIFF: 0.19; 95% CI 0.04,0.33) and those who had
asthma in EARHS I (MEAN DIFF: 0.27; 95% CI 0.11,0.43). Worse
QOL was observed in social class V and those with undetermined
social class (housewives/students). Women had higher scores than
men in the mood (p<0.01), social (p=0.02) and concern domains
(p=0.04) but not in the breathlessness domain (p=0.14). Compared to
those with “new onset asthma” those with asthma at EARHS I had
higher scores in the breathlessness (p<0.01), social (p<0.01) and
concern (p<0.01) domains but not in the mood domain (p=0.24).
These findings show that amongst asthmatics, women and those who
have had disease for a longer period of time report worse quality of
life.
Funded by the National Asthma Campaign.Abstract S138 “Active” asthma and exzema.
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Drug therapy in COPD
S141 BUDESONIDE/FORMOTEROL IN A SINGLE INHALER
(SYMBICORT®) REDUCES SEVERE EXACERBATIONS IN
PATIENTS WITH MODERATE TO SEVERE COPD
L.M. Campbell1, W. Szafranski2 on behalf of the study group. 1Department
of Medicine, University of Glasgow, UK; 2Department of Lung Diseases,
Voivodeship Specialist Hospital, Radom, Poland
The efficacy of budesonide/formoterol in a single inhaler (B/F, Symbi-
cort®) on COPD exacerbations was evaluated in a placebo-controlled,
parallel-group, multicentre study. 812 adult patients with established
COPD (median 5 years since diagnosis, mean age 64 years, mean
baseline FEV1 0.99 L (36% predicted)) received two inhalations of
either B/F 160/4.5 µg (total delivered dose 320/9 µg), budesonide
(B) 200 µg metered dose, formoterol (F) 4.5 µg delivered dose, or pla-
cebo (PL) bid for 12 months.
Numbers of severe exacerbations (requiring oral steroid course
(OSC) and/or antibiotics and/or hospitalisation) were recorded.
Mean severe exacerbation rates were 1.4, 1.6, 1.8, and 1.9 exac/
patient/y in the B/F, B, F, and PL groups, respectively. Severe exacer-
bations were reduced by 24% (p=0.035), 15% (p=0.224) and 2%
(p=0.895) v PL with B/F, B and F; B/F also reduced mean exacerba-
tion rates by 23% v F (p=0.043). The lowest rates of OSC associated
with exacerbations were in the B/F and B groups (0.74 and 0.76
OSC/patient/y v 1.04 and 1.07 with F and PL). B/F and B reduced
the number of OSC by 31% and 29% v PL (both p<0.05), and B/F v
F by 28% (p<0.05).
Thus, budesonide/formoterol in a single inhaler (Symbicort®)
produced statistically and clinically significant reductions in severe
exacerbations in patients with moderate to severe COPD and was
more effective than either budesonide or formoterol alone.
S142 BUDESONIDE/FORMOTEROL IN A SINGLE INHALER
(SYMBICORT®) PROVIDES EARLY AND SUSTAINED
IMPROVEMENT IN LUNG FUNCTION IN MODERATE
TO SEVERE COPD
P. Anderson on behalf of the study group. Dept. Respiratory Medicine,
Sheffield Chest Clinic, Sheffield, UK
COPD patients (n=812, median 5 y since diagnosis, mean age 64
years, mean baseline FEV1 0.99 L (36% predicted)) received 2 inhala-
tions of budesonide/formoterol (B/F, Symbicort®) 160/4.5 µg (total
delivered dose 320/9 µg), budesonide (B) 200 µg metered dose, for-
moterol (F) 4.5 µg delivered dose or placebo (PL) bid for 12 months.
Lung function was assessed by FEV1 and PEF.
All treatments significantly improved FEV1 vs PL. B/F increased FEV1
by 15% v placebo, 9% v B (both p<0.001) and 1% v F (ns). These
improvements were maintained throughout the 12-month study. In the
first day, B/F increased morning PEF (mean change from run-in) by
10.9 L/min (PL by 0.3 L/min, B −0.3 L/min; F 6.4 L/min; B/F v PL and
B, p<0.001, B/F v F, p=0.081). After the first week, B/F increased
morning PEF by 15.6 L/min (PL by 1.1 L/min, B 3.4 L/min, F 8.8
L/min; B/F v PL and B, p<0.001, B/F v F, p=0.002). At 12 months,
B/F improved morning PEF by 26.4 L/min (PL by 2.4 L/min, B 10.6
L/min, F 14.7 L/min; B/F v PL, B, and F all p<0.001) and improved
evening PEF by 23.1 L/min (PL by 3.0 L/min, B 8.6 L/min, F 11.8
L/min; B/F v PL, B and F all p<0.001).
Budesonide/formoterol (Symbicort®) provides rapid and sustained,
clinically relevant improvements in lung function in patients with mod-
erate to severe COPD, with greater improvements in PEF than placebo
or either monocomponent.
S143 BUDESONIDE/FORMOTEROL IN A SINGLE INHALER
(SYMBICORT®) PROVIDES SUSTAINED RELIEF FROM
SYMPTOMS IN MODERATE TO SEVERE COPD
L.M. Campbell1, W. Szafranski2 on behalf of the study group. 1Department
of Medicine, University of Glasgow, UK; 2Dept. Lung Diseases,
Voivodeship Specialist Hospital, Radom, Poland
Symptom relief with budesonide/formoterol (B/F, Symbicort®),
budesonide (B), formoterol (F) or placebo (PL) was compared in
patients with moderate to severe COPD. 812 patients (mean age 64
years) received 2 inhalations of either B/F 160/4.5 µg (total
delivered dose 320/9 µg), B 200 µg metered dose, F 4.5 µg
delivered dose or PL bid for 12 months. Daytime symptom scores of
shortness of breath, cough and chest tightness, night-time awakenings
due to symptoms (all 0–4 [none to severe], total symptom score
(0–16)) and reliever medication use were recorded. B/F decreased
individual and total scores after 1 week v PL, B, and F (all p<0.001).
At 12 months, B/F reduced the total scores vs PL, B and F by 1.12,
0.84 (both p<0.001) and 0.41 (p=0.043). B/F reduced shortness of
breath scores by 0.36 v PL and 0.26 v B (both p<0.001), decreased
chest tightness scores by 0.21 vs PL (p<0.001) and 0.13 v B
(p=0.043), decreased cough scores by 0.19 v PL (p=0.002) and
0.22 vs B (p<0.001) and decreased awakening scores by 0.34 v PL
(p<0.001), 0.20 v B (p=0.003) and 0.16 v F (p=0.019). B/F
increased symptom-controlled days by 7% v PL (p=0.001), increased
awakening-free nights by 14% v PL (p<0.001) and 10% v B
(p=0.001), increased days free from shortness of breath by 12% v PL
(p<0.001) and increased days free from chest tightness by 7.5% v PL
(p=0.015). B/F reduced use of reliever medication by 1.3 and 0.7
inhalations/24h v PL and B (both p=0.001), and increased
reliever-free days by 8.6% v PL (p=0.003). Budesonide/formoterol
(Symbicort®) provides early and sustained relief from symptoms in
patients with moderate to severe COPD.
S144 THE EFFECT OF 3 MONTHS ORAL CLARITHROMYCIN
ON SPIROMETRY, SHUTTLE WALK DISTANCE AND
HEALTH STATUS SCORES IN PATIENTS WITH
MODERATE TO SEVERE STABLE COPD
D. Banerjee1 2, O.A. Khair1, D. Honeybourne2. 1Department of Respiratory
Medicine, City Hospital NHS Trust, Dudley Road, Birmingham, UK.
2Department of Respiratory Medicine, Birmingham Heartlands Hospital,
Bordesley Green East, Birmingham, UK
Introduction and aims: Macrolides antibiotics are commonly used in
the treatment of acute exacerbations of COPD. This study looked at the
possible effects of long-term oral clarithromycin on spirometry, shuttle
walk distance and health status scores in patients with COPD during
the stable clinical state.
Methods: Randomised, double-blind controlled trial of oral
clarithromycin 500mg o.d. (Cl) vs Placebo (Pl) o.d. for 3 months in
stable patients with moderate to severe COPD who have not had an
exacerbation for 6 weeks. The St George respiratory questionnaire
(SGRQ) and Short form—36 (SF-36) were measured. The mean
changes in parameter for each group were compared using either a 2
independent group t test or a Mann-Whitney U test where
appropriate.
Results: 67 patients were randomised to receive Cl (n= 31) or Pl
(n=36). 46 (69%) were male, mean age (SD) was 66.7 (7.9) years
and 27 (40%) were current smokers. Mean (SD) FEV1 and FEV1 %
predicted were 1.12 (0.41) L and 43.2 (11.4) % respectively. All
patients were taking inhaled corticosteroids. Data for 7 patients were
unavailable and intention to treat analyses were performed on the Cl
group (n=26) and the Pl group (n=34). There were no significant dif-
ferences in spirometry or shuttle walk distance parameters. However,
there was a statistically significant improvement in SGRQ symptom
score and SF-36 physical functioning in the Cl group compared to the
Pl group. Differences in the other health status parameters were not
statistically significant.
Conclusion: In this study, long term oral clarithromycin improved
symptom and physical functioning scores in moderate to severe stable
COPD patients.
Abstract S144
Clarithromycin
mean change
(SD)
Placebo mean
change (SD) p Value
SGRQ symptom −7.6 (18.6) 2.6 (13.7) 0.04
SF-36 physical
functioning
6.7 (15.9) −6.2 (19.6) 0.01
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S145 EFFECT OF BUDESONIDE/FORMOTEROL ON SEVERE
EXACERBATIONS AND LUNG FUNCTION IN
MODERATE TO SEVERE COPD
P.M.A. Calverley on behalf of the Symbicort® study group. University Hos-
pital Aintree, Liverpool, UK
Inhaled corticosteroids (ICS) are recommended in the prevention of
COPD exacerbations in patients with an FEV1 <50% predicted.
Whether long-acting β-agonist therapy is equally effective as ICS, or
the combination superior to the components, is not known. We studied
1022 adults (mean age 64 years; mean FEV1 0.99 L (36% predicted))
with a history of at least one exacerbation in the previous year. To
ensure baseline stability, all received formoterol (F) 9 µg bid and oral
prednisolone 30 mg od for two weeks. Patients were then randomised
to receive either F 9 µg, budesonide (B) 400 µg, budesonide/
formoterol in a single inhaler (B/F, 320/9 µg respectively) or an iden-
tical placebo (PL), all given bid for 12 months. Severe exacerbations
(as episodes requiring oral corticosteroid and/or antibiotics and/or
hospitalisation) and lung function on 6 occasions post-randomisation
were measured. B/F prolonged time to the first exacerbation v F
(p<0.01), B and PL (both p<0.05); B/F reduced the relative risk of
exacerbating by 30% v F, 29% v PL (both p<0.01) and 23% v B
(p<0.05). The mean number of exacerbations/patient/ year was
1.38, 1.60, 1.85 and 1.80 for B/F, B, F, and PL. The time to the first
oral steroid course was increased and the number of oral steroid
courses was reduced by B/F compared with all other treatments:
reductions of 45% v PL (p<0.001), 28% v B (p<0.05) and 30% v F
(p<0.05). In addition, significantly fewer patients withdrew while tak-
ing B/F (p=0.001 v PL and F; p<0.05 v B). Post-dose FEV1 increased
significantly with B/F: 14% v PL (p<0.001), 11% v B (p<0.001) and
5% v F (p<0.01).
These data show that combining budesonide and formoterol
produces a greater reduction in the severe exacerbation rate than
either drug alone, even in moderate to severe COPD, and that this can
be achieved with relatively modest doses of the inhaled corticosteroid.
S146 A DOUBLE BLIND DOUBLE CROSS OVER
COMPARISON OF HIGH DOSE COMBINED β2
AGONIST AND ANTICHOLINERGIC
BRONCHODILATORS DELIVERED BY NEBULISER OR
BY INHALER AND SPACER IN MODERATE TO SEVERE
STABLE COPD PATIENTS
S.C. Johnson1, E. Gardener2, S.P. Hanley3. 1Physiotherapy department,
2Department of Research and Development 3Medical Directorate, North
Manchester General Hospital, M8 6RL, UK
Introduction: This abstract reports a comparison of high dose
salbutamol + ipratropium bromide delivered by inhaler+spacer or by
nebuliser in a group of moderate to severe COPD patients. The effects
on breathlessness and peak flow are reported.
Methods: Study design: baseline assessment followed by two
crossover treatment cycles of 28 days. The two treatment periods in
each cycle, given in random order, comprised; (a) 14 days of
nebulised 2.5mg salbutamol and 500mcg ipratropium bromide or (b)
14 days of Combivent™ (100mcg salbutamol +20mcg ipratropium
bromide) 6 puffs via VolumaticJ spacer. A double dummy technique
was used to blind patient and operator. The San Diego Shortness of
Breath Questionnaire (SOBQ) was measured at the end of each treat-
ment period. Peak flow (PEF) was recorded twice daily. Visual
analogue score (VAS) of breathlessness was recorded each evening.
Analysis: where possible analysis was undertaken on an intention to
treat basis. Treatment order effect (whether treatment effect differed
depending on the order of treatment) was assessed using a graphical
technique. A two sample t test was used to detect any between treat-
ment differences.
Results: Fifty patients entered the study, mean age 68 years
(SD7.5) FEV1 0.8 litres (SD 0.31) FEV1% 34% (SD 11.7). Analysis
revealed a treatment order effect for cycle 1 i.e. those randomised first
to active nebuliser had a lower average SOBQ and higher average
PEF for the cycle. This was not seen in cycle 2. As a consequence, fur-
ther analyses was confined to cycle 2, n=36 (32 male). Missing data,
due to hospital admission (n=2) and consent withdrawal (n=1), all
during the active nebuliser phase, caused exclusion from the analysis.
The differences were not significant between nebuliser v inhaler. They
were: SOBQ (n=33) 2.5 (95%CI −1.3 to 6.4) t = 1.3 p =0.19: PEF
(n=32) 2.8l/min (95%CI −3.8 to 9.3) t =0.9 p=0.40: VAS (n=32)
−0.1cms (95%CI −4.2 to 0.2) t= −0.7 p =0.48.
Conclusions: Although patients often request nebuliser treatment,
this study does not support its prescription in stable COPD patients.
Patient and physician
viewpoints in COPD
S147 SURVEY OF ATTITUDE OF 100 PATIENTS WITH COPD
TO ARTIFICIAL VENTILATION AND
CARDIOPULMONARY RESUSCITATION
K.A. Gaber, M. Barnett, Y. Blanchant, C.R. McGavin. Chest Clinic, Derri-
ford Hospital, Plymouth, UK
Doctors are being encouraged to discuss and document end of life
decisions with vulnerable patients admitted to hospital as part of
involving patients in their own management. We wanted to ascertain
the views of COPD patients.
Method: Patients with COPD under follow up by Respiratory Nurse
Specialists (RNS) and the Chest clinic (of Derriford Hospital) were sur-
veyed. Patients were approached by letter and personally by RNS.
Written information about COPD and its clinical management includ-
ing Non Invasive Ventilation (NIV), Invasive Ventilation (IV), and Car-
diopulmonary Resuscitation (CPR) were given and discussed with each
patient. Consent was obtained. Patients were asked to fill in Quality
Of Life Questionnaire (locally developed at Plymouth University). The
following information were obtained; age, sex, spirometry, hospital
admissions, or antidepressant usage in the last 12 months and oxygen
usage. Patients were asked to consider scenario in which they were
admitted to hospital and after standard treatment, failed to improve,
continued to deteriorate or developed cardiopulmonary arrest,
“Reaching that stage, would you wish to have NIV, IV or CPR?”
Results: 100 patients were surveyed (41 were males and 59
females), mean age of 74 (48—92) years. The mean FEV1 was 0.78
(0.41—1.3) l and FEV1% of 42.7% (11—96%). 50% of patients had
FEV1 < 40% predicted and 35% had FEV1 between 40 and 59% pre-
dicted. 24 patients (24%) were on LTOT, 8 (8%) used antidepressant
and 56 (56%) had been admitted to hospital over the last 12 months.
48 patients (48%) wanted all treatments (CPR, NIV and IV) and 12
(12%) wanted non. 19 patients (19%) said No” for CPR but “Yes” to
NIV and IV. 10 patients (10%) said “No” for CPR and IV but “Yes” for
NIV. The remaining 11 patients (11%) gave mixed answers. Using
ANOVAR analysis and Chi Square test there were no significant sta-
tistical differences between the groups. Conclusion; The commonly
available measurable parameters of COPD could not predict patients
views on CPR, IV, or NIV. These issues should be discussed with vul-
nerable patients preferably before hospital admission.
S148 CHRONIC OBSTRUCTIVE PULMONARY
DISEASE—ALIGNING PATIENT AND PHYSICIAN
VIEWS
I. Murdoch1, I. Draffan1, M. Karavali2, V. Higgins2. 1AstraZeneca,
Macclesfield, United Kingdom; 2Adelphi Group Products, Macclesfield, UK
COPD patients suffer many debilitating symptoms which ultimately
impair their quality of life. A Respiratory Disease-Specific Programme
was conducted in respiratory and primary care clinics in 5 European
countries. Primary care physicians (PCPs) and Respiratory Specialists
(RSs) (n=769) completed patient record forms (PRFs) prospectively, on
the type and severity of COPD symptoms and impact of these on
patients’ lifestyle in terms of ability to undertake activities of daily liv-
ing (ADL). Similarly, patients returned a self-completion form (SCF),
detailing the severity, frequency, and impact of their respiratory symp-
toms on ADL. A total of 2446 patients were diagnosed with COPD
(diagnosis recorded as COPD, emphysema or chronic bronchitis) and
72% (n=1768) of these returned a SCF.
PRF data showed that the most commonly reported symptoms of
patients diagnosed with COPD were breathlessness on exertion
(86%), daytime cough (82%), sputum (75%), and nocturnal cough
(67%). SCF data showed that patients also identified these as key
symptoms, recorded as either a moderate or major problem in the
previous 6 months for 71%, 70%, 64%, and 61% of patients report-
ing severity respectively.
For these 4 key symptoms and others (wheezing, breathlessness at
rest, tightening of chest, and nocturnal wakening) COPD patients
regarded these to be more severe than PCPs and RSs. Patients
suggested that COPD restricts their ability to undertake ADLs
(work/housework, leisure activities and ability to exercise) to a
greater degree than that perceived by PCPs (p<0.01) and RSs
(p<0.01).
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These data demonstrate that breathlessness, cough and sputum pro-
duction are frequent and important symptoms in patients with COPD,
and that physicians may underestimate the severity and restrictive
impact of these symptoms, and others, on COPD patients quality of
life.
S149 WHAT DOES THE GENERAL PUBLIC KNOW ABOUT
COPD?
D.M.G. Halpin1, C. Ferenbach2, D. Bellamy3, M. Rudolf4 on behalf of the
BTS COPD consortium. 1Royal Devon & Exeter Hospital, 2St Mary’s Hospi-
tal, Portsmouth, UK; 3James Fisher Medical Centre, Bournemouth and
4Ealing Hospital
As part of continuing activities to promote the implementation of key
messages contained in the BTS COPD guidelines the BTS COPD con-
sortium undertook market research among the general population to
help understand public knowledge about COPD and their attitude to
chronic respiratory symptoms. MORI were commissioned to add a
number of questions drafted by members of the Consortium to their
weekly omnibus survey. A representative sample of 866 adults (age
15 and over) were interviewed in their own homes in 188 locations
around the UK. 49% were lifelong non-smokers, 20% ex-smokers and
31% current smokers. Over 90% of respondents said that they had
heard of asthma, Parkinson’s disease, cervical cancer, MS and
chronic bronchitis. 79% had heard of emphysema but only 35% had
heard of COPD. A larger proportion of smokers had heard of COPD
(45%) compared with non-smokers (24%). Knowledge about smoking
as a causative factor for various conditions was mixed. A majority of
respondents (53%) thought that cervical cancer was the most common
of these conditions. Only just over half of the respondents suggested
that breathlessness on exertion or coughing could be the first signs of
a serious lung disease. Many respondents had experienced persistent
respiratory symptoms, but only just over half had consulted their GP
about them. In 2 out of 3 cases this was because they were
unconcerned or unaware that the symptoms may be important, and in
nearly 1 in 4 cases this was because they thought they would simply
be told to stop smoking. See table.
One in three members of the public state that they had heard of
COPD, but many more recognise the terms chronic bronchitis and
emphysema. Few were aware that COPD is common and is caused by
smoking. Many individuals experience persistent respiratory symp-
toms but nearly half had not reported these to their GP often because
they were unaware of their importance.
S150 WHERE DO COPD PATIENTS DIE?
M. Sridhar1, I. Grace2, M.R. Partridge1. 1Imperial College of Science,
Technology and Medicine, NHLI Division; 2Department of Statistics at
Charing Cross Hospital, London
Background: We analysed mortality statistics for England and Wales
from the Office of National statistics to determine the place of death of
patients certified as having died primarily due to COPD (COAD,
chronic bronchitis or emphysema) between the years 1970 to 2000
(at 5 year intervals). Deaths were classified as having occurred in a
hospital or other health care institution (nursing home, NHS Mental
health Units) or at home (the usual residence of the deceased or other,
including residential homes). As a comparison the place of death of
patients certified as having died with asthma and all causes were also
analysed.
Results: Over the years between 1970 and 2000 there was
gradual and significant increase in the proportion of patients with
COPD dying in hospitals. Examination of all-cause mortality figures
showed a similar trend. See table.
The figures for asthma showed a less striking trend to increase but
this increase was not evident in the younger age group (under 40),
perhaps reflecting the problems with mis-certification of asthma
deaths.
Conclusion: An ever increasing proportion of patients with COPD
die in hospital, reflecting a trend in the population in general. The rea-
son for this trend needs further investigation and the observation
should inform discussions on resource allocation and end of life care
for patients with COPD.
S151 MORTALITY PROJECTIONS FOR OBSTRUCTIVE LUNG
DISEASE IN ENGLAND & WALES
A.L. Hansell1, L. Knorr-Held2, V. Schmid3. 1Dept Epidemiology & Public
Health, Imperial College, London; 2Dept of Mathematics and Statistics,
Lancaster University, UK; 3Dept of Statistics, Ludwig-Maximilians University,
Munich, Germany
Obstructive lung disease is a leading cause of mortality and morbidity
worldwide and accounts for 20% of respiratory mortality in the UK
(British Thoracic Society. The Burden of Lung Disease. London: British
Thoracic Society 2001). Few studies have attempted to project the
future burden of disease and none of these related to the UK. Simple
extrapolation from current rates is likely to be misleading due to strong
cohort and period trends (Lee PN, et al. Thorax 1990;45:657–65).
A recently developed Bayesian method was used to make 10 year
mortality projections for chronic obstructive pulmonary disease
(COPD) and asthma for those aged 45 years and over in England &
Wales, by extrapolating age, period and cohort trends for
1945–1999. Particular advantages of the Bayesian method used are
that a good fit to the data is ensured and statistical uncertainty inter-
vals can be automatically provided. Different smoothing constraints
were tested. The final model was selected on the basis of the best pre-
dictions for the last 10 years of data (1989–1999). Adjusting for
changes in ICD versions made little difference to the accuracy of these
predictions. Also, use of a smoking covariate as a period effect did not
improve predictions. Cohort covariates were unlikely to have
improved predictions as the data hold good information about cohort
trends for the oldest cohorts, which experience the largest number of
deaths.
Projections suggested a median fall in rates for males of 24% (95%
CI: −52% to +14%) by 2009 on a 1999 baseline and corresponding
2% (95% CI: −40% to +65%) rise in rates for females. By five year
age-groups, posterior median projections of rates fell in both sexes,
except in older females: for those aged 75–79 years rates rose then
fell, while rates rose throughout for aged 80 years and over. Numbers
of female deaths were projected to rise to around 14 000 per year,
equalling numbers of male deaths by the end of the decade. Credible
intervals around projections were wide, reflecting marked yearly vari-
ations in the numbers of deaths.
Risk factors in allergic disease
S152 THE EFFECT OF MITE ALLERGEN CONTROL BY THE
USE OF ALLERGEN-IMPERMEABLE COVERS IN ADULT
ASTHMA: THE SMAC TRIAL
A. Custovic, L. Forster, E. Matthews, J. Martin, L. Letley, M. Vickers, J. Brit-
ton, D. Strachan, P. Howarth, D. Altmann, C. Frost, A. Woodcock and
MRC GP research framework. MRC General Practice Research Framework
at the MRC Clinical Trials Unit, Stephenson House, 158–160 North Gower
Road, London NW1 2ND
There is a considerable controversy about the effectiveness of dust mite
allergen avoidance in asthma. We carried out a randomised, parallel
Abstract S149
Symptom
Prevalence
Overall Smokers Non-smokers
Breathlessness on mild exertion 29% 34% 25%
Frequent winter colds 22% 29% 20%
Persistent cough 13% 19% 9%
Persistent sputum production 9% 13% 7%
Any 49% 61% 41%
Abstract S150
1970 1975 1980 1985 1990 1995 2000
p for
trend
COPD 56.9 61.3 62.3 69.9 75.1 78.9 79.4 <0.001
All
cause
60.76 63.04 65.21 69.05 71.98 75.52 78.63 <0.001
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group, double-blind, placebo controlled trial of dust mite avoidance
(allergen-impermeable covers for mattress, pillow, and quilt) in adult
asthmatics. At entry, mite-specific IgE was determined, and patients
were randomised with minimisation on smoking, pet ownership and
mite-specific IgE. Patients and assessors were blind to the patients’
dust mite sensitivity status. From 2479 patients who were screened for
eligibility, 1150 from 135 general practices were randomised to
receive active (n=574) or placebo (n=576) bed covers. PEFR was
recorded twice daily during a 4 week run-in period and during months
6 and 12 of the study. In the first 6 months of the trial patients took
their usual inhaled steroid therapy. Following this, a controlled reduc-
tion of inhaled steroids was attempted until either all inhaled steroid
has been discontinued, or until asthma control deteriorated (Months
7–12). Homes were visited at the start in all patients, and revisited at
6 and 12 months in a 10% random sample to collect mattress dust for
measurement of Der p 1. Der p 1 was significantly lower in the active
group at 6 months (p=0.023), but there was no difference between
the groups at 12 months. 65.4% and 65.1% of patients were mite
sensitive in the active and placebo group respectively. A total of 457
active and 459 placebo patients had PEFR data at both baseline and
6 months. PEFR improved significantly in both groups (active 409.7 to
417.7 l/min, p<0.0001; placebo 419.3 to 428.9 l/min, p<0.0001).
After adjusting for baseline differences using analysis of covariance,
there was no significant difference between the two groups (difference
in means (95% CI), active v placebo: all subjects −2.11 (−6.55,
2.32), p=0.35; mite sensitive subjects −1.71 (−7.28, 3.85) p=0.55).
There was no difference between the groups in complete cessation of
inhaled steroids or the proportionate change in steroid dose during
reduction at 12 months, either in all subjects or in mite sensitive sub-
jects only. In conclusion, allergen-impermeable bed covers seem clini-
cally ineffective for routine management of adult asthma in primary
care in the UK.
S153 EXPOSURE TO INDOOR AEROALLERGENS AND
SUBSEQUENT SENSITISATION AND WHEEZE IN AN
ENGLISH BIRTH COHORT
J.M. Harris, P. Cullinan, P. Mills, S. Moffat, C. White, A.J. Newman Tay-
lor. Occupational & Environmental Medicine, Faculty of Medicine, Imperial
College of Science, Technology and Medicine, London, UK
A prospective cohort study of childhood asthma and allergic disease
based in Ashford, Kent has been underway since 1993. A
consecutive series of newly-pregnant women were recruited (93% of
those eligible) and 642 babies were born. Eight weeks after birth
samples of dust from the living room floor and infant’s beds were col-
lected. Levels of indoor aeroallergens (Der p1, house dust mite, and
Fel d1, cat fur) were measured.
Each child was visited annually, and at age 5–6 sensitivity to Der
p1, Fel d1 and mixed grass pollens was measured in 552 (86%) chil-
dren using skin prick tests. The prevalence of sensitisation (mean weal
diameter 2mm+ greater than the negative control) to these allergens
were 10%, 9% and 9% respectively; 92 (17%) of the children were
atopic. Thirty nine atopic children (7% of cohort) were wheezing at
this age. Rates of sensitisation and atopic, current wheezing by quar-
tiles of exposure categories using measurements from the living room
carpet were as shown in the table.
The patterns above suggest that the association between levels of
Der p1 and Fel d1 experienced in early-life and subsequent
sensitisation/wheeze has an “inverted u” shape. The reductions in risk
at the highest exposure levels may be explained by an immunotoler-
ance or by confounding determinants of sensitisation. Further
investigations into these are underway.
S154 ATOPY, ASTHMA, HAYFEVER AND THE RESPONSE TO
INTRADERMAL TESTING WITH ENVIRONMENTAL
MYCOBACTERIA AMONG CHILDREN IN RURAL
CRETE
C. Zekveld, P. Cullinan, I. Dimitroulis, A. Pedioti1, V. Bibaki-Liakou1, I.
Bibakis1, J. Stanford,2 A. Newman Taylor. Department of Occupational
and Environmental Medicine, Imperial College (NHLI), London; 1Anti-
Tuberculosis Unit, Venezalion Hospital, Heraklion, Crete; 2Department of
Medical Microbiology, University College Hospital, London
Subclinical infection with environmental mycobacteria (eMB) may
exert a strong immuno-regulatory effect. Among 805 children aged
between 8 and 18 years, and living in rural Crete, we examined skin
responses to intradermal inoculation with four locally prevalent eMB
species (M gordonae, M fortuitum, M intracellulare, and M chelonae)
identified by pilot testing with 20 species in three villages. We
compared the skin responses between children with or without atopy
(as judged by skin prick testing), asthma or hayfever. Virtually all chil-
dren had received BCG vaccination.
643 (80%) children had a positive response (3mm or more) to at
least one eMB species; 147 (18%) reacted to all four. 182 (23%) chil-
dren had a positive skin prick test to one or more local aeroallergens;
the prevalences of current wheeze (4%) and seasonal rhinitis (5%)
were much lower.
Intradermal responses to eMB were unrelated to any of the
outcomes in this population. This was true for each or all of the eMB
species; and also for stronger (10mm or more) responses. Moreover
there was no evidence, among atopic children, of a relationship
between eMB skin responses and the presence of absence of allergic
symptoms. These findings do not support the suggestion that early
infection with environmental mycobacteria is protective in the
development of childhood allergic diseases.
S155 DOES VACCINATION INCREASE THE RISK OF
DEVELOPING ALLERGIC DISEASE?: A BIRTH COHORT
STUDY
T.M. McKeever, S.A. Lewis, C. Smith, R. Hubbard. Division of Respiratory
Medicine, University of Nottingham, UK
Objectives: There has been a rise in allergic disease prevalence in
the last couple of decades, and one hypothesis for this increase is the
introduction of widespread immunisation against infectious diseases.
Methods: Using the West Midlands General Practice Research
Database, we have used a previously established birth cohort to
examine the effect of vaccination to diphtheria, polio, pertussis and
tetanus (DPPT) or measles, mumps and rubella (MMR) on the incidence
of doctor diagnosed asthma and eczema.
Results: In univariate analysis there was an association between
vaccination and the development of allergic disease such that
vaccination to DPPT increased risk of asthma (HR 14.0 95% CI 7.3–
26.9) and eczema (HR 9.4 95% CI 5.9–14.9) and similar strong
effects were seen for vaccination to MMR. However there were signifi-
cant interactions between vaccination and consulting behaviour, such
that the effect of vaccination was limited to those in the lowest level of
consulting behaviour, and was no longer significant in subsequent lev-
els of consulting behaviour, suggesting that the initial observed effects
were due to ascertainment bias.
Conclusions: Our data suggest that it is unlikely that currently rec-
ommended routine vaccinations are a risk factor for asthma or
eczema.
Abstract S153
Der p1
levels (µg/g)
n (%)
sensitised
n (%) atopic
wheezing
Fel d1 levels
(µg/g)
n (%)
sensitised
n (%) atopic
wheezing
0.02–0.39 10 (7%) 7 (5%) 0.01–0.53 8 (6%) 7 (5%)
0.39–1.28 18 (14%) 13 (10%) 0.53–1.76 11 (8%) 11 (8%)
1.28–5.66 17 (12%) 11 (8%) 1.76–18 17 (12%) 11 (8%)
5.66–385 7 (5%) 7 (5%) 18–14151 11 (8%) 10 (7%)
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S156 REGULAR OILY FISH CONSUMPTION IS PROTECTIVE
AGAINST SYMPTOMATIC ASTHMA
B. Patel, R. Luben, D. Lomas, N. Wareham. Departments of Public Health
and Primary Care, and Department of Medicine, University of Cambridge,
Hills Road, Cambridge
Oily fish is rich in n-3 polyunsaturated fatty acids (PUFAs). While n-6
PUFAs are the main substrate for the production of arachodonic acid
(AA), n-3 PUFAs are competitive inhibitors of AA metabolism, and
may reduce the production of 4-series leukotrienes and bronchocon-
stricting prostagladins such as PGD2 from AA.
To assess the association between oily fish consumption and symp-
tomatic asthma, we conducted a nested case control study within the
European Prospective Investigation of Cancer (EPIC)-Norfolk cohort.
Between 1993 and 1998 all participants completed a baseline health
and lifestyle questionnaire (HLQ). Cases were selected by a positive
response and controls by a negative response to the question “has
your doctor ever told you have asthma?” in the HLQ. Frequency of oily
fish consumption was also recorded in the HLQ. In 1998 potential
cases and matched controls were asked to complete the East Anglia
Respiratory Questionnaire about respiratory symptoms experienced in
the previous 12 months.
Complete data were available on 333 cases who reported wheeze
in the previous 12 months, and 437 asymptomatic controls.
Significantly more controls than cases reported eating oily fish at least
twice a week (12.4 % v 7.5%, p=0.03). In logistic regression analy-
sis, after adjusting for age, sex, BMI, social class and smoking, regu-
lar oily fish consumption (= twice a week) relative to rare (< than once
a week) was associated with a reduced odds ratio (OR) for
self-reported wheeze (OR 0.5, p=0.01), wheeze with breathlessness
(OR 0.48, p=0.01), awakening with tightness in the chest (OR 0.41
p=0.08) and asthma attack (OR 0.57, p=0.08) in the preceding 12
months. Moreover, in a sub-analysis of 55 controls without diagnosed
asthma who were excluded from the main analysis because of
self-reported wheeze in the previous 12 months, only 7.3% reported
eating oily fish twice a week or more. Relative to rare consumption,
the adjusted OR for wheeze with regular oily fish consumption in this
group was 0.54 (p=0.28).
In conclusion we have shown an association between oily fish con-
sumption and symptomatic wheeze in people with diagnosed asthma
and without diagnosed asthma. These data support the hypothesis that
regular consumption of oily fish may be protective against
symptomatic asthma.
S157 THE EFFECTS OF MATERNAL DIET AND EARLY
ANTIBIOTIC USE ON ALLERGIC DISEASE IN THE
SECOND YEAR OF LIFE
S. Fleming, G. McNeill, G. Devereux, A. Seaton. Department of Environ-
mental and Occupational Medicine, University of Aberdeen, UK
The suggestion that maternal and early life influences may be impor-
tant in the onset of allergic disease is being investigated. A cohort of
2000 pregnant women was identified and their diet assessed by food
frequency questionnaire during pregnancy. Allergic disease was
assessed in their children at 6, 12 & 24 months of age. Questionnaire
data were available from 1371 children for the 2nd year of life.
Wheeze and eczema were associated with male gender, maternal
atopy, social class and maternal smoking but not with maternal
dietary antioxidant vitamins. However when the analysis was
restricted to atopic mothers only (n=714), an inverse association
between maternal vitamin E intake and eczema was found as shown
in the table.
There were positive associations between eczema and early
antibiotic administration, which remained when the analysis was
restricted to antibiotics given for non-skin conditions in the first 6
months and the development of eczema from 7–24 months (OR 1.33,
p=0.038). A similar association with wheeze disappeared when
restricted to antibiotics given for non-chest conditions. This may be an
indication of the effect of early antibiotics on the development of
atopy. Vitamin E intake during pregnancy and early introduction of
antibiotics may be related to the onset of allergic disease in
childhood.
Abstract S157
Wheeze in the 2nd year† (n=98) Eczema in the 2nd year† (n=160)
Maternal vitamin E intake
Diet + supplements Diet only Diet + supplements Diet only
1‡ 1.00 1.00 1.00 1.00
2‡ 0.63 (0.30–1.34) 0.57 (0.27–1.17) 0.77 (0.41–1.44) 0.53 (0.29–0.99)*
3‡ 0.56 (0.27–1.15) 0.61 (0.31–1.23) 0.44 (0.23–0.83)* 0.43 (0.23–0.78)*
4‡ 0.55 (0.26–1.16) 0.50 (0.24–1.07) 0.83 (0.45–1.51) 0.53 (0.28–0.98)*
5 ‡ 0.58 (0.26–1.19) 0.50 (0.23–1.07) 0.41 (0.21–0.80)* 0.48 (0.25–0.91)*
p (trend) 0.107 0.065 0.024* 0.030*
*p< 0.05;†Logistic regression: odds ratio (95% CI) adjusted for gender, maternal age, maternal atopy, social
class, maternal smoking & antibiotics; ‡Quintiles of intake.
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Respiratory muscles
P1 MULTIDISCIPLINARY MOTOR NEURONE DISEASE
CLINICS: DO THEY IMPROVE PATIENT CARE?
B.V. Prathibha, C. Wylie, N. Pease, F.J. Thomas. Nevill Hall Hospital, Bre-
con Road, Abergavenny, South Wales, UK
Motor neurone disease is a progressive neurological disorder which
results in respiratory failure eventually. Currently the respiratory input
into the management of these patients occurs at the terminal stages of
their life. In addition, these patients need input from other specialties
including palliative care and gastroenterology. We describe here a
multidisciplinary approach with a new type of clinic set up so that the
patients are seen by these specialists early on in the illness in the hope
of improving the quality of care.
Aim: The aim was to set up a one stop clinic providing combined res-
piratory, neurological, and palliative care advice with input from vol-
untary organisations (MND association) and social workers and to
assess any perceived benefits from the patients and carers point of
view.
Design: The clinic is scheduled once a month and the three physi-
cians (respiratory, neurology, and palliative care) sit in the same room
with the other organisation representatives in the next room. The
patients are offered an appointment in the specialist MND clinic
following confirmation of the diagnosis by the neurologist. A special
proforma has been designed to include the neurological, respiratory,
gastroenterological, and social aspects of care. At each visit, the dif-
ferent variables including spirometry and blood gases are recorded.
All patients undergo baseline overnight sleep study. The subject of
NIPPV and intubation is introduced during these visits depending on
the symptoms. The patients then make informed choices about their
treatment. A patient feedback questionnaire has been designed and is
given to each new patient.
Results: The clinic was established in November 2001 and to date
11 patients (7 males and four females) have been seen. The median
age is 63 for men and 62 for women. The median FVC at presenta-
tion is 89 % predicted and median PO2 and PCO2 are 11.5 and 4.8
respectively. The decline in the FVC over 9 months is associated with
increasing PCO2 and symptoms. Three have been opted for NIPPV for
symptom palliation. All patients rated the clinic highly, preferred to
come to a single clinic than to three different ones and felt that they
had adequate time to discuss all their concerns and have them
allayed.
Conclusion: MND patients need specialised input from many pro-
fessionals and too often this is patchy and unsatisfactory. The organis-
ation of a combined clinic of the type described above has improved
patient care and communication between the different specialists and
has resulted in the efficient use of time and other limited resources.
P2 OUTCOMES OF ASSISTED VENTILATION IN MOTOR
NEURONE DISEASE
S. Sundaram, I.E. Smith, J.M. Shneerson. Respiratory Support And Sleep
Centre, Papworth Hospital, Cambridge, UK
Assisted Ventilation may prolong survival in patients with respiratory
failure in motor neurone disease (MND), but there are few published
reports.
We performed a retrospective study of all patients referred to our
tertiary care centre between 1993 and 2002.
We identified 109 patients; mean age 60 (SD 9.0) years, 74% of
whom were male. Fifty-one per cent had bulbar symptoms. Sixteen
patients were transferred from intensive care units elsewhere with tra-
cheostomy ventilation (TV). Fifty-five patients were offered non-invasive
ventilation (NIV), of whom 43 accepted and 12 declined treatment.
Thirty seven patients were assessed at our unit and were thought not
to require any assisted ventilation. One patient required only a trache-
ostomy with no assisted ventilation. Nine of the TV patients were
weaned to NIV. Patients who still required TV at the time of discharge
managed to self ventilate by day, but within three months were once
again continuously dependent on it. Among patients offered NIV de
novo, 36 had hypercapnia (mean PaCO2 8.0 kPa) and 19 had
orthopnoea causing sleep disturbance. The arterial blood gases while
self ventilating on air improved in patients treated with NIV. At first fol-
low up, the mean fall in PaCO2 (95% CI) was 2.3 kPa (1.2 to 3.4;
p<0.001) and the mean rise in PaO2 was 1.1 kPa (0.30 to 2.0;
p<0.01). Bulbar weakness was as frequent in patients given NIV as
those that declined (p=0.66).
There have been 86 deaths. Using the Kaplan-Meier method, the
median survival was four months in patients who declined treatment
and 11 months in those thought not to need NIV. There was no differ-
ence in survival between patients transferred intubated from ICU (12
months) and other subjects who started assisted ventilation (14
months; p=0.89).
Many MND patients treated with tracheostomy ventilation can be
weaned to NIV. In our cohort bulbar weakness did not preclude NIV.
Survival was best for patients using assisted ventilation and worst for
those who declined treatment.
P3 OUTCOME OF NON-INVASIVE DOMICILIARY
VENTILATION FOR PREVIOUS POLIOMYELITIS: IMPACT
OF SCOLIOSIS
Y. Tai, D. McKeon, I.E. Smith, J.M. Shneerson. Respiratory Support and
Sleep Centre, Papworth Hospital, Cambridge, UK
Survivors of poliomyelitis can develop new respiratory disability many
years after the acute illness. Scoliosis, muscle weakness, and
decreased respiratory drive may all contribute. We examined the
effect of scoliosis on survival in 51 patients (20 women) with previous
poliomyelitis established on home mechanical ventilation (HMV) in our
centre.
Poliomyelitis was contracted at a median age of 6.5 years; 82% of
the patients had a thoracic scoliosis. The mean interval from contract-
ing poliomyelitis to HMV was 46 (SD 8.8) years. Arterial blood gases
on room air prior to HMV showed PaO2 7.2 kPa and PaCO2 8.6 kPa,
which significantly improved (p<0.05) after one month of treatment to
PaO2 9.5 kPa and PaCO2 6.6 kPa. The improvement was maintained
at a mean follow up of 58 months. The Kaplan-Meir plot for life
expectancy from initiation of ventilation is shown in the figure: survival
was 7.35 years for subjects without scoliosis (solid line) v 12.1 years
for subjects with scoliosis (dashed line) (p=0.048).
Comparing subjects with and without scoliosis there were no differ-
ences in blood gases or overnight monitoring at presentation or during
follow up on HMV; those with scoliosis had a smaller vital capacity
1.18 L v 1.49 L (p=0.013) and were younger when they had
contracted poliomyelitis (median age 5 v 20 years; p=0.003); the
time interval from poliomyelitis to HMV was similar for the two groups
and so those with scoliosis started ventilation at an earlier age. Recal-
culating life expectancy from birth there was no difference between
the two groups (p=0.989).
This study confirms that HMV can normalise arterial blood gas ten-
sions in patients with previous poliomyelitis and the improvement is
maintained. Overall survival is good. Compared to subjects with a
scoliosis survival from the initiation of HMV is worse for subjects with-
out a scoliosis largely because they are older when they develop ven-
tilatory failure.
Abstract P3 Kaplan-Meir plot for life expectancy from initiation of
ventilation.
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P4 COMPARISON OF PRESSURE AND VOLUME TARGETED
NON-INVASIVE VENTILATION IN CHEST WALL
DEFORMITY
J.M. Tuggey, M.W. Elliott. St James’s University Hospital, Leeds, UK
Introduction: The use of domiciliary non-invasive ventilation (NIV) in
chest wall deformity is established and of proven benefit in terms of
arterial blood gas tensions, sleep quality and daytime function. Previ-
ous studies have compared in the short term, volume, and pressure
targeted ventilation. As part of a larger study, we investigated the
effect of ventilation mode on minute ventilation and mask leak.
Method: 10 patients (mean age 64; mean FVC 0.55 l) with chest
wall deformity, established on home NIV completed a randomised
crossover study comparing pressure support and volume ventilation
using the Breas PV403 ventilator. Ventilator parameters were set
following a daytime titration period according to patient comfort and
so that MVe was identical for both PSV and VCV. Patients used the
machine at home for four weeks for each modality. At the end of each
period, patients were admitted for a sleep study, including
measurement of ventilation using a pneumotachometer connected to
the ventilator circuit, adjacent to the nasal mask. Delivered tidal
volume (VTi), expired tidal volume (VTe), expired minute volume (MVe)
and respiratory rate (fR) were measured throughout the night. Minute
leak was calculated by (Vti−Vte) × fR.
Results: See figure.
Ventilation was slightly greater in the volume group. There was sig-
nificantly more leak during PSV than compared to VCV (16 v 6 l/min).
Conclusion: Volume cycled ventilation results in less leak without
compromising ventilation compared to PSV. Excessive amounts of leak
during PSV may result in greater arousals and sleep fragmentation.
JT is funded by the NHS Northern & Yorkshire Executive
P5 COMPARISON OF PRESSURE AND VOLUME CYCLED
VENTILATION IN KYPHOSCOLIOSIS (A RANDOMISED,
SINGLE BLIND, CROSSOVER, PILOT STUDY)
S.E. Higgins, R. Russell, B.E.A. Lams, A.J. Williams, A.C. Davidson. Lane-
Fox Respiratory Unit, St Thomas’ Hospital, London, UK
Introduction: This study compared pressure controlled (PCV) and vol-
ume controlled ventilation (VCV) in patients with kyphoscoliosis (KS).
Two previous studies have been published with conflicting results. One
suggests that some more severe patients were inadequately treated
with PCV (Schonhofer B, et al. Eur Respir J 1997;10:184–91). The
second study found no differences between the modes but suggested
that patient fatigue was reduced using PCV (Ferris G, et al. Am J Phys
Med Rehabil 2000;79:24–9).
Patients & methods: Twelve patients (three female, nine male)
with KS and longstanding chronic respiratory failure (CRF) (PaCO2 at
enrolment was 5.96 + 0.73 kPa) were recruited into the study, (mean
age 59 (8.9) years). All patients were receiving domiciliary nocturnal
pressure ventilation. We measured the following at base line; ABGs,
overnight Pulse Oximetry and transcutaneous CO2, FVC, FEV1, SNIP,
Psychomotor Vigilance (PVT), OSLER Sleep latency, Epworth
Sleepiness Scale, and Actigraphy & Sleep Diary for 10 days. Each
patient was then randomised to one month of PCV or VCV using the
BREAS PV403 ventilator. The subjects were blinded to the mode of
ventilation. At the end of one month all of the above parameters were
remeasured, the mode changed and the parameters remeasured after
a further month. At the end of the study the subjects were asked to
express a preference for month one or month two.
Results: Five subjects were excluded (three due to underlying OSA,
one due to an unrelated illness, and one was unable to tolerate VCV).
In the remaining seven no significant differences were found between
PCV and VCV in most of the physiological variables. The hours of ven-
tilator use was greater during PCV compared with VCV (8:22 v 7:49),
but this did not reach statistical significance (p=0.07). Actigraphy
revealed a significantly lower sleep fragmentation index in the PCV
limb of the study (32.6 v 38.5; p=0.04). This was supported by the
subjects reported sleep quality during PCV (2.17 v 2.45; p=0.01). In
addition, subjects preferred PCV to VCV (p<0.0002).
Conclusions: Patients with KS and CRF are adequately ventilated
with both PCV and VCV modes. However patients prefer PCV, and
subjective and objective sleep quality is improved with PCV.
P6 COMPARISON OF PRESSURE V VOLUME CYCLED
VENTILATION IN KYPHOSCOLIOSIS A RANDOMISED
SINGLE BLIND CROSSOVER STUDY: QUALITY OF LIFE
OUTCOME DATA
R.E.K. Russell, S.E. Higgins, B. Lams, A.J. Williams, A.C. Davidson. Lane
Fox Respiratory Unit, St Thomas’ Hospital, London, UK
Introduction: Patients with kyphoscoliosis (KS) may require long term
ventilatory support as disease progression occurs. The ventilator used
may be either volume (VC) or pressure controlled (PC). It is unclear
which strategy is most beneficial for patients with KS.
Patients and methods: 12 subjects with KS (nine males, mean
age 59 (8)) who were receiving long term ventilatory support were
enrolled in a single blind randomised crossover pilot study. Ventilators
were provided by the manufacturer (Breas PV403) and were set to
provide the same minute volume in either volume or pressure control
mode. Subjects completed the St George’s Respiratory Questionnaire
(SGRQ), the SF-36 health questionnaire, and the Beck depression
score pre treatment and after four weeks on the trial ventilator at each
setting.
Results: One subject was excluded due to intercurrent illness, three
due to obstructive sleep apnoea, and one subject could not tolerate
VC. Pulmonary function and QoL data are shown in table 1. There
were no significant differences between pre treatment values and
those obtained after four weeks on the two ventilator settings.
However these subjects scored on all values much greater than healthy
normals, indicating significant impairment of QoL. Beck depression
scores were within the normal range.
Conclusions: Patients with KS on long term ventilation have signifi-
cantly impaired QoL and the ventilator strategy used (VC or PC) does
not affect this.
P7 ADDUCTOR POLLICIS AND QUADRICEPS STRENGTH IN
COPD
M.G.G. Soliman1, W.D-C. Man1, D. Nikoletou1, M.L. Harris1, G.F.
Rafferty1, N. Mustfa1, M.I. Polkey2, A.J. Williams3, J. Moxham1.
1Respiratory Muscle Laboratories, King’s College Hospital, UK; 2Royal
Brompton Hospital, UK; 3St Thomas’ Hospital, London, UK
Background: Peripheral muscle weakness is common in COPD, but
the cause remains controversial. Better understanding of the
distribution of muscle weakness may reveal the underlying
Abstract P4
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Abstract P6 Beck, SGRQ and SF-36 following PC or
VC ventilation for four weeks.
Beck SGRQ total PF RL
Pre 6.5 39.6 (17.1) 31.4 (28.7) 28.6 (39.3)
PC 6.3 (4.9) 38.7 (16.8) 29.3 (31.3) 39.2 (45.3)
VC 6.8 (5.3) 36.6 (15.4) 32.1 (29) 35.7 (47.6)
6* 74* 73*
SF EV GH
Pre 69.9 (30.7) 45.7 (24.7) 53.9 (25.0)
PC 77.9 (25.7) 50.0 (21.2) 54.7 (22.0)
VC 65.1 (26.0) 43.6 (27.7) 53.7 (21.0)
Norm 82* 61* 63*
Data mean (SD); comparisons made with Wilcoxon rank test. SF-36 data.
*p<0.005 v all study scores.
PF, physical function; RL, role limit; SF, social function; EV,
energy/vitality; GH, general health.
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pathological process; chronic inactivity and disuse atrophy should
lead to preferential involvement of the muscles with the greatest
decrease in utilisation—that is, the lower limbs—whereas the loss of
muscle function should be equally distributed if the underlying patho-
logy is a more generalised process such as inflammation or malnutri-
tion. To address this question, we used the non-volitional technique of
supramaximal magnetic nerve stimulation to assess the strength of the
adductor pollicis and quadriceps muscles.
Methods: 14 patients with stable COPD (not on oral cortico-
steroids) and 14 age matched healthy controls were recruited. Twitch
adductor pollicis tension (TwAP) and twitch quadriceps tension (TwQ)
were determined following supramaximal magnetic stimulation of the
ulnar and femoral nerves respectively.
Results: Patients and controls were well matched for age, weight,
height, and BMI. Mean FEV1 and FEV1predicted for the COPD patients
were 0.86l and 37% respectively. TwAP was similar in the COPD and
healthy elderly groups (7.04 v 7.30N; p=0.69). However TwQ was
significantly lower in the COPD group (68.2 v 104N; p=<0.001).
Discussion: In non-weight losing, stable COPD patients, quadri-
ceps strength is significantly reduced compared with age matched
healthy controls, whereas the strength of the adductor pollicis is
normal. This is indirect evidence that there is not a generalised weak-
ness in stable COPD, and that disuse atrophy is an important contribu-
tor towards peripheral muscle weakness.
WDCM is a Clinical Research Training Fellow of the MRC (UK).
P8 THE RELATIONSHIP BETWEEN RESPIRATORY MUSCLE
STRENGTH AND NEED FOR VENTILATORY SUPPORT IN
POST-POLIO PATIENTS
M.G.G. Soliman, S.E. Higgins, D.R. El-Kabir, B. Pereira, W.D-C. Man,
A.C. Davidson, R.S. Howard, A.J. Williams. The Lane-Fox Respiratory Unit,
St Thomas’ Hospital, London, UK
Respiratory failure requiring nocturnal ventilatory support is a
recognised late complication of previous poliomyelitis and is probably
secondary to respiratory muscle weakness. Respiratory muscle
strength was measured in 50 post-polio patients to assess the relation-
ship between the need for ventilatory support and the degree of respi-
ratory muscle weakness. Tests included forced vital capacity (FVC),
maximum inspiratory (MIP) and expiratory pressures (MEP), and sniff
nasal pressure (SNIP).
During the time of testing, 21 patients were using nocturnal ventila-
tory support (VS) compared with 29 on no support (NS). No
significant differences in age, BMI, or time since acute episode, were
found between the two groups. Respiratory muscle strength (mean
(SD)) are presented in the table.
Of the patients requiring no support, those who had been ventilated
during the acute episode had a significantly lower SNIP than those
who had never been ventilated (48.8 (17.6) v 65.8 (27.4); p=0.04).
Post-polio patients requiring nocturnal ventilatory support have a
greater degree of inspiratory muscle weakness. SNIP is the most sen-
sitive non-invasive test of inspiratory muscle weakness, and may prove
to be a potentially useful tool in monitoring the progression of respira-
tory muscle weakness and subsequent ventilatory failure in post-polio
patients.
P9 COPD ALTERS THE DIAPHRAGM MOTOR AREA RESPONSE
TO TRANSCRANIAL MAGNETIC STIMULATION
N.S. Hopkinson, T. Sharshar, E. Ross, M.J. Dayer, A.H. Nickol, J.
Moxham2, M.I. Polkey. Muscle Lab, Royal Brompton Hospital; 2King’s
College Hospital, London, UK
Background and methods: The threshold and stimulus response
curve to transcranial magnetic stimulation (TMS) of the diaphragm
motor area can provide information about cortical excitability in
health and disease. We studied five patients with severe COPD (mean
FEV1 20.2%predicted) and eight healthy controls. Stimulation series
were delivered over the vertex using a 110mm double cone coil
(Magstim 200 mono-pulse) at a variety of intensities in random order
and the surface diaphragm motor evoked potential (MEP) recorded.
Series were performed at resting end expiration and then, facilitated,
during inspiratory manoeuvres at 20% and 40% of maximum inspira-
tory pressure (MIP) and then again at rest. Healthy subjects also per-
formed a run at 60% MIP. The stimulus response curves for COPD
patients are shown in the figure. This group showed a significant
increase from rest to 20% facilitation but no further increase at 40%.
By contrast controls showed a stepwise increase in MEP to 40% with
no further increase at 60%.
Conclusion: COPD patients have a reduced cortical reserve
perhaps because they are already facilitated at rest by an increased
work of breathing.
This study was funded by the Wellcome Trust.
P10 THE EFFECT OF LONG TERM DOMICILIARY
NON-INVASIVE POSITIVE PRESSURE VENTILATION
(NIPPV) ON RESPIRATORY MUSCLE FUNCTION IN
CHRONIC TYPE 2 RESPIRATORY FAILURE
A.D. Gething, E.M. Williams, A. Phillips, B.V. Prathibha.2 School of
Applied Science, University of Glamorgan; 2Respiratory Department, Nevill
Hall Hospital, Abergavenny
In subjects with acute and chronic type 2 respiratory failure (due to
kyphoscoliosis, sleep hypoventilation, and chronic obstructive pulmo-
nary disease) application of nasal intermittent positive pressure venti-
lation (NIPPV) helps to restore arterial blood gases to normal levels,
and aid breathing by unloading inspiratory muscles.(1) The effect of
NIPPV on inspiratory muscle strength (IMs) and endurance (IMe) was
tested.(2)
Methods: Two patient groups were studied, group one (n=6, age
63 (7) years; mean (SD)) who had just started with NIPPV and group
two (n=6, 66 (14) years) who had undergone domiciliary ventilation
(dNIPPV) for longer than six months. Group one patients were tested
twice, once soon after the initiation of NIPPV and again after three
months of dNIPPV. Inspiratory muscle strength and endurance were
tested by asking the patient to perform three maximal inspiratory
manoeuvres (a measure of IMs) followed by repeated submaximal
(80%) manoeuvres with ever decreasing intermittent rest periods until
task failure (a measure of IMe).(2) All patients were naïve to the IMe
testing procedure.
Results: Group one patients (dNIPPV <1 month) had significantly
(p<0.05) lower PaO2 than group two (dNIPPV >6 month) of 6.7 (2.5)
v 8.6 (1.9) kPa respectively. The PaCO2 was not significantly different
at 7.5 (1.3) v 6.4 (0.9) kPa respectively. The maximal inspiratory
pressure (MIP) a measure of IMs was highest in group two (Group1 32
(4) v Group 2 47 (9) cmH2O) as was sustainable MIP, a measure of
IMe (Group1 102 (50) v Group2 158 (50) time/pressure units). In
group 1, three months of dNIPPV improved MIP from 32 (4) to 48 (14)
cmH2O but had no effect on sustainable MIP.
Conclusions: These data show that using dNIPPV for three months
and longer improves inspiratory muscle strength. Improving inspira-
tory muscle endurance takes longer to achieve and can only be seen
in the patients receiving dNIPPV for over six months (Group two).
There are no long term benefits of using dNIPPV in terms of increasing
inspiratory muscle strength but there are for endurance. How these
improvements in endurance relate to general health status have yet to
be evaluated.
1. Vitacca M, et al. Chest 2000;118:1286.
2. Gething, et al. Thorax 2001;56 (Suppl III):11.
Abstract P8
FVC % MIP MEP SNIP CmH2O
VS 29.9 (25.6) 33.1 (17.7) 54.9 (34.8) 28.2 (14.2)
NS 53.6 (39.9) 49.2 (26.3) 61.6 (33.9) 58.2 (22.3)
p Value 0.01 0.03 0.6 <0.0001
Abstract P9 The stimulus response curves for COPD patients are
shown.
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COPD exacerbations: ITU to
discharge
P11 DEVELOPMENT OF A RESPIRATORY HIGH
DEPENDENCY UNIT: EXPERIENCE FROM THE FIRST 20
MONTHS
D.M.G. Halpin, A. Jackson, C.D. Sheldon, N.J. Withers, S. Dodds. Royal
Devon & Exeter Hospital, Exeter, Devon, UK
Non-invasive ventilation (NIV) has been used at the Royal Devon &
Exeter Hospital since the early 1990s. Patients receiving NIV were
treated on the specialist respiratory ward and as awareness of the
benefits spread, NIV became the treatment of choice for patients
admitted in hypercapnic respiratory failure secondary to COPD. The
number of patients requiring NIV grew steadily and a business case
was prepared for an appropriately staffed and equipped respiratory
high dependency unit (rHDU). Eventually funding was secured from
money allocated to critical care services and the unit opened in
November 2000. Here we present an analysis of our experience over
the first 20 months.
The unit has four beds and is staffed with a nurse:patient ratio of
1:2. It is located in one bay of the respiratory ward. Two hundred and
twenty three patients have been admitted, with 33 admitted more than
once. The mean age was 64.5 yrs (range 18 to 91) and 51% of
patients were male. Most admissions (71%) occurred between 8am
and 8pm and were mainly transfers of patients admitted acutely to the
Emergency Medical Unit. Fifty one admissions (20%) were patients
transferred out of the ITU and 38 had tracheostomies. The median
length of stay was 4.04 days (range 1 to 37).
One hundred and nine patients received NIV, with 19 ventilated
more than once. The mean age was 69.3 yrs (range 18 to 91) and
50% were male. The median duration of NIV therapy was 25.0 hours
(range 0.5 to 505). There were 29 deaths in patients treated with
NIV. In most of these it had been agreed in advance that more inva-
sive treatment would not be undertaken. Ten patients were transferred
to ITU because of failure to respond to NIV.
Twenty six patients received CPAP therapy, with one being treated
more than once. The mean age was 70.2 yrs (range 32 to 88) and
64% were male. The median duration of CPAP therapy was 9.5 hours
(range 0.5 to 134). There were five deaths and four patients were
transferred to ITU because of failure to respond to CPAP.
The opening of the rHDU has allowed significant numbers of
patients with respiratory failure to be managed effectively. Many of
these patients would previously have been admitted to ITU. Appropri-
ate staffing of the unit has allowed admissions to be accepted
throughout the day and night and nearly one in three admissions
occurred outside the normal working day. The rHDU has significantly
enhanced the service we are able to offer patients.
P12 VARIATION IN CONSULTANT’S PROGNOSTIC
ESTIMATES FOR IDENTICAL PATIENTS MAY EXPLAIN
VARIATION IN COPD INTENSIVE CARE UNIT (ICU)
ADMISSION: SIMULATION STUDY FROM ONE
CRITICAL CARE NETWORK
M.J. Wildman2, J. O’Dea, S. Walia, M. Tindall, O. Kostopoulou, Z. Khan.
Critical Care Units City Hospital and University Hospital Birmingham;
2London School Of Hygiene & Tropical Medicine, London, UK
Introduction: Anecdotal evidence suggests variation in gatekeeping
decisions for COPD patients with respiratory failure considered for
ICU.(1) However little is known about the approach of different doctors
to the management of identical patients and the causes for the
suggested variability. This study exploits the fact that consultants on
call will occasionally make ICU admitting decisions on the basis of
information conveyed over the phone. Simulation of such phone calls
allows many clinicians to make decisions about identical patients in a
way that mimics real life.
Methods: One hundred and twenty consultants caring for acute
admissions in the Heart of England Critical Care Network were invited
to take part. An investigator in the role of a registrar who had just
assessed a COPD patient requiring ICU admission phoned consultants
who were told that the patient was likely to arrest soon if not intubated.
All relevant clinical information about the patient was available from
the investigator. Clinicians were asked whether they would admit the
patient to ICU and asked to predict ICU, hospital, and 180 day
survival following admission. The probability of survival for the
patients was subsequently calculated using the SUPPORT model.(2)
Doctors considered three patients all of whom had single organ
failure, but who varied in characteristics shown in multivariate analy-
sis to be predictive of outcome.(2)
Results: Out of 120 clinicians, 98 (82%) took part. Patient one:
88.8% of doctors admitted patient one, with admitters giving a mean
predicted hospital survival of 46.1% and non-admitters a significantly
lower mean predicted hospital survival of 12.7% (p<0.00005).
Patient one’s SUPPORT probability of 30 day survival was 89%.
Patient two: 64.3% of clinicians admitted patient two, with admitters
giving a mean predicted hospital survival of 37.9% v 11.8% for non-
admitters (p<0.00005). Patient two’s SUPPORT probability of 30 day
survival was 94%. Patient three: 39.8% admitted patient three, with
admitters giving a mean predicted hospital survival of 28.2% v 13.0%
for non-admitters (p<0.00005). Patient three’s SUPPORT probability
of 30 day survival was 68%.
Conclusion: Predicted hospital survival for identical patients
following ICU admission differed significantly between clinicians who
would admit compared to those who would not. This study suggests
that an important source of variability in ICU admission may arise from
marked variation in predictions of survival and that objective models
of patient outcome might reduce variability and support equity.
1. Wildman M. BMJ 1998;317:1667.
2. Conners AF Jr, et al. Am J Resp Crit Care Med 1996;154:959–67.
P13 CLINICAL DECISION MAKING: VENTILATING PATIENTS
WITH EXACERBATIONS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD)
F.M.R. Perrin1, C.W.G. Turton1, M. Renshaw2. 1Respiratory Department,
2Clinical Effectiveness Unit, Brighton and Sussex University Hospital, East-
ern Road, Brighton, UK
Introduction: The decision to institute mechanical ventilation in a
patient presenting in acute respiratory failure secondary to an exacer-
bation of COPD can be difficult and controversial. This study aimed to
determine whether there is a real difference in the views held between
respiratory physicians, general physicians, and intensivists, whether
there are significant differences in practice between individual
clinicians and which clinical factors most influence decision making.
Method: A questionnaire was circulated by post to 600 consultants
(200 in each specialty) selected randomly and at meetings to 125
SpRs. It included 25 different demographic, chest and comorbid vari-
ables that were each scored 0 to 3 according to the perceived
relevance of the variable in the decision to embark on a trial of venti-
lation (where 0 was irrelevant and three contraindicated ventilation).
The total score for all the variables was calculated for each clinician
(0 to 75).
Results: 356 questionnaires were returned; 321 were completed
fully and analysed (120 respiratory, 109 general medicine, 92 inten-
sive care). The total scores for the clinicians in each specialty were:
respiratory: mean 37.5, 95% CI 358 to 39.3, range 15 to 68; gen-
eral medicine: mean 39.5, 95% CI 37.7 to 41.4, range 12 to 65;
intensive care: mean 38.8, 95% CI 36.9 to 40.8, range 16 to 64. The
importance placed on the different variables were ordered similarly
across specialties. The most influential factors in deciding not to venti-
late a patient were documented permanent cognitive dysfunction
needing constant supervision, nursing home resident failing all activi-
ties of daily living, lung cancer deemed inoperable due to COPD, pre-
vious CVA such that patient chair bound or aphasic, and previous
difficulty weaning from ventilation. The factors regarded as being least
important were documented depression requiring treatment, osteo-
porosis with vertebral body collapse, continued smoking >20
cigarettes/day, plasma albumin <30g/l, and an above knee amputa-
tion for peripheral vascular disease.
Conclusions: There were no significant differences in clinical deci-
sion making between the specialties but there was wide variation
between individual clinicians. Few of the factors investigated would
contraindicate ventilation alone.
P14 CARDIOVASCULAR COMORBIDITY IS ASSOCIATED
WITH HIGHER MORTALITY IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD) PATIENTS ADMITTED TO
AN INTENSIVE CARE UNIT
K.S. Srinivasan, A. Spiliopopolous, M.K. Sridhar. Staffordshire General
Hospital, Stafford, UK
Background: 30–50% of patients admitted to an Intensive Care Unit
(ICU) with respiratory failure due to COPD die in hospital.(1) (2) Studies
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have highlighted the difficulty of predicting mortality in this patient
group from standard clinical and other scoring systems.(3) We present
results of a retrospective analysis of data examining mortality in an
unselected group of COPD patients admitted to the ICU in a district
general hospital in England.
Patients and methods: Fifty nine patients (31 male, 28 female;
mean age 66.2 years (50 to 86)) with COPD, who had been admit-
ted with respiratory failure to the ICU at Stafford General Hospital in
the last five years were studied. Of these patients, 17 (8 male, 9
female; mean age 72 years (52 to 86)) died while on ICU and 12 (5
male, 7 female) died within a year of their discharge. Age, smoking
history (past or present), usage of oxygen or nebulisers at home, and
associated cardiovascular diseases (ischaemic heart disease, heart
failure, or hypertension), were studied as predictors of mortality. We
do not know the severity of COPD before admission (FEV1) in these
patients. Patients with associated cardiovascular conditions were
found to have the highest mortality. Of the 59 patients, 24 had heart
disease (40%) and the death rate in this group was 54% (13 of 24).
Of these nine died during their stay in ICU.
Conclusion: COPD patients with cardiovascular comorbidity suffer
a higher mortality following admission to ICU with respiratory failure.
This information may have a bearing on prognostication and decision
making in COPD patients being considered for invasive ventilation
and admissions to ICU.
1. Hill AT, et al. Respir Med 1998;92:156–61.
2. Sonell MG, et al. JAMA 1995;274:1852–7.
3. Kaelin RM, et al. Chest 1987;92:971–8.
P15 REFERRAL AND OUTCOME OF PATIENTS WITH AN
EXACERBATION OF COPD REQUIRING ADMISSION TO
INTENSIVE CARE
A. MacDuff1, I.S. Grant2, S. MacKenzie2, P.T. Reid1. 1Depts of Respiratory
Medicine, and 2Intensive Care, Lothian University Health Trust, Edinburgh
Exacerbations of COPD complicated by acidotic respiratory failure
which fail to respond to medical management, including non-invasive
ventilation (NIV), are associated with a high mortality rate. When a
reversible aetiological factor is not present the decision to refer to ICU
is difficult with reservations on outcome and pressure on ICU resources
(Thorax 1997;52 (Suppl 5):S1–S28). To examine our own practice,
we performed a retrospective audit of admissions to the Intensive Care
Units in our Trust. We identified 56 consecutive patients between April
1999 to April 2001 in whom a primary diagnosis of COPD was
recorded. Of these, 37 were excluded as having a reversible cause of
respiratory failure or an alternative diagnosis.
The median age was 64.5 years (range 49 to 78). Nine patients
were previously unknown to respiratory physicians. It was the first
admission with respiratory failure requiring ventilatory support in five
of the nine previously admitted patients. Previous lung function was
only available on five patients: median FEV1 0.7l (range 0.35 to 1.7).
Prior to ICU referral median [H+]= 65.25mmol/l (IQR 61.33–77.7),
PaCO2=12.82kPa (IQR 8.93–15.6) and PaO2=8.2kPa (IQR 6.2–
9.0). The median duration of assessment prior to ICU admission was
5.5 hours (IQR 2–10.1). Seventeen patients required invasive ventila-
tion, one non-invasive ventilatory support. Two patients died in ICU
(one of respiratory failure, one of refractory hypotension). The median
duration of ICU stay for study patients was three days (IQR 2–6.23)
compared to 2.7 days for all ICU patients at the Royal Infirmary and
Western General. Sixteen were successfully discharged to respiratory
unit. One patient died in respiratory failure but 15 patients were dis-
charged and 14 were alive at one year. The median hospital stay was
13 days (IQR 9–19.3) (mean stay acute exacerbations of COPD in
Lothian Trust=8.3 days).
Our data suggest that severe respiratory failure may be the first
presentation of COPD to hospital. Limited time and information may
be available to make an informed decision on referral to ITU, but
length of stay and outcome are comparable to other ICU admissions.
P16 AN AUDIT OF THE USE OF NON INVASIVE
VENTILATION IN ACUTE EXACERBATIONS OF COPD
C.J. Jolley, R. Savine, S. Ellum, O. Gilleard, B.E.A. Lams, A.C. Davidson.
Lane-Fox Respiratory Unit, St. Thomas’ Hospital, London, UK
Introduction: The benefits of non-invasive ventilation (NIV) in the
treatment of acute type 2 respiratory failure secondary to chronic
obstructive pulmonary disease (COPD) are well documented (Thorax
2000;55:550–4).
Guidelines for the use of NIV have been published by the British
Thoracic Society (BTS) (Thorax 2002;57:192–21). We investigated
whether all patients with an acute exacerbation of COPD who fulfil the
BTS’s criteria for NIV are being referred for this treatment.
Methods: We identified 203 patients who were admitted to St
Thomas’s Hospital, London, with an acute exacerbation of COPD
between 1/11/2001 and 10/7/2002 by searching the Accident &
Emergency (A&E) register, High Dependency Unit (HDU), and Patient
At Risk Team databases. The results of arterial blood gas (ABG) analy-
sis on presentation to A&E were obtained from the patients’ A&E
notes. We noted whether the patient was admitted to a general ward,
received NIV on the HDU, or was intubated in A&E.
Results: Fifty four patients were excluded because their admission
ABGs were not available from their A&E notes, leaving 147 patients’
data for analysis. Of 147 patients, 110 were admitted to a general
ward, 33/147 received NIV on the High Dependency Unit, and
4/147 patients were intubated in A&E. The mean (SD) pH of patients
admitted to a general ward was 7.38 (0.06). The mean (SD) pH on
admission of patients referred for NIV was 7.27 (0.09). Of 147
patients admitted via A&E, 18 did not receive NIV despite meeting the
BTS criteria on the basis of their arterial blood gas analysis on initial
presentation. Their mean (SD) pH was 7.28 (0.05).
Conclusion: A significant proportion of patients with acute type 2
respiratory failure secondary to COPD who meet the criteria for NIV
do not receive it. Strategies are required to improve the pick up rate
of patients who would benefit from NIV at the time of their presenta-
tion to A&E.
P17 NON-INVASIVE VENTILATION IN PATIENTS WITH
RESPIRATORY FAILURE: EXPERIENCE FROM A
DEVELOPING COUNTRY
F. Hussain, J. Iqbal, R. Haqqee. Aga Khan University Hospital, Karachi,
Pakistan
Objective: Non-invasive ventilation (NIV) has been found to be effec-
tive in the management of respiratory failure. In developing countries
there is severe shortage of ICU beds and NIV service is still in early
stages of development. Studies are needed, from developing
countries, to determine its effectiveness among patients with different
types of respiratory failure. In this study we have evaluated Asian
patients with both types of respiratory failure as well as patients with
respiratory distress and impending respiratory failure.
Method: The study was conducted at Aga Khan University Hospi-
tal Karachi, Pakistan. All patients who were treated with NIV during
1999–2000 were evaluated. Demographic details, history, and
physical examination of patients were recorded. Laboratory data
included serial arterial blood gas (ABG) analysis, chest radiograph,
blood count, and electrolytes. Details of medical treatment, of NIV and
their outcome were recorded.
Results: A total of 68 patients (35 males) were evaluated. Their
Mean (SD) age was 60 (16.75) (range 16 to 90) yrs. The commonest
indication for the use of NIV was Type II respiratory failure due to
COPD exacerbation. There was significant improvement of mean
PaCO2 within two hours of treatment (76 v 70 mm Hg, p = 0.001) and
of mean pH at 24 hours (7.30 v 7.36, p<0.001). Out of 37 patients,
25 (68%) improved with NIV alone, five (14%) needed invasive ven-
tilation, and seven (19%) were considered unsuitable for invasive ven-
tilation despite deterioration. Mortality was 30% (11 patients). NIV
was applied to 17 patients with Type I respiratory failure; pneumonia,
asthma, and pulmonary oedema were the common underlying
diseases. The mean PaO2 improved within two hours of treatment (53
v 87 mm Hg, p = 0.003). Ten (59%) patients were successfully treated
with NIV alone, six (35%) needed subsequent invasive ventilation,
and one (6%) was considered inappropriate for invasive ventilation
despite deterioration. Six patients died (mortality 35%). Neuromusc-
ular diseases and pulmonary oedema were the common causes
among 14 patients with respiratory distress (respiratory rate >30
along with use of accessory muscles and laboured breathing). NIV
was successful in 9 (64%) patients, 3 (22%) needed invasive ventila-
tion, and two (14%) died. At the time of admission 16 (24%) patients
were considered inappropriate for invasive ventilation, based on the
nature of medical illnesses, prior physical health, and patient’s wishes.
In this group 14 (88%) patients had Type II respiratory failure and two
(12%) had Type I respiratory failure. Overall 8 (50%) out of 16 had a
successful outcome with NIV.
Conclusion: NIV can be used effectively in developing countries to
treat patients with respiratory failure. It can be applied outside ICU
and can obviate the need of invasive mechanical ventilation in
responders. It can be used, with good effect, in patients not suitable
for invasive mechanical ventilation.
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P18 RELATIONSHIP BETWEEN AQ20, SGRQ, AND
EXACERBATION FREQUENCY IN PEOPLE WITH COPD
IN PRIMARY CARE
A. Choudhury, C.M. Dawson, H.E. Kilvington, C.J. Griffiths, G.S. Feder,
J.A. Wedzicha. Department of General Practice and Academic Respiratory
Medicine, St Bartholomew’s and Royal London School of Medicine and
Dentistry, London, UK
Health related quality of life (HRQoL) is closely related to exacerbation
frequency in patients with chronic obstructive pulmonary disease
(COPD). The main obstacle to measuring HRQoL in primary care is
their size and complex nature. The Airways Questionnaire 20 (AQ20)
(Barley EA, et al. Respir Med 1998;92:1207–14) is a short, simple,
disease specific questionnaire. Dimensions range from 0 to 20 (worst
health).
Patients were recruited from general practices in East London.
Patients were aged 40 and above, current or ex-smokers and were
prescribed regular inhaled steroids. We asked patients to complete
the AQ20 and the St George’s Respiratory Questionnaire (SQRQ)
simultaneously at interview.
One hundred and thirty one patients (68 male) of median age 66
years (range 48 to 87) with COPD were recruited from 12 general
practices. Mean (SD) FEV1 was 1.28 (0.55) l, FEV1 predicted 50.0
(18.0)%, mean FEV1/FVC ratio was 57.0 (16.0)%. Patients had a
yearly exacerbation rate of 2.4 (2.5). The median AQ20 score was
11 with a range of one to 19. The median SGRQ total score was 51.0
with a range of 7.7 to 93.3. The AQ20 was strongly correlated to the
SGRQ (Spearman rank correlation); SGRQ symptom (0.548),
activities (0.681), impacts (0.742), and total (0.749).p<0.001. Other
statistically significant findings with AQ20 were predicted FEV1
(−0.271) and pack years smoked (0.242) p<0.005. Patients were
divided into those who had less than three COPD exacerbations per
year (infrequent exacerbators) and those who had three or more exac-
erbations per year (frequent exacerbators).
The AQ20 shows a strong relationship to yearly exacerbation rate.
The AQ20 is simple to implement and can be used to assess health
status for patients with COPD in primary care where time and
resources are limited.
P19 USING A PRIVATE SECTOR PARTNERSHIP TO PROVIDE
SUPPORTED EARLY DISCHARGE FOR ACUTE
EXACERBATIONS OF COPD IN A DISTRICT GENERAL
HOSPITAL
C. Fehrenbach1, E. Neville1, W.F. Holmes2. 1Portsmouth NHS Trust; 2Nes-
tor Healthcare PLC, UK
Home care is successful in about 25% patients hospitalised with an
exacerbation of COPD,(1) though nursing resources are not always
available to provide it. Encouraged by the government’s endorsement
of partnerships between the NHS and the private sector,(2) a six month
home care service was commissioned from Nestor Primecare, for
nurse led 24hr care for selected patients following early hospital dis-
charge. The Trust Respiratory nurses reviewed patients one month after
discharge in clinic.
Following medical assessment in hospital (protocol available), the
nurse accompanied and transported the patient home, and thereafter
provided care over a 10 day period, (mean attendance: five hours).
During the day, patients had direct access to the nurses, and at night
through a dedicated telephone support line. When thought necessary,
readmissions were organised by the nurse, not the patient’s general
practitioners.
In Portsmouth, about 580 000 patients are served by two district
general hospitals and three Primary Care Trusts. During the six months
to July 2002 there were 276 admissions to the Trust coded J44.1
(exacerbation of COPD). The average hospital stay for this condition
locally is eight days. Of these patients, 124 (44%) (50% male)
received supported discharge within 1–2 days of admission. Fifty four
calls for support came from 34 patients but none needed referral to
their GP. There were 18 readmissions during the period of home care
(14%). Seven patients died during readmission, but none of those
remaining at home. Patient satisfaction was high, and only one person
refused home care.
Conclusion: This 10 day service was successful in a higher
proportion of patients than in previous studies, and at a total cost of
£85 000.
1. Gravil JH, et al. Lancet 1998;351:1853–8.
2. DoH. NHS Plan. London: Department of Health, 2001.
P20 A REGULAR VISIT TO PATIENTS ADMITTED WITH COPD
REDUCES FURTHER HOSPITAL ADMISSIONS
R. Rowles, R. Bennett, A. Hill, S. Jones, J. Goldman. Heart and Lung Unit,
Torbay Hospital, Torquay, TQ2 7AA UK
The Torbay Hospital Outreach Respiratory Team (THORT) has been
supporting the early discharge of patients with exacerbations of
COPD since December 1999. It was noted that certain patients were
having frequent admissions often with minor exacerbations that were
then managed at home by THORT. It was proposed that regular main-
tenance visits by the team on patients identified as having frequent
admissions or significant problems with anxiety would reduce these.
The first of these visits was in July 2001. In total 12 patients have
been placed on the maintenance list and data has been collected on
admissions pre and post the start of visits. For the purpose of this study
10 patients were selected who had complete sets of admission data
for 12 months prior to the visits, and had been receiving maintenance
visits for at least two months. Total bed days and THORT days were
averaged over the previous 12 month period, and for the period since
the onset of maintenance visits to give an indication of whether admis-
sions had subsequently reduced.
The results show that in the year prior to the start of visits the aver-
age number of bed days and facilitated discharge days under THORT
per month for the 10 patients studied was 40.1. After the introduction
of maintenance visits the average number of days was 8.7 per month.
The average number of maintenance visits undertaken per month was
12.8.
Although this study has comparable data on a small number of
patients, preliminary results suggest that regular maintenance visits to
patients with COPD identified as having frequent exacerbations do
have a positive impact on their ability to cope at home and avoid
admission to hospital. In conclusion directing resources towards
providing regular support to appropriate patients with COPD would
be seen to be a cost effective way of reducing the use of healthcare
resources by COPD patients over the winter months.
P21 PRIMARY CARE EXPERIENCE OF PATIENTS ADMITTED
TO HOSPITAL WITH AN EXACERBATION OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
A. Coe, A.O.C. Johnson. Pontefract General Infirmary, Pontefract, West
Yorkshire, UK
Although ‘Hospital at Home’ schemes for early facilitated discharge of
patients with exacerbations of chronic obstructive pulmonary disease
(COPD) have become more prevalent, schemes to prevent admission
are less widespread. AC was awarded a Health Action Zone fellow-
ship to investigate the role of a respiratory therapist in assessing and
triaging potential admissions with exacerbations of COPD into those
who require admission, early facilitated discharge (by referral to our
Hospital at Home Scheme) or conventional discharge. This survey was
done to inform the design of the potential new service.
Fifty three patients (mean age 71) admitted to hospital with exacer-
bations of COPD were questioned about their contact with primary
care prior to admission. There were 26 men and 27 women.
Symptoms which prompted admission included increased breathless-
ness (92%), wheeze (72%), cough (55%), increased sputum volume
(49%), sputum colour change (45%), fever (38%). Three patients
denied any change in symptoms. Prior to admission, 25% of the
patients had had no contact with primary care services, 25% had tele-
phone contact only, 34% were seen at home, and 17% were seen in
the GP surgery. Of the 40 patients who had some contact with
primary care, 40% had contact in the morning, 40% in the afternoon
Abstract P18 AQ20, SGRQ, and exacerbation
frequency
Exacerbation
frequency <2 >3 mean diffp Value
Cases (N) 82 49
AQ20 Total 9.3 (4.9) 13.1 (4.2) −3.8 <0.001
SGRQ Total 46.2 (18.9) 59.1 (17.2) −12.9 <0.001
Symptoms 62.1 (21.9) 77.2 (17.5) −15.1 <0.001
Activities 61.0 (25.0) 74.0 (19.5) −13.0 0.003
Impacts 32.7 (18.3) 44.8 (19.4) −12.1 0.002
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and only 12.5% out of hours (no data on three patients). Only 8
patients were seen twice with the same exacerbation prior to
admission.
When asked why they had bypassed primary care most patients
said either that they or a relative thought the situation too urgent for a
GP to manage, or that previous experience was that the GP would
send them to hospital anyway. The three patients with no change in
symptoms had all bypassed primary care and were admitted because
of anxious relatives. In contrast to the time of primary care contact,
attendance at hospital was mostly out of hours (51%) or afternoon
(36%). About half of the admissions were arranged by GPs, a quarter
saw the GP but self presented to A&E anyway, and a quarter
bypassed primary care altogether.
We conclude that many patients and relatives admitted with COPD
have little confidence in primary care’s ability to deal with exacerba-
tions, especially out of hours. A 24 hour service with specialist train-
ing may be able to deal with some patients with exacerbations and
prevent unnecessary admission to hospital.
Bronchoscopic and other lung
investigations
P22 BRONCHOSCOPY PRACTICE IN ENGLAND AND
WALES, 2002
J. Pickles, M. Jeffrey, A. Datta, A.A. Jeffrey. Chest Clinic, Northampton
General Hospital, Northampton NN1 5BD, UK
Aims: To assess current practice in bronchoscopy preparation in Eng-
land and Wales.
Methods: Questionnaires were faxed to respiratory consultants
listed in The BTS Directory.(1) We looked at the population, number of
consultants and bronchoscopies undertaken, topical anaesthetic use,
sedative use and how adequate sedation is judged.
Results: There was a response rate of 76% (344 responses to 452
questionnaires). Median consultant numbers per hospital was three
(IQR 4–6), median population served per consultant was 116 00 (IQR
90–150 000). The majority of bronchoscopists use lignocaine spray
to the throat (70%), sometimes with spray to the nose (43%), together
with gel to the nose (65%). The majority use 4% lignocaine to the
vocal cords (54%) and 2% to the bronchi (71%). Atropine is used rou-
tinely by 13%. Sedation with midazolam (78%) or other combinations
(22%) is routine. The option of sedation is only discussed with the
patients by 8.4% of consultants. Only three operators use formal
sedation scores to assess patient level of sedation. Oxygen saturation
was the commonest measurement used (n=98) to judge sedation.
Otherwise, response to sedation was judged by clinical experience
(n=60), patient response (n=57), and conscious level (n=50).
Conclusion: Despite the recent BTS guidelines there is consider-
able variation in bronchoscopy practice, particularly in sedation prac-
tice. Patient level of sedation is not formally assessed and
combinations of sedatives and analgesics are used contrary to the
recent guidelines on safe sedation practice.(2) Sedation options are not
routinely discussed. The wide variations in practice may reflect the
lack of consistent evidence based guidance on sedation techniques for
bronchoscopy. Further study to determine optimal technique is
required.
1. BTS/Astra Zeneca. The directory of respiratory medicine [7th ed].
Hawker Publishing, 2002.
2. Safe sedation practice. Academy of Medical Royal Colleges and
their Faculties, 2001.
P23 FLUORESCENCE BRONCHOSCOPY IN PATIENTS WITH
ABNORMAL SPUTUM CYTOLOGY
A.K. Banerjee1, P.H. Rabbitts1, P.J.M. George2. 1Molecular Oncology
Group, University Of Cambridge, UK; 2The Middlesex Hospital, London,
UK
Introduction: Patients at risk of lung cancer with abnormal sputum
cytology or bronchial washings but no other evidence of lung cancer
present a management dilemma. Autofluorescence bronchoscopy
detects preinvasive endobronchial lesions and carcinomas with
greater sensitivity than conventional bronchoscopy. We present a
series of patients with abnormal sputum cytology or bronchial wash
cytology investigated further with autofluorescence bronchoscopy.
Methods: Patients selected had no clinical or radiological evidence
of invasive carcinoma and no bronchoscopic abnormality within the
preceding two months. The visible bronchial tree was inspected with
white light and autofluorescence using the Storz bronchoscope. Biop-
sies were taken of all areas appearing abnormal bronchoscopically.
Results: Ten patients were studied, eight males with a mean age of
66.5yrs (range 51 to 79 yrs). All were smokers, mean exposure 47
pack years (range 18.5 to 79). The table shows the bronchoscopy
results and outcomes for the study patients.
Conclusions: In this group of patients, no abnormality detectable
at fluorescence bronchoscopy suggests a good outcome, with no evi-
dence of carcinoma at up to 42 months. Abnormal fluorescence may
reveal the presence of radiologically occult carcinoma, or high grade
preinvasive lesion, but may also be a false positive finding. High
grade preinvasive lesions may exfoliate cells that resemble squamous
carcinoma cells. Fluorescence bronchoscopy may provide useful infor-
mation in this difficult group of patients. This study is limited by the
small numbers and relatively short duration of follow up, but suggests
that a larger study should be undertaken.
P24 ENDOBRONCHIAL MIMICS OF LUNG CANCER: A CASE
REPORT AND REVIEW OF BRONCHOSCOPY DATA
BASE
S. Lohani, P.R. Chadwick, G.R. Armstrong, B.R. O’Driscoll, S.C.O.
Taggart. Respiratory Medicine Department, Hope Hospital, Salford
M6 8HD, UK
Case report: A 72 year old ex-smoker and retired fireman with pre-
vious asbestos exposure, presented with a six week history of cough,
breathlessness, and wheeze. Clinical examination revealed a small
basal effusion. CXR examination confirmed the clinical findings. ESR
was 122 mm/hour. CT scanning revealed a loculated effusion and
loss of volume in right lower lobe (RLL) with associated distal consoli-
dation. Initial and subsequent bronchoscopies demonstrated an endo-
bronchial RLL “tumour” but biopsies were negative for cancer. The
patient was informed that cancer seemed the most likely cause of his
symptoms. However, ultrasound guided aspiration of the fluid
revealed an empyema which grew Actinomyces israelii. This was sub-
sequently demonstrated to be present in both previous biopsy
specimens. The patient made a full clinical and bronchoscopic recov-
ery after six weeks of penicillin treatment.
Review of bronchoscopy data base: Over the past 10 years, our
team has performed 4199 bronchoscopies of which 1122 (27%)
were found to have lesions suspicious of lung cancer. Of these 1004
(89.5%) have had cancer confirmed by histology or cytology and 101
(9.0%) have been treated as cancer although the biopsies were nega-
tive. Of patients with suspicious bronchoscopies, 17 (1.5%) had a
specific non-malignant diagnosis (see table).
Conclusions: Endobronchial mimics of lung cancer account for
>1% of suspicious bronchial lesions. We recommend caution in
informing patients of cancer until either histological confirmation is
obtained or other causes are excluded.
Abstract P23 Bronchoscopy results and outcomes for
the study patients
n Abnormality Bronchoscopy Outcome
5 4 Sputum SQC No abnormality Disease free 7–24 mths
1 Bronch wash
SQC
Disease free 42 mths
3 1 Sputum SQC Abnormal
fluorescence
SQC in areas of abnormal
fluorescence2 Bronch wash
SQC
1 Sputum SQC Abnormal
fluorescence
CIS in area of abnormal
fluorescence (12 mth follow
up)
1 Sputum SQC Abnormal
fluorescence
Normal histology (false +ve)
Disease free at 48 mths
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P25 BRONCHOALVEOLAR LAVAGE, NON-INVASIVE
INVESTIGATIONS AND RADIOLOGY: IMPACT ON
TREATMENT IN PATIENTS WITH HAEMATOLOGICAL
MALIGNANCIES AND PULMONARY INFILTRATES
A.R. Benjamin, E.F. Bowen. Respiratory Medicine Unit, Hammersmith Hos-
pital, London W12 ONN, UK
Pulmonary infiltrates are a frequent complication in immuno-
suppressed patients with haematological malignancies requiring early
diagnosis with prompt appropriate treatment. We investigated the
diagnostic yield of bronchoalveolar lavage (BAL) and non-invasive
sampling (NIS) in this population over a 12 month period and evalu-
ated their impact on treatment modification.We compared high reso-
lution computed tomography (HRCT) findings with these results.
Twenty five bronchoscopies (FOBs) (21 patients) were performed dur-
ing this period. Seventeen out of 21 patients were post bone marrow
transplant and 4/21, on high dose chemotherapy. Pre FOB, 16/25
cases were neutropenic and/or lymphopenic, 15/25 were thrombo-
cytopenic, 22/25 were pyrexial, and 22/25 were on empirical anti-
biotics. All were hypoxic and required supplemental oxygen
periprocedure. Post FOB, 1/21 patient required admission to the
intensive care unit.
Blood cultures, sputum cultures, and nasopharyngeal aspirates
were positive in 3/41, 4/21, and 1/3 samples respectively and
treatment was modified in 2/25, 2/25, and 1/25 cases respectively.
Overall, NIS was positive in 8/25 (32%) cases with subsequent treat-
ment modification in 5/25 (20%) cases. BAL was positive in 10/25
(40%) cases. (7/25 bacterial, 2/25 viral, 1/25 PCP) and treatment
was modified in 8/25 (32%) cases. Where NIS was positive, BAL
confirmed the diagnosis only once and in one case revealed another
organism that changed management further.
In 2/25 cases, chest radiograph (CXR) was not done prior to HRCT.
CXR was abnormal in 16/25 cases, 13 of which proceeded to HRCT
with subsequent treatment modification in 5/13 cases. In 7/25 cases,
CXR was normal of which all had abnormal HRCTs with treatment
modification in 1/7 case. Overall, HRCT led to treatment modification
in 6/22 cases, in which BAL confirmed the suspected aetiology in
2/22 cases.
This data indicates that the sequential use of NIS and BAL gives the
highest diagnostic yield of pulmonary infiltrates. At our institution,
HRCT was not sensitive enough to allow for its confident use as a
diagnostic tool in place of BAL. Although FOB is a high risk procedure
in this population, this data supports BAL as a safe and useful investi-
gation.
P26 CT GUIDED LUNG BIOPSIES: DO THEY PROVIDE THE
DIAGNOSIS?
P.L. Williams, R.K. Rajakulasingam. Department of Respiratory Medicine,
Homerton University Hospital, London, UK
When requesting CT guided lung biopsies we are frequently asked
“Will the patient tolerate a pneumothorax?”. With this in mind we
performed an audit of this technique to assess the success rate of the
procedure, frequency of complications, and the sensitivity and specifi-
city for diagnosing lung cancer.
Using the CT record book to identify cases we recorded details of
all (n=68) patients recorded as having had “lung biopsy” over the
previous four year period. We used patient case notes, the lung can-
cer database, and the computer based histology records and CT
reports to record, where possible, the indication, histology obtained,
whether or not further investigative procedures had been required,
any documented complications, and the final diagnosis.
Of the 68 patients recorded as “lung biopsy”, 1% actually had
pleural biopsy and 4% lung aspirate. Of these there were no compli-
cations and the procedure provided the diagnosis. Sixty four patients
were scheduled for the procedure: percutaneous core needle biopsy
under CT guidance, following infiltration with subcutaneous ligno-
caine. 1-”multiple” passes were made as required/tolerated. Each
patient had a postprocedure CT check for pneumothorax. Of the 64,
6% were cancelled due to radiological improvement and 6%
abandoned due to technical difficulties, leaving 56.
The indication for biopsy was suspected lung cancer in 91%. We
wanted to know whether the procedure provided the final diagnosis or
if further measures needed. Of the 46 patients in whom adequate
information was available, the histological sample from biopsy was
successful in providing the final diagnosis in 71%. Histology was
obtained but further investigations were needed in 26%. No histology
was obtained in 4%. Of the 56 patients who underwent any
procedure pneumothorax preventing biopsy occurred in just 2%.
Smaller pneumothoraces occurred in 13%, and the remaining 85%
experienced no complications.
The sensitivity of the procedure for diagnosing lung cancer was
90%, specificity 100%, and false negative rate 8%. These and the
complication rate compared favourably with other published studies
of lung biopsy. In a DGH this procedure is still useful and we have
demonstrated a relatively low complication rate.
P27 GENERAL PRACTICE OPEN ACCESS SPIROMETRY: WHO
WAS REFERRED IN 2001?
A.H. Kendrick, D. Smith, M.R. Hetzel, J.R. Catterall, G. Laszlo. Department
of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK
We provide an Open Access spirometry service to primary care.
Patients attend from 09:30 to 11:30 Mon to Fri. A technologist
obtains a history, spirometry pre and post β2-agonist via spacer and
pulse oximetry. A report and recommendations are sent to the GP.
Aim: To review the throughput of this service in 2001.
Methods: The records of all patients attending the service were
reviewed. Data are given as median (range).
Results: 706 patients attended, with 55 having further studies after
a trial of steroids. Age was 54.7 yr (10 to 91), 366 were female and
body mass index (BMI) was 27.4 kg.m-2 (14.9 to 52.6). 198 had a
BMI >30 kg.m-2. History: 274 were smokers, 438 had cough, 368
had wheeze, and 397 had sputum production. MRC dyspnoea grade
(n = 696) was Grade 1–110, Grade 2–230, Grade 3–223, Grade
4–116, and Grade 5 – 17. One hundred and ninety six patients had
no medication, 49 were on antibiotics, 261 on a β2 agonist, 24 on an
anti-muscarinic, 177 on oral/inhaled steroids, 32 on a β blocker, 57
on a blood pressure tablet, and 203 patients were on other therapies.
Lung Function: FEV1%predicted was 84.7 (15 to 143), FVC%predicted
was 89.1 (14.7 to 144) and FEV1%FVC was 74.9 (23.9 to 100).
Sixty one studies showed submaximal/variable efforts. One hundred
and fifteen patients had normal spirometry, 68 reversible airflow
obstruction, 438 irreversible airflow obstruction, and 24 a restrictive
defect. For reversibility, absolute change in FEV1 was 0.4 l (0.2 to
1.45) and % change was 29.8% (15.4 to 271). Nine out of 55 ster-
oid trials showed a positive response with the absolute change in FEV1
(post β2 agonist) of 0.45 l (0.2 to 0.8) and % change of 29.8% (15.1
to 64.0). Pulse oximetry (n = 676) showed 34 patients had an O2
saturation <92%. Recommendations: 25 patients with airflow
obstruction to change from β blockers, 145 patients for a trial of
inhaled steroids with repeat spirometry, 40 to be prescribed a β2 ago-
nist, 184 to be referred for further investigations—LTOT (n = 34),
?occupational lung disease (n = 36), ?EIA (n = 27), excessive
dyspnoea for spirometry (n = 63), and restrictive defect (n = 24).
Conclusion: This service (1) accurately assesses simple lung func-
tion, (2) identifies groups of patients requiring further investigation or
a change in therapy, and (3) provides recommendations to assist the
primary care physicians to manage their patients.
P28 SERIAL PEAK FLOW MEASUREMENTS FOR THE
DIAGNOSIS OF OCCUPATIONAL ASTHMA:
IMPROVING THE QUALITY
V. Huggins1, W. Anees1, C. Pantin2, P.S. Burge1. 1Occupational Lung
Disease unit, Birmingham Heartlands Hospital, UK; 2Department of Respi-
ratory Medicine, North Staffordshire Hospital, Stoke-on-Trent, UK
Serial measurements of peak expiratory flow (PEF) are usually the most
appropriate first step in the investigation of occupational asthma.
Different centres have reported widely different success in obtaining
records of sufficient data quantity for diagnosis. We have investigated
different methods of instruction and determined the return rate and
quality of the resulting record for the diagnosis of occupational asthma
using predefined criteria.
Abstract P24
Diagnosis No Diagnosis No
Benign polyps 3 Tracheopathica 1
Active tuberculosis 3 Hyalinising granuloma 1
Carcinoid 2 Sarcoid 1
Leiomyoma 1 Healed tuberculosis 1
Bronchial adenoma 1 Organised blood clot 1
Vasculitis 1 Actinomycosis 1
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Methods: Three instruction methods have been investigated: 159
were instructed by post (postal group), 86 were personally instructed
by a PEF specialist (personal group), and 40 were instructed by
others—for example, GPs, occupational health physicians, or nurses.
Results: The postal return rate was 56% and the personal return
rate 85%, adequate data quantity was similar in the postal and per-
sonal groups (54.8% and 58.8% respectively). Pre-existing records
plotted from graph charts were only adequate in 23%, compared with
pre-existing records plotted from occupational forms (61% adequate).
Failure of the record to contain consecutive periods of >3 workdays
was the most common reason for inadequate data quantity.
Conclusion: The quality and return rate of PEFs for diagnosing
occupational asthma is better when patients have been given specific
instructions from a PEF specialist and recording is on a dedicated
form.
P29 DIFFERENCES IN INDICES OF PEAK EXPIRATORY FLOW
VARIABILITY BETWEEN WORKERS WITH
OCCUPATIONAL ASTHMA AND IRRITANT (GRAIN
DUST) EXPOSED HEALTHY SUBJECTS
W. Anees1, D. Blainey2, V. Huggins1, K. Robertson2, P.S. Burge1. 1Occupa-
tional lung disease unit, Birmingham Heartlands Hospital, Birmingham,
UK; 2Broomfield hospital, Chelmsford, Essex, UK
Introduction and Aims: Serial peak expiratory flow (PEF) records
have been recommended as a first line investigation in workers
suspected as having occupational asthma. It is unclear, however, to
what extent they can differentiate between workers with occupational
asthma and healthy workers exposed to irritant agents, and which
index of PEF variability is best at doing so.
Methods: Indices of PEF variability were compared in three groups
of subjects. (1) Forty healthy grain exposed farmers and dockers. (2)
Forty two consecutive subjects with independently confirmed occupa-
tional asthma. (3) Forty eight non-occupational asthmatics.
Results: The index of PEF variability that best separated the occu-
pational asthmatic workers from the others was the difference in mean
PEF between rest and work periods. The upper 95% confidence limit
of this index for the grain workers was 2.8% of predicted PEF (16
L/min), for non-occupational asthmatics 3.3% predicted PEF (15
L/min). Sensitivity for diagnosing occupational asthma using this
index was 70%. Only 40% of workers with confirmed occupational
asthma had a PEF diurnal variability >17% of predicted, the upper
limit for grain workers. An increase in diurnal variation on work days
of >7% (the upper 95% limit for non-occupational asthmatics) had a
sensitivity of only 27% for the diagnosis of occupational asthma. The
difference between maximum PEF on work days and minimum PEF on
rest days was poor at separating occupational asthmatic workers from
those with non-occupational asthma.
Conclusion: Difference in mean PEF between work and rest days
is the best simple index for differentiating subjects with occupational
asthma from those with non-occupational asthma or irritant exposed
healthy subjects.
P30 REPEATABILITY OF CHLORIDE LEVELS IN EXHALED
BREATH CONDENSATE (EBC)
A. Zacharasiewicz, N. Wilson, A.M. Li, CH. Lex, J. Hooper, A. Bush.
Department of Paediatric Respiratory Medicine, Royal Brompton Hospital,
UK
Background: Reproducibility of measurements of EBC is controversial
(Effros, et al. Am J Respir Crit Care Med 2002:165:663–9). It has
been suggested that there is a wide variation in dilution of the
collected sample, which would make interpretation of measurements
difficult.
Aim: to assess the repeatability of Sodium [Na] and Chloride [Cl]
measurements in EBC in healthy adults and in asthmatic and cystic
fibrosis (CF) children.
Methods: EBC were collected for 10 minutes using a Condenser
(Ecoscreen (Jaeger) and wearing a nose clip. [Na] and [Cl] were
measured with a CIBA Corning M 644 NaCl Analyser. Samples of
five healthy adults were collected five times within one day with a 20
minute interval each. To measure period repeatability, the collection
was repeated on another day within eight weeks. Technical
repeatability was measured by aliquoting each sample into two tubes.
Within day repeatability was also assessed in seven asthmatic and
eight CF children from two collections within two hours. Repeatability
was calculated according to Chinn (Chinn S. Thorax 1991;46:454–
6).
Results: Na could not be detected in >30% EBC, so was not ana-
lysed further. For normals, the mean (SD) [Cl] was 4 (0.95) mmol/L;
the technical repeatability within one sample, calculated by the single
determination range was ±1.96 mmol/L, and the within subject day
repeatability assessed as the 95% range for change within a day was
±1.16 mmol/L, the within period (eight weeks) range of change was
±2.18 mmol/L. For asthmatics, the mean [Cl] was 4.4 (0.9) mmol/L
with a range of change of ±2.98, in CF patients the mean [Cl] was 5
(1.5) mmol/L and 95% range for change was ±3.38 mmol/L.
Conclusion: The variability of measured levels is similar for within
test (paired estimates of the same sample), within day and between
visits, for both normals and children with asthma and CF. Thus our
data suggest that the major source of variability of [Cl−] can be
explained by limitation of the measurement assay method used, rather
than as an effect of intrinsic variability in EBC collection per se. The
wide use of EBC is most likely dependant on the development of highly
sensitive and reproducible assays, rather than further refinements of
the collection technique.
P31 DOES AIRFLOW OBSTRUCTION OR INHALATION OF
SALBUTAMOL INCREASE THE VOLUME OF EXHALED
BREATH CONDENSATE COLLECTED IN STABLE COPD
AND ASTHMA?
S. Manney1, J.G. Ayres1, J. Baker2. 1Air Pollution Laboratory, Heartlands
Research Institute, Birmingham Heartlands & Solihull NHS Trust, Bordesley
Green East, Birmingham, B9 5SS, UK; 2Division of Environmental Health &
Risk Management, University of Birmingham, Edgbaston, Birmingham,
B15 2TT, UK
Introduction: Exhaled breath condensate (EBC) collection, although
widely accepted as a method for measuring molecules in exhaled
breath, is not well characterised methodologically. Factors such as
airflow obstruction, bronchodilator therapy, or respiratory rate may
affect the volume of EBC volume achieved. The main aims of this study
were to examine whether EBC volume collected could be increased
post salbutamol inhalation, and whether EBC volume collected was
directly linked to airflow obstruction as assessed by FEV1.
Methods: Eighteen volunteers were studied (10 COPD, eight asth-
matics). Each completed six collections over three days. On each
occasion, subjects were asked to refrain from taking short acting bron-
chodilators for six hours before the study. Two collections were made
on each day (breathing via mouthpiece and two way valve into two
Teflon tubes in ice for 15 minutes), pre and post inhalation of 200 µg
salbutamol. Spirometry was completed on all volunteers at the end of
both collections. On each of the three days, volunteers completed the
same protocol for reproducibility of volumes.
Results: There was no correlation between airflow obstruction and
EBC volume collected.
There was no significant difference in EBC volume pre and post
bronchodilator when considering all 18 patients (2.26 ml (SD)(0.35)
pre; 2.31 ml (0.35) post) (p=0.46). For patients with COPD the
respective volumes were 2.21 ml (0.30) and 2.35 ml (0.32) (NS)
while for asthma they were 2.33 ml (0.42) and 2.22 ml (0.37)
(p=0.04).
Conclusion: EBC volume was not related to the degree of airflow
obstruction and bronchodilator inhalation did not increase EBC
volume.
P32 A NOVEL DEVICE FOR THE PRECISE MEASUREMENT OF
RESPIRATORY HEAT AND MOISTURE LOSS
J.B. McCafferty1, P.K. Kew2, A. Haston2, J.A. Innes1. 1Respiratory Unit,
Western General Hospital, Edinburgh; 2Department of Mechanical and
Chemical Engineering, Heriot-Watt University, Edinburgh
Background: It is proposed that respiratory heat and moisture loss
(RHML) are altered by airway inflammation and that measurements of
Abstract P31 FEV1 v EBC volume produced.
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RHML may yield a useful non-invasive marker of such inflammation.
Simple exhaled temperature and humidity measurements are however
insufficient to characterise RHML as heat and moisture loss are
affected by respiratory pattern and inspirate temperature and humid-
ity. To precisely measure RHML in normal subjects and patients with
airway disease we have developed a novel device which can control
inspired air temperature, humidity, minute ventilation, and tidal
volume.
Methods: The device is a compact trolley mounted air conditioning
module delivering air at up to 1500 ml/s with a controllable tempera-
ture (3°C to 40°C) and moisture content (5 to 40 g/kg dry air). Air is
delivered to the inspiratory side of a 2 way valve by means of a flow
past configuration. Temperature and humidity sensors located on
inspiratory and expiratory sides of the breathing valve allow accurate,
continuous recording of the thermodynamic state of air entering and
leaving the respiratory tract. A computer linked to an ultrasonic flow-
meter in the expiratory limb is used to generate auditory and visual
feedback cues to help subjects control respiratory rate and flow
respectively, allowing standardisation of ventilatory pattern between
subjects. RHML at steady state is calculated as the product of mass
flowrate and “enthalpy” difference between inspired and expired air.
Six normal volunteers breathed inspirate at 7°C at a target minute ven-
tilation of 15 l/min with either a slow deep pattern (rate 10/min, tidal
volume 1455 (101) ml (SD)) or rapid shallow pattern (30/min, tidal
volume 525 (36) ml).
Results: Mean respiratory heat loss was 15.7 (1.4) Watts during
rapid shallow breathing and increased to 18.3 (1.3) Watts during the
slow deep pattern (p=0.009). At the same tidal volumes respiratory
water loss was measured as 334 (30) µl/min and 408 (46) µl/min
respectively (p=0.008).
Conclusions: This new measurement device was sufficiently sensi-
tive to detect a significant increase in RHML with increasing tidal vol-
ume at fixed minute ventilation in normal subjects. When normal
ranges are defined it will be used to measure RHML under matching
conditions in patients with COPD, asthma, and cystic fibrosis.
P33 EFFECT OF VARYING RESPIRATORY PATTERN ON
EXHALED BREATH CONDENSATE COLLECTION
S. Tate, J. McCafferty, J.A. Innes, A.P. Greening. Respiratory Medicine
Unit, Western General Hospital, Edinburgh
Background: Exhaled breath condensate (EBC) has been proposed
as a non-invasive means of measuring pulmonary inflammation. At
present little is known about how the respiratory pattern during collec-
tion influences the properties of the EBC sample. We hypothesised that
variations in respiratory pattern would have significant effects on vol-
ume and concentration of EBC.
Methods: Ten control subjects had EBC collected three times for six
minute periods each on the same day. For the three collections
subjects were instructed to follow constant respiratory rates (RR) for the
six minutes (10, 20, and 30 breaths per minute in random order), at
a constant flow rate (500 mls/s) resulting in three different tidal
volumes (Vt), (1500, 750, and 500 mls) but constant total respired
volume for the three collections (90 L). A custom built air conditioning
unit was used which allowed inspired air temperature and humidity to
be kept constant. The expiratory limb of the unit housed heat and
humidity sensors which allowed determination of heat (W) and mois-
ture loss (mg/g dry air) from the respiratory tract. The system was
linked to a flow meter and computer with an audiovisual cue so that
the subjects could maintain the necessary RR and flow rate. A
commercial breath condenser system (Jaeger) was fixed to the expira-
tory port to allow collection of EBC. Total volume achieved and solute
concentration (nitrite) were measured for each collection.
Results: A strong correlation was found between EBC volume (µl)
and Vt (r = 0.73, p<0.0001). However nitrite concentration was unaf-
fected by Vt (r = 0.04, p=0.83) or total volume collected (r = −0.1,
p=0.62). There was a strong correlation between moisture loss from
the respirator tract and Vt (r = 0.7, p=0.0001). Calculated total water
loss in six minutes related to actual EBC volume collected gave a
measure of efficiency of collection. This calculated efficiency was also
related to Vt (r = 0.5, p=0.018).
Conclusion: Collected EBC volume is enhanced significantly at
higher tidal volumes. This appears a function of increased moisture
loss with higher Vt but also increased condenser efficiency. Increased
yield of EBC volume does not result in dilution of non-volatile solutes in
the sample. The influence of other variables such as flow rate and
inspired temperature on EBC collection need to be examined.
COPD: Assessment and
treatment
P34 MECHANISMS OF BRONCHIAL
HYPER-RESPONSIVENESS IN COPD
P.P. Walker, P.M.A. Calverley. Department of Medicine, University Hospi-
tal Aintree, Liverpool, UK
Bronchial hyper-reactivity (BHR) is a hallmark feature of asthma and a
common, though not fundamental, feature of COPD. In asthma the
response represents narrowing of the airway lumen due to contraction
of airway smooth muscle (ASM). In COPD there is a relationship
between BHR and airflow obstruction and we hypothesise that respon-
siveness is related less to changes in ASM and resistance and more to
increase in hyperinflation. Hence an increase in residual volume (RV)
will reduce the ability of the airway-parenchymal interface to
overcome narrowing of the airway lumen.
We studied 10 subjects with mild to moderate COPD—baseline
FEV1 1.59l (SD) (0.45l), FEV1 % predicted 55% (16%), FEV1/FVC ratio
0.49 (0.1)—who underwent standard methacholine challenge testing.
At baseline subjects had moderate increases in airway resistance
measured by body plethysomnography (Raw 3.04 − predicted 1.86),
moderate increases in resistance (R5Hz 0.67 − predicted 0.32) and
impedance (Z5Hz 0.77 − predicted 0.32) measured by IOS and
moderate reduction in inspiratory capacity (2.53l − predicted 2.91l).
Median PC20 was 0.54 (range 0.1 to >16) and all but one subject
achieved a PC20 at <2 mg/ml.
After challenge mean FEV1 fell by 34% to 1.05l (p<0.01), mean
FVC fell by 38% to 2.08l (p<0.01), mean SVC by 30% from 3.74l to
2.61l (p<0.04), and IC by 38% to 1.60l (p<0.01). TLC, when
measured, was constant therefore these changes represent significant
increases in RV. Airway resistance by body plethysomnography (Raw)
increased overall (3.04 v 12.16) but showed minimal change in three
subjects while measurement in five other subjects was technically diffi-
cult. IOS measurements showed an overall modest increase in imped-
ance (0.77 v 1.01; p<0.01) which was due to a fall in reactance
(−0.35 v −0.55; p<0.04). There was no significant change in
resistance (0.67 v 0.83; p<0.12).
In individuals with COPD who are subject to bronchial challenge
assessment of changes in FEV1 does not give a true measure of change
in respiratory system resistance. BHR is likely to be determined less by
ASM contraction and more by increases in hyperinflation, which in
turn alter the ability of the lung to overcome airway narrowing.
P35 CHRONIC BRONCHITIS, SMOKING AND
SOCIOECONOMIC STATUS IN THE NHANES III
DATASET
M. Sridhar1, G. Netuveli2, A. Sheikh2. 1NHLI Division of Faculty of
Medicine; 2Department of Primary Health Care & General Practice, Char-
ing Cross Hospital, UK; Imperial College of Science, Technology & Medi-
cine, London, UK
Background: While some studies have suggested that differences in
the prevalence of chronic bronchitis in the various socioeconomic
groups is due to differences in smoking habits, others suggest an
explanation unrelated to smoking.
Methods: We have examined the relation between the prevalence
of chronic bronchitis, smoking and socioeconomic status (SES) in a
subset of the extracted from the US NHANES III data set representing
a population of 115 million adults between the ages of 30 and 75
years. A measure of SES was constructed using household income and
education. Current smoking status, duration of smoking, and intensity
of smoking were also noted. Symptom identified bronchitis (SIB) and
doctor diagnosed bronchitis (DDB) were used as outcome measures.
Data was analysed using logistic regression analysis with appropriate
population weighting.
Results: SIB was significantly related to age above 70 years, Afri-
can and Hispanic ethnicity, upper SES, and smoking. DDB was
related to age, being male, African and Hispanic ethnicity, SES, and
smoking. Of these, being male, ethnicity, and higher SES were protec-
tive. In SIB, within each stratum of SES, the only consistently significant
variable was current smoking status. No significant interaction
between smoking and SES was detected. When DDB was used as out-
come measure, the current smoking status was significantly associated
only in the upper middle SES strata. For both outcomes, stratification
according to current smoking status revealed SES to be significant in
current smokers only.
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Conclusions: Socioeconomic status had a significant influence on
the prevalence of SIB that was independent of cigarette smoking. The
protective effect of higher socioeconomic status was most significant
for current smokers. This effect seemed to be independent of smoking
behaviour in the different SES strata and merits further scrutiny.
Acknowledgements: An NHS R&D National Primary Care
Fellowship supports AS. GN is supported by a grant from the National
Asthma Campaign, UK.
P36 MEDICAL RESEARCH COUNCIL DYSPNOEA SCALE IS A
MEASURE OF FUNCTIONAL CAPACITY AND GLOBAL
PERCEIVED HEALTH STATUS
C. McAlpine1, W. Cochrane1,2, B. Watson2, M. Heatley1, S. Dogan1, G.
Dovey-Pearce1, G. Afolabi1. 1Northumbria Healthcare NHS Trust,
Northumbria, UK; 2Northumbria University, Northumbria, UK
Introduction: The Medical Research Council Dyspnoea scale (MRCD)
has been used to categorise disability in patients with COPD, though
it remains unclear what the scale measures.
Participants: All 218 participants had stable COPD. Sixty per cent
reported MRCD scale grade 3, 29% grade 4, and 11% grade 5. Forty
four per cent were male and mean (95% CI) age was 68.8 (67.8 to
69.7) years.
Methods: Participants were graded on the MRCD scale on the
basis of self report information. Incremental shuttle walking test (ISWT)
distance, spirometric, and anthropometric measurements were
recorded. Self report data were recorded to assess: perceived health
status (Chronic Respiratory Disease Questionnaire (CRDQ)); personal
cognitions of illness (Illness Perceptions Questionnaire); affect (Hospi-
tal Anxiety and Depression Scale); and self efficacy (COPD Self
Efficacy Scale). χ2 And Oneway and Kruskal Wallis ANOVA analysis
were carried out to assess differences in respondent characteristics
across MRCD grade.
Results: Mean percent predicted FEV1 was 9.93% higher people
with grade 3 than those with grade 5 (F = 4.33, p=0.01). Resting
oxygen saturation was significantly higher in people with grade 3
compared with those with grades 4 and 5 (F = 9.11, p<0.001).
People with grade 3 had a mean ISWT of 235.0 m compared with
153.0 and 117.7 m for grades 4 and 5 respectively (F = 20.05,
p<0.001). On the CRDQ, mastery, and emotional functioning were
significantly higher, and fatigue and dyspnoea were significantly
lower, in people with grade 3 compared with those with grade 4 and
5 (p<0.02). Anxiety was significantly higher in people with grade 3
compared with those with grade 4 (χ2 = 6.13, p=0.04) and people
with grade 5 had a higher perception of treatment control compared
with those with grade 4 (χ2 = 8.24, p=0.016). Of people with grade
3, 31.8% regarded themselves as being in good health, compared
with 16.7% with grade 4, and only 4.5% with grade 5 (χ2 = 10.38,
p=0.006). There were no significant differences across MRCD grade
in body mass index, age, depression, self efficacy, or gender.
Conclusion: Only the ISWT and patients’ Global Perceived Health
showed significant differences across all three grades of MRCD scale.
The MRCD scale reflects patients’ functional capacity but also their
global perceived health status.
P37 THE INFLUENCE OF BMI ON LUNG CT DENSITOMETRY
IN EMPHYSEMA
D.G. Parr1, M. Needham1, B. Stoel2, J. Stolk2, R.A. Stockley1. 1Lung Investi-
gation Unit, University Hospital, Birmingham, UK; 2Division of Image
Processing, Leiden University Medical Centre, Leiden, the Netherlands.
Lung CT densitometry correlates well with pathological and
physiological measures of emphysema and is the most sensitive meas-
ure for detecting disease progression in alpha-1 antitrypsin deficiency
(AATD) (Dowson, et al. Am J Respir Crit Care Med 2001;164:1805–
9). Long term reproducibility is subject to errors arising from limitations
in the reconstruction algorithm, with changes in denser tissues affect-
ing lung density measurements by altering beam hardening effects.
Emphysematous lung is of similar density to air, and therefore changes
in air densitometry reflect influences on lung densitometry. We looked
at the effect of body mass index (BMI) on measured values for air den-
sity within the patient. Using a lung phantom, we then measured the
effects on lung densitometry of an increase in chest wall thickness as
would occur with increasing BMI.
Methods: We performed voxel densitometry of tracheal air on sin-
gle slice inspiratory high resolution CT images at the level of the aor-
tic arch in 41 patients with AATD (PiZ) and related the results to BMI.
In addition, a thoracic phantom containing fixed, whole dog lung
(KCARE, KCH, London) was imaged before and after attaching to the
outer surface two flexible water filled containers of total volume 3.5L
(Durex,UK) simulating increased chest wall mass. Lung densitometry
was performed on two images taken from each series using the
PULMO-CMS software (B Stoel, Leiden University). Three techniques
were used; relative area at a threshold of –910 HU, the 15th percen-
tile point and the mean lung density.
Results and conclusions: Tracheal air density measurements cor-
related well with BMI (Spearman’s rho = 0.55, p<0.001). Lung phan-
tom densitometry was influenced by chest wall thickness as shown in
the table.
A change in BMI over time will alter measured lung density. The
effect of an increase in BMI could therefore be to reduce apparent
emphysema severity
P38 CT SCANNING IN SUBJECTS WITH COPD AND THEIR
RELATIVES
P.P. Walker1, J. Griffiths1, J. Curtis2, E. Thwaite2, P.M.A. Calverley1.
1Department of Respiratory Medicine; 2Department of Radiology, University
Hospital Aintree, Liverpool, UK
Participants in a prospective COPD genetics study underwent thoracic
HRCT scanning. Ninety two scans were performed in 71 subjects with
COPD and 21 smoking siblings. We documented the frequency of
lung nodules and other abnormalities and assessed their follow up to
identify possible tumours. We also correlated spirometry and
presence of visually scored emphysema on CT and compared the
presence of bronchiectesis with clinical symptoms. Mean FEV1 was
1.46l, % predicted FEV1 50%. COPD severity by GOLD criteria: grade
1= 9(10%), grade 2A= 20(22%), grade 2B= 30(33%), grade 3=
12(13%), no COPD= 21(23%).
Twenty one (23%) subjects had lung nodules—4/21 in siblings
without COPD. No malignancies have to date been confirmed. Ten
(11%) subjects required investigation for other abnormalities including
lobar collapse and asbestosis. Thirty nine additional radiology inves-
tigations have been completed so far (29 CT). Twenty one (23%) sub-
jects had bronchiectesis on CT scan. In this population 42/92 subjects
had chronic bronchitis clinically but only 6/21 subjects with
bronchiectesis had symptoms of chronic bronchitis—no positive corre-
lation.
The worse the spirometry the more likely emphysema was to be
present but 33% of smokers with normal spirometry had CT evidence
of emphysema. Pulmonary nodules were common and hence resource
implications high. Spirometry was imprecise in identifying mild-
moderate emphysema but severe obstruction correlated well with CT
findings. In subjects without a recent infection bronchiectesis is
frequently present without symptoms.
Abstract P37
Densitometry method
Slice 1
thin dog
Slice 1 fat
dog
Slice 2
thin dog
Slice 2 fat
dog
Relative area (−910HU) 30.233 23.421 38.706 30.007
15th Percentile point
(HU)
−926.0 −920.3 −932.1 −929.5
Mean lung density (HU) −856.8 −847.6 −851.8 −841.6
Abstract P38
GOLD criteria No CT emphysema CT emphysema
Normal 14 7
GOLD 1 5 4
GOLD 2A 5 15
GOLD 2B 2 28
GOLD 3 0 12
iii58 Poster presentations
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
P39 MULTIDIMENSIONAL (IDS) ASSESSMENT OF COPD IN
THE COMMUNITY: CLINICAL IMPACT IS
UNDERESTIMATED BY CURRENT GUIDELINES
A.D. Lawrence, N.P. Keaney. Chest Clinic, Sunderland Royal Hospital,
Sunderland, Tyne & Wear, UK
The staging of the severity of COPD is based on the degree of airflow
limitation. Specific FEV1 cut points are used by the BTS, ATS, and ERS
Guidelines. GOLD mentions the impact of COPD, and the imperfect
relationship between impaired spirometric values and symptomatol-
ogy, COPD also has systemic consequences. The IDS system of classi-
fying COPD incorporates airflow limitation (impairment), dyspnoea
(disability) and nutritional depletion (BMI-systemic involvement).
Our community database provided information on 401 patients
(203 female) attending COPD clinics in eight general practices in
Sunderland. Airflow limitation was classified according to standard
BTS, ATS, ERS, and GOLD criteria using pre and post bronchodilator
FEV1, and compared with IDS.
Use of post bronchodilator FEV1 does not perturb the IDS
classification. All guidelines significantly underestimate the impact of
COPD with their methods of classifying severity from spirometric
impairment alone.
P40 A COMPARISON OF INTENSIVE, MDI-DELIVERED AND
NEBULISED BRONCHODILATOR THERAPY IN SEVERE
COPD
T.K. Rogers, A. Venners, H. Drayton, P. Camplin, G. Segust, R. McCook.
Chest Clinic, Doncaster Royal Infirmary, Armthorpe Road, Doncaster, S.
Yorks, DN2 5LT, UK
Background: We have investigated whether nebulised therapy
provides superior bronchodilation to a combination of high-dose anti-
cholinergic and long acting β2 agonist therapy, delivered via MDI and
large volume spacer, in a well characterised group of stable patients
with severe COPD (FEV1<40% predicted).
Methods: We undertook a comparison of three regimes of four
times daily nebulised therapy (salbutamol 5 mg /ipratropium bromide
500 µg / Combivent 1 nebule) each used for a week in randomised
order, against combined therapy with salmeterol 50 µg twice daily
and ipratropium bromide 160 µg four times daily via MDI and large
volume spacer, in an open label, sequential, cross over study. The out-
come measure was self recorded peak flow rates, measured in the
morning, pretreatment (am), afternoon (pm) and night time (nocte).
Results: Seventy three patients were enrolled, until the required
number of 42 subjects with adequate data was obtained. Each of the
three nebulised regimens was highly significantly, and probably clini-
cally, superior to the MDI therapy, but there was no significant differ-
ence between them (ANOVA and paired t tests), see table.
Conclusions: Overall in this group of patients with severe COPD,
nebulised therapy produced greater improvement in peak expiratory
flow rate than could be achieved with intensive MDI-based therapy.
P41 ECONOMIC IMPLICATIONS OF REDUCTIONS IN COPD
REHOSPITALISATION DUE TO TREATMENT WITH
INHALED CORTICOSTEROIDS (ICS)
M.D. Spencer. GlaxoSmithKline, Greenford, UK
Background: A study in an Ontario observational database has
demonstrated reductions in the rate of COPD rehospitalisation and
death of 24% and 29% respectively using ICS (Sin, et al. Am J Respir
Crit Care Med 2001;164:580–4). Based on Hospital Episode Statis-
tics there were 78 908 admissions for COPD in the year 2000/1 in
England & Wales, with an average length of stay of 9.1 days, Sin and
Tu’s data suggest over 15 000 of these would have been rehospitali-
sations (assumes current ICS usage 50%). This equates to a hospitali-
sation cost of over £155.8 m with over £31 m for rehospitalisations.
Methods: The economic implications of reductions in exacerba-
tions have been assessed by modelling these risk reductions on a
hypothetical population of 1000 patients, accounting for uncertainty
in parameters by second order “Monte Carlo” simulation techniques.
The implications of a hypothetical increase in the use of ICS by
patients with an initial hospitalisation from 50% to 100% in England
& Wales are then considered.
Results: For the hypothetical cohort of 1000 patients a comparison
with and without ICS produces a reduction in hospital days of 622
(95% CI 494 to 760) equivalent to a cost saving of £135.6K (95% CI
95K to 189K). Applying this to an increase in ICS use from 50% to
100% for all patients with an initial hospitalisation, would result in a
reduction in hospital days of 19 751 (95% CI 15 799 to 24 256)
equivalent to a cost saving of £4.29m (95% CI £3.08m to 5.74m),
thus offsetting a considerable portion of the drug purchase cost.
Conclusion: These results suggest that, additional to the obvious
clinical benefits of avoiding COPD hospitalisation and mortality, valu-
able NHS resources may also be freed. In addition the financial cost
(over £4m) of these hospital days may undervalue these resources
during periods of high hospital bed occupancy.
P42 THE ASSOCIATION OF SURVIVAL WITH THE USE OF
INHALED CORTICOSTEROIDS (ICS) SEEN IN
OBSERVATIONAL STUDIES OF COPD CANNOT BE
EXPLAINED BY UNOBSERVED MARKERS OF DISEASE
SEVERITY (FEV1% PREDICTED, HEALTH STATUS, BODY
MASS INDEX)
M.D. Spencer. GlaxoSmithKline, Greenford, UK
Background: Recent COPD studies performed in observational
databases have shown benefits of ICS and ICS + LABA in terms of
reductions in mortality and of hospitalisation (Sin, et al. 2001;
Soriano, et al. 2002). A criticism of such studies, is the lack of
randomisation and hence potential bias caused by the confounding of
unobserved factors. This study investigates the relationship of a
number of potential markers of disease severity in COPD to ICS
prescription, and hence the potential for confounding.
Methods: The Health Survey for England 95, 96, and 97 (96 only
for health status) forms the population for this study. Respondents with
Abstract P39 Table 1
IDS criteria
Stage I FEV1 >50%, mild/mod dyspnoea, no nutritional
depletion
Stage II FEV1 35–49%, mild/mod dyspnoea, no nutritional
depletion
Stage III FEV1 <35%, severe dyspnoea, nutritional
depletion
Abstract P39 Table 2
IDS GOLD ATS BTS ERS
Pre % Pst % Pre % Pst % Pre % Pst % Pre % Pst % Pre % Pst %
Normal – 1 – 8 – 9 6 25 – 10
Mild stage I 37 37 15 21 73 71 51 41 39 40
Moderate stage II 6 5 5823 5118 18 14 26 25 34 30
Severe stage III 57 57 4 2 9 6 17 9 27 20
Abstract P40
Time of
day
MDI Ipra/
Salmeterol
Nebulised
Salbutamol
Nebulised
Ipratropium
Nebulised
Combivent
am 189 (10) 223 (13) 224 (12) 227 (12)
pm 201 (11) 227 (13) 229 (12) 234 (13)
nocte 204 (11) 229 (13) 226 (12) 231 (13)
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an FEV1/FVC ratio <70% and an FEV1% predicted of <70% were
selected for analysis. Mean age = 65.9 and 42.2% were women. The
relationship between disease severity and ICS prescription in COPD
was investigated and the statistical significance tested using the inde-
pendent t test.
Results: No statistically significant relationship was found between
ICS prescription and BMI (p=0.518), whilst in the case of FEV1% pre-
dicted and of health status measured by both the EQ-5D and by the
SF-6D patients taking ICS had on average worse scores than those not
taking ICS (all p<0.001). See table.
Conclusions were unchanged when the population was limited to
only those patients receiving at least one respiratory medicine.
Conclusions: In respondents to The Health Survey for England with
objective airflow obstruction there was no association between ICS
prescription and FEV1, BMI or health status that could explain benefits
seen in other studies. The benefits of ICS seen in observational studies
are unlikely to be explained by these differences between those taking
and not taking ICS.
P43 AUDIT OF LTOT PRESCRIPTIONS IN BLAENAU GWENT
B. Perreira, S. Venn, B.V. Prathibha. Nevill Hall Hospital, Brecon Road,
Abergavenny, South Wales, UK
Introduction: The ex-mining area of Blaenau Gwent has a high inci-
dence of occupational and smoking related lung diseases. Provision of
high quality clinical care to those individuals with severe disease
includes the appropriate prescription of LTOT along with education to
facilitate compliance. This audit was conducted with the aim of estab-
lishing whether the prescription and use of long term oxygen therapy
in Blaenau Gwent complies with established guidelines.
Method: Audit criteria and standards were set using guidelines
given in the Royal College of Physicians report Domiciliary Oxygen
therapy services. Patients in Blaenau Gwent using oxygen concentra-
tors in June 2000 were identified from Health Authority records. Crite-
ria were measured from a review of hospital notes and by using a
short postal questionnaire.
Results: Fifty patients were identified as using oxygen concentra-
tors in Blaenau Gwent in June 2000. Notes were obtained for 48 of
these patients (96%) and questionnaires were returned from 44
patients (88%). Thirty five (73%) of the patients were under the care of
a respiratory physician. Only 15 (31.2%) had documented evidence
of complete adherence to the guidelines prior to LTOT prescription (all
under the care of a respiratory physician), although 39 (81.3%) of the
patients had blood gases recorded. Thirty three (69%) had
documented evidence of prescription for 15 hours a day, although the
information given to patients was not recorded in the majority of
cases. Of the respondents to the questionnaire, 38 (86.4%) reported
using their oxygen for long periods of time rather than intermittently
and 34 (77.3%) reported daily use of 15 hours or more. Thirty six
(81.8%) understood to use the oxygen correctly and 22 (50%) were
able to give a written explanation for their need of oxygen therapy.
Conclusion: The majority of patients who are prescribed LTOT
report using it appropriately, although fewer understand the reason
for treatment. However, it is of concern that appropriate assessment
prior to LTOT prescription can only be confirmed in 31% cases and a
chest physician had not seen 27% of the patients receiving LTOT. Fol-
lowing this audit a specially designed nurse led LTOT clinic has been
started with referral to the chest physician. A patient information book-
let has been introduced along with a blood gases record. A further
audit will be conducted in one year to assess the impact of the clinic
on the quality of care that patients using LTOT receive.
P44 WEIGHT CHANGE IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD): NOT JUST A PROBLEM
OF UNDERNUTRITION
C.E. Weekes1, N.T. Bateman2. 1Departments of Nutrition & Dietetics; 2Res-
piratory Medicine, Guy’s and St Thomas’ Hospital NHS Trust, London, UK
Weight loss is frequently reported in patients with COPD and is asso-
ciated with increased morbidity and mortality. In contrast, for the past
30 years the general population has become more overweight and
therefore at increased risk for heart disease and diabetes. While
reviewing patients for a nutrition intervention study it was noted that
many patients presenting to chest clinic were overweight. The aims of
this study were to establish the number of outpatients with COPD who
were overweight, obese, or at risk as a result of weight loss.
Two hundred and seventy six consecutive patients with COPD (143
male; 133 female) were reviewed by the dietitian during a routine visit
to the chest clinics at Guy’s and St Thomas’ Hospitals. Weight, height,
and history of weight change were recorded, together with smoking
status, presence of oedema, and steroid use. Medical records were
reviewed to establish the length of chest related hospital stays and
mortality. Mean age was 67.3 (10.3) years and body mass index
(BMI) 26.2 (6.7) kg/m2. Patients were categorised as underweight,
acceptable, overweight, or obese (BMI <20.0, 20.0 – 24.9, 25.0 –
29.9 or >30.0 kg/m2). Weight change was considered significant if
it exceeded 5% in either direction.
Approximately half the patients were overweight (n = 80 (29%)) or
obese (n = 61 (22%)) while one in six (n = 43 (16%)) were
underweight. Sixty one (22%) patients reported significant weight loss
and 53 (19%) reported weight gain. Oedema was noted in 26 (9%)
patients.
Recent weight loss was associated with chest infection in 25 (9%)
patients, gastrointestinal symptoms in nine (3%), and social reasons in
five (2%), while 22 (8%) patients reported gradual weight loss over
one to two years. Twenty two (8%) patients with significant weight loss
had BMI >20.0 kg/m2, and 15 (5%) had BMI >25.0 kg/m2.
Recent weight gain was associated with smoking cessation in 17
(6%) patients, oedema in six (2%) and recent oral steroid use in two
(<1%). The remaining 28 (10%) reported a gradual increase over sev-
eral years.
There was a non-significant trend for increasing BMI to be
associated with shorter length of hospital stay (5.9 (12.7) days for
underweight to 2.9 (8.4) for obese) but neither BMI nor weight change
were associated with mortality.
The majority of publications on COPD are on the undernourished,
yet it would appear from this study that about half the outpatients with
COPD seen in this Trust were overweight or obese. The effect of being
overweight on patients with COPD deserves further study.
P45 BRONCHOSCOPIC LUNG VOLUME REDUCTION (BLVR)
WITH ENDOBRONCHIAL VALVE IMPLANTS
T.P. Toma, N.S. Hopkinson, N. Shen, J. Hillier, P. Goldstraw, C. Morgan,
D.M. Hansell, M.I. Polkey, D.M. Geddes. Royal Brompton Hospital, Impe-
rial College, London, UK
Background: Surgical lung volume reduction (LVRS) can palliate
symptoms in selected patients with advanced emphysema. We
hypothesised that a similar effect could be achieved by blocking seg-
mental bronchi leading to areas of bullous emphysema.
Aim: In this study we investigated the safety and efficacy of BLVR
using the Emphasys® valve implant and delivery system, in patients
unsuitable for surgical LVRS.
Methods: Three male patients have undergone so far unilateral
BLVR under general anaesthesia. Three valves were placed in each
patient in the most affected lobe as evaluated on ventilation/perfusion
scans and CT scans.
Results: See table. BVR was effective in shrinking emphysematous
lung and expanding a collapsed lobe in one patient. The effect was
Abstract P42
Mean (Median) by ICS prescription group
FEV1 % predBMI EQ-5D SF-6D
ICS 47 (47) 26 (25) 0.66 (0.69) 0.66 (0.65)
No ICS 55 (57) 26 (25) 0.78 (0.79) 0.74 (0.78)
Abstract P45
FEV1 (l)
Shuttle
distance (m)
Residual
volume (l)
Diffusion
capacity (%
predicted)
Before procedure0.82 (0.26) 246 (120) 6.72 (1.37) 29.5 (9.4)
After 7 days 1.06 (0.10) 336 (49) 5.66 (1.18) 38 (8.8)
Values in the table are expressed as mean (standard deviation).
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sustained at one month follow up. Post procedure complications
included: one pneumothorax at day 36 which resolved without drain-
age, and one COPD exacerbation at day 40 treated with antibiotics
and steroids. None of the implants became dislodged.
Conclusion: This pilot study suggests that lung volume reduction
can be achieved in humans with flexible bronchoscopy and specific
valve implants. The implants are safe and easy to place and have the
potential for extending indications and reducing morbidity, mortality
and costs in patients with severe emphysema.
Sleep assessment and
treatment
P46 AN ATTEMPT TO ASSESS THE DURATION OF PROBABLE
MORBIDITY PRIOR TO THE DIAGNOSIS OF
OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSAS)
R. Ghiassi, M.R. Partridge. The Sleep Laboratory, Imperial College of Sci-
ence, Technology and Medicine, NHLI Division at Charing Cross Hospital,
London, UK
Recent work from Canada has suggested that hospital admissions and
physician costs in the two years prior to diagnosis of OSAS was sig-
nificantly higher in those with OSAS than in a control group.1 In the
year prior to diagnosis it has also been shown that prescribed medi-
cation costs were significantly higher; medication being needed for
hypertension, ischaemic heart disease, and congestive heart failure.2
The rate of road traffic crashes and occupational accidents is also
higher amongst those with untreated OSAS.
To gain an insight into the duration of possible prediagnosis
morbidity, we administered a questionnaire to 117 consecutive OSAS
patients being treated with CPAP who attended this laboratory for
review. Of these 107/117 (91.5%) reported that prior to diagnosis
someone had complained about loud snoring and responders
recorded that first mention of this had been a median of 12 years prior
to diagnosis (range 2 to 47). Also 91/117 (77.8%) reported
witnessed apnoea prior to diagnosis and this had been observed a
median eight years prior to diagnosis (range 1 to 49). Ninety seven
out of 117 (82.9%) reported sleepiness in the day time now or in the
past and this had been present for a median of seven years (range 0.5
to 62 years). Seventy eight respondents were in employment and
37.2% of these reported having had two or more jobs in the last five
years. Of the respondents, 85 were drivers and 21 of these (24.7%)
reported having had a road traffic accident in the previous five years
with five respondents having had two and one having had four such
crashes. Overall these results suggest the likelihood of significant pre-
diagnosis morbidity and greater public and primary care awareness
of OSAS is needed.
1. Kryger M H, et al. Sleep 1996;19:S111–16.
2. Otake K, et al. Thorax 2002;57:417–22.
P47 URINARY SYMPTOMS DO NOT CORRELATE WITH
SEVERITY OF OBSTRUCTIVE SLEEP APNOEA OR
COMPLIANCE WITH CPAP
K.E. Lewis1, A.J. Watkins2, L. Seale1, I.E. Bartle1, P. Ebden1. 1Prince Philip
Hospital, Dafen, Llanelli, Wales, SA14 8QF, UK
Introduction: Studies have found increased urinary disturbance in
patients with obstructive sleep apnoea (OSA). The reason remains
unclear and may be due to in part to prostatic symptoms in middle
aged men. We examined whether higher urinary symptom scores
prior to treatment are correlated with more respiratory disturbance in
OSA, and if more symptoms reduce compliance by interfering with
machine use.
Methods: Seventy four consecutive males with OSA, mean (SD)
age of 55.2 (9.0) years, mean BMI 34.5 (5.9), mean Epworth Sleepi-
ness Score 15.4 (5.2), mean AHI 28.1 (22.8) per hour and mean 5%
dip rate of 31 (21.7) per hour were prospectively studied. They com-
pleted the International Prostate Symptom Score and American
Urological Questionnaire prior to CPAP therapy. Machine clock timers
were hidden and machine on time was checked at one month. Corre-
lations between the various subscores for urinary symptoms and meas-
ures of respiratory disturbance and machine on time were assessed
using Spearman’s rho.
Results: Our patients had a mean Total Urinary Score of 5.72
(4.27), range 0 to 19. The correlation between Urinary Obstructive
Scores and AHI was rho −0.229 (p=0.121). The correlation between
Urinary Irritative Scores and AHI was rho −0.100 (p=0.506). The cor-
relation between Urinary Total Scores and AHI was rho −0.197
(p=0.185).
Machine on-time was correlated to Urinary Obstructive Scores with
rho −0.221 (p=0.301) to Urinary Irritative Scores with rho −0.030
(p=0.798) and Total Urinary Scores rho 0.032 (p=0.790).
Conclusion: Patients with OSA have Urinary Scores similar to the
normal population as measured by standard urology tools, and any
increased urinary disturbance, prior to CPAP is not significantly corre-
lated with either the respiratory disturbance or reduced compliance
with CPAP.
P48 APOLIPOPROTEIN E: A ROLE IN SLEEP DISORDERED
BREATHING?
R.L. Riha, P. Brander, M. Vennelle, N.J. Douglas. Dept of Medicine,
University of Edinburgh, Royal Infirmary, Edinburgh
Apolipoprotein E e4 (Apo E e4) is an important risk factor for the
development of early onset Alzheimer’s disease, as well as being an
independent risk factor for cardiovascular disease. A recent study by
Kadotani et al1 demonstrated a correlation of Apo E e4 with a higher
apnoea/hypopnoea index in a population with sleep disordered
breathing (SDB). The aim of our study was to examine the distribution
of Apo E alleles and genotype in patients in the UK with SDB
compared to controls.
Method: A case control study was undertaken from 1997–2002.
One hundred consecutive patients with SDB were recruited randomly
from the clinic register. Each case was matched to a sibling. All cases
and controls were asked to complete a self administered questionnaire
and underwent clinical examination. All subjects underwent routine
PSG or home monitoring. Studies were scored manually. All subjects
had 20 ml of blood taken. Genotyping was performed on DNA
extracted from peripheral blood lymphocytes using PCR-RFLP with
polymorphisms for the three Apo E alleles determined according to
published techniques.
Results: Results for 38 matched pairs are presented. Male:female
ratio was 46:30. Mean age did not differ significantly between index
patients and siblings (50.5 (SD)(8) v 60 (10)) nor did BMI (27 (2) v 28
(4)). AHI was significantly higher for cases (41 (IQR 27–52) v 13 (IQR
10–20). There was no significant difference in the distribution of either
alleles or genotypes of Apo E between cases and controls (genotypes
shown). See table.
The K statistic for alleles between cases and controls was 0.35
(p<0.0001) and for genotypes was 0.32 (p=0.002). Allelic frequency
in the population was equivalent to that of the UK population: E2
(0.13); E3 (0.71); E4 (0.16).
Discussion: There is no difference in distribution of Apo E alleles
and genotypes between subjects with SDB and their siblings. Our
results are supported by two other studies looking at Apo E in relation
to SDB.2 3 Further samples will be genotyped both for Apo E and other
candidate genes in this ongoing study.
Acknowledgements: nursing staff & technicians of the Scottish
National Sleep Laboratory; Dr N McArdle; Genetics Core, Wellcome
Trust Clinical Research Facility, Edinburgh.
Supported by: Helen Bearpark Scholarship; AFUW fund; ERS LTT
fellowship.
1. Kadotani, et al. JAMA 2001:285:2888–90.
2. Saarelainen, et al. Clin Gen 1998:53:147–8.
3. Foley, et al. JAMA 2001:286:1447–8.
Abstract P48
E3/E3 E2/E3 E3/E4 E2/E2
Cases 16 7 13 1
Controls 22 5 10 2
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P49 REACTION TIME (RT) TESTS IN OBSTRUCTIVE SLEEP
APNOEA (OSA) AND NARCOLEPSY PATIENTS: THE
PSYCHOMOTOR VIGILANCE TASK (PVT) IS A BETTER
DISCRIMINATOR THAN THE SIMPLE UNPREPARED
REACTION TIME (SURT)
D.C. Randall, S.N. Pilsworth, M.A. King, J.M. Shneerson, I.E. Smith. Pap-
worth Hospital Sleep Centre, Cambridge, UK
RT tests are commonly used to assess performance of patients with
sleep disorders and healthy subjects who undergo sleep deprivation
but it is unclear which is most suitable for use in the clinical setting as
an additional tool for assessing the effectiveness of treatment. The aim
of this study was to compare the performance of four groups: healthy
volunteers, treated narcolepsy patients, OSA patients treated with
nCPAP, and untreated OSA patients (desaturation index = 15,
Epworth Sleepiness Scale score = 10) on two different tests of
sustained attention used in our lab: the PVT and the SURT.
Methods: Subjects completed the 10 min tasks in the afternoon, in
random order. Subject demographics are presented in the table.
Results: One way ANOVA showed that there was a significant dif-
ference between the four groups on PVT slope (time on task
decrement) (F(3,48) = 6.3, p<0.005). Bonferroni post hoc tests revealed
that both narcolepsy and untreated OSA patients showed more reac-
tion fatigue—that is, an increase of reaction time over time—on this
task than did healthy volunteers (p<0.01). Mann-Whitney tests also
revealed significant differences between the groups on SURT mean RT
and number of gaps. These were due to narcolepsy patients having
slower reaction times and a greater number of gaps (RT > 1s) (for
both, p<0.05) than both healthy volunteers and treated OSA patients.
There were no significant differences between the untreated OSA
patients and the other groups on this task.
Discussion: Despite treatment, narcolepsy patients showed impair-
ments on both tasks of sustained attention. Unlike the PVT, the SURT
did not distinguish between untreated patients with OSA and healthy
volunteers or those on nCPAP and may not be appropriate to follow
treatment effects.
P50 ANALYSIS OF SLEEP STAGE USING A NEURAL
NETWORK: COMPARISON TO MANUAL SCORING IN
PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA (OSA)
F. Buchanan, N. Wiltshire, J.R. Catterall A.H. Kendrick. Sleep Unit, Dept
Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK
Sleep is a continuum, often with short 2–3s events. Traditional scoring
using Rechtschaffen & Kales (R&K) uses multiple channels and assigns
one of seven sleep stages to each 30s epoch with further analysis for
arousals. Neural net analysis uses 1s epochs and analyses sleep using
one EEG channel, assigning a probability of a sleep stage to each
epoch.
Aim: To compare R&K scoring to neural net in patients with OSA.
Methods: Patients underwent one night’s full polysomnography
(SleepLab 1000e, Jaeger). A single scorer manually scored the study
using R&K and American Sleep Disorders Association arousals
criteria. Data files were converted into European Data Format (EDF)
and analysed using a neural network (Bio Sleep v4.0, Oxford BioSig-
nals) using a single EEG channel. Median filter was set to 15s and a
threshold of 0.25 was used to score arousals, which had a minimum
duration of 3s. Data are median (range).
Results: Twenty two patients (two female) were compared. Median
Apnoea index was 2.45 (0 to 67.1) and Apnoea-hypopnoea index
was 16.6 (0.7 to 93.2). The conversion to EDF took 40 mins and
analysis 15 mins, as against a median of 120 mins using R&K. The
EEG analysis is summarised below (see table).
Conclusion: The differences observed between R&K and Neural
Net reflect the shorter epoch analysis time of 30s against 1s. Neural
network analysis provides (1) a simple computerised scoring of over-
night sleep studies; (2) a more sensitive analysis of the sleep
continuum, and (3) reduces the overall time of analysis of sleep stud-
ies as compared to R&K.
P51 COMPARISON OF R&K AND BIOSLEEP SYSTEMS FOR
ANALYSIS OF OBSTRUCTIVE SLEEP APNOEA
F. Diamantea, P.P. Walker, S. Lowe, D. Barr, T. Mckown, P.M.A. Calver-
ley. Department of Medicine, University Hospital Aintree, Liverpool, UK
At present the gold standard in the objective assessment of sleep
apnoea is still polysomnography with data analysis using the
Rechtschaffen & Kales (R&K) guidelines for 20–30 second sleep
epochs. This is time consuming, expensive and relates poorly to symp-
toms. An attractive alternative based on neural net technology is the
BioSleep system. It is a single channel method, which provides second
by second measurements and classifies sleep as awake, light or deep
using probability assessment rather than the traditional 6–7 point
staging system. This may provide better analysis of microarousals and
also shortens technician analysis time to less than five minutes.
We compared BioSleep to R&K analysis using the same data set
from 28 patients with moderate or severe OSA (Mean AHI = 52.4 (SD
18.4)) during split night polysomnography in which therapeutic CPAP
was administered for half the night. BioSleep (B) was as good as R&K
(R) at detecting differences between CPAP and air in terms of arousals
(B: 44 v 80; p<0.001, R: 51 v 79; p<0.02), arousal index (B: 12 v
22; p<0001, R: 18 v 29; p<0.005), deep sleep % time (B: 30% v 8%;
p<0.0001, R: 24% v 7%; p<0.0001) and light sleep % time (B: 70%
v 92%; p<0.001, R: 76% v 93%; p<0.0002). BioSleep found greater
differences in number of awakenings (B: 24 v 36; p<0.02, R: 2.8 v
3.2; p=0.53) and total time awake (B: 0.9hrs v 1.27hrs; p<0.05, R:
0.46hrs v 0.35hrs; p=0.15) but was inferior at detecting differences
in sleep onset latency (B: 0.12 v 0.14; p=0.80, R: 0.26 v 0.10;
p<0.001). BioSleep gave a more detailed picture of sleep architecture
that was clearly different with therapy. Direct comparison showed that
BioSleep predictably scored more awakenings and less total sleep
time and sleep maintenance efficiency but there were no significant
differences in % light or deep sleep, number of arousals or arousal
index.
BioSleep is a method of sleep analysis comparable to R&K for sev-
eral important parameters. While not replacing R&K for investigation
of REM related and complex sleep disorders BioSleep provides addi-
tional information compared to R&K while shortening analysis time
and this makes it an attractive analysis method for more widespread
use.
P52 THE EFFECT OF RECORDING SITE IN ACOUSTIC
ANALYSIS OF SNORING
M.J. Drinnan1, A.M. MacDonald1, M. Reda2, J.A. Wilson2, G.J. Gibson3.
Departments of 1Medical Physics; 2ENT surgery; 3Respiratory Medicine
Freeman Hospital, Newcastle upon Tyne, UK
Introduction: Several groups have investigated acoustic analysis of
snoring, in order to investigate the mechanism of snoring, to
distinguish obstructive sleep apnoea from non-apnoeic snoring and to
predict the outcome of corrective surgery. However, the recording site
has varied, and it is not known how this affects the acoustic
parameters measured.
Methods: We studied 47 subjects prior to laser-assisted
palatoplasty for severe snoring. All underwent preoperative
polysomnography and patients with AHI > 25/h were excluded.
Abstract P49
Groups
Mean age
(SEM)
Mean Epworth
Score (SEM)
Healthy volunteers N=17, 7 male 42 yrs (2.6) 4 (0.5)
Treated narcolepsy N=9, 5 male 41 yrs (6.5) 9 (1.5)
Treated OSA N=16, all male 53 yrs (2.0) 5 (0.6)
Untreated OSA N=10, 9 male 48 yrs (4.0) 13 (0.9)
Abstract P50
R&K Neural net p Value
Analysed time (hr) 6.95 (1.9–8.4) 6.98 (1.9–8.3) NS
Total sleep time (hr) 5.10 (1.4–7.4) 4.87 (1.4–6.8) NS
Sleep efficiency (%) 73.9 (37.2–92.6) 77.6 (45.6–94.5) NS
Number awakenings 25.5 (6–58) 38 (9–102) p<0.05
Time awake (min) 65.0 (17–218) 82.3 (22.3–245) NS
Deep sleep (min) 58.7 (0–231) 37.0 (0–106.2) p<0.05
Arousals/hr 20.7 (5–86.1) 14.4 (2–41.0) p<0.05
Arousal duration (s) 5.75 (4.7–6.5) 6.0 (5.0–7.0) p<0.05
R&K, Rechtschaffen & Kales.
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Sound was recorded continuously from a throat microphone and an
external microphone 1m above the patient’s head. We analysed all
snores, defined as sound level peaks during sleep, lasting 0.1 to 3
seconds, and at least 45dBA in amplitude measured 1m above the
patient’s head, and calculated three acoustic parameters for each
snore: centre frequency, SD frequency (a measure of spread about the
centre frequency) (Clin Otolaryngol 1996;21:119–23), and peak fac-
tor ratio (the ratio of peak to RMS sound energy) (Clin Otolaryngol
1999;240:130–3). For each subject we calculated the mean value for
each of the three parameters, for the external and throat microphones
separately.
Results: We analysed an average of 1018 snores per subject. The
mean values for each acoustic parameter are given in the table.
Discussion: Clearly, the recording site has a profound influence on
the acoustic qualities of snoring sounds. In particular, frequency-
domain indices (centre and SD frequency) are affected, implying the
throat microphone preferentially attenuates the higher frequencies.
Conclusion: When performing acoustic analysis of snoring
sounds, it is essential that the recording site is selected with care.
Acknowledgements: We wish to than the British Lung Foundation
for their financial support of this work.
P53 EFFECTS OF SIMULATED OBSTRUCTIVE APNOEA ON
THE CAROTID BARORECEPTOR: VASCULAR
RESISTANCE REFLEX
C.M. Bowker, V.L. Cooper, S. Davis, S.B. Pearson, M.W. Elliott, R. Hains-
worth. Leeds University Teaching Hospitals, Leeds, UK
Obstructive sleep apnoea may lead to hypertension. This study was
designed to determine whether the changes in inspiratory pressure
and the asphyxia that occurs in this condition can change the gain
and/or setting of the carotid baroreflex to maintain arterial pressure at
a higher level.
In eight healthy subjects (aged 21–62) we changed the stimulus to
carotid baroreceptors using a neck chamber and graded pressures of
−40 to +60 mmHg and assessed vascular resistance responses in the
forearm from changes in the blood pressure (Finapres) divided by bra-
chial flow velocity (Doppler ultrasound). Stimulus response curves
were defined during (a) sham (no additional stimulus), (b) inspiratory
resistance (∼10 mmHg), (c) breathing asphyxic gas (12% O2, 5%
CO2), and (d) resistance and asphyxia. Sigmoid functions were
applied to the curves and the maximal differential (equivalent to peak
gain) and the corresponding carotid pressure (equivalent to “set
point”) were determined.
The sham test had no effect on either the gain or the “set point”.
Inspiratory resistance alone had no effect on blood pressure. However
it reduced the gain from −3.0 (0.6) to −2.1 (0.4) units (p<0.5) but the
curve was not displaced. Asphyxia alone increased blood pressure
(+7.0 (1.1) mmHg, p<0.0005) and displaced the curve to higher
pressures by +16.8 (2.1) mmHg (p<0.0005) but had no effect on
gain. The combination of resistance and asphyxia both reduced gain
and displaced the curve to higher pressures.
These results show that inspiratory resistance decreases the gain of
the baroreceptor reflex and in combination with asphyxia also shifts
the curve to higher blood pressure levels. If these changes were
sustained, they would provide a mechanism to link hypertension with
obstructive sleep apnoea.
P54 PREVALENCE OF SLEEP DISORDERED BREATHING IN
PATIENTS WITH CONGESTIVE HEART FAILURE
A. Rashid, J. Chambers, A.J. Williams. Sleep Disorders Centre and Dept of
Cardiology, St. Thomas’ Hospital, London, UK
Introduction: Despite recent advances in medical and surgical
therapy, congestive heart failure (CHF) remains a common and serious
condition. CHF has been associated with sleep disordered breathing
(SDB) in 51% patients (Javaheri, et al. Circulation 1998;97:2154–9),
including Cheyne-Stokes respiration (CSR) in 40%, and obstructive
sleep apnea (OSA) in 11%. SDB is associated with frequent arousals,
leading to a persistent activation of the sympathetic nervous system
and elevation of catecholamines with deleterious effects on left
ventricular function. Heart rate variability (HRV) is considered to be a
surrogate for arousals and serves as an independent prognostic indi-
cator for cardiovascular events (Narkiewicz et al. Auton Neurosci
2001;90:89–94).
Methods: Patients suffering from CHF were selected on the basis of
echocardiographic findings of ejection fraction (EF) less than 35%.
We contacted 72 patients by letter, out of whom 36 patients (32 male
and four female) agreed to participate in the study. Patients were sent
portable pulse oximeters with a digital probe to wear overnight. The
oximeters returned were studied for episodes of desaturations, and an
oxygen desaturation index (ODI) was calculated. Desaturations were
defined as dips in oxygen saturation greater than 3% and SDB was
defined as an ODI greater than five.
Results: The overall prevalence of SDB in CHF patients was found
to be 47.2% (17/36) and the mean ODI amongst these patients was
22.2/hr. The prevalence in patients with an EF less than or equal to
25% was 53.8% (7/13) with a mean ODI of 26.2/hr, whereas in
patients with an EF between 25% and 35%, it was 43.5% (10/23)
with an ODI of 19.5/hr. Increased heart rate variability was noted but
was not found to correlate with SDB in our study. Twenty four out of 36
patients had increased HRV associated with concomitant dips in oxy-
gen saturation in only 13. The remaining 11 patients having no SDB
as defined here and raising the question as to additional burden of
“subclinical” respiratory disturbance.
Conclusion: Our study confirms that nearly half the patients
affected by CHF, even in stable condition, have severe nocturnal res-
piratory disturbances, which increase with increasing severity of CHF.
P55 IS MORE CPAP BETTER IN CLINICAL PRACTICE IN THE
MEDIUM/LONG TERM?
E. Morrish, S.N. Pilsworth, M.A. King, J.M. Shneerson, I.E. Smith.
Papworth Hospital, Cambridge, UK
Background: In a trial setting, hours of continuous positive airway
pressure (CPAP) use by obstructive sleep apnoea (OSA) patients is
correlated with the fall in subjective sleepiness at one month.(1) Our
aim was to examine this relationship in a clinical setting after a longer
follow up.
Methods: A retrospective review of patients who (a) were
diagnosed with OSA according to the criteria as in(1) (oxygen desatu-
ration >4% index (DI) >10/hr and Epworth Sleepiness Scale (ESS)
score >10); and (b) were started on CPAP in the year 2000 and con-
tinued to use it for an average of >1 hour each night after >100
days. Correlation was assessed using Kendall’s tau_b coefficient.
Results: One hundred and three subjects (82 male) met the study
criteria (table). Hours of CPAP use per night and change in ESS were
not significantly correlated (r = −0.094; p=0.170).
Discussion: In a month long trial setting only 4% of subjects with-
drew from using CPAP.(1) In our experience approximately 15–20%
discontinue CPAP in the long term. Those who use CPAP very little and
gain no benefit will increase the correlation between hours of CPAP
use and change in ESS early on. After a longer period of time these
people have stopped using CPAP. The hours of use of long term com-
pliers with CPAP may be more dependent on intrinsic sleep
requirement, the benefits gained from decreased snoring and the level
of belief in a decreased risk from cardiovascular events rather than a
simple relationship with perceived change in daytime sleepiness.
1. Stradling JR, et al. Sleep 2000;23(suppl 4):S150–3.
P56 TREATMENT OF SLEEP APNOEA/HYPOPNOEA
SYNDROME (SAHS): A RANDOMISED TRIAL OF
STANDARD CARE VERSUS ENHANCED NURSE
INTERVENTION IN A DISTRICT GENERAL HOSPITAL
S. Palmer1, S. Selvaraj1, C. Dunn1, L.M. Osman2, J. Cairns3, D. Franklin4,
G. Hulks4, D.J. Godden1. 1Highlands and Islands Health Research Institute;
2University of Aberdeen; 3Health Economics Research Unit; 4Highland
Acute Hospitals NHS Trust
Background: Patients commencing CPAP therapy in Inverness (DGH)
undergo a hospital titration study, telephone nurse review at four days
Abstract P52
Parameter External mic Throat mic Difference
Centre frequency 562 Hz 351 Hz −211 Hz (p=0.0005)
SD frequency 875 Hz 304 Hz −571 Hz (p=2×10−18)
Peak factor ratio 2.36 2.37 −0.01 (ns)
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and consultant review at six weeks (standard care). A study carried
out at the Scottish National Sleep Laboratory found that enhanced
nurse intervention after diagnosis improved outcome after CPAP
therapy (Hoy CJ, et al. Am J Respir Crit Care Med 1999;159:1096–
1100). Our randomised trial compared impact of standard care ver-
sus an enhanced nurse intervention on symptoms and quality of life in
patients treated in the DGH setting.
Methods: Seventy consecutive SAHS patients were randomised to
receive standard care (SC, n=35) or standard care plus a specialist
nurse home visit at seven days (HV, n=35). Patients completed a
symptom score, Epworth score, Hospital Anxiety and Depression
Score (HADS), and SF-36 at baseline and three months after initial
review. CPAP hours of use were recorded.
Results: CPAP therapy resulted in significant improvements in
symptoms, Epworth, HADS (table), and in the energy/vitality and
mental component summary scores of the SF-36 in both groups. There
was no difference between groups in any outcome measure or in
hours of use of CPAP.
Conclusion: CPAP led to marked improvement in patients with
SAHS treated in the DGH setting. There was no difference between
our two groups, both obtaining a similar magnitude of improvement to
that reported in the enhanced care group from the National Sleep
Laboratory.
Funded by the William Sutherland Trust.
P57 CONTINUOUS POSITIVE AIRWAYS PRESSURE (CPAP)
TREATMENT CAN REDUCE ANXIETY AND DEPRESSION
IN OBSTRUCTIVE SLEEP APNOEA
K.E. Lewis1, A.J. Watkins2, L. Seale1, I.E. Bartle1, P. Ebden1. 1Prince Philip
Hospital, Dafen, Llanelli, Wales SA14 8QF; 2EBMS, University of Wales
Swansea, Swansea, Wales SA2 8PP, UK
Introduction: We tested the hypothesis that CPAP treatment will
improve anxiety and depression scores and if effects are correlated to
machine use.
Methods: Eighty consecutive patients (74 male), age 51.2 (9.7)
(mean (SD)) years, mean BMI 35.5 (5.7), mean Epworth Sleepiness
Score 14.4 (5.2), mean AHI 25.1 (22.8), and mean 5% dip-rate of
31 (21.7) per hour, were prospectively studied. They completed the
Hospital Anxiety and Depression Score at autotitration and after
approximately one month of treatment with CPAP. Clock timers were
hidden and machine “on time” was recorded at one month as a surro-
gate marker for machine use.
One sample t tests assessed if change in anxiety and depression
were statistically significantly different from zero. Pearson’s correla-
tion assessed the relationship between “on time” and changes in HAD
scores.
Results: Patients were followed for a mean of 33.7 (13.4) days.
Data was available on 70 patients. No patients reported life events or
medication changes over this period. The mean anxiety score fell from
7.8 (3.7) to 6.3 (4.2) and the mean value for depression fell from 6.0
(3.7) to 4.9 (3.4) post treatment. Test statistics are −4.03 and −4.11
for hypotheses of zero change in anxiety and depression,
respectively; p<0.001 in both cases. Pearson’s correlations between
change in anxiety and depression with machine use are r= −0.297
(p=0.012) and r = −0.382 (p=0.001), respectively.
Conclusion: OSA patients have similar anxiety and depression
scores to the normal population but there were statistically significant
improvements in both scores after only a short period of treatment. We
conclude that CPAP has a graded effect, with the greatest benefits
observed in those using their machines the most.
Lung cancer
P58 OUTCOME OF A CODED x RAY SYSTEM TO FACILITATE
REFERRAL OF CASES OF SUSPECTED LUNG CANCER
J. Hughes, C. Garvey, C. Smyth, M.J. Ledson, M.J. Walshaw. Liverpool
Lung Cancer Unit, Royal Liverpool University Hospital, Liverpool, UK
Chest radiography is an important investigation in patients with
persistent chest symptoms, and can be an early indication of
malignant disease. This is of particular importance when the x ray
abnormality is an incidental finding, for example on a preoperative
routine film. In order to ensure the rapid investigation of patients with
suspected lung cancer, we have introduced a coded x ray reporting
system for chest x ray taken in Liverpool, including those performed in
the community. When lung cancer is suspected, the reporting radiolo-
gist codes the report accordingly and the result is faxed to the relevant
clinician, with a suggestion that the patient is referred to the rapid
access service. In addition, all reports are electronically sent to the
lung cancer specialist nurse, who monitors the referrals and ensures
that the clinician acts on the report. We have audited the outcome of
the first 477 patients in whom the radiologist flagged as suspected
lung cancer using this coding system. Two hundred and fifty six were
GP requests; nine of these were subsequently admitted to hospital,
215 were referred to the rapid access outpatient service, 24 were
referred to a chest outpatient clinic, and eight refused further
investigation. Within the secondary care sector, 206 were taken: 41
were admitted from the A&E department, one was a clinic attendee,
and 164 were inpatients of whom 74 were discharged to attend the
rapid access outpatient service. Eight of the latter group were surgical
patients in whom the finding of a suspicious x ray lesion was inciden-
tal. In the remaining 15 cases, further investigation was not deemed
necessary by the supervising clinician. Mean time from chest x ray to
attendance at the rapid access outpatient clinic was 14 days, and
mean time from referral to first appointment was 8.5 days. Overall
268 patients (56%) were subsequently diagnosed with lung cancer.
Thus, we have shown that this x ray coding system allows the rapid
access of patients with suspected lung cancer to the relevant service.
Furthermore, processing the reports through the dedicated lung cancer
nurse acts as a safety net and ensures that cases are not missed by
busy clinicians. We recommend the use of such coding systems to cli-
nicians charged with providing rapid access lung cancer services.
P59 AVOIDING LATE PRESENTATION OF LUNG CANCER: A
PROACTIVE APPROACH TO MANAGEMENT OF
ABNORMAL CHEST RADIOGRAPH REPORTS
J. Brown, P. Murphy, A. Bramwell, J. Wide, J. Corless, J. Hendry. St.Hel-
ens and Knowsley Hospitals NHS Trust, Whiston Hospital, Warrington
Road, Prescot, Merseyside L35 5DR, UK
Late presentation with lung cancer may preclude radical treatment.
System breakdowns may result in abnormal chest radiograph (CXR)
Abstract P55 Study group baseline demography and outcome measures
Baseline
demography
Median (5th, 95th
percentiles) Outcome measures
Median (5th, 95th
percentiles)
Age (years) 52.5 (29.2, 67.3) CPAP use (hrs/night) 6 (2.2, 8.5)
Weight (kg) 111 (76, 158.1) Length of use (days) 523 (231.6, 802)
BMI 36.2 (27.5, 53.5) ESS 6 (0, 16)
DI (dips/hr) 40 (10, 60) Change in ESS −10 (−20.8, −1)
ESS 17 (10, 23)
Abstract P56
SC HV
P for diff
SC v HVBase 3 months Base 3 months
Symptoms 28.4 12.8* 27.4 12.9* 0.65
Epworth 15.3 7.8* 13.8 7.5* 0.76
HAD Anx 8.2 5.9* 8.4 5.9* 0.59
HAD Dep 7.2 3.9* 7.1 4.6* 0.45
Data are mean values; *Differs from baseline (p<0.01).
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reports not reaching the necessary clinician or being acted upon. In
January 2000 we introduced a more pro-active approach to the han-
dling of CXR reports that raise the possibility of lung cancer via a “fail-
safe” system. In partnership with our radiologists a coding system was
used for CXR’s requested both from primary and secondary care.
CXR’s with features strongly suggestive of a bronchial neoplasm were
coded “TCXX” by the radiologist. Where neoplasia could not be
excluded, a repeat film after 4–6 weeks was advised and a “TPXX”
coding was given. All abnormal reports were immediately forwarded
to the lung cancer team. Typically we would contact the patients’ GP
by telephone to discuss the report and requested an urgent referral
from the GP. We later audited all new patients attending our rapid
access lung cancer clinic over a one year period to assess the impact
of this system.
Results: The codes were initially not applied to all abnormal CXRs,
especially by trainee and locum radiologists. Of 228 new patients
seen, 102 (45%) had CXRs coded TCXX/TPXX and 126 (55%) had
abnormal CXRs with no coding. The percentage of patients later con-
firmed to have lung cancer were: TCXX (71%), TPXX (23%), and no
code (63%). The mean (range) time from day of CXR to clinic attend-
ance was 8.5 (1 to 21) days in the TCXX group and 16 (1 to 162)
days in the no code group (p<0.001). A survey of 66 local GPs found
that 86% felt that the failsafe system was helpful and should be contin-
ued. A recent re-audit has found that 69% of abnormal CXR’s now
receive the appropriate code.
Conclusions: A “failsafe” chest radiograph system is an effective
tool that helps to ensure that patients with lung cancer are seen
promptly and do not “slip through the net”.
P60 COMPULSORY REFERRAL FOLLOWING ABNORMAL
CHEST x RAY VERSUS CHOICE
S.M. Jones1, J. Hammond2, A. Dunn2, A. Healey2, I. Ryland1, J. Curtis2, C.J.
Warburton1, J.E. Earis1. 1Aintree Chest Centre; 2Department of Radiology,
University Hospital Aintree, Liverpool, UK
The British Thoracic Society recommends that General Practitioners
should immediately refer patients to a respiratory physician if a radi-
ology report suggests the possible diagnosis of lung cancer (Thorax
1998:53 (Suppl 1):S1–8). Some Units see such patients directly from
the x ray department while others (including ours) rely on the patients
GP to refer patients to the rapid access clinic.
An audit of 2369 reports from GP requested chest x ray, dating
from 1st January to 28th February 2002 was conducted. In total, 63
reports were suspicious of malignancy. Of these, 40 advised referral
to a chest physician, 16 advised computerised tomography (CT) scan,
and seven did not give any advice. Of the 63 positive reports 48 were
referred to a chest clinic (31 to the rapid access lung clinic and 16 to
another chest clinic). Four patients were already under regular chest
follow up and six were under the care of other physicians. Three
patients had CT scan undertaken by the Consultant Radiologist and no
further action deemed necessary. One patient was admitted via the
Casualty Department because of symptoms and one elderly lady in a
nursing home subsequently died without being seen. The time to being
seen in a clinic ranged from zero to 49 days with a median of eight
days.
We have found that only five patients were not referred to
outpatients of whom three were investigated with CT directly by the x
ray department. One of the remaining two patients presented with
symptoms within two days to casualty and only one was missed (this
was an elderly lady in a nursing home). Thus we have found that most
patients with abnormal x rays are referred in a timely fashion but sug-
gest that the x ray report should specifically suggest rapid access clinic
referral. This system preserves both primary care and patient choice
and prevents inappropriate referrals.
P61 EXPERIENCE FROM THE FIRST 24 MONTHS OF A FAST
TRACK LUNG CANCER CLINIC
L. Dobson, D.M.G. Halpin, C.D. Sheldon, N.J.Withers. Royal Devon &
Exeter Hospital, Exeter, Devon, UK
In May 2000 a dedicated Fast Track Lung Cancer Clinic was
introduced at the Royal Devon & Exeter Hospital to facilitate referrals
via the newly established two week wait (TWW) for suspected
tumours. The clinic commenced as a weekly, Consultant provided
service with the capability to see up to five urgent referrals weekly.
General Pactitioners were informed about the new clinic by means of
a letter, which also included local guidelines for referral via the “two
week wait criteria”. Here we present an analysis of our experience
over the first 24 months of this initiative.
A total of 378 new referrals were seen, with 180 (47.6%) of these
being referred by the two week wait. Other referrals were via urgent
GP letter (95), non-urgent GP letter (73), and Consultant referral (30).
Of the TWW referrals seen, 169 (93.9%) were appropriate
according to local guidelines and 100% of these referrals were seen
within two weeks. Over the 24 month period the number of referrals
via the TWW route has increased from 36 (1st six months of audit) to
64 (final six months).
Of the 378 patients seen in the FTLCC, 148 (39.1%) have been
diagnosed with primary lung cancer or mesothelioma. A further 11
have been diagnosed with secondary cancer. Eighty eight (48.8%) of
the TWW referrals had a diagnosis of primary lung cancer. Since the
introduction of the TWW and the FTLCC there has been a sizeable
decrease in the number of patients diagnosed as lung cancer follow-
ing an emergency admission.
The establishment of a FTLCC has enabled us to fully achieve the
TWW target. Referrals via the TWW are increasing and, in the main,
are appropriate. The FTLCC may have reduced the number of patients
admitted acutely with newly diagnosed lung cancer, but further follow
up data will be required before this hypothesis can be confirmed.
P62 APPROPRIATENESS OF REFERRAL PATTERNS UNDER
THE TWO WEEK RULE FOR LUNG CANCER
R.A. Heinink, H. Moudgil. Princess Royal Hospital NHS Trust, Apley Castle,
Telford, UK
The Calman-Hine proposals for the management of lung cancer have
forged the “two week rule” as the expected standard practice.
Although many Trusts are able to meet these targets, less is known
about the appropriateness of the actual General Practitioner (GP)
referral patterns. This is particularly relevant against a background of
direct or partial booking schemes for hospital appointments
increasingly being made available to GPs. At this Trust, over a 12
month period to April 2001, there were 126 requests as possible lung
cancer categorised under the two-week rule; 124 (98%) of these had
been received centrally by the next working day and 121 (96%) had
been offered outpatient appointments within the two weeks. At least
113 (90%) of these patients met at least one of the preset published
criteria for respiratory referral. Four of the 13 inappropriate referrals
were from one GP practice. Of the 126 referrals, for 92 the criteria
were based on radiological abnormalities alone with similar numbers
(both n=46) specifically prompted by the radiologists or on the GPs
own initiative. Chest film changes accompanied 15 patients with hae-
moptysis and one had stridor. Haemoptysis alone was reported in six.
Collectively, these two week rule referrals made up 48 (36%) of the
132 patients with diagnosed malignant disease presenting to the
chest. A further 35 were diagnosed having been admitted acutely, 22
were detected at follow up clinics (including post admission), 15 were
referred as routine whether by their GPs (n=9) or via other consultants
(n=6), similarly nine others urgently outside two week rules by GPs
(n=6) or via other consultants (n=3), and one patient remained with a
non-respiratory physician throughout. Two others are undefined.
Although we cannot presently comment on the patterns of referral of
those outside the two week rule, this audit provides an insight into the
appropriateness of two week referrals encountered here. It recognises
the heterogeneous modes of presentation and referral but as expected
singles out abnormal radiology as the main determinant. Importantly it
also defines a large number (n=24) still electively referred outside the
two week rule by both GPs and hospital teams. It concludes (1) that the
majority (90%) referred under the scheme met the appropriate criteria
for referral, (2) that only 48 (38 %) of these were then found to have
malignant disease, and (3) that there are areas for improvement
advising referral guidelines and timescales both within primary and
secondary care.
P63 HAEMOPTYSIS IN PATIENTS WITH A NORMAL CHEST
x RAY: CURRENT PRACTICE OF UK CHEST PHYSICIANS
BASED ON A POSTAL SURVEY
N. McAndrew1, J. Woolley1, D.R. Baldwin2, A.L. Burton3. 1Wrexham
Maelor Hospital, Wrexham, LL13 7TD; 2Nottingham City Hospital,
Nottingham NG5 1PB; 3Royal Preston Hospital, Preston PR2 9HT, UK
Do patients who present with an isolated episode of haemoptysis and
a normal chest x ray (CXR) need further investigation? If so, should this
be with bronchoscopy (Br), computerised tomographic scan of the tho-
rax (CT) or both? We sent a postal questionnaire to 610 UK chest
Poster presentations iii65
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
physicians posing five clinical scenarios. The scenarios described
patients with isolated haemoptysis and a normal CXR: a 35 year old
never smoker (35NS); a 59 year old smoker with acute bronchitis
(59S); a 70 year old smoker who had a violent coughing fit (70S); a
65 year old smoker with haemoptysis “out of the blue” (65S); a 70
year old never smoked (70NS). We received 291 replies (48%)
(table).
Older patients and smokers are more likely to be investigated
(p<0.0001, 35NS v 70NS; p<0.01, 70S v 70NS; χ2). A minority
would not investigate minor haemoptysis occurring during acute bron-
chitis. CXR surveillance is more popular than CT alone (p<0.001;χ2).
For smokers nearly 1/3 of respondents would rely on bronchoscopy
alone. The most popular strategy employs both bronchoscopy and CT,
(p<0.025, Br alone v CT & Br). The reliance on bronchoscopy alone
is interesting as there is some evidence to suggest CT has greater sen-
sitivity for picking up lesions not visible on CXR (ERJ 2001;18(Suppl
33):P2595). CXR surveillance may have little benefit to the patient
because it is less sensitive than either CT or bronchoscopy and
because it will inevitably delay diagnosis. This survey has illustrated a
lack of consensus in a difficult area of respiratory medicine.
P64 THE EFFECTIVENESS OF A LUNG CANCER MULTI
DISCIPLINARY TEAM (MDT): A DISTRICT GENERAL
HOSPITAL (DGH) EXPERIENCE
J.T. Samuel, S. Abubakar, A. David, K.J. Taylor, T.J. Charles. Glan Clwyd
District General Hospital & The North Wales Cancer Center, Rhyl,
Denbighshire LL18 5UJ, UK
Introduction: A number of strategies have been developed to combat
lung cancer in the United Kingdom starting with the Calman Hine
Report in 1995. The MDT approach incorporating various medical
and paramedical specialities has been uniformly advocated to
provide efficient and effective delivery of care. The effectiveness of the
MDT approach has not been evaluated.
Aim: To assess the effectiveness of a lung cancer MDT in the man-
agement of lung cancer.
Methods: We audited the management of patients with lung can-
cer from Glan Clwyd DGH over a one year period before and after
MDT was instituted at the North Wales Cancer Centre.
Results: See table.
Conclusions: In our audit, there were no significant differences in
the diagnosis or treatment of patients after the formal MDT approach
was adopted. More non-invasive investigations were performed and
data collection was more extensive and structured. Further larger
audits on the effectiveness of the MDT approach in lung cancer are
required to determine if it indeed provides more effective delivery of
care than previously practised.
P65 ANALYSIS OF HISTOLOGY RESULTS TO IMPROVE
PROTOCOLS FOR THE DIAGNOSIS OF LUNG CANCER
S.M. Jones, P.P. Walker, I. Rylands, M. Babores, J.E. Earis, C.J. Warbur-
ton. Aintree Chest Centre, University Hospital Aintree, Liverpool, UK
There is still considerable variation in schematics for the management
of pulmonary malignancies. This is particularly true for pleural disease
where evidence is lacking. We looked at all 1012 cytological or his-
tological assessments performed, in 654 patients referred between
January 2000 and January 2001 with suspected pulmonary
malignancy to produce local recommendations.
Pleural fluid cytology was analysed for diagnosis in 202 patients,
of whom 48 had 2–4 samples taken. Twenty of 264 (9%) samples
showed malignancy. In the 48 cases where a second sample was
analysed only 3/48 were positive. In all three the initial result had
been “suspicious or suggestive” of malignancy. Thirty eight sets of
pleural biopsies were performed in 34 patients and 7/38(18%)
showed malignancy. Twenty one patients with pleural effusions had a
bronchoscopy. This was unhelpful in 18/21 irrespective of whether
initial pleural cytology was reported as suspicious (7) or not (11). The
3/21 patients with diagnostic bronchoscopic abnormalities all had
central abnormalities on CT.
At bronchoscopy where no lesion was visible 154 patients had a
blind wash, brush biopsy or both. Eight of 154 (5%) had positive
cytology and the addition of a brush biopsy increased the yield from
2% (2/92) to 11% (6/62). In 104 patients where a visible lesion was
biopsied, an additional wash, brush biopsy or both increased the
diagnostic yield by 6%—positive biopsy in 44 (42%), wash only in
two (2%), brush only in three (3%), and wash and brush only in one
(1%). Thirteen patients with a visible lesion and negative histology had
a second bronchoscopy and 4/13 (31%) produced positive histology.
We recommend (1) Diagnostic rate for blind pleural procedures is
small but significant. If initial pleural cytology is not “suspicious”
further aspiration without biopsy is unhelpful. (2) Bronchoscopy should
not be performed for undiagnosed effusions in the absence of central
CT abnormalities. (3) If blind samples are taken at bronchoscopy then
a wash and a brush should be performed. (4) Wash, brush biopsy,
and bronchial biopsy should be performed for all visible endobron-
chial lesions. (5) Repeat bronchoscopy is a reasonable option in some
patients although histology is obtained in <50%.
P66 RADICAL TREATMENT FOR NSCLC IN NORTHERN AND
YORKSHIRE REGION
E.T. Peel, C. Bennett. North Tyneside General Hospital, Northern & York-
shire Cancer Registry Information Service, UK
The casenotes of 400 consecutive patients with histologically
confirmed non-small cell lung cancer (NSCLC) diagnosed in 1998
and registered with Northern and Yorkshire Cancer Registry
Information Service (NYCRIS) database, were audited. The aim of the
study was to determine the proportion of NSCLC patients receiving
radical treatment (surgery or radical radiotherapy – dose >50Gy)
and how they were assessed.
Data is presented on 368 patients (92%) in the table.
In patients not receiving radical treatment, the commonest reasons
for those decisions were: advanced lung cancer (54%), died (18%),
refused (13%), other disease (12%). The open and close rate was 8%.
We conclude that staging and performance status are not well
documented, although the majority of patients have significant comor-
bid illness, the main determinant of suitability for radical treatment is
the extent of the disease.
Abstract P63
No Ix Ix
Repeat CXR(s)
alone CT alone Br alone CT & Br
Repeat CXR(s)
& Br
Repeat CXR(s),
CT & Br
35NS 72% 28% 18% 2% 3% 1% 1% 1%
59S 13% 87% 15% 3% 30% 27% 10% 1%
70S 2% 98% 9% 5% 32% 38% 9% 3%
65S 1% 99% 2% 3% 32% 51% 7% 4%
70NS 7% 93% 19% 8% 25% 30% 7% 3%
CXR, chest x ray; CT, computed tomography; Br, bronchoscopy.
Abstract P64
Pre MDT Post MDT
Patient number 104 107
Emergency admissions 42% 29%
Diagnosis in 2 weeks 66% 64%
Histology 74% 68%
CT thorax 79% 62%
Surgical rate 9% 5%
Chemotherapy/radiotherapy 53% 54%
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P67 LUNG CANCER IN WOMEN THROUGH THE 1990s
A. Bastin, D. Eraut, A. Davison, A.S. Haque, A. Hutchings, A. Lamont, C.
Trask. Southend Associate University Teaching Hospital, Southend on Sea,
Essex SSO ORY, UK
Lung cancer incidence is rising in females (F) and falling in males (M)
in the UK. Smoking in young females increased in the early 90s. We
have analysed the pattern of lung cancer in 2127 new cases (1421
M (67%) + 706 F (33%)) presenting over a 10 year period from 1990
to 1999 from the Southend Lung Cancer Study. This includes every
case in a well defined population of 325 000. The mean age of F was
70.8 yrs (SD 10.3) and M 71.7 yrs (SD 9.7) (p<0.04)). There was a
higher percentage of F never smokers (8.5%) compared with M
(1.9%) (p<0.001). The proportion of never smokers was greater in
elderly F compared to younger F (p=0.019). There was a higher per-
centage of M ex-smokers (60.2%) compared with F (51.1%)
(p<0.001). There were 39.6% of F current smokers compared to
37.9% M (p=0.47). The proportion of current smokers falls with
increasing age at diagnosis in both M and F (test for trend p<0.001).
We found a lack of evidence that the proportion of F to M had
increased from 1990 to 1999 overall (test for trend p=0.3) nor in
under 65s alone (p=0.151). In patients with confirmed squamous,
adeno, or small cell histology (total 1342), there was an overall differ-
ence (p=0.001) in the proportion of histological types between M and
F: squamous cell carcinoma 54% M v 41% F; adenocarcinoma 23%
M v 28% F; small cell carcinoma 23% M v 31% F (χ2 p<0.001). Never
smoking F were more likely to have adenocarcinoma than F who
smoked (χ2 p<0.001). We found no evidence that the proportion of
adenocarcinoma in smokers and never smokers changed over time in
M and F (test for trend p=0.67). The proportion for M (10.5%) and F
(8.9%) having either radical radiotherapy or surgery differed by 1.6%
(95% CI −1.1% to 4.2%) (χ2 p= 0.26).
Conclusion: In comparing M and F with lung cancer through the
90s we have found: (I) F to be slightly younger than M; (ii) differences
in histological types, with adenocarcinoma and small cell being more
common in F and squamous cell carcinoma in M; (iii) more F never
smokers; (iv) older F were more likely to be never smokers than
younger F; (v) F never smokers were more likely to have adenocarci-
noma than F smokers; (vi) no difference in the proportion of men and
women presenting over time, and (vii) no evidence of a gender bias in
those receiving “curative” treatment.
P68 LUNG CANCER IN OCTOGENARIANS, THE ROLE OF
THE SURGEON
I.R. Ramnarine, S. Thomas, A.N.A. Jilaihawi, D. Prakash. The Department
of Thoracic Surgery, Hairmyres Hospital, East Kilbride, Glasgow,
G75 8RG, UK
Objective: To analyse the pattern of management of patients in their
eighties referred to the surgeon with clinical evidence of lung cancer.
Methods: A retrospective series of 62 80 year old patients (42
males) with a clinical diagnosis of lung cancer referred to the surgeon
over a 15 year period. The surgical management of these patients
was reviewed.
Results: Pathological confirmation of tumour type was in 54
patients (87%) with 39 lung cancers (28 squamous cell, eight adeno-
carcinoma, one large cell, and one small cell carcinoma), seven
diffuse malignant mesotheliomas, three metastases, and five other
tumour types. Of the lung cancer patients, 10 had tumours that were
unresectable (mean survival 8.4 months) and 29 had resectable
lesions. Of the latter group, eleven patients had comorbid disease
making them inoperable (mean survival 6.4 months). Eighteen patients
had lung tumour resection. There were four pneumonectomies, 13
lobectomies, and one bilobectomy. Ten patients had stage 1, five had
stage two, and three had stage 3a lung pathology. Operative
mortality was 11% (two patients). One, two, and three year survivals
were 72%, 64%, and 23% respectively. Four of the nine late deaths
were from tumour spread and there are seven disease free survivors.
Conclusion: Age should not be a discriminating factor in determin-
ing operability in lung cancer patients. The surgeon plays an
important role in the management of octogenarians with lung cancer
offering a wide range of services from minor diagnostic procedures to
definitive surgery.
P69 COPYING CORRESPONDENCE TO CHEST CLINIC
PATIENTS: A SURVEY OF PATIENT VIEWS
S. Lohani, P.J. Sullivan, R. O’Driscoll, S.C.O. Taggart. Respiratory Depart-
ment, Hope Hospital, Salford, M6 8HD, UK
Introduction: As part of the NHS plan to improve communication
between health professionals and patients by 2004, it is expected that
all future patients will receive copies of correspondence. It is likely that
this directive will have important effects on the way in which providers
deliver their service in addition to changing the way they relate to their
patients.
Methods: From mid April to mid June 2002, we surveyed all
patients attending our general respiratory clinics in addition to those
visiting our dedicated Lung Cancer Clinic. Patients were asked to
complete a self administered questionnaire with tick box format,
designed to identify which patients wished to receive all or some cop-
ies of their correspondence and which patients preferred to receive no
copies. The patient’s wishes were then recorded on their correspond-
ence and letters were forwarded to the patients if required. Patients
were requested to discuss any errors in their medications at their next
clinic visit. Our medical secretaries recorded any incidents arising out
of the introduction of this system. Patient preferences for receiving
copies of correspondence at general respiratory and specialist lung
cancer clinics (table).
A significantly greater proportion of patients attending our
dedicated Lung Cancer Clinic preferred to receive no copies of corre-
spondence than their general respiratory counterparts (27% v 14%,
p=0.013 using Fisher’s exact test). Overall, 84% of our patients
expressed a preference to receive copies of correspondence.
Throughout the study period, no incidents were recorded bar one
patient who wished to point out a medication error.
Conclusions: Based on our two month experience, we recommend
caution for those planning to introduce copies of correspondence to all
patients attending clinics as a small proportion would not wish to
receive this. This proportion rises to almost a third for those patients
attending Lung Cancer Clinics.
Abstract P66
N
Median
age
% Not staged
explicitly
% PS
recorded
Median
FEV1
% Co-morbid
illness
Surgery alone 36 64 81 3 1.8 75
Surgery + radical DXT 7 62 100 0 2.6 43
Surgery + palliative DXT 3 75 100 33 1.1 66
Radical DXT alone 21 69 86 19 1.7 71
Palliative DXT 164 70 80 15 1.5 67
No surgery or DXT 137 72 90 12 1.5 69
Abstract P69 Patient preferences for receiving copies
of correspondence at general respiratory and
specialist lung cancer clinics
Preference for
correspondence
General
respiratory Lung cancer Total
All or some copies 273 (86%) 45 (73%) 318 (84%)
No copies 44 (14%) 17 (27%) 61 (16%)
Total 317 62 379
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Lung injury, inflammation, and
infection
P70 EPIDEMIOLOGY OF LUNG FUNCTION AND
IMMUNOLOGY IN PIGEON BREEDERS: FIVE YEAR
FOLLOW UP
T. Ismail, F. Boyd, C. McSharry, P. Lynch, C. Lynch, G. Boyd. Department
of Respiratory Medicine and Immunology, North Glasgow University
Hospitals NHS Trust, UK
Background: The immunopathogenesis of pigeon fanciers’ allergic
alveolitis is unresolved. Most studies rely on subjects presenting at
clinics and proper epidemiological evaluation is lacking. Changes in
lung function, immunology, and associated symptoms among a cohort
of pigeon fanciers were assessed.
Methods: Forty pigeon fanciers had serial lung function, serum
antibody to inhaled avian antigens and symptoms monitored for five
years.
Results: Between 1997 and 2002 there was a significant
reduction in FEV1 (T = −2.87, p=0.007) and FEV1/FVC (T = −3.68,
p=0.001). Twenty one subjects were seropositive in 1997 and a fur-
ther four subjects showed evidence of new sensitisation in 2002 and
there was no significant increase in the paired mean titre. The % pre-
dicted FEV1 correlated inversely with serum antibody titre (r = −0.380,
p=0.019) and peripheral blood CD8 lymphocyte proportion (r =
−0.319, p<0.05). The antibody titre also correlated inversely with the
CD4:CD8 ratio (r = −0.325, p=0.014). Eleven subjects had symptoms
of extrinsic allergic alveolitis in 2002 compared to 13 subjects in
1997.
Conclusion: Serial lung function in statistically determined cohort
of pigeon fanciers seems to deteriorate significantly depending on the
extent of the humoral antibody response to the inhaled antigens. These
changes are associated with underlying immune dysfunction involving
the imbalance of T-helper and T-cytotoxic lymphocytes. Subclinical
inflammatory changes are common among pigeon fanciers and may
be predictive of disease progression.
P71 SERIAL LUNG FUNCTION FOLLOWING PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION
L. Warren, L. Cormican, M. Gillion, D. Wilson, R. Freeman, S. Schey1,
H. Milburn. Departments of Respiratory Medicine; 1Haematology, Guy’s
Hospital, St. Thomas Street, London, SE1 7EH, UK
Background: Pulmonary function tests (PFTs) are an established
tool in the prediction of respiratory complications following allogenic
bone marrow transplantation (BMT) for haematological malignancy.
Most of these patients are now managed with allogenic and
autologous peripheral blood stem cell transplants (PBSCT), a
procedure less toxic than BMT and thought to result in fewer
pulmonary complications.
Methods: In this observational study we have followed serial
pulmonary function tests in 70 patients up to 81⁄2 years following
PBSCT for multiple myeloma (n= 35) and leukemia (n= 35, 43 % AML,
6 % ALL, 14 % CML, 37 % CLL) to determine whether there were any
groups which were particularly susceptible to respiratory complica-
tions. The selection of CD34+ cells was performed in 22 cases during
the harvesting of peripheral blood stem cells prior to transplantation.
Results: Over the duration of the study there was a notable
decrease in TLCO (figure) and an increase in RV (non-significant) in
those who received CD34 selected, in comparison to non-CD34
selected grafts.
There was deterioration in lung function data (FEV1 and FVC) in the
AML population in comparison to the combined PBSCT population.
Conclusion: Even though PBSCT is associated with fewer
pulmonary complications, certain subgroups of patients are more
prone to changes in lung function over time. This justifies the perform-
ance of serial lung function in these patients.
P72 LUNG REPAIR BY HAEMATOPOIETIC STEM CELLS (HSC)
AFTER BONE MARROW TRANSPLANT (BMT)
S.M. Janes, T. Hunt, M. Brittan, R. Jeffery, S. Forbes, K. Hodivala-Dilke, M.
Alison, N. Wright, R. Poulsom, M.J.D. Griffiths. Cancer Research UK, Lon-
don WC2A 3PX, UK
Introduction: Recent data suggest that HSC contribute to repopula-
tion of the pulmonary parenchyma after BMT (Krause DS, et al.
Cell 2001;105:369–77; Kotton DN, et al. Development
2001;128:5181–8). The aim of this study was to define in mice
following BMT the phenotype and time course of the appearance of
donor-derived cells in the pulmonary parenchyma.
Methods: Six week old female recipient mice were irradiated with
10 Gray as a split dose two hours apart to ablate their BM and then
received male wild type whole BM by tail vein injection. Four mice
were sacrificed at weekly intervals for six weeks and then at eight and
10 months. Lung sections were hybridised with FITC-labelled Y
chromosome paint (Star-FISH, Cambio, Cambridge, UK) to detect cells
of donor origin. For the mouse tissue we combined in situ
hybridisation for the Y chromosome with immunohistochemistry for
specific markers for macrophages, myofibroblasts, endothelial and
epithelial cells.
Results: Y+ cells were widespread in the lung parenchyma a week
after BMT, engraftment peaked between four and six weeks, and per-
sisted for at least 43 weeks (figure). Y+ cells were absent from the air-
way epithelium and the endothelium of venules and arterioles. Y+ cells
stained positively with epithelial cell markers T1α, Lectin lycopersicum
esculentum, and CAM5.2.
Conclusions: Donor-derived HSC (Y+) cell’s morphology and
staining suggests that they become part of the alveolar epithelium. The
role of BM derived stem cells in lung repair is unknown but may be a
novel target for manipulation or a means of delivering gene therapy to
the distal lung.
SJ is supported by a training fellowship from the MRC UK.
P73 PERIPHERAL BLOOD CHANGES AND CRYPTOGENIC
FIBROSING ALVEOLITIS. POSSIBLE MARKERS OF
DISEASE?
V.A. Varney, D.T. Salisbury, H. Parnell. Department of Respiratory
Medicine, St Helier Hospital, Wrythe Lane, Carshalton, Surrey SM5 1AA,
UK
Background: Cryptogenic fibrosing alveolitis (CFA) is a disease
associated with activated alveolar macrophages at broncho alveolar
lavage. In the peripheral blood, autoantibodies and elevation of the
ESR are common but not diagnostic. The prevalence of CFA has
increased in the last decade providing more patients for studies.
We have observed a consistent feature (not yet described) of eleva-
tion in peripheral blood monocytes (MØ), mean red cell volume
(MCV), and serum gamma glutamyl transferase (GGT). In all cases
Abstract P71 Mean TLCO of CD34 and non-CD34 selected
groups.
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alcohol intake and drugs were excluded as a cause. Full liver function
tests were otherwise normal along with vitamin B12 and folate levels.
A bone marrow was examined in three cases confirmed a true
macrocytosis without any other myelodysplastic features.
Methods: Ninety one patients (age 41–86 years) presenting with
a new diagnosis of CFA had their baseline haematology and
biochemistry studied. The results were compared with an age and
gender matched reference range obtained from the same laboratory
of non-CFA general population controls. The abnormalities at baseline
were noted to be persistent throughout the patients treatments.
Results: See table.
Conclusion: Ninety one CFA patients showed a statistical increase
in peripheral blood monocytes, MCV, and serum GGT. This observa-
tion requires further investigations and may represent a systemic
disease with cytokine or other mediator effects on the bone marrow
responsible for these changes.
P74 PULMONARY VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) RECEPTOR EXPRESSION IN ACUTE
RESPIRATORY DISTRESS SYNDROME (ARDS)
A.R.L. Medford1, L. Armstrong1, N.B.N. Ibrahim2, K.M. Uppington1, A.B.
Millar1. 1Lung Research Group, University of Bristol Division of Medicine,
Southmead Hospital, Bristol, UK; 2Department of Pathology, Frenchay
Hospital, Bristol, UK
Previous work in our laboratory suggested a role for VEGF (an
angiogenic and permeability factor) in the pathogenesis of ARDS
(Thickett DR, et al. Am J Resp Crit Care Med 2001;164:1601–5).
VEGF receptors (VEGFR1, VEGFR2) are thought to be predominantly
expressed in vascular endothelium and monocytes. Modulatory VEGF
neuropilin co-receptors (NP1 and NP2) expression occurs in a variety
of human tissues. The expression of these receptors in human normal
and ARDS lung has not been extensively investigated. We
hypothesised that there would be expression of these receptors on
both sides of the alveolar-capillary membrane with significant upregu-
lation in ARDS lung consistent with VEGF having a significant role.
Immunohistochemistry was performed on post-mortem human lung
sections from normal subjects and patients with late ARDS (n=4) using
semiquantitative densitometric analysis via Histometrix software.
RT-PCR was performed on cultured human type II alveolar cells (AE2),
alveolar macrophages (AMs) and peripheral blood monocytes (PBMs)
from normal subjects and ARDS patients. In normal lung, VEGF,
VEGFR1 and VEGFR2 protein were expressed in vascular endothe-
lium, alveolar epithelium, and AMs. NP1 and two were confined to
the alveolar side. In late ARDS lung, there was significant upregulation
of VEGF, VEGFR1, VEGFR2, NP1 but not NP2. NP1 and 2 expression
was also evident on the vascular side of the alveolar-capillary
membrane. RT-PCR confirmed VEGFR1, VEGFR2, and NP1 mRNA
expression in AMs and AE2 cells. PBMs expressed only VEGFR1
mRNA. These data confirm the presence of VEGF receptors and
co-receptors on the alveolar side of human lung in addition to the
known vascular endothelial expression of VEGFR1 and 2. There is sig-
nificant upregulation of these receptors in late ARDS consistent with
VEGF having a significant role in ARDS on both sides of the alveolar-
capillary membrane. The type 2 alveolar epithelial cell and alveolar
macrophage appear to be additional targets for VEGF in human lung.
P75 VASCULAR ENDOTHELIAL GROWTH FACTOR ISOFORM
(VEGF165b, VEGF165 AND VEGF189) EXPRESSION IN
HUMAN AND MURINE INJURED LUNG
A.R.L. Medford1, L. Armstrong1, S. Godinho1, D.O. Bates2, S.J. Harper2,
A.B. Millar1. 1Lung Research Group, University of Bristol Division of
Medicine, Southmead Hospital, Bristol, UK; 2Microvascular Research
Laboratory, Department of Physiology, University of Bristol, Southwell
Street, Bristol, UK
Previous work in our laboratory suggested a role for VEGF in the
pathogenesis of ARDS (Thickett DR, et al. Am J Rep Crit Care Med
2001;164:1601–5). However, VEGF is compartmentalised in normal
human lung (Kaner RJ, et al. Mol Med 2001;7:240–6). More recently,
VEGF165b has been identified as an inhibitory splice variant found in a
variety of human tissues including lung (Bates DO, et al. Cancer Res
2002;62:4123–31). There is mounting evidence that the VEGF
isoforms have different biological roles. We hypothesised that the
VEGF165b would be significantly expressed in normal lung and that the
distribution of the VEGF165b, VEGF165, and VEGF189 isoforms would be
altered in acute respiratory distress syndrome (ARDS). Total RNA was
extracted from cultured “normal” human type 2 alveolar epithelial
cells (AE2, n = 4), as well as alveolar macrophages (AMs, n = 11)
from normal subjects, at risk and ARDS patients. RNA was also
extracted from C57BL/6 mice after lipopolysaccharide (LPS) induced
lung injury (n = 9) and sham controls (n = 2). RT-PCR with VEGF
isoform-specific primers was performed to assess VEGF165b, VEGF165,
and VEGF189 mRNA expression. VEGF165b was expressed in all
samples (n = 26). In injured murine lung, VEGF165 and VEGF189 were
both expressed compared to only VEGF165 in normal murine lung. Sev-
enty five per cent (n = 6) of samples expressing only VEGF165 were
from normal lung. 75% (n = 12) of samples expressing both VEGF165
and VEGF189 were from injured lung. Expression of VEGF splice vari-
ants appears to be influenced by lung injury whereas the inhibitory
splice variant is endogenously expressed in the lung. This may
partially account for the high levels of compartmentalised VEGF in
normal human lung. The relative expression of the inhibitory and the
active isoforms may determine the functional role, in particular the
pathogenic role of VEGF in ARDS. Further research is required to
define the exact relative expression of these isoforms.
P76 AN AUDIT OF THE MANAGEMENT OF COMMUNITY
ACQUIRED PNEUMONIA IN SOUTHAMPTON GENERAL
HOSPITAL
S.K. West, S. King. Respiratory Department, Southampton General
Hospital (SGH), UK
Introduction: The publication of the British Thoracic Society (BTS)
guidelines into community acquired pneumonia (CAP) (Thorax
2001:56(Suppl IV):iv1–iv64) prompted a review of clinical practices
at Southampton General Hospital (SGH). The aim was to assess the
present use of the core prognostic features outlined in the guidelines
(confusion, urea, respiratory rate, and blood pressure) and their rela-
tion to management decisions.
Method: The patient group was all those admitted to SGH between
September and November 2001 (inclusive) given the diagnosis of
pneumonia on their discharge summary. Patients were then excluded
according to the BTS exclusion criteria. The data was collected from
the patients’ notes; specifically initial investigations, core prognostic
features, severity of the pneumonia, antibiotic prescription, and
patient outcome. The results were then compared with the guidelines
and national statistics.
Results: Seventy three notes were obtained from 113 requested, of
which 38 met the inclusion criteria. The main reason for exclusion was
a recent hospital stay. The average age was 70 years and the length
of stay nine days. Only seven patients had any documented
assessment of severity, three of which were said to be severe. Subse-
quent use of information within the notes indicated that 45% could be
classified as severe, 42% non-severe, and 13% mild. Measurement of
core prognostic features varied, with blood pressure measured in 97%
of cases, urea 82%, respiratory rate 74%, and mental test score 50%.
Other problems with note keeping included minimal inclusion of
radiographic results in the notes. The majority of antibiotic choices
were appropriate in type but with 70% of first line antibiotics being
given intravenously despite only 45% classifiable as severe. The over-
all death rate was 23.6% with three unrelated deaths. Two patients
were subsequently changed to palliative management and four deaths
were attributed directly to CAP. Thus the death rate from CAP was
10.5% with 89% of these initially graded as severe. 53% of all those
graded as severe died.
Abstract P73
Parameter
(normal range
units)
Control mean
(SD)
CFA mean
(SD)
p Value
unpaired T test
MCV 89 (4.20) 94 (6.1) p<0.001
(84–98) FL n=160 n=91
MØ 0.35 (1.1) 0.68 (0.24) p<0.001
(<0.6) 109/l n=160 n=91
GTT 29 (22) 40.2 (31.7) p<0.02
(7–40) u/l n=150 n=61
CFA, Cryptogenic fibrosing alveolitis; MØ, peripheral blood
monocytes; MCV, mean red cell volume; GGT, serum gamma
glutamyl transferase.
Poster presentations iii69
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
Conclusions: There is presently minimal use of any formal severity
assessment and a possible over reliance on intravenous antibiotics.
This audit may provide a background on which to investigate the ben-
efits of severity assessment forms in the care of all those admitted
locally with possible CAP.
P77 STAPHYLOCOCCUS AUREUS CELL WALL DEFICIENT
BACTERIA ARE HIGHLY RESISTANT TO CELL WALL
ACTIVE ANTIBIOTICS AND HAVE AN ALTERED PROFILE
TO OTHER CLASSES OF ANTIBIOTIC
C. Elmer , P. Cook , F. Nattress , P. Cheung2, T. Fawcett3. 1University Hos-
pital of North Durham; 2Centre for Comparative Public Health, University of
Durham; 3School Of Biological and Biomedical Sciences, University of
Durham, UK
Background: Bacteria may lose all or part of their cell walls under
certain environmental conditions, including the presence of cell
wall-active antibiotics. Cell wall deficient bacteria (CWDB) are hard to
detect by light microscopy or culture, but can proliferate in vivo and on
specialised media. We investigated whether cell wall deficiency con-
fers stable resistance to penicillin and its affect on the response to
other antibiotics.
Method: Staphylococcus aureus cells were cultured in the presence
of sublethal levels of penicillin G on various media, including one
optimal for CWDB. Minimum inhibitory concentration (MIC)
estimations were performed after three step increases in penicillin con-
centration and on cells that had been passaged in the absence of
penicillin. Cells were examined by Gram staining and electron micro-
scopy. Different strains of CWDB were subjected to disc diffusion tests
for a range of other antibiotics.
Results: CWDB have a different colony morphology, stain Gram
negative and have indistinct margins and altered cell morphology on
electron microscopy. The MIC for penicillin increased following serial
passages, particularly on CWDB optimal media (32 units/ml,
compared with 1 unit/ml on DST medium, after 12 passages). After
seven passages without penicillin the cell wall was regained, but peni-
cillin resistance was maintained. CWDB were resistant to other cell
wall active antibiotics. They also exhibited altered profiles in compari-
son to the wild type cells for erythromycin, trimethoprim, tetracycline,
novobiocin, and nitrofurantoin.
Conclusion: In the presence of sublethal levels of antibiotics and
media optimal for CWDB, S aureus rapidly develops a high degree of
stable penicillin resistance. We propose that loss of the cell wall,
though rarely demonstrated in clinical microbiology laboratories, is an
important cause of antimicrobial resistance to cell wall active antibiot-
ics. Surprisingly these cells show significant alterations in sensitivity to
other classes of antibiotics too. This could have profound implications
for antibiotic therapy.
P78 IgA1 PROTEASE FROM NON-TYPABLE HAEMOPHILUS
INFLUENZAE CLEAVES TWO SITES IN HUMAN IgA1
HINGE REGION
D. Mistry, S. He, R.A. Stockley. Lung Investigation Unit, Queen Elizabeth
Hospital, Birmingham, UK
Bacterial IgA1 proteases are thought to be important virulence factors
in respiratory tract infections. This group of proteolytic enzymes
specifically cleave one of several post-proline peptide bonds within the
hinge region of human immunoglobulin A1.
We have partially purified an IgA1 protease with a different cleav-
age specificity, from a clinical isolate of non typable Haemophilus
influenzae (NTHI), by anion exchange chromatography. Proteolytic
assays were carried out with human IgA1, IgA2, and serum albumin.
PCR of the NTHI genome was carried out with IgA1 protease
sequence-specific primers to identify the gene(s) coding for the IgA1
protease(s) producing this cleavage pattern.
The protease specifically cleaved human IgA1 and did not cleave
human IgA2 or serum albumin. However, the IgA1 protease cleaved
more than one site within the hinge region of human IgA1. PCR ampli-
fication produced one IgA1 protease gene (iga) product. The PCR
products contained homologous sequences to other iga genes of the
serine-type IgA1 proteases and interspersed between these sequences
were new deletions and insertions. The results indicate that the NTHI
contains one iga gene sequence that encodes one IgA1 protease,
which cleaves more than one peptide bond in the IgA1 heavy chain.
The iga gene sequence may produce the unique cleavage specificity
of the NTHI IgA1 protease and further work will require the identifica-
tion of the residues essential for the IgA1 protease activity, to allow the
design of specific inhibitors to this important class of proteolytic
enzymes.
P79 ELEVATED NASAL NITRIC OXIDE CORRELATES WITH
REDUCED NASAL MUCOCILIARY CLEARANCE IN
BRONCHIECTASIS
A. Shoemark, S. Kharitonov, P. Barnes, R. Wilson. Host Defence Unit,
Royal Brompton and Harefield NHS Trust and National Heart and Lung
Institute, Imperial College of Science Technology and Medicine, London,
UK
Effective mucociliary clearance (MCC) is an important first line host
defence against infection. Nitric oxide (NO) is also thought to aid in
host defence through its antibacterial properties and by increasing
ciliary beat (Runer et al. 1998). NO is upregulated in the presence of
infection and inflammation (Kharitonov et al. 1995). The aim of this
study was to establish the relationship between nasal MCC and NO
in patients with bronchiectasis, a disease associated with impaired
host defence and inflammation.
Nasal MCC and NO were measured in 30 non-smoking subjects
with stable bronchiectasis confirmed by CT scan, age 25–82 yrs
mean 57, male (11), and eight control subjects with no respiratory
problems. Eight patients regularly used nasal corticosteroids. Subjects
with cystic fibrosis or primary ciliary dyskinesia were excluded as
nasal NO is known to be low. NO was measured directly from the
nostril during a breath hold using a chemiluminescence analyzer
(LR2000 Logan research ltd. Rochester, UK). Three patients could not
hold their breath for long enough for the test to be performed correctly.
Nasal MCC time was measured by the saccharin test.
In bronchiectasis subjects without nasal corticosteroids, nasal NO
was significantly (p<0.05) elevated in patients (n=6) with nasal MCC
>60 minutes, mean 658ppb (SD 186), compared to patients (n=13)
with nasal MCC =60 minutes, mean 402ppb (180), and controls,
mean 418ppb (136). There was a correlation between nasal MCC
and NO in patients with clearance = 60 minutes. r = 0.6, p<0.05.
Although no significant difference in NO was found between subjects
with no nasal corticosteroids and patients regularly taking nasal
corticosteroids, in subjects regularly taking nasal corticosteroids there
was no correlation between nasal MCC and NO.
In conclusion nasal NO is elevated in bronchiectasis patients with
delayed nasal mucociliary clearance. This finding may be due to
increased inflammation in the upper respiratory tract. Delayed
clearance occurs despite any increase in ciliary beat that might occur
with increased NO.
P80 STUDY OF EXHALED NITRIC OXIDE IN STABLE
BRONCHIECTASIS
L.J. Ozerovitch, A. Shoemark, S. Kharitonov, P. Barnes, R. Wilson. Host
Defence Unit, Royal Brompton and Harefield NHS Trust and National
Heart and Lung Institute, Imperial College of Science Technology and
Medicine, London, UK
We have previously shown that nitric oxide (NO) is elevated in some
patients with stable bronchiectasis, but in others levels are normal.
Exhaled NO levels are high along with systemic markers of inflamma-
tion (CRP and peripheral blood neutrophil count) during an exacerba-
tion and fall after antibiotic therapy. These results suggest that NO is
a marker of lung inflammation. The present study was conducted to
compare those patients with elevated NO when stable to those with
normal levels.
Twenty three patients with bronchiectasis shown on CT scan under-
went a protocol of investigation which included full lung function tests,
sputum examinations, blood investigations, ciliary studies, sweat test,
shuttle walking test, and St George’s Respiratory Questionnaire
(SGRQ).
There was no relationship between NO and walking distance nor
any component of the SGRQ. There was also no relationship between
NO and extent of bronchiectasis on CT scan, blood inflammatory
markers, sputum bacteriology, sputum eosinophil count, nor any lung
function parameter. There were correlations between gas transfer (%
predicted) and walking distance (p<0.05); walking distance and CRP
(p<0.05); gas transfer (% predicted) and Total SGRQ (p<0.05); walk-
ing distance and Total SGRQ and also the Activities component
(p<0.004); and Total SGRQ and FEV1 (% predicted) (p<0.05).
In conclusion we do not know why some patients with stable bron-
chiectasis have elevated exhaled NO. We are continuing to study
more patients using the same protocol, and also carrying out a more
detailed analysis of the CT scans—for example, airway wall
thickness—and a long term study to see if elevated NO influences the
subsequent clinical course.
iii70 Poster presentations
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
Clinical asthma and the
nurse’s role
P81 CHILDHOOD ASTHMA IN THE HIGHLANDS OF
SCOTLAND: MORBIDITY AND SCHOOL ABSENCE
J.B. Austin1, S. Selvaraj2, G. Russell3. 1Highland Primary Care NHS Trust;
2Highlands and Islands Health Research Institute; 3University of Aberdeen,
UK
Background: The prevalence of childhood asthma in Scotland is one
of the highest in the world. Allergic diseases may cause significant
morbidity. The aims of this study were to describe the prevalence of
asthma, eczema, and hay fever in the Highlands of Scotland and in
the Shetland Isles and to examine factors in relation to quality of life
and social deprivation.
Methods: A total population survey of 12 year old children using a
parent completed questionnaire.
Results: 86.3% (2658/3080) returned questionnaires. Of the
2549 questionnaires analysed, 476 (18.7%) reported asthma, 362
(14.2%) wheeze in last 12 months, 508 (19.9%) hay fever, and 555
(21.8%) eczema. Of the children reporting asthma or wheeze, 35.4%
(229/647) had missed school because of asthma or wheeze, 38.0%
(246/647) had missed physical education. Of subjects with lifetime
wheeze, 62.5% (354/566) reported sleep disturbance. Deprivation
measured by DEPCAT scores was associated with maternal smoking
and bronchitis in the child but not with allergic diseases.
Conclusion: Compared with previous studies, the prevalence of
asthma is unchanged but eczema has increased in Highland adoles-
cents. Allergic disease has a significant impact on school attendance
and physical activity. Deprivation is associated with maternal smoking
and bronchitis in the child but not with allergic diseases. The impact of
allergic diseases in rural areas may be different from urban areas.
Acknowledgement: This study was funded by Chest, Heart and
Stroke Scotland.
P82 CAN ASTHMA LIAISON NURSES REDUCE
UNSCHEDULED CARE IN A DEPRIVED MULTIETHNIC
POPULATION? ELECTRA: THE EAST LONDON
CONTROLLED TRIAL FOR HIGH-RISK ASTHMA
C. Griffiths, G. Foster, G. Feder, H. Tate, S. Eldridge, N. Barnes1, A. Liv-
ingstone, T. Coats1, for The Electra Group. Dept General Practice and Pri-
mary Care, Barts and the Royal London Hospital, London, E1 4NS; 1The
London Hospital, London E1, UK
Introduction: Evaluations of specialist nurses have focused on educa-
tion in secondary care rather than liaison with primary care, and have
not been set in multiethnic populations.
Design: Cluster randomised control trial comparing liaison nurse
intervention versus best usual practice.
Setting: Forty four general practices in Tower Hamlets, east London
Participants: 324 adults and children with asthma recruited after hos-
pital admission or accident and emergency attendance.
Intervention: Intervention practices received two educational visits
from liaison nurses to promote care of high risk patients. Participants
from intervention practices received structured self management
education from a liaison nurse. Control practices received one liaison
nurse visit to discuss standard asthma guidelines. Participants from
control practices received an inhaler technique check.
Main outcome measures: Participants free of unscheduled care;
time to first unscheduled contact.
Results: Fifty per cent of participants were south Asian, 34% white,
and 16% other ethnicities. Primary outcome data was available for
319/324 (98%) participants. Intervention by specialist nurse
increased time to reattendance with an exacerbation (hazard ratio
1.17 (1.01–1.36) p<0.05) and percentage of participants not attend-
ing with exacerbations (p=0.056). Time to re-attendance was
increased for white participants (1.33 (1.08–1.56) p=0.006) but not
south Asians (1.18 (0.96–1.45) p=0.12).
Conclusions: Asthma liaison nurse intervention reduced unsched-
uled care in a deprived multiethnic population; white participants ben-
efited but south Asians did not. Interventions are needed that improve
asthma morbidity in non-white people with asthma.
Funded by the National Asthma Campaign.
P83 DEVELOPMENT OF CENTRALISED ASTHMA NURSE
SPECIALIST FOLLOW UP SERVICE FOR PATIENTS WHO
ATTEND OUT OF HOURS FOR ASTHMA
C. Calder, M. Reilly, L.M.Osman, A. Douglas, J.G. Douglas. Chest Clinic,
Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK
Background: Local audit of patients attending out of hours (OOH) for
asthma highlighted gaps in follow up in primary care. One possible
solution was asthma nurse specialists (ANSPs) based in OOH centre,
providing a centralised service for reviewing these patients.
Aim: Improvement in primary care management of patients attend-
ing OOHS for asthma.
Design: Twenty four practices in two Local Health Care Coopera-
tives matched by size and deprivation category were randomised to
12 practices whose patients would participate in ANSP service and
12 practices whose asthma care remained the same. Patients, aged
5–60, were recruited over 14 months.
Method: Two part time ANSPs with advanced asthma qualifica-
tions were employed. Patients were identified from OOH’s
cooperative and Accident & Emergency daily. The Intervention group
was sent a flyer followed by an asthma assessment telephone call by
the nurses offering an appointment for a review at the Primary
Resource Centre or at one rural practice between 09:00 to 18:00. A
letter of invitation was sent if no telephone or if unable to contact. Prior
to review and telephone call the nurses read primary care notes and
repeat asthma prescriptions for each patient. The review, taking
approximately 45–60 minutes, included asthma education, medi-
cation advice, and self management plans. Following review and or
telephone call a summary liaison form was sent to the GP.
Results: Telephone assessment 177/237 (77%), contact time was
median 9 (2–29) days. Attended review 62/237 (26%), contact time
was median 18 (8–72) days. Refused review 81/237 (34%), 48
(20%) because had hospital/GP review already. Thirty eight out of
237 (16%) defaulted review appointment. Unable to contact 56
(24%) patients. Nurse management recommendations advised for
46/62 (74%) of those reviewed, of which 16 (35%) recommenda-
tions were acted on in the practice.
Conclusion: There was a poor response from patients to
centralised review. This type of service may not be appropriate for
OOH’s attenders
P84 WHAT TREATMENT FACTORS INFLUENCE
READMISSION AFTER A HOSPITAL ADMISSION FOR
ACUTE ASTHMA?
W. Rea, G. Perkins, A. Abhyankar, D.R. Thickett. Queen Elizabeth Hospi-
tal, Birmingham B15 2TH, UK
The most severe forms of asthma attack are the life threatening forms
which result in hospitalisation. Once patients have been stabilised as
an inpatient, the clinician is faced with the question of what to do with
the inhaled therapy of patients admitted with acute exacerbations of
asthma? The purpose of this study was to see if discharge medication
influenced subsequent readmission rate.
Methods: All patients with a coding diagnosis of asthma were
traced through hospital computer system. In 2000 there were 357
patients so labelled. Audit was carried out on 100 patients’ notes.
Patients with a greater than 20 pack year smoking history or a diag-
nosis of COPD anywhere in the notes were excluded unless asthma
had been diagnosed by a consultant chest physician. Subsequent to
the case note audit, the patients were sent a short questionnaire at the
end of 2001, inquiring about admissions to hospitals other than QEH.
Steroid use and casualty attendance. Questionnaire letters have been
received back from 54 out of 100.
Results: The BTS asthma step of the admitted patients correlated
well with the risk of subsequent readmission (r2= 0.89, p=0.01).
Patients with step 0 or step 1 asthma treatment had a low asthma
readmission rate in the subsequent year (6%). Overall readmission
rate was 41% in the year following discharge. Of those readmissions,
25% were to a different trust. Treatment by a respiratory specialist did
not decrease the rate of readmission but did result in slightly longer
hospital stays (1.2 days p=0.05 Mann Whitney U test).
Median dose of inhaled corticosteroid dose was 400 µg BDP upon
admission and 800 µg equivalent upon discharge (p=0.009). There
was no difference in the median steroid dose of patients admitted sub-
sequently (805 µg) compared to those who were not admitted
(800 µg, p=0.9). The time to first readmission after the index
admission in 2000 was significantly longer in patients treated with
long acting β agonists (105 days) compared to the group untreated
Poster presentations iii71
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
with LAB (27.5 days, p=0.02 Mann Whitney U test). Of patients dis-
charged from hospital, 38% have subsequently been prescribed a
long acting β agonist.
Conclusions: The level of treatment received by patients seems to
reflect their risk of hospitalisation in this cohort. Readmission rates are
high and admission to more than one hospital is common in Birming-
ham. Specialist care has little effect upon crude readmission rates. The
routine use of LAB following hospital discharge needs evaluating in a
clinical trial.
P85 PSYCHIATRIC MORBIDITY IN DIFFICULT ASTHMA
E. Conway1, C. Kelly1, J. Gamble3, L. Heaney2 3. Departments of 1Mental
Health; 2Medicine, Queen’s University Belfast; 3Regional Respiratory
Centre, Belfast City Hospital Belfast BT9 7BL, UK
Introduction: Near fatal/fatal asthma are associated with psychiatric
morbidity (PM). Studies have demonstrated PM in asthmatics of vary-
ing severity using questionnaire screening tools, but it is unclear how
this relates to ICD10 psychiatric diagnosis (gold standard). The aim of
this study was to: (1) examine psychiatrist diagnosed morbidity in a
population of difficult asthmatics (persisting symptoms/frequent exac-
erbations despite high dose inhaled steroids/long acting β agonist,
and (2) relate ICD10 diagnosis to response to the Hospital Anxiety
Depression Questionnaire (HAD), a commonly used screening tool,
with defined normal values.
Methods: Sequential new referrals to a difficult asthma clinic com-
pleted HAD questionnaire and were invited to attend for psychiatric
interview as part of a systematic evaluation protocol. Psychiatric inter-
view was performed, by an experienced medical liaison psychiatrist,
blinded to all clinical information. After interview, an ICD10 diagno-
sis was recorded and treatment instituted as appropriate.
Results: Seventy eight patients were recruited (seven refused
psychiatric assessment but were otherwise protocol compliant, five
were non-compliant with the protocol). Of the remaining 66 subjects,
33 (50%) had an ICD10 psychiatric diagnosis; only seven (10%) were
receiving current treatment. Depressive illness (F32) was common (20
(30%)) followed by generalised anxiety disorder (F41) (5 (8%)) plus a
variety of other conditions. Anxiety (13.1 (0.82) v 8.5 (0.7)) and
depression (10.1 (0.71) v 4.8 (0.47)) scores were significantly higher
in subjects with an ICD10 diagnosis (p<0.001). The positive (PPV)
and negative predictive value (NPV) for abnormal HADS scores for all
psychiatric diagnoses were 60% and 86% respectively and for
depressive illness, PPV 76%, NPV 96%.
Conclusion: There is a high prevalence of psychiatric morbidity,
particularly depression, in difficult asthmatics, based on psychiatric
interview, most undiagnosed at referral. HADS score has poor overall
positive predictive value for psychiatric illness but normal depression
score virtually excludes the commonest condition, depressive illness.
We are currently examining the predictive role of undiagnosed
psychiatric disorder in asthma outcome and optimal screening instru-
ments in this population
P86 PSYCHOSOCIAL FACTORS IN ADULTS AT RISK OF
ADVERSE ASTHMA OUTCOMES: RELATIONSHIPS WITH
SYMPTOM CONTROL AND QUALITY OF LIFE
J.R. Smith1, M. Koutantji1, S. Mildenhall2, B.D.W. Harrison2, M. Noble3.
1University Of East Anglia; 2Norfolk & Norwich University Hospital; 3Acle
Medical Centre, UK
Background: Despite effective treatments, a proportion of asthmatics
suffer from poorly controlled disease and consequent reduced quality
of life (QoL), hospital admissions, near fatal, and fatal asthma attacks.
This study assesses psychosocial characteristics of adults at risk of such
adverse asthma outcomes and examines relationships with symptom
control and QoL.
Methods: Ninety two adults with severe asthma (on BTS Step 4/5
treatment and/or with previous admissions for asthma) who exhibited
poor compliance (failure to attend clinics or comply with asthma man-
agement in other ways) were recruited via hospitals and GP practices
in Norfolk and Suffolk. Cross-sectional socio-demographic/socio-
economic data and self report measures of symptom control, QoL,
psychiatric morbidity, perceived control over asthma, coping, and
aspects of self management were collected via interviews in patients’
homes.
Results: In common with those experiencing fatal and near fatal
asthma, these patients represent a socioeconomically disadvantaged
group (for example, 60% not working, 63% receiving free
prescriptions) with reduced QoL (mean 1.17 on a 0 (very good) to 2
(very poor) scale), high levels of psychiatric morbidity (for example,
36% experiencing moderate-severe anxiety, 33% reaching cut off for
psychiatric caseness), and inadequate self management (for example,
82% not monitoring asthma, 39% smoking, 61% owning pets). High
psychiatric morbidity, low perceived control over asthma and various
indicators of low socioeconomic status were significantly correlated
with poor symptom control and reduced QoL (all p<0.001). Being
overweight, use of coping strategies which involve focussing on
asthma (both p<0.05) or hiding asthma and, interestingly, high com-
pliance (both p<0.001) were also associated with poorer asthma
related QoL.
Conclusions: Various mechanisms may explain associations
between psychosocial characteristics, symptom control, and QoL in at
risk asthmatics and the direction of relationships is likely to be two
way. Further psychological research to improve understanding in this
area and an intervention study which attempts to address
psychosocial issues in improving outcomes for at risk asthmatics are
underway.
P87 RELATIONSHIP BETWEEN AIRWAY OBSTRUCTION AND
SYMPTOM CONTROL IN PATIENTS WITH DIFFICULT
ASTHMA
S. Aburuz1, J. McElnay 1, J. Millership1, J. Gamble 3, L. Heaney2.3. 1School
of Pharmacy; 2Department of Medicine, Queen’s University Belfast;
3Regional Respiratory Centre, Belfast City Hospital, Belfast
Introduction: Several studies have demonstrated a poor relationship
between symptom control and airways obstruction in patients with
asthma. We examined this relationship in a population of difficult
asthmatics (persisting asthma symptoms/frequent exacerbations
requiring systemic steroids despite maintenance high dose inhaled
corticosteroids (ICS) and a long acting β2 agonist) attending a hospi-
tal outpatient clinic.
Methods: FEV1% and asthma control scores (ACSs) (Juniper et al.
2001) were measured at the first clinic visit and at a follow up visit
after a variable period of evaluation and treatment (9 (6.2) months).
Results: Fifty seven patients (37 females; median age 40 years;
range 19–72 years; median ICS dose at presentation 2000 µg; range
1000–6400 µg BDP equivalent; median rescue steroid courses 12
months pre-referral = 5). Patients had poor control at the initial visit
(mean ACS 4.1 (1.3); FEV1% 66.3 (22.7)). At the initial visit, FEV1%
was correlated with limitation of activity (p=0.003), shortness of
breath (p=0.018), wheezing (p=0.025) and ACS (p=0.018). FEV1%
was significantly improved at the follow up visit (75.3 (22.6),
p<0.0001) with an associated improvement in ACS (2.8 (1.3),
p<0.0001). However, at the follow up, there was no correlation
between FEV1% and any measured index of asthma control. At the ini-
tial visit, 25 patients had severe obstruction (FEV1% < 60%) and had
significantly poorer ACSs (mean 4.6 v 3.7, p=0.003). At the follow
up, 15 patients had FEV1% < 60% but no difference in ACSs (2.7 v
2.8, p=0.9). Best FEV1% was significantly less in this latter group (62
(21) v 96% (16%), p<0.0001) consistent with fixed airflow
obstruction. When this group was excluded, FEV1% at follow up, was
significantly correlated with night waking (p=0.02), wheezing
(p=0.05), and ACS (p=0.036).
Conclusion: FEV1% correlates well with asthma symptoms in diffi-
cult asthma patients with poor control but not when control improves.
This loss of relationship is due to subjects with fixed airflow obstruction
where good subjective control does not exclude the presence of
significant obstruction.
1. Juniper E, et al. Resp Med 2001;95:319–23.
P88 UTILITY OF HISTORY IN THE DIAGNOSIS OF CHRONIC
COUGH
J.C. Ojoo, S.A. Mulrennan, J.A. Kastelik, R. Thompson, A.E. Redington,
A.H. Morice. Academic Department of Medicine, University of Hull, Castle
Hill Hospital Cottingham, UK
Background: Patients referred to specialist cough clinics often have a
history of prolonged period of cough, multiple investigations, and
unsuccessful trials of therapy. It may be that symptoms in these patients
are atypical making diagnosis of underlying condition difficult.
Aim: To determine presenting symptoms of patients with chronic
cough in relation to their diagnosis.
Methods: In a prospective study based on a therapeutic rather than
investigative protocol, consecutive patients with a history of cough for
over eight weeks referred to the Hull Cough Clinic were enrolled.
iii72 Poster presentations
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
Assessment was by structured history, physical examination, chest
radiograph, spirometry, and reversibility to nebulised salbutamol.
From this information a diagnosis was made and patient had an eight
week therapeutic trial. Further therapeutic trials were carried out
depending on response to treatment and the likely diagnoses. Investi-
gations were carried out in cases of failed therapeutic trials and to
exclude specific pathology (in this study lung cancer, localised
bronchiectasis and interstitial lung disease).
Results: One hundred and eleven (73 female) patients mean (SD)
age 56 yr (12.8) were recruited. Main initial diagnoses were gastro-
oesophageal reflux disease (GER) 52 (46.9%), asthma 23 (20.7%),
and rhinitis 19 (17.1%). Sixty three patients have had at least two
clinic visits. Of those discharged so far, median (range) duration of
cough was 8.2 yr (0.25 to 64) and mean duration of follow up was
14 weeks (2.4 clinic visits). Twenty four out of 63 (38%) patients were
discharged at the second and 10/23 (43%) at their third visit. The
main underlying diagnoses at discharge were GER (25.7%), asthma
(22.9%), and rhinitis (11.4%). Twenty per cent required investigations
to arrive at the diagnosis and exclude other pathology, the rest were
managed successfully on the therapeutic protocol. Symptoms
associated with diagnosis of asthma were dyspnoea (p=0.007),
wheeze (p=0.04) and choking (p=0.03), GER were heartburn
(p=0.01) and sour taste in the mouth (p=0.06) and for rhinitis were
postnasal drip (p=0.05) and breathlessness (0.03).
Conclusion: In patients in whom we have made a diagnosis and
are satisfied with treatment, the presenting complex of symptoms is
indicative of the underlying cause of their cough. This finding
highlights the importance of the history taking in the assessment of
patients with chronic cough.
P89 FACTORS ASSOCIATED WITH POST
BRONCHODILATOR FEV1 IN ADULTS WITH ASTHMA
M.A. Berry, R.H. Green, A.J. Wardlaw, I.D. Pavord. Glenfield Hospital,
Groby Road, Leicester, LE3 9QP, UK
Fixed airflow obstruction occurs in a minority of asthmatic patients but
is a predictor of overall mortality. Smoking has been identified as a
factor associated with airflow limitation in asthma but evidence impli-
cating other factors has been conflicting. In one study ten Brinke et al
(Am J Respir Crit Care Med 2001;164:744–8) identified elevated
induced sputum eosinophil count as an independant risk factor for
persistent airflow limitation in a homogeneous population of severe
asthmatics. We have investigated factors associated with the post
bronchodilator FEV1 in a heterogeneous population of 249 adults with
a clinical diagnosis of asthma of variable severity and evidence of air-
flow variability and/or airway hyper-responsiveness. Patients had
either never smoked or were ex-smokers with less than five pack years
smoking history. Patients underwent methacholine challenge testing,
pre and post bronchodilator spirometry, skin, and radioallergosorbent
testing to commonly encountered aeroallergens and induced sputum
analysis. Multiple independent linear regression analysis was used to
identify any independent predictors of post bronchodilator FEV1% of
predicted. Duration of symptoms, atopy, dose of methacholine
required to cause a 20% fall in FEV1 (PC20), induced sputum eosinophil
count and induced sputum neutrophil count were not significant inde-
pendent predictors of post bronchodilator FEV1 (r2 = 0.060,
p=0.162). Patients with post bronchodilator FEV1 of less than 80%
predicted had significantly higher induced sputum eosinophil counts
(geometric mean 3.95%) than those with FEV1 above 80% predicted
(geometric mean 1.88%, mean fold difference 2.10, 95% confidence
interval 1.19 to 3.72, p=0.011). Measures of current airway inflam-
mation and responsiveness do not independently predict persistent
airflow limitation, as measured by post bronchodilator FEV1%
predicted in a heterogeneous population of non-smoking adult
asthmatics. Although sputum eosinophil counts are higher in patients
with persistent airflow limitation, sputum eosinophilia is not predictive
of airflow limitation and cannot be implicated as causative.
P90 EMITS: IMPACT OF A CHANGE IN TRANSPORT POLICY
ON RESPIRATORY HEALTH IN OXFORD
S.J. MacNeill1, M. Barnes1, R. Pitman2, P. Cullinan1. 1Occupational & Envi-
ronmental Medicine, Faculty of Medicine, Imperial College of Science,
Technology and Medicine, 1b Manresa Rd, London SW3 6LR, UK; 2Com-
munity Services, Oxford City Council, Ramsay House, 10 St Ebbe’s St,
Oxford OX1 1PT, UK
EMITS (Environmental Monitoring of an Integrated Transport Strategy)
was established to examine the effects of a change in transport policy
on public health as well as on other aspects of life in Oxford. The
Oxford Transport Strategy (OTS) was implemented in June 1999 and
involved many changes, focused primarily on the city center where all
traffic was barred from some streets and private vehicles from others.
Between 1998 and 2000, 1386 children aged 6 to 10 were
recruited from seven Oxford schools. Schools were visited two to three
times a year in different seasons for five day periods. On each day of
each visit, research nurses measured the childrens’ peak expiratory
flow and distributed questionnaires enquiring about respiratory symp-
toms on the previous day. Parents were also sent questionnaires
enquiring about the medical history of the child and the presence of
pollutants and irritants in the home. Regression analyses of daily peak
flows among all children showed that lung function improved
significantly by 5.87 units (std err= 0.71, p<0.001) post-OTS after
controlling for potential confounders. Similarly, the odds of wheeze
decreased post-OTS (OR=0.84, 95% CI 0.77 to 0.92).
While it is not clear at this stage that these improvements can be
attributed solely to the transport strategy, they suggest that traffic man-
agement can result in valuable improvements in public health.
P91 HARIG: ASTHMA CARE IN THE HUNTINGDON PCT
2002
D. Lightfood, J. McAllister, for the HARIG Group. Hinchingbrooke NHS
Trust, Huntingdon; Huntingdon PCT, UK
Introduction: Asthma has considerable impact in terms of morbidity
and health care costs. The ACE(1) survey suggests that over 30% of
patients who report feeling well to their health professional suffer daily
asthma symptoms.The HARIG study set out to raise asthma awareness
within the Huntingdon PCT and use the results to develop a strategy for
asthma care.
Method: A shortened version of the “Impact of asthma”
questionnaire was used for the study. This was freely distributed in all
GP surgeries and given to patients who attended to request repeat
scripts and for review. A freepost address was supplied for return of
questionnaires.
Results: PCT population was estimated at 147 000 patients. 493
responses received, with asthma prevalence estimated at 5%, returns
approximately 6.7% of asthma population. Female:male split was
60%:40%. Average duration of asthma was >5 years, with a
predominance of sufferers in the 18–65 year age group. Thirty seven
per cent of patients reported daily asthma symptoms, with this figure
higher than 50% in some GP practices. More than 30% of patients
experienced significant night time waking. There was considerable
variance in use of reliever medication with 32% of patients reporting
use at least once per day but this figure was as high as 67% in one
practice. 45% of respondents reported that asthma has at least a mod-
erate effect on their lives, but this did not always correlate with the
reporting of other symptoms.
Conclusion and discussion: Amongst the HARIG questionnaire
respondents there is considerable unmet need for asthma symptom
control. The results broadly mirror those of the ACE survey with around
one third of respondents suffering continued symptoms. There may
however have been some selection bias in those who responded to the
survey and the results may not be a representative sample of the whole
PCT population. Within the Huntingdon PCT there may be further
opportunity for standardisation of care and sharing of good practice
between GP surgeries.
This project has been supported with a project grant from
GlaxoSmithKline Pharmaceuticals PLC.
1. Jones KG et al. Int J Clin Pract 2002;56:89–93.
P92 IMPULSE OSCILLOMETRY IN SUBJECTS WITH SEVERE
ASTHMA
W. Anees, S. Manney, J. Mukhopadhyay, D. Petkova, J.G. Ayres. Severe
and Brittle Asthma Unit, Birmingham Heartlands Hospital, Birmingham
B9 5SS, UK
Introduction: Many subjects with severe asthma describe a worsen-
ing of symptoms on lying flat. This is felt to be due to an increase in
vagal tone.
Aims: (1) To describe airway resistance and capacitative
reactance measurements as assessed by impulse oscillometry (IOS) in
subjects with severe asthma and to relate them to spirometric param-
eters. (2) To see whether IOS parameters are affected by posture. (3)
To determine whether IOS could identify subjects who clinically had
vocal cord dysfunction.
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Methods: Forty one subjects with severe asthma attending a
tertiary referral centre underwent spirometry and IOS whilst sitting
using an MS-IOS digital instrument (Jaeger AG). IOS was repeated on
lying flat. Subjects were clinically assessed (by JGA) as to whether
they had a significant component of vocal cord dysfunction.
Results: Eighty per cent were female, mean age 43.6 years with
an FEV1 69.5% predicted. Mean total airway resistance (R5) was
increased at 203% predicted with 73% of subjects having abnormally
high values (>150% predicted). Proximal airway resistance (R20) was
a mean of 141% predicted being >150% predicted in 32%. An
increase in R20 occurred on lying down (p=0.03) with a fall in distal
capacitative reactance (X5) (p=0.05) for the group as a whole.
Although total airway resistance (R5) did not increase significantly
(p=0.18), increases in R5 on lying down did correlate with body mass
index (r=0.47, p=0.003). R5 was inversely correlated with FEV1 and
peak expiratory flow (r=−0.42) but R20 did not. X5 also correlated
with FEV1 (r=0.52). IOS parameters or change in IOS parameters
could not identify subjects who clinically had vocal cord dysfunction.
Conclusion: Increased airway resistance using IOS was demon-
strated in some patients with severe asthma and increased
significantly on lying down, possibly due to an increase in vagal tone.
It was not helpful for identifying subjects thought to have vocal cord
dysfunction.
Pulmonary vascular
biology/pulmonary
hypertension
P93 THE EFFECTS OF ACUTE HYPOXIA ON PROLIFERATION
AND p38 MAP KINASE ACTIVITY IN HUMAN FIBROBLASTS
FROM THE PULMONARY AND SYSTEMIC CIRCULATIONS
H. Mortimer, A. Peacock, P. Scott1, D. Welsh. Scottish Pulmonary Vascular
Unit, Western Infirmary; 1Institute Biomedical and Life Sciences, University
of Glasgow, UK
Introduction: We have previously shown that proliferation and p38
MAP kinase phosphorylation in pulmonary artery fibroblasts is
increased by hypoxia in animal models (Welsh, et al. Am J Resp Crit
Care Med 1998 and 2001). We now wish to know whether this is
true in man. In this study, we have examined the effect of acute
hypoxia on human pulmonary and mammary artery (systemic)
fibroblast proliferation and p38 MAP kinase activity.
Methods: Fibroblasts were harvested from human pulmonary
artery (HPAF) and mammary artery (HMF) obtained from cardiotho-
racic surgery and utilised between passages 3–10. Cells were
quiesced for 24 hours then stimulated by acute hypoxia for 24 hours
(PO2=20 mmHg) with or without 0, 0.1, 1, 3, 5, and 10% serum.
Fibroblast proliferation was measured by [3H]thymidine uptake and
p38 MAP kinase activity was measured by Western Blotting analysis.
Results: [3H]Thymidine incorporation was increased by acute
hypoxia (p<0.01) in the HPAF cells, but not in the HMF cells. Acute
hypoxia also gave rise to p38 MAP kinase activation in the HPAF cells
and to a lesser extent in the HMF cells (results not shown).
Conclusion: Acute hypoxia stimulated the proliferation of HPAF
cells but not HMF cells. The increase in p38 MAP kinase activity to
hypoxia may suggest a role in the regulation of cell cycle associated
events. These results are consistent with our animal findings showing
that these effects transcend species and may be important in man.
Chest, Heart and Stroke (Scotland) and British Heart Foundation.
P94 ERYTHROCYTE SUPEROXIDE DISMUTASE ACTIVITY IN
INFANTS WITH PERSISTENT PULMONARY
HYPERTENSION AND CONGENITAL DIAPHRAGMATIC
HERNIA
G.M. Walker, K.F. Kasem, C.F. Davis, M.R. Maclean. University of
Glasgow, Glasgow, UK
Introduction: The antioxidant enzyme system is the primary
intracellular defence system of the lung against oxygen toxicity.
Endogenous SOD is the major mammalian antioxidant enzyme and
catalyses the dismutation of superoxide anion to hydrogen peroxide.
Reduced SOD activity has been demonstrated in animal models of
Congenital Diaphragmatic Hernia (CDH)1 and in post mortem
specimens from infants with persistent pulmonary hypertension of the
newborn (PPHN).2 Erythrocyte SOD activity from live infants with these
disorders has not been reported.
Methods: Blood was sampled from seven infants with PPHN and
five with CDH. All were near term and mechanically ventilated.
Following centrifugation and plasma removal, erythrocytes were
stored at −20°C until analysis. SOD activity was calculated
spectrophotometrically using the auto-oxidation of pyrogallol.3
Haemoglobin concentration was calculated using a standard
Drabkin’s reagent. Differences in median values were calculated using
the Mann-Whitney test.
Results: Median erythrocyte SOD activity of infants with PPHN was
1374.15 µ/g Hb (range 1114 to 1791). Erythrocyte SOD activity of
infants with CDH was significantly lower (median = 1213.5, range
1016 to 1490.5, p=0.01).
Conclusion: Infants with CDH have lower erythrocyte SOD activity
compared to similarly ventilated patients. This gives further evidence
to explain the clinical fragility and poor response to inhaled nitric
oxide seen in CDH.
1. Kapur P, et al. J Pediatr Surg 1999;34:354–6.
2. Asikainen TM, et al. Pediatr Pulmonol 2001;32:193–200.
3. Marklund S, et al. Eur J Biochem 1974;47:411–15.
P95 SUPEROXIDE AND SUPEROXIDE DISMUTASE IN
PULMONARY HYPOXIC VASOCONSTRICTION
P.H. Milliken, R.M. Wadsworth. University of Strathclyde, UK
Superoxide is known to cause vascular damage and can consume
protective NO that maintains a low pulmonary pressure. There is evi-
dence suggesting that hypoxia upregulates NADH/NADPH oxidase
and xanthine oxidase in the smooth muscle and endothelial cells of the
pulmonary artery, increasing superoxide production. Superoxide dis-
mutase (SOD) is widely distributed in the cells of the vasculature,
destroying superoxide, however, the role of SOD in hypoxic vasocon-
striction is unknown.1 Therefore, the effect of endogenous SOD inhibi-
tion and superoxide generation on hypoxic pulmonary
vasoconstriction was investigated.
Male Sprague-Dawley rats were anaesthetised and the trachea and
pulmonary artery cannulated. The lungs were ventilated with 20% O2
(normoxia), and perfused with 30 ml of modified Krebs solution.
U46619 give preconstriction before a 10min hypoxic challenge
(5%CO2, 95% N2). The lungs were then returned to normoxia for
10 mins before changing the perfusate to one containing either 1mM
DETCA (high affinity Cu2+ chelator that inhibits endogenous SOD) or
10 µM LY83583 (superoxide generator). The lungs were allowed to
equilibrate for 30 mins, before repeating the hypoxic and normoxic
challenges. The NO donor SNAP (1.7x10-8 – 1.7x10-5 moles) was
used after hypoxia in the LY83583 experiments.
Hypoxia induced a sustained monophasic increase in pulmonary
pressure, that was reproducible (1.8 (0.2) mmHg 1st challenge and
1.7 (0.3) mmHg 2nd challenge, n=5). LY83583 augmented the
hypoxic vasoconstriction (3.5 (1.0) mmHg, n=7), and attenuated the
SNAP induced vasodilation. These results suggest that superoxide can
support or enhance hypoxic vasoconstriction, perhaps by consuming
endogenous NO. However, there was a significant reduction of
hypoxic vasoconstriction in the presence of DETCA (1.0 (0.3) mmHg,
n=7, p<0.05). Overall, these results suggest that hypoxic vasoconstric-
tion can be modified by endogenous superoxide, however this
interaction may be dependent upon the site of superoxide generation
and the concentration of superoxide, as there is likely to be a greater
amount of superoxide present in the experiments involving LY83583.
PH Milliken is funded by the British Heart Foundation (FS/
2001056).
1. Demiryürek AT, et al. Pharmacol Ther 1999;84:355–65.Abstract P93 (A) HPAF. (B) HMF.
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P96 MICE OVER EXPRESSING THE 5-HT TRANSPORTER: A
NEW MODEL FOR PULMONARY HYPERTENSION?
I. Morecroft, L. Loughlin, J. MacKenzie, A. Harmar1, M.R. Maclean. Insti-
tute of Biomedical and Life Sciences, University of Glasgow, Glasgow,
G12 8QQ; 1Dept Neuroscience, Edinburgh University, Edinburgh,
EH9 9JZ, UK
The 5-hydroxytryptamine transporter (5HTT) may play a key role in
pulmonary vascular remodelling in primary pulmonary arterial hyper-
tension (PAH) and secondary hypoxia-related PAH. Attenuated
hypoxic pulmonary hypertension has been reported in mice lacking
the 5HTT transporter gene and there is 5HTT over-expression in
patients with PAH (Eddahibi et al. J Clin Invest 2000;105:1555–62;
Eddahibi S et al. J Clin Invest 2001;108:1141–50). Here we examine
the development of PAH in mice over expressing the 5HTT gene
(5HTT+ mice) and C57BL/6 × CBA wild type mice (WT) mice (female,
1 year old) exposed to two wks chronic hypoxia. Right ventricular
(RV):total ventricular (TV) ratio was used as an index of pulmonary
hypertension. In WT mice, RV/TV ratio was not altered after two wks
hypoxia (0.205 (0.005) cf. 0.238 (0.012), n=6–7). In 5HTT+ mice,
however, RV/TV ratio was increased (p<0.001, n=7) from 0.194
(0.009) to 0.297 (0.018). The number of remodelled small (<80 µm
i.d.) vessels (assessed histologically) increased (p<0.001, n=6) from
2.61 (0.7%), (control hypoxic) to 7.8 (0.5%) (5HTT+ hypoxic). ET-1,
NA, and 5HT induced contraction was measured using wire myogra-
phy in small pulmonary arteries (∼200 µm i.d.) and were, in WT mice
vessels (pEC50s: 9.8 (0.3) > 9.0 (0.2) > 6.9 (0.2) respectively). NA
constriction was markedly reduced in the 5HTT+ mice and the poten-
cies of ET-1 and 5HT were reduced (pEC50s: 8.4 (0.3) and 5.6 (0.3)
respectively). In the 5HTT+ mice exposed to hypoxia however, there
was a marked restoration of the contractile response to NA (pEC50:
8.6 (0.1)) and an increase in the response to ET-1 and 5HT (pEC50s:
8.6 (0.3) and 6.9 (0.4) respectively). The maximum response to ET-1
was increased by ∼40%. In WT mice lung membranes, the 5HTT lig-
and 3[H]-β-CIT bound with a Bmax of 1.068 (0.022) fmolmg-1 and a KD
of 0.869 (0.054) nM (n=3). Non-specific binding was assessed using
cold fluoxetine. Binding was markedly increased in the 5HTT+ mice,
with a Bmax of 13.32 (0.25) fmolmg-1 and a KD value of 3.745 (0.033)
nM (n=3). The results indicate that PAH is accelerated in 5HTT+ mice
and this is associated with remodelling, increased lung 5HTT and
increased contractile responses to 5HT, ET-1 and restoration of
NA-induced contraction. 5HTT+ mice may provide a novel model of
genetically susceptible PAH.
P97 HUMAN UROTENSIN-II ACTS AS A PULMONARY
VASOCONSTRICTOR IN AN IN VIVO RABBIT MODEL
OF PULMONARY HYPERTENSION SECONDARY TO LEFT
VENTRICULAR DYSFUNCTION
G.A. Deuchar1, M.R. Maclean2, M.N. Hicks1. 1Department of Medical
Cardiology, Glasgow Royal Infirmary; 2Institute of Biomedical and Life Sci-
ences, University of Glasgow , Glasgow G12 8QQ, UK
The recently cloned peptide, human Urotensin-II (hU-II) has been
shown to be the most potent vasoconstrictor identified to date, being
an order of magnitude more potent than endothelin-1. In the
pulmonary circulation, hU-II has been shown to result in a greater
vasoconstrictor effect in isolated main pulmonary arteries from rats
with pulmonary hypertension (PHT) secondary to chronic hypoxia.
However, in isolated human pulmonary arteries, a vasoconstrictor
response to hU-II was only uncovered following nitric oxide synthase
(NOS) inhibition (MacLean, et al. Br J Pharmacol 2000;130:201–4).
Here we investigated the pulmonary and systemic effects of hU-II alone
and in the presence of the NOS inhibitor L-NAME in a previously
described in vivo rabbit model of PHT secondary to LVD (Deuchar, et
al. Cardiovasc Res 1998;38:500–7). Briefly, eight weeks following
coronary artery ligation or sham operation, ejection fraction (EF) was
assessed using echocardiography and experiments were carried out
in closed chest anaesthetised rabbits. Pulmonary arterial pressure
(PAP) and systemic aortic pressure (AOP) were measured directly
before and after cumulative administration of hU-II (0.001–5.0
nmoles.kg-1) either alone or following the infusion of L-NAME (30
µmoles.min-1). Coronary ligated rabbits had reduced EF (45.2 (1.0%)
v 73.0 (0.9%), p<0.001), elevated basal PAP (16.8 (0.4) mmHg v
13.6 (0.2) mmHg, p<0.001) and evidence of right ventricular hyper-
trophy as measured by right ventricular/final body weight ratio (0.69
(0.03) g/kg v 0.48 (0.01) g/kg final body weight, p<0.001). A small
significant pulmonary pressor effect was demonstrated to hU-II alone,
with the maximum response being greater in rabbits with PHT (2.6
(0.5) mmHg, n=8, v 1.0 (0.3) mmHg in controls, n=8, p<0.05). Fol-
lowing NOS inhibition, there was a trend towards the maximum pul-
monary pressor effect being increased in both groups (8.5 (2.6)
mmHg, n=12, and 4.8 (1.5) mmHg, n=13, in rabbits with PHT and
controls respectively). In contrast, it was shown that hU-II had no effect
on systemic AOP in any of the experimental groups. In conclusion,
hU-II appears to act as a selective pulmonary vasoconstrictor with no
effect on AOP.
P98 THE PROSTACYCLIN ANALOGUE CICAPROST,
INDUCES HETEROLOGOUS DESENSITISATION IN
PULMONARY ARTERY SMOOTH MUSCLE CELLS VIA
PROTEIN KINASE A DEPENDENT INHIBITION OF
ADENYLYL CYCLASE
A. Sobolewski, K.B. Jourdan, P.D. Upton, N.W. Morrell. Department of
Respiratory Medicine, University of Cambridge, Addenbrooke’s and Pap-
worth Hospitals, Cambridge, CB2 2QQ, UK
Prostacyclin is the major arachidonic metabolite produced in vascular
cells and is a powerful vasodilator of the pulmonary vasculature. Long
term infusion of prostacyclin analogues is an effective treatment for
primary and secondary pulmonary hypertension, but due to desensiti-
sation of the agonist response, increased doses are required to main-
tain efficacy. The aim of this study was to investigate the mechanisms
of prostacyclin desesnsitisation using the prostacyclin analogue
cicaprost in rat pulmonary artery smooth muscle cells (PASMC).
PASMC were isolated from precapillary pulmonary arteries of WKY.
For timecourse studies confluent, serum-starved PASMC, were
pre-incubated with cicaprost (63nM, for 15min to 12h), washed and
stimulated with cicaprost (63nM, 15 min). In further studies other con-
ventional Gsα-adenylyl cyclase coupled agonists (ISO, 1µM),
adrenomedullin (ADM, 100nM), bradykinin (BRAD, 1µM) forskolin
(FSK, 3µM) were added to PASMC pre-incubated with cicaprost
(63nM, 6h). For resensitisation experiments cicaprost pre-incubated
PASMC (63nM, 3h) were placed in serum-free media for 3 to 24 h
prior to cicaprost addition (63nM, 15 min). For inhibitor studies a one
hour pre-incubation with the PKA inhibitor, H89 (1µM) or the PKC
inhibitor, bisindolylmaleimide (BIS, 100nM) was introduced prior to
cicaprost pre-incubation (6h, 63nM). Experiments were terminated
with 0.1M HCl and assayed for cAMP activity using an ELISA kit.
Desensitisation of the cAMP response occurred after 6 hours
pre-incubation with cicaprost (n=3, p<0.05). Desensitisation also
occurred with ISO, BRAD, ADM in addition to FSK (n=3, p<0.05). The
desensitisation effect was reversible, with cAMP returning to control
levels 12 hours after removal of the agonist (n=3, p<0.05). PKA inhi-
bition abrogated cicaprost desensitisation (80 (5%)), whereas the PKC
inhibition reversed the effect to a lesser extent (59 (3%)). In conclusion,
chronic treatment of PASMC with cicaprost, induced heterologous,
reversible desensitisation by inhibition of adenylyl cyclase activity.
Our data suggest that the desensitisation by cicaprost is mediated pre-
dominantly by PKA, and to a lesser extent, PKC inhibitable isoforms of
adenylyl cyclase.
P99 BONE MORPHOGENETIC PROTEIN-4 INHIBITS HUMAN
LUNG FIBROBLAST PROLIFERATION VIA EFFECTS ON
CELL CYCLE REGULATORS
T.K. Jeffery, P.D. Upton, R.C. Trembath1, N.W. Morrell. Respiratory Medi-
cine Unit, Department of Medicine, University of Cambridge, School of
Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK; 1Division of
Medical Genetics, University of Leicester, Leicester, UK
Introduction: Mutations in the bone morphogenetic protein type II
receptor (BMPR2) have been identified in patients with primary pulmo-
nary hypertension. Given that BMPR2 mutations may inhibit
BMP-effects on cell proliferation we examined the effect of BMP-4 on
the cell cycle and signal transduction via Smad-1 and p38MAPK
pathways in human lung fibroblasts. Since this is the first time that pul-
monary fibroblasts have been used to examine BMP-4 responses we
also characterised BMPR2 receptor expression, ligand binding, and
the effect of BMP-4 on fibroblast growth.
Methods: Human fetal lung fibroblasts (HFL-1) were used. BMPR2
expression was determined using RT-PCR. Ligand binding studies were
carried out by constructing competition curves for 125I-BMP4 against
BMPs 2, 4, and 7, and TGFβ1. To determine the effect of BMP-4 on
the cell cycle, propidium iodide stained cells were analysed utilising a
fluoresence activated cell sorter (FACS). Western analysis using anti-
bodies directed towards phospho-p38MAPK, phospho-Smad-1 and the
cell cycle proteins, p21, p27, cyclin D, and cyclin dependent kinase-2
(cdk2) was performed.
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Results: BMPR2 mRNA was expressed in HFLs and binding experi-
ments demonstrated that BMP-2 and BMP-4 competed equipotently for
125I-BMP-4 binding, BMP-7 was weakly competitive and TGFβ did not
compete. BMP-4 dose-dependently (1–100 ng/ml) inhibited 3H-
thymidine incorporation as well as proliferation of HFLs. FACS analy-
sis demonstrated that BMP-4 (50 ng/ml) inhibited cells from exiting the
G0/G1 phase of the cell cycle. BMP-4 up regulated the expression of
inhibitors of the G0/G1 phase of the cell cycle, p21, and p27, with a
corresponding down regulation in expression of the positive
regulators, cyclin D and cdk2. Phospho-Smad-1 and phospho-p38MAPK
were rapidly induced in response to BMP-4.
Conclusion: BMP-4 leads to cell cycle arrest in HFL-1 cells via
induction of p21/p27 and inhibition of cyclin D/cdk2. The relative
contribution of p38MAPK and Smad-1 on BMP-4 induced cell cycle arrest
remains to be determined.
Funded by: British Heart Foundation and NHMRC of Australia (TK
Jeffery).
P100 THE RESPONSE OF FIBROTIC AND NON-FIBROTIC
PATIENTS WITH SCLERODERMA ASSOCIATED
PULMONARY ARTEIAL HYPERTENSION (SScPAH) TO
CONTINUOUS AMBULATORY ILOPROST THERAPY: IS
A SIMILAR THERAPEUTIC APPROACH JUSTIFIED?
D. Mukerjee, B. Coleiro, C. Elliott, C. Knight, C.M. Black, J.G. Coghlan.
Departments of Rheumatology and Cardiology, Royal Free Hospital, Pond
Street, London NW3 2QG, UK
Background: It is now accepted that patients with non-fibrotic
SScPAH respond to epoprostenol therapy in a similar fashion to
Primary Pulmonary Hypertension (PPH). We have observed that PHT
underlying SSc-associated fibrosis is not predominantly hypoxia-
driven and postulated that the mechanisms underlying fibrosis/non-
fibrosis-associated PAH in SSc may be similar and thus responsive to
the same therapeutic strategy.
Methods: Forty seven patients were initiated on continuous ambu-
latory iloprost therapy between 1996–2001 as they met the funding
criteria for this therapy. Functional impairment was quantified using
the Six Minute Walk Test (SMWT).
Findings: Forty seven SSc patients (M:F = 7:40) with a mRAP=10
mmHg, mPAP=42 mmHg, mean SVO2=59 %, and mean CI=1.8
were started on ambulatory iloprost. There was no significant
difference in haemodynamic parameters between fibrotics (n=20)/
non-fibrotics (n=27). Initial mean SMWT=175m fibrotics/215m
non-fibrotics, a mean improvement of 29% in the fibrotics (226m) and
36 % in non-fibrotics (291m) at 12 weeks. This change was clinically
significant in both groups: gain of 52 m in fibrotics/ 78m
non-fibrotics. At 24 weeks this benefit was maintained (272m in
fibrotics/321m in non-fibrotics) with a mean gain of 28 metres in both
groups. Six month survival was 81%, with 23 (49%) patients surviving
>1 year of therapy (14 fibrotics/9 non-fibrotics).
Conclusion: In a SSc patient cohort similar in structure in terms of
initial hemodynamic findings, treated with ambulatory iloprost, the
response to therapy in terms of functional benefit is similar in fibrotic
and non-fibrotic patients. This justifies inclusion of SSc patients with
pulmonary fibrosis associated PHT in trials of newer therapies.
P101 ELEVATED PULMONARY: AORTIC RATIO IN PATIENTS
WITH PULMONARY ARTERIAL HYPERTENSION
ASSOCIATED WITH SYSTEMIC SCLEROSIS
F. Guarasci, D. Manuel, M. Akil, C. Davies, D. Fishwick, E.J.R. Van Beek,
D.G. Kiely. Pulmonary Vascular Disease Unit, Dept of Radiology and Dept
of Rheumatology, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK
Pulmonary arterial hypertension (PAH) occurs in approximately 15%
of patients with systemic sclerosis (SS) and is associated with a poor
prognosis. A number of screening regimes using non-invasive
techniques are currently used to identify patients for cardiac catheteri-
sation. We have examined whether the pulmonary:aortic (P:A) ratio
measured using CT may be a useful non-invasive predictor of PAH in
these patients.
Twenty one patients (three male), mean age 60 yrs (range 45–70
yrs) with SS and suspected pulmonary hypertension were studied.
Patients underwent HRCT and CTPA in addition to right heart
catheterisation. CT scans were interpreted by investigators blinded to
the results of the other investigations. The main pulmonary artery and
aortic diameter were measured transversely at the same level and the
ratio calculated.
Of the 21 patients studied, 19 had PAH at rest (MPAP at least
25mmHg). There was a significant correlation between MPAP
measured at RHC and P:A ratio, r=0.50, p=0.02. All 16 patients with
an elevated P:A ratio >1 had PAH. Patients with a P:A ratio >1 com-
pared to patients with a P:A ratio <1 had a significantly greater
MPAP: 43 (13) v 26 (14) mmHg (95% CI 2 to 31mmHg, p=0.02).
Using a P:A ratio of >1 to identify patients with PAH at cardiac cath-
eterisation had a PPV of 1.0 and a NPV of 0.4.
In conclusion, an elevated pulmonary to aortic ratio measured using
CT scanning techniques predicts the presence of PAH in patients with
systemic sclerosis. In these patients undergoing CT scanning of the
thorax an elevated ratio should alert the physician to the possibility of
pulmonary hypertension.
P102 THE HAEMODYNAMIC EFFECTS OF “PULSED”
INHALED NITRIC OXIDE IN PATIENTS WITH
PULMONARY HYPERTENSION
T. Siddons, T.W. Higenbottam, F. Guarasci, I. Armstrong, K. McCormack,
D.G. Kiely. Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital,
Glossop Road, Sheffield, UK
We examined the acute haemodynamic effects of pulsed inhaled nitric
oxide (iNO) in patients with pulmonary hypertension. Patients with
pulmonary arterial hypertension (n=35), chronic thromboembolic pul-
monary hypertension (n=17), and hypoxic lung disease (n=7) were
challenged acutely with pulsed iNO at a dose of 1.6 x 10−7 moles per
breath during right heart catheterisation. The iNO was delivered in
pulses via nasal cannulae using a breath activated device for five min-
utes. Pulsed iNO significantly reduced mean pulmonary artery
pressure (MPAP): 45.0 (14) v 47.2 (13) mm Hg, pulmonary vascular
resistance (PVR): 785 (432) v 878 (456) dynes.s.cm-5, and increased
CO: 4.4 (1.6) v 4.2 (1.5) l/min (p<0.001). There was no significant
change in mean arterial pressure (MAP): 92 (16) v 91 (14) mmHg but
a significant (p<0.05) fall in systemic vascular resistance (SVR): 1696
(560) v 1784 (568) dynes.s.cm-5. We identified four response types
(1) Non responder = reduction in PVR <20%. (2) Pressure response
type = reduction in mPAP and PVR > 20%. (3) Flow response type =
reduction in PVR >20% with a reduction in mPAP <10 % and a clini-
cally significant increase in CO. (4) Resistance response type = reduc-
tion in PVR >20% with reduction in mPAP between 10–20% and a non
clinically significant increase in CO (see table).
Pulsed iNO appears to be an effective acute pulmonary
vasodilator. Further work needs to be performed to examine whether
these response types predict outcome from therapy or mortality.
P103 COMPASSIONATE TREATMENT OF PULMONARY
HYPERTENSION WITH LONG TERM INHALED NITRIC
OXIDE AND ORAL SILDENAFIL (VIAGRA®)
T. Siddons, T.W. Higenbottam, K. Amsha, I. Armstrong, K. McCormack,
D.G. Kiely. Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital,
Glossop Road, Sheffield, UK
Despite recent encouraging reports of trials of analogues of prostacy-
clin and antagonists of the endothelin-1 receptors, many patients with
pulmonary hypertension (PH), still receive no treatment as a result of
the expense and/or difficulty in administering these therapies. We
examined the effects of long term pulsed inhaled nitric oxide (iNO) or
oral sildenafil (Viagra®) in eleven disabled patients with PH associated
with other disease processes and in two patients with primary PH, who
did not receive funding for prostaglandin therapy. Patients were
offered compassionate treatment with either pulsed iNO or sildenafil,
one patient receiving first pulsed iNO then sildenafil after a wash out
period.
Abstract P102
n Response type
MPAP (mmHg) CO (L/min)
PVR
(dynes.s.cm−5)
Base
During
iNO Base
During
iNO Base
During
iNO
36 Non-responder 48.4 48.5 4.3 4.4 11.3 11.1
9 Pressure 43.3 33.7 4.3 4.6 8.8 6.3
8 Flow 49.5 47.8 3.7 4.8 12.3 9.0
6 Resistance 42.8 37.2 3.9 4.2 10.2 7.7
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Sildenafil at doses of 25 to 50 mg three times per day resulted in a
significant improvement in shuttle walking test 274 (189) m v 201
(116) m at baseline (p=0.045). Two patients discontinued therapy
due to deterioration, but six patients continue on sildenafil with a
mean duration of therapy of 16 months (range 4–22). In contrast, all
patients given pulsed iNO for 12 hours overnight deteriorated, with
no patient continuing on therapy for longer than 11 months (mean six
months, range 2–11).
In conclusion, although long term nocturnal therapy with pulsed
iNO appears to be an ineffective treatment for pulmonary
hypertension, sildenafil appears to be an effective and well tolerated
form of therapy in this heterogeneous patient population.
P104 FLOW VELOCITY PROFILES AND HAEMODYNAMICS
IN PULMONARY HYPERTENSION: A PILOT STUDY
T. Saba, J. Foster1, M. Cockburn1, M. Cowan1, A. Peacock. Scottish Pulmo-
nary Vascular Unit; 1Department of Radiology, Western Infirmary,
Glasgow, Scotland
Standard assessment of the pulmonary circulation including mean pul-
monary artery pressure (MPAP), cardiac output (CO), and pulmonary
vascular resistance (PVR) predict prognosis in pulmonary hypertension
(PHT) but do not always predict the severity of exercise intolerance.
We wondered whether flow velocity profiles, which are likely to reflect
the haemodynamic response to exercise, would help to explain the
differences in symptoms between patients with similar resting haemo-
dynamics.
Method: We used cardiac triggered cine MRI to measure mean
velocity (MV) and peak velocity (PV) in the right pulmonary artery in
three subjects with PHT and one normal subject (see table 1) within
two days of cardiac catheterisation and six minute walk testing
(6mwt). Studies were performed at rest (R) and after three minutes of
straight leg raising exercise (EX).
Results: See figures 1 and 2.
Conclusions: Resting pulmonary haemodynamics may not predict
exercise tolerance in PHT. Exercise MRI is feasible in this group of
patients and flow velocity profiles obtained in this way may help to
explain the differences in symptoms between patients with similar pul-
monary haemodynamics.
P105 HAEMODYNAMICS DURING EXERCISE ARE A BETTER
MEASURE OF VASODILATOR RESPONSE IN HUMAN
SUBJECTS WITH PULMONARY HYPERTENSION
R. Syyed, A.J. Peacock. Scottish Pulmonary Vascular Unit, Western
Infirmary, Glasgow, UK
Patients with pulmonary hypertension (PHT) are deemed “non-
responders” (NR) if they show no response to vasodilators at rest. We
therefore decided to investigate the effects of vasodilators on
pulmonary haemodynamics during exercise.
Methods: We investigated four patients, (two female, two male)
with PHT to determine pressure and flow changes over a range of
flows. Flow was changed by straight leg raising. A micromanometer
tipped continuous pulmonary artery pressure (PAP) catheter was
inserted. All four were non-responders to a vasodilator challenge
(defined as a reduction of >20% in pulmonary vascular resistance).
Resting pressure was measured and then three mins of supine
alternate straight leg raising was performed, while the subjects
inhaled air or nitric oxide (NO, 40–80 ppm) and oxygen (O2, 15L
min). Cardiac Output (CO) was measured by non-invasive impedence
cardiography. Subject data was pooled using the method described
by Poon (J Appl Physiol 1998;64:854–9). The best-fit line for Pressure
Flow (P-Q) plots was determined by linear regression. An adjusted two
paired student t test was used to compare the line gradients.
Results: We found that although total pulmonary vascular
resistance (as defined as mean PAP/ CO) showed no change at rest,
the slope of the P-Q plots decreased with vasodilators during exercise
(p<0.0005) (see figure).
Conclusion: In each of these four subjects, whilst there was no
vasodilator response at rest, there was an improving relationship
between pressure and flow during exercise whilst receiving the
vasodilators NO and O2. In patients with PHT, the assessment of
vasodilator response may be better performed during exercise than at
rest.
P106 FUNCTIONAL AND HAEMODYNAMIC RESPONSE
AFTER PULMONARY THROMOBENDARTERECTOMY
FOR THROMBOEMBOLIC PULMONARY
HYPERTENSION
F. Reichenberger, J. Parameshwar, D. Hodgkins, J. Dunning, J.
Pepke-Zaba. Papworth Hospital, Papworth Everard, Cambridge, UK
Pulmonary Thrombo-Endarterectomy (PTE) is the treatment of choice in
pulmonary hypertension due to proximal chronic thromboembolism.
We evaluated the midterm functional and haemodynamic outcome
until one year after PTE. The functional capacity was assessed using
the six minute walking distance (6MWD). Haemodynamic parameters
were obtained during right heart catheterisation with Swan Ganz
catheter and cardiac output with thermodilution method. Until March
2002, 88 patients underwent PTE (44 male, 43 female, mean age 52
(18–81) years) at Papworth Hospital. Fifty eight patients completed a
three months follow up, and 35 patients 12 months follow up. Two
patients were followed up by other centres and two patients did not
attend follow up visits. Preoperative functional and haemodynamic
data show a severely reduced 6MWD and cardiac index with
Abstract P104 Figure 1 Flow velocity profiles in subjects. Two
and three showed flattening with exercise.
MVcm/s
2
PVcm/s
4.0
R
21.7
4.5
EX
20.5
10.6
EX
26.0
10.2
R3
28.8
PV
R EX
MV MV MV
PV
Abstract P104 Figure 2 Flow velocity profiles in subjects one and
four, showing peaking with exercise.
MVcm/s
1
PVcm/s
5.8
R
15.9
7.2
EX
22.5
23.1
EX
66.3
17.8
R4
51.4
R EX
MV MV MV
PV
PV
Abstract P104
Diagnosis Age
MPAP
mmHg CO l/min PVR 6mwt (m)
1 PPH 59 47 3.7 12.7 438
2 PPH 66 40 2.6 15.4 210
3 PortoPHT 31 41 6.3 6.5 260
4 Normal 48 16 3.4 4.7 550
Abstract P105 Pressure flow changes during exercise.
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increased right atrial pressure (RAP) and mean pulmonary artery pres-
sure (mPAP). Three months after surgery there was a significant
increase in 6MWD and cardiac index, and a decrease in RAP and
mPAP. These changes were statistically significant (t test p<0.0001).
The functional and haemodynamic improvement sustained also 12
months postoperatively (see table). None of the patients died between
three months and 12 months follow up.
Conclusion: Patients have a significant and sustained functional
and haemodynamic improvement after PTE with normalisation of
haemodynamic parameters in the majority of patients. The main
improvement is achieved within three months after surgery.
Cystic fibrosis: Inflammatory
consequences of chronic
infection
P107 NEUTROPHIL APOPTOSIS AND BACTERIAL
INFECTION IN CYSTIC FIBROSIS
A.P. Watt1, J. Courtney1, J. Moore 2, J.S. Elborn1, M. Ennis1. 1Respiratory
Research Group, Centre for Infection, Inflammation and Repair, The
Queen’s University of Belfast; 2Department of Bacteriology, Belfast City
Hospital, Belfast, UK.
In cystic fibrosis (CF), impaired mucociliary clearance leads to chronic
endobronchial bacterial infection and inflammation, mediated by neu-
trophils. Pseudomonas aeruginosa infection is associated with an
exaggerated inflammatory response and colonisation with Burkholde-
ria cepacia is often accompanied by progressive pulmonary deterio-
ration. Apoptosis of inflammatory cells is considered an essential
requirement for the resolution of an inflammatory response. It was
hypothesised that the number of neutrophils undergoing apoptosis
would alter with the agent of infection in CF lungs. The aim of this
study was to assess the relationship between levels of neutrophil
apoptosis and sputum microbiology in matched clinically stable CF
patients. In this preliminary study 29 patients were recruited: six (4M)
with no Gram negative infection, 10 (4M) colonised with P
aeruginosa, 9 (4M) with B cepacia infection and 4 (3M) with other
Gram negative infections such as Stenotrophomonas maltophilia. Spu-
tum was induced as previously described (Kelly, et al. 2002). Cells
were recovered from sputum plugs. Apoptosis was investigated by
staining sputum cells with propidium iodide (PI) and annexin V (AV),
and subsequent flow cytometric analysis. Non-parametric statistic
analyses were used throughout. The % of necrotic granulocytes
(AV−PI+) was significantly higher in the P aeruginosa group (17.1
(2.5%), p=0.008) and the B cepacia group (13.9 (1.3%), p=0.008)
compared to those with no Gram negative infection (7.5 (1.6%)). B
cepacia patients also had a significantly higher % of secondary
necrotic cells (AV+PI+) than those with no Gram negative infection
(13.6 (2.3%), 5.8 (1.9%), p=0.02) whilst those with no Gram nega-
tive infection had a significantly higher % of cells which were neither
apoptotic nor necrotic (AV− PI−) than the B cepacia group (77.6
(5.2%), 58.3 (4.4%), p=0.02). These preliminary results indicate that
neutrophil apoptosis is associated with the type of organism
colonising the CF lung. The greater number of granulocytes in cell
death pathways from patients infected with P aeruginosa or B cepacia
suggests that this may be a mechanism of greater inflammation and
subsequent lung injury in CF.
P108 A COMPARISON OF INFLAMMATORY MARKER
LEVELS IN CLINICALLY STABLE CYSTIC FIBROSIS
PATIENTS WITH CHRONIC INFECTION BY UNIQUE
AND EPIDEMIC STRAINS OF PSEUDOMONAS
AERUGINOSA
A.M. Jones1, L. Martin2, R. Bright-Thomas1, M.E. Dodd1, S. Elborn3, A.K.
Webb1. 1Manchester Adult CF Centre; 2School of Pharmacy, Queen’s Uni-
versity, Belfast; 3Northern Ireland Adult CF Unit, Belfast
Introduction: There are an increasing number of reports of
Pseudomonas aeruginosa cross infection outbreaks at cystic fibrosis
(CF) centres. The clinical significance of acquisition of an epidemic
strain for patients who already harbour P aeruginosa is unclear. If epi-
demic strains are more virulent they may be more likely to provoke an
enhanced host inflammatory response. We compared levels of inflam-
matory markers in clinically stable CF patients who harbour epidemic
and unique strains of P aeruginosa.
Methods: Patients at the Manchester Adult CF Centre were invited
to participate if they were clinically stable and had received a course
of intravenous antibiotics 4–6 weeks earlier. Patients were grouped
upon the basis of bacterial fingerprinting results into those who
harbour epidemic and unique P aeruginosa strains; patients
co-infected with Burkholderia cepacia complex were excluded. The
following were measured: total white cell (WCC) and neutrophil blood
counts; sputum neutrophil elastase (NE), interleukin (IL)-8, tumour
necrosis factor (TNF) α; plasma IL-6, NE/α1-antitrypsin complexes;
serum C-reactive protein (CRP); and urine TNFr1. The groups were
compared using t tests and Mann Whitney U tests.
Results: The two groups (unique v epidemic) (n=20 patients both
groups) were well matched for mean age (28.5 v 28.0 years),
percentage predicted (%) FEV1 (44.4 v 45.7), %FVC (60.1 v 67.0)
and BMI (20.8 v 20.4). The two groups had similar mean (SD) WCC
(10.3 (2.8) v 11.5 (3.3)) and neutrophil (7.4 (2.8) v 7.6 (3.1)) counts.
There were no significant group differences in median (range) levels of
sputum NE (22.0 (10.5 to 38.6) v 17.3 (7.1 to 173.5) µg/ml), IL-8
(13 449 (5521 to 56514) v 9989 (3782 to 155 500) pg/ml), and
TNFα (11 (0 to 169) v 9 (0 to 278) pg/ml), plasma IL-6 (5.8 (1.3 to
25.7) v 6.4 (1.2 to 38.8) pg/ml) and NE/α1-antitrypsin complexes
(246 (109 to 2115) v 229 (118 to 533) ng/ml), serum CRP (8 (1 to
29) v 8 (1 to 71) mg/L) and urine TNFr1 (1167 (286 to 3531) v 988
(286 to 5082) pg/ml).
Conclusions: There are no differences in levels of inflammatory
markers between clinically stable adult CF patients who harbour epi-
demic and unique strains of P aeruginosa.
P109 A PSEUDOMONAS AERUGINOSA EXOTOXIN,
PYOCYANIN, IMPAIRS PHAGOCYTOSIS AND
CLEARANCE OF APOPTOTIC CELLS
S.M. Bianchi, L.R. Usher, D.H. Dockrell, G.W. Taylor, M.K.B. Whyte. Res-
piratory Medicine Unit, University of Sheffield, Sheffield, UK
Pseudomonas aeruginosa infection in patients with cystic fibrosis and
bronchiectasis is characterised by a profound neutrophilic inflamma-
tion, with neutrophil products (for example, elastases) implicated in tis-
sue injury. We have shown that pyocyanin, a pseudomonas exotoxin,
accelerates neutrophil apoptosis (programmed cell death) potentially
promoting bacterial persistence (Usher, et al. J Immunol
2002;168:1861–8). We hypothesised that accelerated neutrophil
death may result in further tissue injury if apoptotic cell clearance was
impaired. We therefore studied the effects of pyocyanin on the inges-
tion of apoptotic neutrophils (APMN) by monocyte-derived macro-
phages (MDM). All data are expressed as controls versus 24 hour
pyocyanin pretreatment. We have observed a time (100 (0%) v 22.7
(7.1%), p<0.001) and concentration dependent reduction in MDM
ingestion of APMN in the presence of pyocyanin. We have shown that
the reduced interaction is not due to loss of viability (23.2 (2.5) v 22.7
(1.2) cells/x400 field, p=0.440) or induction of MDM apoptosis by
physiological concentrations of pyocyanin (0.6 (0.15%) v 0.93
(0.41%), p=0.108). Similarly we have demonstrated no loss in MDM
function as assessed by basal and lipopolysaccharide induced MDM
cytokine production. The impairment of phagocytosis has been shown
to be specific to APMN as MDM phagocytosis of opsonised latex
bead is not impaired (33.3 (4.2%) v 29.7 (2.3%), p=0.312). Also we
have determined that the pyocyanin-induced defect is specific to the
MDM—APMN killed by constitutive ageing or following exposure to
pyocyanin are ingested similarly by healthy MDM. Using flow
cytometry we have shown that pyocyanin is capable of inducing high
levels of reactive oxygen species (ROS) within the MDM—however it
Abstract P106
6MWD
(metres)
RAP
(mmHg)
mPAP
(mmHg)
Cardiac
Index
(l/min/qm)
preop (88) 238 ± 115 10 ± 6 48 ± 11 1.7 ± 0.5
3 mo postop (58) 386 ± 124* 3 ± 4* 24 ± 9* 2.5 ± 0.7*
1 year postop (35) 382 ± 123 3 ± 3 22 ± 10 2.4 ± 0.5
t test: p<0.001.
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does not appear that this mechanism is responsible for the defect as
alternative sources of ROS (for example, hydrogen peroxide) do not
result in similar impairment of phagocytosis, and antioxidants are
unable to recover phagocytic capacity. We conclude that pyocyanin
reduces MDM phagocytosis of APMN in vitro. This represents a novel
mechanism by which microorganisms may contribute to immune eva-
sion, bacterial persistence, ongoing inflammation, and lung injury.
P110 BURKHOLDERIA CEPACIA COMPLEX: A MULTILOCUS
SEQUENCE TYPING (MLST) SCHEME BASED
APPROACH
K.M. Thickett1 2, E. Mahenthiralingam3, D. Honeybourne1 2, C.G. Dowson2.
1Adult Cystic Fibrosis Unit, Department of Respiratory Medicine,
Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK;
2Department of Biological Sciences, University of Warwick, Coventry,
CV7 4AL, UK; 3Cardiff School of Biosciences, Main Building, Museum
Avenue, PO Box 915, Cardiff University, Cardiff, Wales, UK
The accurate identification of Burkholderia cepacia complex in cystic
fibrosis (CF) is challenging. A polyphasic taxonomic approach is often
employed in the study of B cepacia complex, including total protein
electrophoresis, fatty acid analysis, biochemical tests, PCR amplifica-
tion of rDNA, random PCR amplification (RAPD), pulse-field gel elec-
trophoresis, and ribotype analysis. However, molecular diagnostic
probes based upon the polymerase chain reaction (PCR) provide a
rapid and frequently highly discriminatory means of identifying micro-
bial infection. Recently recA sequence analysis has helped to unravel
the phylogenetic relationships within the B cepacia complex and has
formed the basis for a rapid PCR based identification of B.cepacia
complex genomovars.1 Multi locus sequence typing (MLST) is a pow-
erful, portable and rapid means of undertaking identification, typing
and population genetic analysis and enables population based analy-
ses not possible by pulse field gel electrophoresis (PFGE) or other
macrorestriction profiling and allows the establishment of a world
wide data base for the unambiguous identification of different strains.
We have currently developed six loci for use in an MLST scheme for B
cepacia complex including RecA, recA, beta subunit of ATP synthase
atpd, poly-hydroxyalkoanoate polymerase phaC, glutamate syn-
thetase (NADPH) large chain precursor, gltB, DNA gyrase β subunit,
gyrB and GTP binding protein lepA. Southern blotting of whole chro-
mosomes and restriction digests of total chromosomal DNA from B
cepacia complex, (B cepacia genomovars I and III, Burkholderia mul-
tivorans, Burkholderia stabilis, and Burkholderia vietnamiensis) has
been used to confirm the presence of loci as single copies. We
describe preliminary phylogenetic relationships from these loci using
isolates widely distributed across a recA phylogenetic tree.
1. Mahenthiralingam E, et al. J Clin Micro 2000;38:3165–73.
P111 STRAIN DEPENDENT SYSTEMIC INVASION AND
INFLAMMATION IN A MURINE MODEL OF ACUTE
PULMONARY BURKHOLDERIA CEPACIA INFECTION
J.C. Davies1 2, R. Shaw1, T. Lloyd1, D.M. Geddes1, E.W.F.W. Alton1. 1Dept
of Gene Therapy, Imperial College; 2Dept of Paediatric Respiratory Medi-
cine, Royal Brompton Hospital, London, UK
Burkholderia cepacia infection in CF may be asymptomatic, adversely
affect lung function or invade systemically leading to the potentially
fatal “cepacia syndrome”. Certain genomovars appear more
detrimental than others, possibly related to invasiveness and
pro-inflammatory activity: cepacia syndrome has been reported with
GII and GIII organisms, and GIII infected lung transplant recipients
have increased mortality. To explore this further, we tested a variety of
B cepacia strains in a murine model of acute pulmonary infection.
C57Bl/6 mice (6/group) were infected by nasal sniffing with 109 CF
organisms including: 18822 & 13010 (GIIa&b), ET12 (GIII), and
18870 & 14294 (GIVa&b) (BCCM/LMG, Belgium). Forty eight hours
later blood was obtained by abdominal venesection, the spleen was
removed, and a BAL performed. Homogenised spleens were cultured
in a semi-quantitative fashion on cepacia-specific medium. Growth
was scored as 0 (negative), 1 (scanty colonies), 2 (multiple colonies),
or 3 (confluent growth). Consistently high levels of systemic invasion
were seen in animals infected with GIII and GII strains (scores of 3 in
every animal). In contrast, the GIV strains produced less frequent and
lower levels of invasion (mean (SEM) score GIVa 0.8 (0.4), GIVb 1.7
(0.2); p<0.05 compared with other infected groups). BAL neutrophil
counts were higher in all infected groups than in PBS controls (p<0.05
or less), the highest levels being in groups GIII and GIIb. ET12 was
significantly more pro-inflammatory than all the other strains, when the
cytokines TNFα, IL-6, and IL-1β were measured both in BAL and serum.
Although the GII strains were more invasive than the GIV, this was not
reflected by differences in these ctyokines. This animal model confirms
a differential host response to various B cepacia organisms, which
appears to be related both to genomovar and strain. Strains from GII
and GIII, those associated with cepacia syndrome in patients, were
highly invasive. Further, the GIII organism elicited the greatest inflam-
matory response, both locally and systemically, suggesting a
mechanism for the reported poor outcome after lung transplantation.
Further studies, both in animal models and in the clinical setting are
warranted, to improve attempts to identify patients most at risk of dis-
ease.
P112 VARIABILITY IN PRO-INFLAMMATORY ACTIVITY OF
PURIFIED LIPOPOLYSACCHARIDE (LPS) FROM
SELECTED BURKHOLDERIA CEPACIA GENOMOVARS;
THE ROLE OF LPS STRUCTURAL DIFFERENCES AND
CHEMOTYPE
A. De Soyza1 2, R. Demarco De Hormaeche2, P. Corris1. 1Lung Biology and
Transplantation group, University of Newcastle upon Tyne; 2Freeman Hos-
pital and Department of Microbiology and Immunology, University of
Newcastle upon Tyne, UK
Gram negative bacterial infections are a major cause of morbidity in
adult cystic fibrosis patient. As compared to those infected with Ps
aeruginosa alone the outcomes of Burkholderia cepacia infected
patients are poorer. There also appears to be variability in outcomes
within the B cepacia infected population (Frangolais, et al. Am J Respir
Crit Care Med 1999). The most striking disease pattern is Cepacia
Syndrome a fatal pneumonitis-sepsis syndrome. There are many host
and pathogen factors which may contribute to this variability. The des-
ignation of closely related but distinct species, Genomovars I to VII,
within the B cepacia complex may offer some insights into this variable
pattern. Genomovars III, II, and V are the most prevalent in CF. We
have shown poor outcomes in Genomovar III infected patients
post-transplant (De Soyza, et al. Lancet 2001). As lipopolysaccharide
(LPS) is a major mediator of sepsis we have investigated the
pro-inflammatory potential of B cepacia LPS.
Methods: We selected three strains of B cepacia after pilot work
suggested widely varying biological activity. These strains, GII (LMG
14273 and 13010) and GIII (LMG12614, an ET12 clone), were
grown overnight and harvested. The bacteria were sonicated and
treated with DNAse and proteinase K. LPS extraction using hot phenol
was undertaken with final DNA/ protein contamination approx 5%.
The purified LPS (1–100ng) were added to differentiated U937 mac-
rophages and the tissue culture supernatants were collected at 0 and
24 hrs. Time course experiments were also undertaken up to 48 hrs.
The supernatants were tested for septic shock related cytokines IL-1,
IL-6 and TNF using ELISA. We silver stained 16% urea/SDS-PAGE
gels to assess LPS structure.
Results: A dose-response was seen. The greatest difference was
noted between the purified LPS at a dose of 100ng for TNF induction
where LMG 12614 (ET12) was twice as effective at induction as com-
pared to LMG 14273 (GII). LMG 13010 (GII) was as effective as the
GIII, LMG12614. The gels confirmed that all were of rough LPS
chemotype. The two high cytokine inducers LMG12614 and 13010
(GIII and GII) appeared to have the same LPS banding patterns; rough
LPS with two distinct bands whilst LMG 14273 a distinct LPS pattern.
Conclusions: The observed differences between B cepacia
complex strains LPS may in part explain the variable clinical outcomes.
We identified differences between genomovars demonstrating that
within the two most common genomovars there is a wide spectrum of
activity. One GII strain appears to have the same LPS as the ET-12 GIII
strain which may explain why some GII patients can develop Cepacia
Syndrome. The chemotype of the LPS e.g. rough or smooth may be less
important than the structural motifs within each LPS.
P113 LIPOPOLYSACCHARIDE STRUCTURAL PROFILES ARE
NOT ALTERED IN GENOMOVAR III BURKHOLDERIA
CEPACIA QUORUM SENSING KNOCKOUTS
A. De Soyza, R. Demarco De Hormaeche, P. Corris. Lung Biology and
Transplantation group, University of Newcastle, Freeman Hospital and
Department of Microbiology and Immunology, University of Newcastle
upon Tyne, UK
Background: Attempts at creating vaccines using isolated bacterial
antigens have been relatively unsuccessful for many important patho-
gens such as Pseudomonas. Gram negative bacteria form biofilms in
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cystic fibrosis lungs that appear to protect bacteria within the biofilm
from antibiotics even at bactericidal levels. The maturation of biofilms
is dependent on quorum sensing systems. Quorum sensing mutants
produce greatly attenuated infections in animal models and may offer
the possibility of an attenuated strain (perhaps with additional
mutations in virulence genes) for use as a biological vaccine. Recent
data has shown that quorum sensing also controls virulence related
genes for proteases and iron binding siderophores. The effect of quo-
rum sensing on a major bacterial pro-inflammatory moiety,
lipopolysaccharide (LPS) is less clear. Work with Pseudomonas aeru-
ginosa has demonstrated that migA a lipid A glycosyltransferase, has
a quorum sensing box upstream. There is no data in the Cepacia field
assessing the effect of quorum sensing knockouts on LPS structure. Two
Burkholderia cepacia quorum sensing mutants, H111-I and H111-R
have been created that are defective in the acylhomoserine lactone
(AHL) synthase cepI and the AHL receptor cepR respectively. The effect
of these mutations are to impair biofilm formation. These strains there-
fore may be potentially considered for investigation as starting points
for biological vaccines. The effect of these mutations on LPS is however
unclear.
Methods: The wild type parent genomovar III, strain H111 and the
two mutants were kindly gifted (Dr B Huber, University Munich). These
were grown in Luria Broth (LB) with appropriate selective antibiotics
over 24 hours at 37°C. The organism were then centrifuged and
resuspended to a standard optical density at 600nm of 0.2.
SDS-PAGE was conducted with subsequent silver staining to assess
any changes in LPS profiles.
Results: Silver stained SDS-PAGE gels revealed the LPS of all three
strains were of smooth chemotype with multiple bands suggesting
variable O side chain lengths. There were however no differences
between the strains in terms of number or pattern of the bands seen on
the gels suggesting the O chains of the LPS were not affected by the
quorum sensing mutations. There appeared to be no differences in the
LPS core. As opposed to data from Pseudomonas spp quorum sensing
B cepacia mutants with smooth LPS do appear to have a change in LPS
structure under the above growth conditions.
Conclusions: If quorum sensing mutants are to be considered as
starting points for biological vaccines it may be important to create
quorum sensing mutants in a wild type genomovar III strain with a LPS
that has a low inflammatory potential.
Cystic fibrosis: Treatments and
outcomes
P114 COMPARISON OF THE HALOLITE® ADAPTIVE
AEROSOL DELIVERY (AAD™) SYSTEM WITH A HIGH
OUTPUT NEBULISER SYSTEM IN CYSTIC FIBROSIS
PATIENTS
R.J. Marsden1, S.P. Conway2 , M.E. Dodd3 , F.P. Edenborough4, A.S.
Rigby5, C.J. Taylor5, P.H. Weller6. 1Profile Therapeutics, UK; 2St. James’
Hospital, Leeds; 3Wythenshawe Hospital, Manchester; 4Northern General
Hospital, Sheffield; 5Sheffield Children’s Hospital, Sheffield; 6The Birming-
ham Childrens’ Hospital, Birmingham, UK
The HaloLite AAD system (AAD) has been developed to improve
inhaled medication delivery by giving feedback during and at the end
of treatment. It will not deliver aerosol during nose breathing, talking,
or if there is a poor mouthpiece lip seal. A multicentre randomised
parallel study (MAL 25 –70) comparing AAD with conventional high
efficiency nebulisers (NEB) was conducted at CF centres in Australia,
Canada, USA, and Europe. Patients established on DNase and
inhaled antibiotics were randomised to AAD or NEB within seven
days following an exacerbation requiring oral or IV antibiotics.
Patients used the study device to take their inhaled medications for
182 days. The primary outcome variable was change in FEV1 from
day 0–182. Secondary outcome variables were days antibiotic use,
exacerbation frequency, time to first exacerbation, safety, adherence
to prescribed regimen, and compliance with device (by overt
electronic monitoring in 20% of the sample). Patients completed a
questionnaire to assess device acceptability.
259 patients were randomised (133 AAD, 126 NEB) median age
17 years, median FEV1 56% predicted. Preliminary analysis of mean
change in % predicted FEV1 from baseline to day 182 was −3.5% for
AAD and −2.4% for NEB. Difference in means = 1.1% confidence
interval = −4.2% to 6.3%, p=0.7. There was no statistically significant
difference between AAD and NEB for the secondary outcome
variables except for a higher incidence of chest tightness per 1000
days (0.97 for AAD and 0.32 for NEB (p<0.05)). Completed
questionnaires showed that compared to their previous nebuliser 69%
of AAD patients felt that they received more dose compared to 30.4%
for NEB; 56% of AAD patients felt better compared to 30% for NEB;
82% of AAD patients preferred the trial device compared to 37% for
NEB. These differences were significantly different (p<0.0001). Fifty
one per cent of prescribed doses were taken beyond 90% of the pro-
grammed dose for AAD compared with 26% of prescribed doses
where the compressor was run for >6 minutes for NEB (p<0.006).
Conclusions: There were no differences in the efficacy outcome
variables between the devices. A higher incidence of chest tightness
for AAD may be indicative of more successful delivery of antibiotic to
the lung. Patient acceptability of the device was better for AAD than
for NEB. Patients take more doses to an acceptable level using AAD.
P115 COMPLIANCE IN CYSTIC FIBROSIS PATIENTS USING
TWO DIFFERENT AEROSOL DELIVERY SYSTEMS
S.P. Conway1, M.E. Dodd2, R.J. Marsden3, P.H. Weller4. 1St. James’ Hos-
pital, Leeds, UK; 2Wythenshawe Hospital, Manchester, UK; 3Profile Thera-
peutics, UK; 4The Birmingham Childrens’ Hospital, Birmingham, UK
CF patients may use conventional high output nebulisers (NEB) for up
to an hour a day to aerosolise therapies aimed at preserving lung
function. Poor techniques such as nose breathing, talking and
inadequate lip seal compromise the time spent breathing correctly on
the mouthpiece1 and hence the amount of drug delivered to the lungs.
HaloLite (AAD) has been designed to generate aerosol only whilst
patients breathe correctly through the mouthpiece. The system
provides feedback to the patient during treatment and signals once the
pre-programmed dose has been successfully delivered. The aim of this
study was to compare compliance with AAD to compliance with NEB.
Patient Logging System (PLS) monitoring technology was used in a
device study comparing AAD with NEB to overtly monitor 50 of 259
patients (from study MAL 25–70) over 182 days. “Adherence” (doses
started/by the number of doses prescribed) and “compliance” (the %
of doses taken correctly) were recorded. For AAD a correctly taken
dose was defined as delivery of >90% of the pre-programmed dose,
and for the NEB when the Porta-Neb® PLS compressor was run for
>6minutes. “True compliance” is adherence X compliance. FEV1 was
recorded on day 0 and 28. The use of oral or IV antibiotics was
recorded on day 0 and 28. The sample included 30 AAD and 20
NEB patients. Provisional data shows that adherence was 62% for
AAD and 47% for NEB (p>0.05). Compliance was 84% for AAD and
43% for NEB. “True compliance” was significantly higher for AAD
(51%) compared to NEB (27%) (p=0.006). For NEB there was no cor-
relation between true compliance and % change in FEV1 after 28 days,
neither was there a correlation between true compliance and % of
change in FEV1 for the subgroup of patients who did not need oral or
IV antibiotics for an exacerbation (n=14). For AAD there was no cor-
relation between true compliance and FEV1 , however for the subgroup
of patients who did not need oral or IV antibiotics for an exacerbation
there was a correlation between % change in FEV1 and true
compliance for AAD (n=17) (R=0.53) (p<0.03).
Conclusion: These data show that the AAD system increases true
compliance and may contribute to the maintenance of FEV1.
1. Denyer J, et al. Does inhalation duty cycle in-vitro predict inhaled
dose during domiciliary nebulizer use? Drug delivery to the lungs VIII
1997.
P116 PORTACATH COMPLICATIONS IN CYSTIC FIBROSIS
PATIENTS
M. Suresh, W. Lenney, G. Hooper, C. Mayer, J. Forrest, A. Walsh. Aca-
demic Dept. of Child Health, North Staffs. Hospitals Trust, Staffs, UK
Introduction: Cystic fibrosis (CF) patients requiring repeated
intravenous antibiotic courses eventually benefit from insertion of per-
manent vascular catheters such as a Portacath. There is little
information on complications arising from such procedures, which
need to be taken into consideration when discussing the relative merit
with patients and parents.
Patients: Over a 12 year period out of a population of 78 patients
18 (six male, 12 female) have received 30 Portacaths. Ten patients
were <18 years old, 11 have only needed one Portacath to date,
three have required two, two have needed three, and two have
received four Portacaths.
Results: Average length of use: 36.7 months. Longest surviving
Portacath: 8 years 10 months. Reasons for failure: Catheter
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disconnection one, systemic/infective complications three, lung
collapse one, leakage four, blockage with pain six. Short survival of
the first Portacath is a marker for failure with subsequent Portacaths.
Discussion: Complications are relative frequent and unpredict-
able. Our findings are similar to others in CF and oncology patients.
Needle-phobia is a common experience in CF Clinics but the use of
Portacaths needs full discussion with families and should not be
entered into lightly.
P117 ANTIBIOTIC RELATED RENAL IMPAIRMENT IN ADULT
CF PATIENTS
M. Al-Aloul, B. Govin, P.A. Stockton, M.J. Ledson, M.J. Walshaw. Regional
Adult CF Unit, The Cardiothoracic Centre, Liverpool, UK
Colonisation with multiresistant Pseudomonas aeruginosa (Pa) in CF
results in repeated use of a limited number of antibiotics to which the
organisms are sensitive, increasing the risk of toxic effects. In
Liverpool, we have a multiresistant strain colonising many CF patients
that is only sensitive to aminoglycosides and polymyxins, antibiotics
that are known to cause renal damage that may be associated with
excess levels and also cumulative lifetime dose. To assess the impact
of repeated dosing with these antibiotics, we have compared renal
function in those colonised with multiresistant Pa with a group of CF
patients with similar clinical parameters but who are colonised by sen-
sitive Pa strains. Overall, 52 patients (32 multiresistant) were studied
(mean age (range): multiresistant 23.6 years (15 to 42) v sensitive
24.9 (18 to 37); FEV1 % predicted: 61.3 (16 to 95) v 61.8 (17 to
115); BMI: 21.6 (18 to 28) v 20.6 (14 to 27); CF related diabetes: 9
v 4 (all P=NS)). During exacerbations, all patients had aminoglyco-
side levels measured and adjusted after the 4th dose as per protocol
and no episodes of acute toxicity were noted. Renal function was
measured by estimation of serum urea and electrolytes and 24 hour
urinary creatinine clearance when patients were in a stable clinical
state. Patients produced satisfactory 24 hour urine collections, demon-
strated by sufficient urine volume and total urinary creatinine
excretion. All patients had serum creatinine and urea levels within the
normal range, but those colonised with multiresistant strains had a
lower creatinine clearance (mean 75 mls/min (range 11 to 115) v
101 mls/min (28 to 171)), (p<0.002), and had received more IV
aminoglycoside courses (mean 23 per patient (range 0 to 100)) v (8
(0 to 30)), (p<0.007)), and more IV colomycin courses (22 (0 to 80)
v 7.4 (0 to 50)), (p<0.006)). Also, the total number of IV courses cor-
related with worsening renal function (r=0.39, p<0.001). We
conclude that repeated dosing with these potentially nephrotoxic
drugs has damaged the renal function in those patients colonised by
multiresistant Pa strains, and in some patients we can now no longer
use these important antibiotics. This study illustrates the need to
prevent colonisation by such strains if possible in CF patients. This is
best achieved by measures designed to prevent cross infection, includ-
ing suitable patient segregation.
P118 VARIATION IN REPORTED INTAKE OF PANCREATIC
ENZYME REPLACEMENT THERAPY IN ADULTS WITH
CYSTIC FIBROSIS
S. Thornton, S. Kelly, F. Edenborough. Adult Cystic Fibrosis Unit, Northern
General Hospital, UK
Background: Pancreatic Enzyme Replacement Therapy (PERT), the
number of enzymes taken with food, is assessed as part of the annual
review. In this centre both the doctor and dietitian review
independently, however it is the amount each patient reports to the
doctor which is recorded on the UK National Cystic Fibrosis (CF)
database.
Aim: To investigate whether reported intakes of PERT capsules dif-
fer when assessed by dietitian, doctor, or using a food diary.
Methodology: Patients attending their annual review at the CF
Centre between July 2000 to May 2002 were asked the number of
PERT capsules they consumed with meals, snacks, nutritional
supplements, drinks etc each day. This is the recall method and is
recorded by the dietitian (in conjunction with diet history) and the doc-
tor on the same day. Patients are also requested to complete at least a
three day food diary (two weekdays and one weekend day). They
record the quantities and types of food, fluid and PERT consumed on
those days. The numbers of PERT recorded by each method were com-
pared.
Results: There was significantly less PERT intake reported using the
recall method by dietitian, 3.6 ± 10.3 enzymes (p=0.04, t Test) com-
pared to the database documented value (doctor).
The number of enzymes recorded on the food diaries was also
lower than the database documented value (doctor), 3.8 ± 9.1
enzymes but was not significant (0.07, t Test).In addition, there is con-
siderable variation in the number of PERT capsules reported using
each method (table).
Conclusion: The actual over reporting of enzyme intake for the UK
CF database is slight overall, however for an individual patient the
report can vary by over 100% difference. It is also shown that 40% of
patients are more than 25% inaccurate in their reporting. This may
have implications for their individual enzyme assessment and monitor-
ing. In light of this evidence we suggest that consideration is made to
the method of assessment used.
P119 INTRAVENOUS ANTIBIOTICS INCREASE EXHALED
NITRIC OXIDE IN CHILDREN WITH CYSTIC FIBROSIS
A. Jaffé, G. Slade, J. Rae, A. Laverty. Portex Respiratory Unit, Great
Ormond Street Hospital for Children & Institute of Child Health, London, UK
Introduction: Data on the effect of intravenous (IV) antibiotics on
exhaled nitric oxide (NO) in CF and on correlation of NO with lung
function are conflicting because of lack of standardisation for the
measurement of NO.
Aims: To assess the effect of IV antibiotics on exhaled NO in CF
children and to correlate NO with lung function. Methods: Exhaled
NO was measured on line during a slow exhalation according to ATS
guidelines using an exhalation flow of 50 mL/s (NiOX, Aerocrine,) in
CF patients admitted for IV antibiotics. Pulmonary function was
measured according to ATS guidelines (Masterscreen, Jaeger). Meas-
urements before and after treatment were compared by Wilcoxon
Signed Ranks Test. Spearman correlation tests were used to assess
correlation. A value of p<0.05 was considered significant.
Results: Fourteen CF subjects (10 female), median age (range)
12.1 years (5.9 to 16.0) were studied. Genotypes were as follows:
∆F508/∆F508, n=10; ∆F508/N1303K, n=1; ∆F508/−, n=3.
Reasons for admission were: infective exacerbation, n=4; routine
quarterly antibiotics, n=10. Cough swab or sputum culture on admis-
sion: Pseudomonas aeruginosa, n=6; Staphylococcus aureus, n=6
(one had coliforms and one had Stenotrophomonas maltophilia in
addition); no growth, n=2. Median (range) length of treatment was
8.5 (6–15) days. There was a significant improvement in mean (SEM)
%FEV1 from 60.0 (6.3) to 68.0 (5.4) (p=0.02) and %FVC from 66.3
(5.5) to 75.1 (4.9) (p=0.003). There was a significant increase in NO
following treatment (median (range): pre; 5.8 ppb (2.0 to 14.3), post;
9.2 ppb (0.8 to 25.1), p=0.02). There was no correlation between
NO and %FEV1 or %FVC.
Discussion: NO is raised in lung diseases with an inflammatory
component, however this is not true for CF, and is further supported by
these results. Various hypotheses have been proposed to account for
this. These include: entrapment in sputum; degradation by superoxide
production from activated neutrophils; NO reductase in P aeruginosa;
reduced inducible NO synthase expression in epithelial cells. Our
results support these hypotheses as it is likely that antibiotic treatment
results in a reduction in P aeruginosa colony forming units, neutrophil
activation and airway sputum volume.
Conclusion: IV antibiotics increase exhaled NO in CF. However,
NO does not correlate with lung function and is not a useful marker of
lung disease in CF.
Abstract P118
% difference from database (doctor) <25% 26–50% 51–75% 76–100% >100%
% reported to dietitian 61 30 2 7 2
% reported on food diary 60 30 5 5 0
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P120 FACTORS DETERMINING DIAPHRAGM STRENGTH IN
CHILDREN AND YOUNG ADULTS WITH CYSTIC
FIBROSIS
N. Hart1 3 5, P. Tounian2, M.I. Polkey3, A. Clement1, J. Moxham4, F. Lofaso5,
B. Fauroux1. 1Paediatric Pulmonary Department; 2Gastroenterology Depart-
ment, Armand Trousseau Hospital, Paris, France; Respiratory Muscle Labo-
ratories, 3Royal Brompton Hospital; 4Kings College Hospital, London, UK;
5Department Of Clinical Physiology, Raymond Poincare Hospital, Garches,
France
Respiratory failure is the major cause of death in patients with cystic
fibrosis (CF). Although the diaphragm is the most important muscle of
inspiration, it is unclear as to whether there are any alterations in dia-
phragm strength in patients with cystic fibrosis (CF). In the current
study, we hypothesised that diaphragm strength would be determined
by airflow obstruction and pulmonary hyperinflation, gas exchange
impairment, inspiratory muscle load, and nutritional status of the
patient. 20 patients with CF were studied (mean age 15.1 (2.8)
years). We measured twitch transdiaphragmatic pressure (Tw Pdi) in
response to bilateral anterior magnetic phrenic nerve stimulation to
quantify diaphragm strength; forced expiratory volume in 1 sec (FEV1)
and functional residual capacity (% Pred FRC) as estimations of airflow
obstruction and hyperinflation; and diaphragm pressure time index
(PTIdi) as an indicator of diaphragm load. Nutritional status was evalu-
ated using body mass index adjusted for age and sex (BMI z-score),
fat mass (FM), fat-free mass (FFM) and arm-muscle circumference
(AMC). These were determined from measurements of height, body
weight, mid-arm circumference (AC), and skinfold thickness (SK) at
four different sites (biceps, triceps, subscapular, and suprailiac). FM
and FFM were calculated from SK and weight. AMC was calculated
from the formula AC − (0.134 * biceps SK/2 + triceps SK/2). FM,
FFM, and AMC were expressed as percent predicted for statural age
(% PredSA). Results are expressed as mean (SD). Tw Pdi was 24.3 (5.5)
cmH2O; % Pred FEV1 was 44.5 (21.4); % Pred FRCpl was 159.8
(40.9); PaO2 was 9.5 (1.5) kPa; PaCO2 was 5.5 (0.6) kPa; and PTIdi
was 0.05 (0.03). Univariate regression analysis demonstrated Tw Pdi
correlated with % Pred FEV1 (p=0.001; r = +0.68); % Pred FRCpl
(p=0.005; r = -0.65); PaO2 (p=0.001; r = +0.68); PaCO2 (p=0.03; r
= −0.50); BMI z-score (p=0.003; r = +0.63); % PredSA AMC (r =
+0.45; p=0.04); and % PredSA FFM (r = +0.47; p=0.04). There were
no correlations between Tw Pdi and % PredSA FM (p=0.1) and PTIdi
(p=0.2). In conclusion, in children and young adults with CF,
diaphragm strength falls as airways obstruction and hyperinflation
increases, gas exchange impairment worsens, and nutritional status
declines. However, load does not have effect of diaphragm strength.
Dr N Hart was supported by the Scadding-Morriston Davies Joint
Respiratory Medicine Fellowship, a European Respiratory Society
Long Term Fellowship and a grant from the Association Française
Contre Les Myopathies.
P121 INCREASED ENERGY EXPENDITURE DUE TO
COUGHING IN ADULTS WITH CYSTIC FIBROSIS
A.A. Ionescu, R. Colasanti1, L.S. Nixon, C.E. Bolton, M. Williams1, D.J.
Shale. Section of Respiratory Medicine University of Wales College of
Medicine; 1School of Applied Sciences University of Glamorgan, Cardiff,
UK
Patients with Cystic Fibrosis (CF) have increased resting energy
expenditure (REE). We hypothesised that frequent coughing, occurring
spontaneously and during physiotherapy in most patients, adds to the
REE and overall energy expenditure (EE), which may contribute to
weight loss.
We measured breath by breath REE (K4b, Cosmed) in 12 clinically
stable patients and 10 healthy subjects. A steady state baseline was
recorded and each subject coughed voluntarily three times after
breathing in to TLC. A further 10 patients had REE measured on
repeated occasions by the same method. During 45, 10minute
recordings of REE 144 spontaneous coughs occurred. The REE before
coughing occurred and after each coughing episode was recorded.
The mean recovery time (VE, l/min back to baseline) after the three
voluntary coughs (41 seconds) was used to calculate the EE after
spontaneous coughing as the area under the curve after each cough
by locally designed software. We also compared the REE after spon-
taneous coughs to the baseline REE, because the duration of the base-
line record was variable (mean 106, maximum 371, minimum 8
seconds). There was no difference in EE after three coughs (ratio to
baseline), between patients and healthy subjects (p>0.05). The FEV1
(patients) was inversely related to EE after three coughs, r =−0.0.58,
p=0.04. Recovery time was similar to the healthy subjects. Spontane-
ous coughs in patients increased the EE by a mean (95% CI) 7.9 (2.7
to 13.3) % compared with baseline, mean (95% CI) 32.63 (30.51 to
34.75), and 30.66 (28.59 to 32.73) kcal/kg/min, p<0.01. The REE
(area under curve over time) with spontaneous coughs was greater
than REE recorded when spontaneous coughs were removed from the
10 minutes measurement; mean (95% CI) 28.0 (24.7 to 31.3) and
21.5 (18.6 to 24.3), respectively, p=0.016.
Cough increased the REE in adults with CF. For accuracy REE meas-
urements in CF should include any spontaneous coughs that occur.
Due to the frequency of coughing, the energy costs are likely to
increase the negative energy balance in some patients.
Sponsored by the Cystic Fibrosis Trust UK.
P122 SEQUENTIAL SINGLE LUNG TRANSPLANTATION FOR
SEPTIC LUNG DISEASE; A SINGLE CENTRE
COMPARISON BETWEEN CF AND NON-CF
BRONCHIECTASIS
A. De Soyza1, K. Gould 2, G. Parry3, J.H. Dark3, P.A. Corris1 3. 1Lung Biol-
ogy and Transplantation Group; 2Department of Microbiology; 3Cardiotho-
racic Transplantation, Freeman Hospital, University of Newcastle,
Newcastle upon Tyne, UK
Background: The outcomes for transplantation for septic lung condi-
tions including Cystic Fibrosis (CF) and non-CF bronchiectasis have
been comparable to those for non-septic lung conditions despite the
additional risks associated with these conditions. Given the current
organ donor shortage it is important to compare outcomes for each
pre-transplant outcome within a single centre to allow appropriate
allocation of organs. It is recognised that certain pre-transplant indica-
tions such as Pulmonary Fibrosis and Pulmonary Hypertension are
associated with poor transplant outcomes. We have not previously
compared the outcomes of Cystic Fibrosis and non-CF Bronchiectasis
at this centre.
Methods: We identified all patients receiving lung transplants at
this centre for septic lung diseases through our transplant database. A
survival table was constructed and the two groups were compared
using the log rank (Mantel-Cox) test for real survival. Pre-transplant
recipient characteristics were also compared including pre-transplant
body mass index, pre-transplant FEV1, need for non-invasive
ventilation and median time post transplant.
Results: We have transplanted 96 CF patients and 26 non-CF
Bronchiectatics (NCFBr) over 10 years. Median age at transplantation
CF group 25.4 yrs (range 16 to 49.5) and NCFBr median 48 yrs
(range 25 to 56) p<0.05. Survival was comparable between groups
at one year CF 81%, NCFBr-76.5% p=0.46. At five years survival
was 70% for CF and 72% for NCFBr p=NS. Pre-transplant FEV1%
predicted was similar between groups median in the CF group
=19.1% (range 8 to 35%) and NCFBr 18 (9 to 49%) p=NS. In each
group early deaths were predominantly related to sepsis: The early
deaths were due to sepsis in the CF group (9/96) and also in the
NCFBr group 13% (4/29) Fishers exact test p=0.3. Median
pre-transplant Body mass index (BMI - kg/m) was 17.8 (range 12 to
24) for CF and NCFBr =23 (range 16 to 32), Mann Whitney,
p<0.01. No patient in the Bronchiectasis group required non-invasive
ventilation pre-transplant whilst 11/96 CF patients had NIV
pre-transplant Fisher exact test p=0.11. Similarly there were 12/96
CF patients infected with Burkholderia cepacia complex organisms
whilst no NCFBr were infected with this organism p=0.11
pre-transplant Fisher exact test p=0.11.
Conclusions: Cystic Fibrosis patients had poorer pre-transplant
nutrition and were more likely to be infected with B cepacia complex.
There were however no statistical differences in post transplant
survival noted. We conclude that despite these features CF patients
are as likely to benefit from pulmonary transplantation than older
non-CF bronchiectasis patients.
P123 RECOMBINANT SENDAI VIRUS-MEDIATED CFTR
cDNA TRANSFER
S. Ferrari1–4, R. Farley1–4, F. Munkonge1–4, U. Griesenbach1–4, S. Smith1–4,
J. You2, A. Iida2, B. Wainwright3, D. Geddes1–4, M. Hasegawa2, E. Alton1–4.
1Department of Gene Therapy, NHLI, London, UK; 2DNAVEC Research Inc,
Japan; 3University of Queensland, Brisbane, Australia; 4UK CF Gene
Therapy Consortium, Edinburgh-London-Oxford, UK
To assess applicability for Cystic Fibrosis (CF), recombinant Sendai
virus (SeV) carrying the CFTR gene was tested on different models of
airway epithelial cells. In vitro CFTR activity was assessed at two days
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post-infection in murine mammary epithelial cells (C127 −/−) using a
radioactive iodide efflux assay after challenge with forskolin/IBMX
(F/I). Cells infected with a SeV vector carrying a mutated CFTR
sequence (SeV-mCFTR) were used as controls whilst T84 were used as
positive controls and results expressed as ∆k .min-1 (s.e.m). T84 cells
showed maximal efflux rate 2 min after F/I addition (0.24 (0.02),
n=30) compared to C127 −/− values (0.004 (0.004), n=11),
p<0.001. All three SeV-CFTR clones tested showed a characteristic
delayed peak three minutes after F/I addition (SeV-CFTR 23–3 (0.34
(0.04), n=12); SeV-CFTR 23–4 (0.26 (0.03), n=6); SeV-CFTR 1–3
(0.16 (0.05), n=12). As for untreated C127 −/− cells, treatment with
SeV-mCFTR did not lead to any change in efflux (−0.01 (0.02), n=12).
In vivo experiments were carried out in G551D CF transgenic mice by
administration of SeV-CFTR 23–3 and 23–4 (5 x 107 pfu, n=9)
through nasal perfusion and CFTR activity analysed at day 2, 7, 14,
and 28. SeV-mCFTR (n=9) was used as control. Two days
post-infection, NPDlow Cl- values in animals treated with SeV-CFTR
23–3/23–4 (-0.11 (0.97) mV) were significantly (p<0.05) higher
(that is, towards non-CF values) than those observed in animals treated
with SeV-mCFTR (-3.25 (0.73) mV). NPDlow Cl- in animals treated with
SeV-CFTR 23–3/23–4 remained significantly (p<0.05) higher at day
7 (0.20 (0.73) mV as opposed to −1.55 (1.23) mV in controls). Base-
line values at day seven for animals treated with SeV-mCFTR (30.8
(3.6) mV) were not different to untreated CF mice, but in mice treated
with SeV-CFTR 23–3/23–4 they were not different from those
observed in wild type mice (12.1 (1.5) mV, p<0.01 compared to con-
trols). By day 28, baseline and low chloride values had reversed to
typical G551D CF mouse values. In conclusion we have shown that
SeV can mediate CFTR gene transfer both in vitro and in vivo.
P124 GENE SILENCING THROUGH RNA INTERFERENCE AS
PUTATIVE THERAPY FOR CF
U. Griesenbach1 4, S. Escudero-Garcia1 4, R. Farley1 4, S, Cheng2, D.M.
Geddes1 4, N.J. Caplen3, E.W.F.W. Alton1 4. 1Department of Gene
Therapy, National Heart and Lung Institute, Faculty of Medicine, Imperial
College, London, UK; 2Genzyme Corporation, Framingham, USA;
3Medical Genetics Branch, NHGRI, National Institute of Health, Bethesda,
USA; 4United Kingdom CF Gene Therapy Consortium, UK
Gene silencing through dsRNA-mediated RNA interference (RNAi) has
been described in C elegans and Drosophila. We, and others, have
recently described RNAi in mammalian cells mediated by small
dsRNAs of 21–23 nucleotides (nts) termed short interfering RNAs (siR-
NAs) (Caplen NJ, PNAs 2002). Here, we provide preliminary proof
of principle that gene silencing through RNAi can be achieved in lung
in vivo. Balb/C mice (female 6–8 weeks) were simultaneously
transfected with pcDNA3CAT (80µg/mouse ) and 22 nts siRNA cor-
responding to CAT (40µg/mouse ) or an irrelevant control siRNA,
each complexed with the cationic lipid GL67 (n=12 in both groups).
Forty eight hours after transfection the lungs were harvested and CAT
activity assayed. CAT expression was reduced by 90% in animals
treated with CAT siRNA, when compared to controls (control siRNA:
736.9 (437) pg CAT/mg protein, CAT siRNA: 80.1 (31.4) pg
CAT/mg protein, p<0.001. A potential confounding factor is the
co-transfection of the plasmid and siRNA, allowing for a non-
posttranscriptional silencing mechanism of action. To address this, we
compared the silencing of the green fluorescent protein (eGFP) using
a siRNA against eGFP either in cells co-transfected with eGFP plasmid
and siRNA or cells stably expressing a destabilised version of eGFP
(eGFPd2) transfected with siRNA alone. The degree of silencing in
both cases exceeded 90%. We have recently shown that, in contrast
to the liver, uptake of DNA into the nucleus of airway epithelial cells is
extremely inefficient in vivo. However, cytoplasmic transfection can be
readily achieved. RNAi has been shown to primarily act within the
cytoplasmic compartment and so may offer a major advantage over
conventional antisense strategies that have been proposed for several
disorders. Although the pathophysiology in CF is not completely
understood, several proteins may provide good targets for gene
silencing, including the epithelial sodium channel (EnaC), as well as
several pro-inflammatory cytokines, such as IL-8 and chaperones,
which retain delta F508 CFTR within the endoplasmic reticulum.
P125 INFECTION OF THE MURINE LUNG WITH
NON-TRANSMISSIBLE RECOMBINANT SENDAI VIRUS
EXPRESSING THE SECRETED PROTEIN INTERLEUKIN 10
U. Griesenbach1, T. Shiraki-Iida1 2, S. Ferrari1, H.L. Gautrey1, X. Hou2, A.
Iida2, D.M. Geddes1, M. Hasegawa2, E.W.F.W. Alton1. 1Department of
Gene Therapy, Faculty of Medicine, Imperial College London, London, UK;
2DNAVEC Research Inc., Tsukuba, Ibaraki, Japan
We have previously shown that a transmission-competent recombinant
Sendai virus carrying mouse interleukin 10 cDNA (SeV-IL10) infects
the airways efficiently. A second generation, and for human use
potentially safer SeV has recently been generated, in which the gene
for the membrane fusion protein (F protein) has been deleted from the
viral genome (SeV/∆F) (Li et al. J Virol 2000;74:6564–9). The F pro-
tein is essential for virus entry into the cell and is supplied in trans dur-
ing vector production. However, following infection and virus
replication of the vector genome in vivo the virus cannot re-infect
neighbouring cells. Here, we assessed the efficiency of F-defective
SeV (SeV-IL10/∆F) in lungs of mice and in primate trachea. The lungs
of C57Bl/6 mice were transfected by placing SeV-IL10/∆F or a SeV-
LacZˇ∆F control virus (7×104 and 7×107 CIU/mouse) as a single 100
µl bolus into the nasal cavity and the solution was sniffed into the
lungs. Lung tissue and serum was harvested 2, 7, and 14 days after
infection. IL10 production was measured in lung homogenate and
serum using standard ELISA. In lung homogenate expression was
highest two days after infection and was 2 and 4 logs above control
levels for 7×104 and 7×107 CIU/mouse, respectively. At day seven
expression in mice transfected with the higher dose had dropped to
1.3% of the day two levels, but only to 13% in the lower dose. At day
14 the lower dose still showed low but significant IL10 expression,
whereas the higher dose was not longer different from control levels.
High levels of serum IL10 were detected two days after infection with
7×107 CIU/mouse, but not in animals infected with 7×104
CIU/mouse, and were still significantly increased seven days after
infection (SeV-IL10/∆F: 3500 (492) and 75 (18) pg/ml at day two
and seven respectively, SeV-LacZˇ∆F: 5.5 (5.4) and 0 pg/ml at day
two and seven respectively, n=6, p<0.05). When compared to the
previously used transmission-competent, first generation SeV virus (his-
torical data), there was no difference in IL10 expression in lung
homogenate or serum. We also transfected fresh and mucus depleted
segments of primate trachea with SeV-IL10/∆F or a SeV-LacZˇ∆F
control virus (106 and 107 CIU) ex vivo (n=1) and preliminary results
indicated efficient transfetion of fresh and mucus-depleted tissue
(Fresh: SeV-IL10/∆F = 405048 pg/mg, ∆FSeV-lacZˇ: 3294 pg/mg,
Mucus depleted: SeV-IL10/∆F = 470874pg/mg, SeV-LacZˇ∆F: 20966
pg IL10/mg protein). In conclusion, the non-transmissible second gen-
eration SeV-IL10/∆F infects airway epithelium as efficiently as the first
generation virus. Preliminary results indicate that the virus titre at least
in part determines the decline of transgene expression and that SeV-
IL10/∆F infects primate trachea efficiently.
Rehabilitation, symptoms, and
smoking
P126 PILOT DATA: PULMONARY REHABILITATION IN
RESTRICTIVE LUNG DISEASE
K. Dix, C. Daly, R. Garrod1, M. Howard, C. Rayner. St George’s Hospital
NHS Trust; 1School of Physiotherapy St George’s Hospital and Kingston
University, UK
Introduction: Pulmonary rehabilitation is a proven therapy for
patients with obstructive pulmonary disease , however little is known
concerning the effects in patients with restrictive disease. This study
reports on data from an seven week, ×2 weekly, “real life”
programme of exercise and education in which patients with both
restrictive and obstructive disease were admitted.
Methods: Outcome measures were baseline spirometry. Exercise
tolerance using Shuttle Walk Test (SWT), health related quality of life
using St George’s Hospital Respiratory Disease Questionnaire
(SGRQ), mood state using Hospital Anxiety and Depression Scale
(HAD).
Results: Sixty seven patients completed the course. Of these
patients, 57 had baseline spirometry from which 48 were classified as
obstructive; mean FEV1, 1.09 (0.4), FVC 2.5 (0.7) l and 9 restrictive,
mean FEV1 1.42 (0.4), FVC 1.8 (0.5) l .
Both obstructive and restrictive patients showed a statistically
significant effect of rehabilitation on SWT; mean difference (SD) 47.8
(86.9) (p=0.0005), 91.1 (64.1) m (p=0.002) respectively. However,
the difference between the groups (43.3) m was not significant
(p=0.16). There were statistically significant improvements in SGRQ
(p=<0.001) and depression (p=<0.001) for the obstructive group and
a trend in response for the restrictive group.
Conclusion: Low power means we cannot rule out the possibility of
type II error for difference in SWT between the groups. Data from an
uncontrolled “real life “ study indicates that patients with restrictive
disease may show greater improvements in exercise tolerance than
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obstructive disease. This report highlights the need for baseline spiro-
metry in the assessment and thorough evaluation of pulmonary
rehabilitation in differing populations.
P127 OXYGEN COST SCORE FOLLOWING 4 STEP COPD
PROGRAMME AND COMMUNITY BASED
PULMONARY REHABILITATION
K. Holt, S. Dryden, I. Houghton, I. Eccleston. Wyre Primary Care Trust,
Lancashire, UK
Since January 2000 Wyre PCT has been implementing a 4 step
COPD Health Improvement Programme (HImP) to ensure correct diag-
nosis and optimal, guidelines led, therapy. The programme,
developed in collaboration with Blackpool Victoria Hospital Chest
Clinic, involves spirometry assessment by a mobile spirometry service
visiting all General Practices with further assessment and patient man-
agement by COPD trained Practice Nurses. Following diagnosis (step
1), inhaled steroid trial (step2), anticholinergic trial (step 3), and long
acting β 2 trial (step 4), community based pulmonary rehabilitation
(PR) is now (since July 2001) offered to those patients motivated to
attend. PR, led by a Physiotherapist and a Respiratory Nurse, is
offered at two sites in the PCT; a Local Authority Sports Centre and a
Village Community Centre. Patients attend for two hours twice a week
for eight weeks and are then invited to attend one hour a week for
ongoing supervised exercise. The Oxygen Cost Score (OCS) is used to
assess breathlessness by functional ability at each stage of the HImP
and PR programme.
Data from 55 COPD patients (10mild, 21moderate, and 30 severe
using BTS criteria for severity) were used to examine dyspnoea,
measured by OCS; before entering the 4 step programme (stage 1),
on completion of the 4 step programme and before entering PR (stage
2), on completion of the eight week PR programme (stage 3).
The mean OCS and mean improvement (MI) after stage 2 and 3 is
shown in the table.
Conclusions: These preliminary data suggest that COPD patients
demonstrate an improvement in functional ability following a four-step
community based HImP with further improvement gained by attending
community PR. Patients with moderate and severe COPD appear to
demonstrate greater improvement from PR than from the 4 step
programme. The number of mild COPD patients referred for PR are too
small to be meaningful.
P128 BREATHLESSNESS AND ANXIETY MANAGEMENT
COURSE FOR PATIENTS WITH COPD UNSUITABLE
FOR CONVENTIONAL PULMONARY REHABILITATION
K. Pye, J. Batten, L. Davies. Aintree Chest Centre, University Hospital
Aintree, UK
Pulmonary rehabilitation is known to improve health status, symptoms,
and exercise tolerance in patients with COPD. Particularly in second-
ary care, many COPD patients are unsuitable for conventional PR due
to concomitant disease or extremely limited mobility. This breathless-
ness and anxiety management course, run by COPD nurse specialists,
was designed specifically for these patients. All are receiving optimal
medical therapy and are clinically stable at entry and have been
deemed unsuitable for conventional PR. Patients attend once a week
for 2 hrs over a six week period. Individual assessment is made and
anxiety management, breathing control, relaxation techniques,
partially supervised physical exercise, and support and practical
advice tailored as appropriate. There were 41 patients referred to the
course, but only 19 attended for initial assessment (12 not motivated,
three transport problems, three repeated COPD exacerbations, four
misc). Assessment at visit one and final visit consists of resting pulse
and respiratory rate, 6MWD (with pre and post Borg scores), SGRQ,
HAD, and MRC dyspnoea scale. Patients who exacerbated were
allowed to continue if well enough, those patients who did not
complete the course were not reassessed. Mean (SD) age 69 (7)
years, 11 (58%) female, FEV1 1.03 (0.48) litres, % pred FEV1 36.9
(11.9), pH 7.39 (0.04), pO2 10.4 (2.3) kPa, pCO2 4.8 (0.7) kPa (on
air).
Nine patients did not complete the course (six repeated COPD
exacerbations, two worsening of pre-existing arthritis, one developed
lung cancer).
There was no significant difference in age, sex, lung function, or
exercise tolerance between those patients who completed the course
and those who did not. There was a significant improvement in resting
respiratory rate (18.4 to 15.6, p<0.05), change in Borg score after
6MWD (4 to3.1, p<0.05), HAD depression score (7.5 to 5.7,
p<0.05) and the Activity (82.5 to 73.3, p< 0.01) and Impacts (60.9
to 51.06, p<0.05) score of the SGRQ. Although the 6MWD was not
significantly improved in this small group there was a trend to
improvement (202 to 280m).
Individually tailored programs are time consuming and drop out
rate is high. However, those that do complete the course benefit in
terms of health status and symptoms. Although numbers are small
these results are encouraging and merit further study.
P129 DIFFERENT EXERCISE RESPONSES IN SUBJECTS WITH
IDIOPATHIC HYPERVENTILATION
S. Jack, C.J. Warburton. Aintree Chest Centre, University Hospital Aintree,
Liverpool L9 7AL, UK
Hyperventilation may occur as an acute and a chronic phenomenon.
In addition, it may occur in isolation (idiopathic) or may co-exist with
other disease processes. There are very little data on homogeneity
within any of these subgroups.
We have studied 40 subjects referred through our chest clinics with
symptoms suggestive of idiopathic hyperventilation (IH) and normal
lung function. IH was confirmed by resting arterial hypocapnia and
sustained hypocapnia during ramp-incremental exercise. Further
analysis of the ventilatory response to exercise revealed that 11 of the
40 subjects demonstrated acute upon chronic hyperventilation at exer-
cise onset (defined as RER >1.0), six of the 40 subjects demonstrated
acute upon chronic hyperventilation at rest which continued during
early exercise. Twenty three of the 40 subjects did not demonstrate
acute hyperventilation in addition to their chronic hyperventilatory
state.
There were no differences between the three groups in the Hospital
Anxiety and Depression scores, Nijmegen Questionnaires, and St
George’s Respiratory Questionnaires or in maximally achieved
parameters during cycle ergometry and in breath—hold tolerance
both on 21 and 100% O2. Resting respiratory rate was higher (mean
(SD) 33.7 (6.7br/min) in the chronic group compared to the those
demonstrating acute hyperventilation in addition to their chronic
hyperventilation (mean (SD) 27.7 (8.3)) (p<0.02). There was a signifi-
cant correlation between anxiety, resting PETCO2 and BHTs and
between PETCO2 at rest and at maximal work rate achieved in the
chronic group (p<0.05). Resting RR was significantly correlated with
resting VE and resting PETCO2 also in the chronic group. These rela-
tionships were not evident in the two groups which demonstrated
acute and chronic hyperventilation. There was a significant correlation
in these groups between anxiety and resting heart rate, which may be
explained by anticipatory anxiety.
These data demonstrate that within this population of seemingly
homogenous subjects with IH, there are different responses to
exercise. This does not appear to alter the overall symptomatology of
the groups or their other physiological indices. Whether the different
responses to exercise relate to chronicity of symptoms needs further
study.
P130 THE DAILY EXPERIENCES OF PATIENTS LIVING AND
COPING WITH LONG TERM OXYGEN THERAPY (LTOT)
M. Logue, J.G. Daly, R. Sharkey. Altnagelvin Hospital Derry N Ireland
Aim: To describe experiences of patients who had been using oxygen
at home for at least one year.
Patients: Five women and two men (mean age 58yrs) were identi-
fied from a hospital register of known oxygen dependant patients.
Inclusion criteria: diagnosis of chronic respiratory disease, using
oxygen >16hrs daily and able to communicate verbally.
Design and methods: A phenomenological method was used to
describe the daily problems encountered by patients living with LTOT
Abstract P127 The mean OCS and mean
improvement (MI) after stage 2 and 3
Stage 1 Stage 2 MI Stage 3 MI
Mild 3.25 4.5 1.25 4.75 0.25
Moderate 4.35 4.4 0.5 5.35 0.95
Severe 3.66 3.83 0.17 4.73 0.9
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and how they coped. Unstructured audio-taped interviews lasting
approx 60 minutes were conducted in the patients’ home. Interviews
were directed by the patients. Tapes were transcribed verbatim,
checked for accuracy, and analysed using Colaizzi’s method.
Main Findings: Themes which emerged included that of feeling
unprepared, living life on a lead, feeling stigmatised, and no longer
your own person.
Feeling unprepared related uncertainty about the purpose of treat-
ment, and impact on lifestyle. Descriptions ranged from nervousness to
fear about the equipment and oxygen as well as a sense of being left
to “get on with it” unsupported. All were unprepared for the timing of
the introduction and felt disappointed that it had come “too soon in
life”. Living life on a lead referred to restrictions caused by physical
attachment to the equipment, lack of spontaneity, and pre-planning
activities around oxygen. Feeling stigmatised related to a sense shame
or embarrassment felt if seen in public with cumbersome cylinders and
visible tubing. Coping descriptions referred to “camouflage” to
conceal equipment outside, “brazening it out”, or “just going
without”. No longer your own person related to descriptions of
reduced autonomy, changes in status and role, and reliance on family
or others. Coping descriptions related to social support and spiritual
belief.
Conclusions: The patients in this small study would have benefited
from the support of a respiratory nurse to provide counselling and sup-
port prior to the introduction of LTOT as well as follow up. Sense of
stigma prevented some patients from using oxygen for outdoor activi-
ties. In the light of the ongoing review of domiciliary oxygen services,
the experiences of these patients may have a bearing on the process
of assessment and counselling prior to provision of LTOT and
lightweight oxygen systems.
P131 A SURVEY OF THE PHARMACOLOGICAL
MANAGEMENT OF THE SYMPTOM OF DYSPNOEA
L.J. Alloway1, C.L. Davis2, P. Hockey3. 1St Barnabas Hospice, Worthing;
2Countess Mountbatten House, Southampton; 3Southampton University
Hospitals NHS Trust, Southampton, UK
Background: The symptom of dyspnoea is an increasing clinical
problem, with rising incidence and longevity of patients with respira-
tory diseases. The current evidence base for treatment is sparse and
often contradictory.
Aims: To determine current clinical practice in the symptomatic
pharmacological management of dyspnoea, when disease related
treatments are optimised, in patients with malignant and non-
malignant diseases. To compare practice in two groups: respiratory
and palliative medicine consultants.
Methods: Postal survey to consultant members of British Thoracic
Society and Association of Palliative Medicine, with letter from the
“Respiratory Centre” accompanying the anonymous survey. Data was
analysed using nonparametric statistics to compare the results from the
two groups.
Results: 896 surveys were sent. Of these 46% were returned: 37%
useable (32% respiratory (R), 45% palliative medicine (PM)), 13%
respondents did not specify which specialist register they are
henceforth excluded from analysis.
Strong opioids are most frequently used first line for the
symptomatic treatment of dyspnoea in both groups, followed by Ben-
zodiazepines. χ2 Test was significant (p<0.0001) showing opioids
used more frequently by PM and weak opioids were more frequently
(p<0.003) prescribed by R physicians.
The majority of both groups (R 72%, PM 61%) agreed that there is
not enough evidence available to support the use of their choice of
drug.
PM physicians used significantly more: Lorazepam (p<0.0001),
Cannabinoids (p<0.0001), Levomepromazine (p<0.0001), and neb-
ulised saline (p<0.0001). Oxygen was used more frequently by R
(p<0.002).
PM physicians were more likely (p<0.02) to prescribe the same
drugs for non-malignant as for malignant diagnoses. R physicians
were significantly (p<0.03) more concerned about respiratory depres-
sion with opioids in patients with non-malignant disease, compared to
PM.
Conclusions: The data shows there are significant differences in
the prescribing practices of PM and R physicians. It highlights
concerns regarding lack of evidence base for practice and over 95%
of the total sample felt more research was needed in this area.
Supported by an Educational Grant from Link Pharmaceuticals Ltd.
P132 USE OF THE PULMONARY FUNCTIONAL STATUS
AND DYSPNOEA QUESTIONNAIRE AS AN OUTCOME
MEASURE IN MULTIDISCIPLINARY PULMONARY
REHABILITATION
W.D. Edwards, S.J. Miller, T.L. Griffiths. Cardiff and Vale NHS Trust and
The Section of Respiratory Medicine, University of Wales College of Medi-
cine, Llandough Hospital, Penarth Vale of Glamorgan, CF64 2XX, UK
Background: The Pulmonary Functional Status and Dyspnoea Ques-
tionnaire (PFSDQ) was developed as a self completed measure of
changes in the ability to perform activities of daily living and the asso-
ciated intensity of dyspnoea. It has been validated in patients with
COPD. (Lareau, et al. Heart Lung 1994;23:242–50). A prime goal of
pulmonary rehabilitation is to improve patients’ independence and
quality of daily life. Hence, we sought to determine whether this ques-
tionnaire might be an appropriate outcome measure for use in
multidisciplinary pulmonary rehabilitation programmes.
Method: Fifty one patients with chronic respiratory disease attend-
ing multidisciplinary pulmonary rehabilitation completed the PFSDQ at
the start and end of their programme. In completing the PFSDQ,
patients rated each of 78 commonly performed activities on a 0 (best)
−10 (worst) scale to indicate the level of change from pre-morbid
activity level and the dyspnoea associated with each activity. Patients
also scored their overall experience of dyspnoea on “most days” in
the last year, “today” and during “most day to day” activities.
Results: See table.
Conclusion: The PFSDQ is sensitive to the effects of multidiscipli-
nary pulmonary rehabilitation with the majority of scores changing
significantly. It may, therefore, represent a useful additional outcome
measure, based as it is, on the activities of daily living.
P133 HIGH LEVELS OF CIGARETTE SMOKING IN AN HIV
INFECTED POPULATION—TIME TO FORGET
OPPORTUNISTIC INFECTIONS AND CONSIDER
LIFESTYLE DISEASES?
I. Levy, C. Smith, E. Kaya, C.A. Sabin, M.A. Johnson, M.C.I. Lipman. Royal
Free Hospital and School of Medicine, London NW3, UK
Antiretroviral (ARV) therapy has transformed the management of HIV
disease. Improved immunity has led to reduced direct HIV-related mor-
bidity and mortality; and a new focus on risk reduction for chronic
Abstract P132
Before rehab
Mean (SD)
After rehab
Mean (SD) Significance
Activity level
Total score for all activities 249.0 (151.7) 187.8 (154.3) 0.000
Mean score per activity 9.6 (13.8) 7.3 (12.9) 0.004
Dyspnoea score
Total score for all activities 194.3 (131.7) 161.1 (124.9) 0.007
Mean score per activity 5.6 (6.6) 4.9 (6.8) 0.3
Number of episodes of severe dyspnoea per month 7.2 (6.5) 8.3 (7.4) 0.5
Score “most days” 5.7 (2.2) 4.9 (2.2) 0.002
Score “today” 5.2 (2.0) 4.2 (2.2) 0.002
Score in “day to day activity” 5.5 (2.0) 4.6 (2.1) 0.001
Poster presentations iii85
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
conditions such as cardiovascular disease. This is especially important
as many of the ARVs induce significant metabolic complications such
as hyperlipidemia. We sought to characterise smoking habits within
an HIV infected population, using a questionnaire-based evaluation
linked to our prospective HIV database. Over a six week survey
period, 394 ambulant subjects were enrolled (85% male, median age
34 - IQR 29–39, 30% previous clinical AIDS diagnosis, 73% using
ARVS). Forty five per cent were current smokers and 24% ex-smokers.
The current smokers were heavy users with a median pack year con-
sumption of 15, IQR 6–25, and 75% reporting the first cigarette of the
day within one hour of waking. They had a significant increased self
reported incidence of chest infections compared to ex-smokers and
non-smokers. Of the current smokers, 74% had tried to quit. Nicotine
replacement and no cessation aids were the two most frequently used
methods (44% each). The majority of ex-smokers stopped without spe-
cific cessation aids (69%). Cardiovascular risk factors were common,
with elevated blood lipids reported in 20%. 30% of individuals had a
family history of heart disease, and up to 10% drank more alcohol
than the current recommended upper limits. Our study, the largest
undertaken in Britain so far, reveals high levels of cigarette smoking
within individuals who demonstrate considerable risk factors for smok-
ing related disease. Smoking cessation work should target this at risk
population.
P134 THE EFFECT OF SCHOOL TUTOR GROUP SMOKING
PREVALENCE ON THE RISK OF INCIDENT SMOKING
IN SECONDARY SCHOOL CHILDREN: A
LONGITUDINAL STUDY
A.W.P. Molyneux1, S.A. Lewis1, M. Antoniak1, W. Browne3, A. McNeill4,
R.J. Madeley2, C.A. Godfrey5, R. Britton1. 1City Hospital; 2University Hospi-
tal Nottingham; 3Institute of Education; 4St George’s Hospital, London;
5Centre for Health Economics, University of York, UK
Rationale: Peer smoking is associated with starting smoking in child-
hood, but this effect may be biased by smokers’ selection of smoking
peers and their overestimation of smoking among their peers
compared to non-smokers. We have prospectively investigated the
effect of tutor group smoking prevalence (an objective, unbiased
measure of peer smoking) on the uptake of smoking in Nottingham-
shire school children.
Methods: A questionnaire survey of past and current smoking
behaviour, parental, and sibling smoking histories was performed in
pupils in Years 9 and 10 (aged 13 to 15) in 10 secondary schools in
Nottinghamshire, UK in 2000, and repeated in 2001. Data were
linked to identify all children who started smoking between the two
surveys (incident smokers). We calculated the prevalence of current
smokers in each pupils school tutor group in 2000. The independent
determinants of incident smoking were analysed by multiple logistic
regression and multilevel modelling.
Results: We obtained paired data on 2109 pupils in 2001 (73%
follow up). Of the 1766 non-current smokers in 2000, 267 (15%)
were incident smokers by 2001. Tutor group smoking prevalence was
a significant risk factors for incident smoking after adjusting for female
sex, parental and sibling smoking; the risk of incident smoking was
independently greater for those in the highest quartile v lowest quartile
of tutor group smoking (19% v 12% respectively, adjusted odds ratio
1.78, 95% Confidence Intervals 1.20 to 2.65). Multilevel modelling
showed a negligible effect of schools.
Conclusions: Tutor group smoking prevalence is an important,
independent, and unbiased determinant of incident smoking in
teenagers.
Funded by the Wellcome Trust.
P135 A SURVEY OF SMOKING ATTITUDES AND
BEHAVIOURS OF YOUNG PEOPLE ACCESSING A
YOUTH PROJECT IN A DEPRIVED AREA OF
NOTTINGHAM
E.L. Jones1, N, Romilly2, A. Challenger3, R. Burton2, E. Broadfield1, S.A.
Lewis1, J.R. Britton1. 1Division of Respiratory Medicine, City Hospital, Uni-
versity of Nottingham; 2The Zone Youth Project, Aspley, Nottingham; 3New
Leaf Smoking Cessation Service, Nottingham, UK
Rationale: Cigarette smoking is the single most important avoidable
cause of mortality and morbidity in the developed world and although
overall smoking prevalence is falling, young people in socioeconomi-
cally deprived areas in the UK continue to take up smoking at an
alarming rate.
Methods: We conducted a questionnaire survey of 11 to 20 year
olds The Zone Youth Project, a voluntary sector project in one of Not-
tingham’s most deprived areas, over a month period at all drop-in
cafes, dance sessions, schools outreach, and sexual health sessions. A
measurement of exhaled carbon monoxide (CO) was performed in
consenting individuals.
Results: 264 valid questionnaires were returned and 75% of
respondents consented to exhaled CO measurement. The median age
of respondents was 14.0 (11–21) with 42% male. 49% were self
reported current, regular smokers. Amongst the smokers the median
CO reading was 8ppm (1–32) median Fagerstrom score 3.0 (0–7)
and median number of cigarettes smoked per day 10. Most smokers
obtained their cigarettes from newsagents, friends, or “faghouses”
(contraband) and 94% came from households with at least one smok-
ing adult. Of those who smoked, 65% would like to quit smoking and
85% had made previous unsuccessful attempts, giving up for an aver-
age of 0–3 weeks. 84% said that they would like the chance to use
some kind of NRT with a preference for gum amongst the girls and
patches amongst the boys. Family support and willpower rated high-
est amongst non-pharmacological aids with one to one support from a
counsellor also scoring highly.
Conclusions: Our survey confirms the expected high prevalence of
smoking in this group but the proportion of those young smokers who
would like to quit and who have previously tried and failed was higher
than expected. Views expressed will guide the design of specific
smoking cessation services in this group.
Funded by Cancer Research UK.
P136 SMOKING CESSATION SERVICES FOR TEENAGE
SMOKERS: QUALITATIVE AND PILOT INTERVENTION
STUDIES
A.W.P. Molyneux1, S.A. Lewis1, T.J. Coleman2, A. McNeill3, R.J. Madeley2,
C.A. Godfrey4, J.R. Britton1. 1City Hospital; 2University Hospital
Nottingham; 3St George’s Hospital, London; 4Centre for Health Economics,
University of York, UK
Rationale: Most adult smokers started smoking as adolescents. Half
of adolescent smokers would like to stop smoking and 70% have tried
unsuccessfully to give up. There is little provision of smoking cessation
services for teenagers. We carried out a study in secondary schools to
investigate teenage smokers’ views of how smoking cessation help
should be provided to them, and developed and piloted a prototype
school-based smoking cessation intervention based upon these
findings.
Qualitative Study Methods: We invited teenage smokers (aged
13 to 16, previously identified by a questionnaire survey), from six
secondary schools in Nottinghamshire, UK, to attend focus groups to
discuss smoking behaviours, knowledge, and attitudes to smoking ces-
sation, delivery of smoking cessation services to teenage smokers, and
barriers and motivators to use of such services. Group discussions
were recorded and transcribed. Transcripts were coded, sorted and
indexed using a framework analysis by three researchers. Emergent
themes are presented.
Results: 135 smokers participated in 25 groups. Teenage smokers
would prefer help with cessation that is non-judgmental, confidential,
and delivered by trained counsellors to individuals or small friendship
groups, at school in school time, with the opportunity to use Nicotine
Replacement Therapy.
Pilot Study Methods: We conducted an uncontrolled pilot study of
a prototype cessation intervention in three schools. We invited smok-
ers (aged 14 to 16, identified by a survey) to attend the intervention
alone or in small friendship groups, receiving six weekly smoking ces-
sation counselling sessions delivered by a trained counsellor, with a
six week course of Nicotine Replacement Therapy (NRT) given as
appropriate under medical supervision. Self reported abstinence was
validated by an exhaled carbon monoxide of <5 ppm. Results 158
smokers were screened and 155 enrolled, 91 (59%) female, mean
age 15, smoking mean 10 cigarettes per day. One hundred and forty
nine (96.1%) participants set a quit date, 138 (89%) used some NRT,
of whom 47 used a six week course. At the final visit 21 (14%) were
abstinent and 82 participants (53%) attended.
Conclusions: This study suggests that this school based smoking
cessation intervention is acceptable to teenage smokers, that it is fea-
sible and associated with reasonable cessation rates.
Funded by the Wellcome Trust.
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P137 AN ASSESSMENT OF SMOKING IN ACUTE MEDICAL
INPATIENTS
E. Poon, C.W. Lau, L.Y.C. Yam, C.W. Lam1. Pamela Youde Nethersole
Eastern Hospital; 1Ruttonjee Hospital, HK
Aim: To investigate the epidemiology and smoking habits of hospital
inpatients and to assess the willingness of smokers to quit.
Study population: Inpatients of acute medical wards of the
Pamela Youde Nethersole Eastern Hospital, Hong Kong.
Method: A questionnaire survey was prospectively administered
by nursing staff on admission of all patients to the acute medical wards
between 15th April and 22nd April 2002. Data collected included
age, gender, smoking status/history, and an assessment of willingness
to quit. Patients who could not provide such information were
excluded.
Results: There were 446 admissions to six acute medical wards
over the one week period. Out of the 418 (93.7%) questionnaires
returned, there were 208 males (49.8%). Mean ages were 66.2
(17.5) years (males) and 69.7 (18.0) years (females). 171 (41.1%)
patients had ever smoked (135 males). Males smoked more than
females (29.8 (22.7) v 15.9 (14.2) pack years (p<0.0001)) and
started smoking at a younger age (35.8 (17.4) v 45.5 (16.3) years
(p=0.008)). 57 (13.6%) current smokers (47 males) had smoked 25.4
(22.4) pack years. Of these, 35 (61.4%) had ever thought of quitting,
33 (57.9%) acknowledged a willingness to quit, and 26 (45.6%)
accepted help towards quitting. Neither current age, age at which
smoking commenced, or overall consumption in pack years was
related to attitude towards smoking cessation, although those who had
smoked less tended to be more willing to quit. Males had thought
more about and were significantly more willing to quit than females
however, an equal proportion of both sexes accepted help with cessa-
tion. 114 (27.3%) ex-smokers (89 males) had quit for 12.5 (11.4)
years, having smoked 28.5 (21.7) pack years.
Conclusions: 41.1% of medical inpatients surveyed had ever
smoked. 13.6% were current active smokers and of these 45.6%
agreed to intervention with help in smoking cessation. The hospital
inpatient setting provides a good opportunity to assess smoking status
with a view to assisting smokers to quit.
The therapy of asthma
P138 BODIPY-TMR-CGP 12177: AN IRREVERSIBLE
FLUORESCENT PROBE FOR THE HUMAN
β2-ADRENOCEPTOR WITH AGONIST PROPERTIES
J.G. Baker, I.P. Hall, S.J. Hill. Institute of Cell Signalling, Medical School,
Queen’s Medical Centre, Nottingham NG7 2UH, UK
Current methods to study native receptors in cells from patients are
thwarted by the need for large numbers of cells. Fluorescent
techniques offer an opportunity to work at the single cell level.
BODIPY-TMR-CGP12177 (BOD-CGP) is a fluorescent analogue of the
hydrophilic β-adrenoceptor (β2-AR) antagonist CGP 12177. It can
stimulate cAMP accumulation (EC50 = 28.2 (4.0) nM, n=3) and gene
transcription (EC50 =25.3 (3.6) nM; EMAX=47% of the maximum isopre-
naline response) in CHO-K1 cells expressing the human β2-AR and a
cyclic AMP response element reporter gene (CHO-β2 cells). Studies
using 3H-CGP-12177 indicated that BOD-CGP was able to displace
the specific binding of this radioligand to the human β2-AR with an
apparent KD of 15.8 (3.0) nM, n=4. Pretreatment with BOD-CGP
(100nM) reduced the maximal specific binding of 3H-CGP 12177 by
50%, even after the fluorescent ligand had been washed out two hour
previously. This provides strong evidence that BOD-CGP is effectively
irreversible over this time period. Visualisation of the binding of the
fluorescent BOD-CGP to single living cells (CHO-β2) using confocal
microscopy demonstrated clear membrane labelling at concentratons
of 30nM BOD-CGP and above. Analysis of the total pixel intensities of
each image enabled an estimate of the KD for BOD-CGP to be deter-
mined from saturation analysis (27.6 (6.4) nM; n=4). The binding of
50nM BOD-CGP to living cells was also inhibited by increasing con-
centrations of the β2-antagonist ICI 118551 (IC50 = 4.30 (0.86) nM;
n=4) and CGP 12177 (0.76 (0.40) nM; n=3). Simultaneous imaging
of the binding of this red fluorescent ligand (BOD-CGP) to a
β2-AR-Green Fluorescent Protein fusion protein in CHO-K1 cells
indicated that BOD-CGP did not induce receptor internalisation. A
similar observation was made with the low efficacy agonist
salbutamol, whereas the full agonist isoprenaline caused substantial
receptor internalisation. In conclusion, we have fully characterised a
novel fluorescent ligand for the human β2-AR and shown that it can be
used to visualise receptors in single living cells. The irreversible nature
of this ligand should make it readily applicable to the study of β2-ARs
in acutely isolated native human cells in health and disease.
JGB is a Wellcome Trust Clinical Training Fellow.
P139 DO SELECTIVE TOPICAL β ANTAGONISTS FOR
GLAUCOMA HAVE LESS RESPIRATORY SIDE EFFECTS?
J.A. Nightingale1, J.F. Kirwan2. 1Royal Brompton and Harefield NHS Trust;
2Institute of Ophthalmology
Topical β antagonists are prescribed for glaucoma in approximately
500 000 people in the UK. We have previously shown that prescrip-
tion of these drugs is associated with an excess incidence of airways
obstruction.(1) Selective topical β antagonists are marketed as being
less likely to induce airways obstruction than non-selective topical β
antagonists.The aim of our study was to determine whether selective
topical β antagonists are associated with a smaller risk of developing
airways obstruction than non-selective topical β antagonists.
Data obtained from the Mediplus® UK primary care database were
used to perform a historical cohort study to determine one year
incidence of airways obstruction in subjects following treatment with
topical β antagonists for glaucoma for the period 1993–1998. Cases
were defined as having received a first prescription of a drug specifi-
cally used in the management of airways obstruction. Only subjects
with no history of airways obstruction were included. Analysis was
performed using proportional hazard modeling to minimise potential
confounding.
For selective topical β antagonists 12 of 324 treated subjects devel-
oped airways obstruction, compared with 112 of 9094 controls
(adjusted hazard rate 3.0 (95% confidence interval 1.6 to 5.4)). For
non-selective topical β antagonists the corresponding figures were 69
of 2321 subjects compared with the same control group (adjusted
hazard rate 2.2 (95% confidence interval 1.6 to 3.0)). There was no
significant difference between groups (p=0.5), both being associated
with a significantly increased risk of airways obstruction.
We conclude that selective topical beta antagonists do not appear
to have less respiratory side effects than non-selective topical β
antagonists in the treatment of glaucoma.
1. JF Kirwan, et al. BMJ 2002:(in press).
P140 SMALL AIRWAY RETICULAR BASEMENT MEMBRANE
(RBM) THICKENING IN CLINICALLY STABLE LUNG
TRANSPLANT RECIPIENTS (SLTR) IS NOT AFFECTED
BY THREE MONTHS TREATMENT WITH INHALED
CORTICOSTEROIDS (ICS)
C. Ward1, A. De Soyza, A. Fisher, G. Pritchard, P. Corris. Lung biology
and transplantation group, university of Newcastle Upon Tyne; 1The Free-
man Hospital, NE7 7DN, UK
Introduction: Recent publications have demonstrated potentially
pathological changes in clinically stable lung transplant recipients
(SLTR), with frank airway remodelling demonstrated in allograft recipi-
ents with established BOS. In asthma Rbm thickening has been dem-
onstrated at an early stage and it is suggested that ICS treatment
reduces this. There is no such data regarding Rbm thickening in small
airways sampled at transbronchial biopsy (TBB) of lung allografts.
Hypotheses: Rbm thickening exists in small airways of lung
allograft recipients. ICS treatment may decrease small airway Rbm
thickening.
Abstract P140 *Normal large airway Rbm (Ward, et al. Am J
Respir Crit Care Med 2001;164:1718–21).
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Methods: Thirty one SLTR >3 months post transplantation,
randomised to three months 400µg CFC BDP bd or a formulation
designed to yield at least an equivalent small airway dose (200µg
HFS BDP bd Autohaler). Bronchoscopy BAL and TBB pre and post ICS.
TBB were fixed in 10% buffered formalin, embedded in paraffin and
H+E stained. Assessment of airway Rbm thickness was carried out at
Image analysis from serial stepwise sections by a blind experienced
observer, exceeding ERS criteria (>1mm Rbm always scored). Ethical
considerations required the use of a normal range for RBM thickness
in large airway biopsies (Ward, et al. Am J Respir Crit Care Med
2001;164:1718–21). Rbm is thought to be systematically thicker in
large airways. See figure.
Conclusion: Small airway Rbm thickening exists even in SLTR, but
its significance with regard to the subsequent profound remodelling in
BOS (1) is not known. three months of moderate ICS did not affect
Rbm thickening. Further longitudinal studies, including the effect of
anti-remodelling strategies are possible.
P141 RAPID EFFECTS OF SINGLE DOSE FLUTICASONE
PROPIONATE ON ALLERGEN-INDUCED EARLY
ASTHMATIC RESPONSES IN MAN
R.I. Ketchell, M.I. Allenby, M.W. Jensen, G.W. Clarke, B.J. O’Connor.
Department of Respiratory Medicine and Allergy, GKT School of Medicine,
King’s College, Bessemer Road, London, SE5 9PJ, UK
Background: There is no evidence to date to suggest that inhaled glu-
cocorticosteroids (GCS) affect the early asthmatic response (EAR) fol-
lowing allergen inhalation in sensitised asthmatic subjects. This is
perhaps surprising as we have previously demonstrated that single
dose inhaled fluticasone propionate (FP) attenuates airway responsive-
ness to the mast cell stimulus adenosine 5’-monophosphate (AMP)
within two hours (Ketchell, et al. J Allergy Clin Immunol 2002:(in
press)).
Objective: The aim of this study was to assess the effect of inhaled
FP on allergen-induced airway narrowing.
Methods: In a randomised, double-blind placebo controlled, cross-
over study in mild steroid-naïve asthmatics, 12 subjects with a known
EAR to inhaled allergen, underwent two constant-dose allergen
challenges separated by 3–4 weeks. Each challenge was preceded
two hrs earlier by a single dose of inhaled FP 1000µg or matched pla-
cebo via an accuhaler™. The EAR was measured as the % change in
FEV1 from baseline at 5, 10, 15, 20, 30, 45, 60, 90, and 120 min-
utes following allergen challenge and the area under the curve during
the first two hours (AUC0–2hr).
Results: FP 1000µg significantly attenuated the EAR compared to
placebo with a 45.1 (12.2) % reduction in AUC0–2hr (p=0.04). A
reduction in FEV1 was observed at each time interval, although differ-
ences were not significant until the 90 minute time point (p=0.01). The
mean maximal % fall in FEV1 was observed at the 15 min time interval
and was 18.9% following a single dose of FP 1000µg and 21.6% fol-
lowing placebo (ns)
Conclusions: This study confirms rapid anti-inflammatory effects of
inhaled FP in man. The time interval of protection suggests an effect on
mast cell mediator responses such as increased microvascular perme-
ability and/or mucosal blood flow rather than on mast cell degranula-
tion and immediate smooth muscle responses. Inhaled GCS may
provide additional beneficial topical effects in the management of
acute allergic asthma.
P142 FOUR MONTH ADJUSTABLE OR FIXED BD DOSING
WITH BUDESONIDE/FORMOTEROL IN A SINGLE
INHALER REDUCES SYMPTOM SEVERITY
P. Ind1, J. Haughney2, D. Price2, J-P. Rosen3, J. Kennelly3. 1Hammersmith
Hospital, UK; 2University of Aberdeen, UK; 3AstraZeneca UK, Luton, UK
Aim(s): To evaluate the efficacy of budesonide/formoterol combina-
tion (B/F; Symbicort Turbuhaler) administered as either adjustable or
fixed bd dosing.
Methods: Patients (mean age 48 years) were randomised to
adjustable maintenance (n=782; B/F two inhalations bd for four
weeks, thereafter 1–4 inhalations bd depending on asthma symptoms
for 12 weeks) or fixed B/F dosing (n=771; two inhalations bd for 16
weeks). Primary efficacy variables were reduction in symptom severity
(according to GINA definitions) and total exacerbations.
Results: Changes in symptom severity are shown in the table.
Ninety four per cent of patients (both groups) reported no exacerba-
tions. The average number of daily inhalations was 15% lower in the
adjustable dosing group.
Conclusions: Patients treated with both adjustable and fixed-dose
B/F demonstrated a reduction in symptom severity as shown by the
marked shift from moderate to mild intermittent. Overall there was a
46% reduction in patients graded as moderate persistent and a dou-
bling of patients categorised as mild intermittent. A reduced overall
daily dose was observed in the adjustable arm.
P143 SYMBICORT USED IN A GUIDED SELF MANAGEMENT
PLAN PROVIDES ADDITIONAL ENABLEMENT TO
ASTHMA PATIENTS COMPARED WITH FIXED DOSING
J. Haughney1, D. Price1, J-P. Rosen2, K. Morrison2. 1University of Aberdeen,
UK; 2AstraZeneca UK, Luton, UK
Aims: To assess the effect on patient enablement of a guided self
management plan compared with fixed dosing in asthma patients pre-
scribed Symbicort.
Methods: After a four week run-in on budesonide/formoterol two
inhalations bid, patients received adjustable dosing (n=124) or fixed
dosing (n=104) for 12 weeks. Patients completed a validated Patient
Enablement Instrument1 (PEI) within eight weeks of the last clinic visit.
The PEI has six questions (“As a result of your treatment do you feel
you are: Q1: able to cope with life; Q2: able to understand your ill-
ness; Q3: able to cope with your illness; Q4: able to keep yourself
healthy; Q5: confident about your health; Q6: able to help yourself”).
Patients’ responses are scored 0 (“same or less” or “not applicable”)
to two (“much better”). A mean difference in total score of >0.82
between groups, or an individual’s total score of =6 is considered to
reflect a relevant treatment benefit.3
Results: The baseline and demographic characteristics of the two
groups were well matched. The total PEI scores were (mean (SD)) 6.24
(3.73) and 5.44 (3.84) in the adjustable and fixed dosing groups,
respectively (difference 0.8 (95% CI −0.2 to 1.8), p=0.12). A statisti-
cally significantly greater proportion of patients receiving adjustable
dosing had a score of >6 compared with fixed dosing (57% v 43%,
p=0.04). There were no significant differences between responses to
Q1, Q3, Q5, and Q6.
Conclusions: Guided self management with Symbicort provides a
greater level of patient enablement than fixed dosing.
1. Howie JG, et al. Fam Pract 1998;15:165–71.
2. Dowell J, et al. Br J Gen Pract 2001;51:200–5.
3. Howie JG, et al. Br J Gen Pract 1995;45:121–6.
Abstract P142
Symptom severity
Screening (week 0) Baseline (week 4)
Endpoint (week 16 or
time of withdrawal)
A* F** A F A F
Number of patients 775 766 775 766 754 737
Severity status (%)
Severe persistent 6 6 4 4 4 4
Moderate persistent 45 47 34 33 25 25
Mild persistent 31 29 32 31 31 30
Mild intermittent 18 19 30 33 40 40
*A=adjustable; **F=fixed.
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P144 AIRWAY DRUG DELIVERY: SIZE MATTERS—BIGGER IS
INDEED BETTER
O.S. Usmani, M.F. Biddiscombe, P.J. Barnes. Department of Thoracic
Medicine, National Heart and Lung Institute, Imperial College School of
Medicine, London, UK
Current inhaler devices are inefficient as the dose delivered is a poly-
disperse distribution of drug particle sizes, and only 20% reaches the
lungs. Aerosol particle size influences drug deposition and in vitro
models conclude 2–6µm as optimal. Monodisperse aerosols are the
appropriate research tools to investigate particle size effects, as the
dose is within a narrow size distribution. We hypothesised that engi-
neering such aerosols of salbutamol would identify the ideal broncho-
dilator particle size and improve inhaled therapeutic drug delivery.
We previously described our use of a spinning top aerosol genera-
tor to produce such aerosols, and reported larger particles were sig-
nificantly more potent bronchodilators in asthmatics—6µm∼3µm
>1.5µm, at 1/10th standard MDI doses. The 6µm particles achieved
equivalence with 200µg MDI salbutamol. No adverse effects were
observed. We then hypothesised the differences were a result of the
deposition characteristics of each particle size, in that larger particles
were better matched to their target site of action.
We therefore undertook to assess lung and extrathoracic deposition
patterns using 2D planar imaging and 99mTc-labelled monodisperse
salbutamol (30µg dose) aerosols, in 12 asthmatic subjects with simul-
taneous measures of clinical efficacy. The smaller particles achieved
greater total lung deposition; 1.5µm (56%), 3µm (50%), 6µm (46%),
however the larger particles were more efficacious 6µm∼3µm >1.5µm
(FEV1, p<0.05). We quantified regional deposition in the lungs and
found more of the larger particles in the central+intermediate zone;
6µm (75%), 3µm (66%), 1.5µm (56%). The penetration index
confirmed greater peripheral lung penetration of the smaller particles;
1.5µm (0.79), 3µm (0.60), 6µm (0.36); (p<0.05).
The data support our hypothesis that for β2-agonists, regional
airway targeting to the conducting airways is more important than
alveolar deposition. Particles in the higher part of the respirable range
achieve the greatest clinical response and we advocate small doses,
when correctly delivered, may improve the therapeutic index. We
now aim to investigate the effects of inspiratory flow and respiratory
disease severity on aerosol deposition. With resurgence of interest in
inhalation drug delivery as a means of systemic therapy, we must take
the opportunity to research basic aerosol science to enhance the effi-
ciency of clinical airway drug delivery.
P145 THE MEASUREMENT OF THE SUBMICROMETER SIZE
DISTRIBUTION OF METERED DOSE INHALERS (MDI)
M. Crampton1, R.P. Kinnersley1, J.G. Ayres2. 1Divison of Environmental
Health & Risk Management, University of Birmingham, Birmingham,
B15 2TT; 2Department of Respiratory Medicine, Birmingham Heartlands
Hospital, Birmingham, B9 5SS, UK
Recent studies indicate that toxicity of materials in ultrafine aerosol
form is greater than that of the same material in coarser aerosol form.
At the same time it has been observed that the HFA formulation of
beclomethasone (Qvar) is more potent compared to the CFC product.
A pertinent difference between the two is that the former yields smaller
particles.
The size distribution by number of a range of pMDIs (including
Qvar [3M], Salbutamol [GSK], HFA-Fluticasone [GSK], Beclometha-
sone [GSK], Budesonide [AstraZeneca]) was measured to determine
the proportion of particles in the sub-micrometer range. Measurements
were made by Electrical Low Pressure Impactor (size range
30nm–10µm) and a Scanning Mobility Particle Sizer (size range
10–100nm). All devices tested yielded high numbers of fine and
ultrafine particles, the number being greater for HFA than for CFC
propelled MDIs (% < 100 nm, HFA-Qvar:76%, HFA-Salbutamol:75%,
HFA-Fluticasone:76%, CFC-Belcomethasone:65%, CFC-Budesonide:57%).
We suggest that the number of fine and ultrafine particles, the concen-
tration of drug per particle, the molecular properties and the
hydroscopic properties of the drug, may all influence MDI potencies.
See figure.
This work was supported by an academic grant from 3M Pharma-
ceuticals.
P146 PD20 TO METHACHOLINE IS PREDICTED BY AIRWAY
INFLAMMATION AND REMODELLING: A SYSTEMATIC,
LONGITUDINAL, STEROID INTERVENTION STUDY OF
AIRWAY BIOPSY (Ebb) AND BAL PARAMETERS
C. Ward1, D. Reid2, M. Pais2, B. Orsida2, B. Feltis2, R. Bish2, D. Johns2 , E.
Haydn Walters2. 1Lung Biology and Transplantation Group, University of
Newcastle upon Tyne and The Freeman Hospital, UK; 2University of
Tasmania and Monash University, Australia
Introduction: We have recently shown that PD20 may be predicted
from a model including terms measuring airways remodelling; (Reticu-
lar basement membrane (Rbm) thickening) and inflammation
quantified at BAL.1 In this study we have refined our paradigm, includ-
ing information on large airway biopsy (ebb) inflammation and the
effect of inhaled corticosteroid treatment.
Hypothesis: Ebb provides complimentary inflammatory indices to
BAL, which supports a link between inflammation, airway remodelling
and PD20.
Methods: A double blind, randomised, placebo-controlled, paral-
lel group study of inhaled fluticasone propionate (up to 12 months
FP 750µg bd) in 35 symptomatic, mild to moderate atopic
asthmatics with previously described BAL inflammation, Rbm
thickening and PD20.1 Quantification of ebb inflammation by
immunohistochemistry/image analysis.1 Matrix analysis of individual
univariate correlations, with subsequent “best subsets” multiple
regression.
Results: Cross sectional, multiple regression analysis explained
56% of the variability in BHR, 23% related to log EG2 (eosinophil)
counts, 19% to log Rbm thickness, and 14% to BAL epithelial cells
improving our previous model (overall 40%; 1). Following three
months FP ebb inflammatory cell counts fell significantly, with no
further FP effect, for example, baseline median ebb EG2 count 8/mm
basement membrane (bm), (range 0–32), three month; 2/mm bm
(0–22; p<0.01 v baseline), 12 month median 2/mm bm (0–72, NS v
3 months). Changes in ebb inflammation preceded an effect on Rbm
thickness and the maximal effect on BHR (@12 months FP, 1).
Conclusion: Ebb and BAL are complimentary, and further support
the view that PD20 to methacholine reflects airway remodelling and
inflammation in asthmatic subjects. A lack of specificity for any one
part of asthma pathophysiology may represent a strength of BHR test-
ing.
Chris Ward is an ERS research fellow.
1. Ward, et al. Thorax 2002;57:309–16.
P147 RELATIONSHIP BETWEEN ADHERENCE TO
PRESCRIBED REGIMENS AND ASTHMA CONTROL IN
PATIENTS WITH DIFFICULT ASTHMA
S. Aburuz1, J. McElnay 1, J. Millership 1, J. Gamble 3, L. Heaney2 3. 1School
of Pharmacy; 2Department of Medicine, Queen’s University Belfast;
3Regional Respiratory Centre, Belfast City Hospital, Belfast
Introduction: Non-adherence with prescribed therapy is a major
problem in the management of chronic illness. The aim of the present
study was to examine the relationship between asthma control and
adherence to oral therapy (prednisolone (P) and theophylline (T)) and
high dose inhaled steroids (HDIS) in a population of difficult asthmat-
ics (persisting asthma symptoms/frequent exacerbations requiring sys-
temic steroids despite maintenance high dose inhaled corticosteroids
plus a long acting β2 agonist).
Method: A range of parameters was used to assess adherence and
asthma control in patients, with difficult to control asthma, attending aAbstract P145 Size distribution of pMDIs (number weighted).
Qvar ELPI
Qvar SMPS
Sambutamol ELPI
Sambutamol SMPS
Fluticasone ELPI
Fluticasone SMPS
Beclomethasone ELPI
Beclomethasone SMPS
10
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
1.0E+10
100 1000 10000
Aerodynamic diameter (nm)
T
o
ta
l
p
a
rt
ic
le
s
in
o
n
e
a
ct
io
n
a
ti
o
n
d
N
/d
lo
g
D
p
(c
m
3
)
Poster presentations iii89
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
hospital outpatient clinic. Plasma P was measured by HPLC. Plasma T
was measured by fluorescence polarization immunoassay. Urinary
Cortisol (C) was measured by HPLC and corrected for creatinine (UCC
ratio). Non-adherence was recorded if (a) Prednisolone: no plasma P
detectable; (b) Theophylline: no plasma T detectable. Adherence to
HDIS was recorded if morning UCC ratio was suppressed below 8.0
nmol C/mmol creatinine. Asthma symptom control scores (ASCSs)
were recorded using the Juniper Asthma Control Questionnaire.(1)
Results: Eleven (25%) patients of 44 patients taking T and 14
(56%) of 25 patients taking P were non-adherent. Of 43 patients tak-
ing HDIS (median 2000µg; range 1000–4000µg BDP equivalent), 31
(72%) had suppressed UCC ratio. ASCS, wheezing a morning symp-
toms were significantly lower (p<0.05) in patients with UCC suppres-
sion. There was no relationship between FEV1% and suppression of
urinary cortisol. Asthma control did not vary with adherence with theo-
phylline or prednisolone.
Discussion: There was a high prevalence of non-adherence with
prescribed oral therapy in patients with difficult asthma. Asthma con-
trol was related to the presence of urinary cortisol suppression in
patients receiving HDIS, which may reflect non-adherence with
inhaled therapy. Failure to suppress urinary cortisol can be used as a
marker of possible non-adherence to HDIS in this population.
1. Juniper E, et al. Resp Med 2001;95:319–23.
P148 EARLY ANTIBIOTIC PRESCRIPTION AND ALLERGIC
DISEASE IN UK ADULTS
P. Cullinan, J.M. Harris, P. Mills, S. Moffat, C. White, F. Figg, A. Moon,
A.J. Newman Taylor. Occupational & Environmental Medicine, Faculty of
Medicine, Imperial College of Science, Technology and Medicine, London,
UK
To investigate any association between treatment with antibiotics in
early life and subsequent atopic or allergic disease, we studied a
population of adults in southeast England. 1063 men and women
(93% of those eligible), parents of a birth cohort based in Ashford,
Kent, agreed to participate. Allergic diseases were defined by
responses to a questionnaire; atopy was measured by responses to
skin prick tests with common aerollergens. Prescription information for
the first five years of life was successfully obtained from the general
practice records of 746 (70%) subjects. There were no important dif-
ferences in the rates of atopy or allergic disease between those whose
records were or were not available for examination.
Thirty six percent of adults were atopic; 14% reported a history of
asthma and 29% hay fever. 564 (76%) had at least one antibiotic
prescription, with a median of three. The median age at first prescrip-
tion was 1.5 years. Older subjects were more likely not to have a pre-
scription record, indicating a temporal increase in prescription
patterns. There was a clear association with family size, whereby
adults with fewer siblings were significantly more likely to receive at
least five prescriptions by the age of five years (p<0.001). There was
no evidence of any association between atopy and total antibiotic
prescriptions in total (adjusted OR 1.01, 95% confidence interval
(0.97 to 1.05) per prescription), a pattern which did not alter at any
age or by antibiotic class. Asthmatics—with or without atopy—were
more likely to have received an antibiotic prescription by the age of
five years (adjusted OR 1.08 (1.03 to 1.13) per prescription). This
relationship increased with age at prescription (adjusted OR 1.02 per
prescription by age 1; 1.18 age 1–2; 1.14 age 2–3; 1.23 age 3–4;
1.32 age 4–5). A similar but less marked pattern was observed for
hay fever, again with or without evidence of pollen sensitisation.
These findings do not rule out a positive association between antibiotic
use and subsequent allergic disease; but are more probably explained
by a protopathic bias.
P149 IS A TWO WEEK TRIAL OF ORAL PREDNISOLONE
PREDICTIVE OF TARGET LUNG FUNCTION IN
PAEDIATRIC ASTHMA?
C. Lex, D.N.R. Payne, N.M. Wilson, A.M. Li, A. Zacharasiewicz, A. Bush.
Department of Paediatric Respiratory Medicine, Royal Brompton Hospital,
London, UK
The optimum length of a steroid reversibility trial in children is not
known. We have used a two week trial of oral prednisolone to deter-
mine target lung function for subsequent asthma therapy. The aim of
this study was to determine whether in fact on subsequent visits some
children actually exceeded this “target lung function”.
Methods: Twenty five severe asthmatic children (median age 13
(range 6–16) years were studied. Severe asthma was defined as per-
sistent symptoms despite treatment with >1600µg/d of inhaled
budesonide or equivalent, long-acting β2-agonist ± regular steroids.
FEV1 was measured following high-dose systemic steroids (oral
prednisolone 40 mg/day for 14 days) and compared with the highest
FEV1 obtained in subsequent visits during the following year. Results:
The mean (SD) FEV1 as a percentage of the predicted value following
the formal steroid trial was 74,28 ± 19,66 (range 38–103). A total of
8 (32%) children actually obtained an increase of >10% above their
“target” FEV1 during the following year at routine clinic spirometry.
There were no important changes in prescribed asthma medications
(for example, cyclosporine, methotrexate, s.c. terbutaline), which
might have accounted for this in these eight children. In 17/25 (68%)
children FEV1 measured in subsequent visits remained stable or
declined. The mean age of both patient groups was equal, and it was
not possible to predict which children would exceed “target lung func-
tion” from baseline characteristics or post-steroid FEV1.
Conclusions: A two weeks course of prednisolone is not necessar-
ily predictive of target lung function. Further studies are needed to find
out whether a higher dose or longer duration of the steroid trial is
more predictive, or whether adding an acute inhalation of β2-agonist
at the end of the trial may increase predictive power.
Tuberculosis
P150 TUBERCULOSIS INCIDENT AND OUTBREAK
SURVEILLANCE IN ENGLAND AND WALES: REPORTS
FROM JANUARY 1999 TO JUNE 2002
A. Story, J. Watson. Communicable Disease Surveillance Centre, Respira-
tory Division, Tuberculosis Section, 61 Colindale Avenue, London,
NW9 5EQ, UK
We are currently developing a central information resource on tuber-
culosis incidents and outbreaks that can be used to inform future man-
agement. The aims of this surveillance initiative are to gain insight into
the occurrence and distribution of tuberculosis incidents and
outbreaks; monitor and evaluate the effectiveness of control measures
and inform policy; network relevant parties as an accessible
information resource for one another; and provide a means of record-
ing examples of best practice and lessons learned.
In order to more fully understand the terms and specification
required for this new aspect of tuberculosis surveillance we have retro-
spectively collated tuberculosis related incidents and outbreaks
reported to CDSC from January 1999 to June 2002.
A total of 47 reports associated with actual and potential tuberculo-
sis transmission involving health workers and institutions have been
received, 33 of which relate to health and allied professionals posing
an infection risk. Similarly, 29 reports relating to education workers
and institutions, including one outbreak, which involved extensive
contact investigation have been received. There are four reported
instances of tuberculosis among prisoners and one incident involving
a prison guard. A total of 22 instances of tuberculosis presenting a
potential public health threat to airline passengers have been
reported, 18 involving passengers and four airline employees.
Incidents and outbreaks reported to CDSC to date represent only a
sample of the total episodes. It is planned that the development of a
more formal system to capture, collate, and report on tuberculosis inci-
dents and outbreaks will enable a more accurate assessment of their
frequency, distribution and public health impact to be made.
P151 TRENDS IN TUBERCULOSIS CASE FATALITY IN
ENGLAND AND WALES 1988–2000
A.R. Martineau1, P.D.O. Davies2. 1Department of Respiratory Medicine,
Newham General Hospital, London E13 8SL, UK; 2Aintree Chest Centre,
University Hospital Aintree, Liverpool L9 7AL, UK
To determine trends in tuberculosis (TB) case fatality in England and
Wales according to age and disease site we analysed published noti-
fication and mortality data for TB from 1988–2000 (see table
overleaf). In contrast to 1974–1987,(1) case fatality for TB of all sites
and age groups combined fell over this period despite increasing inci-
dence of disease. Declining case fatality is likely to be due to changes
in TB epidemiology: younger patients with higher rates of
extra-pulmonary disease and lower case fatality rates accounted for
an increasing proportion of TB cases over the study period. Improve-
ments in TB notification rate, under diagnosis of TB at post mortem and
improved case management may also have contributed to the
decreasing case fatality rates observed.
1. Nisar M, et al. Thorax 1991;46:438–40.
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P152 ERRORS IN THE NOTIFICATION OF TUBERCULOSIS
C. Seehra1, F.A. Drobniewski2, P.G. More 2, D.C.S. Hutchison3. 1Lambeth,
Southwark & Lewisham Health Authority (LSLHA); 2PHLS Mycobacterium
Reference Unit, Dulwich; 3Respiratory Medicine, King’s College Hospital,
London, UK
Introduction: In the UK, clinical disease with Mycobacterium
tuberculosis (MTB) is notifiable by law, whether cases are MTB culture
positive or culture negative treated as MTB. Notification initiates con-
tact tracing and provides epidemiological data. Two main sources of
error exist: (1) Under notification (failure to notify cases of MTB infec-
tion). (2) Over notification (notification of cases not due to MTB infec-
tion). Both errors can occur and we have examined local procedures,
with emphasis on over notification.
Methods: We have studied notified patients treated at King’s Col-
lege Hospital (KCH) and resident in LSLHA. Over notification in 1996
to 2000 inclusive was defined for this audit by comparison of notified
cases with microbiologically confirmed cases. Under notification (lim-
ited to 1999) was detected by search of KCH Pharmacy data base for
patients prescribed anti-tuberculosis chemotherapy, but not notified as
TB.
Results: In 1996 to 2000, 279 cases were notified as tuberculosis,
229 (82%) being MTB culture positive. Forty one culture negative
cases were notified, 32 being clinically probable MTB and nine prob-
ably not. Nine cases were culture positive with non-MTB mycobacte-
ria. Thus 18 notified patients definitely or probably did not have MTB
infection, an over notification rate of 18/279 or 6.5% (CI 4 to 10).
18/50 or 36% (CI 23 to 51) of all notified cases who were not MTB
culture positive were erroneously notified as MTB.
In 1999, 45 cases were notified. The Pharmacy data base
identified 11 unnotified MTB cases, giving an under notification rate
of 11/45 or 24.4% (CI 13 to 40). Four notified patients did not have
MTB infection, giving an over-notification rate of 4/45 or 8.8% (CI 2
to 21).
Conclusion: Combining over and under notification rates for 1999
yields a net under notification rate of 7/45 or 15.6% (CI 7 to 29). The
microbiological data base should lead to notification of all MTB posi-
tive cases. Culture negative cases contribute an important error and
must be verified by other means, the Pharmacy data base proving to
be the most successful. Denotification procedures must be more vigor-
ously pursued.
P153 UPDATE ON AN OUTBREAK OF ISONIAZID
MONO-RESISTANT TUBERCULOSIS IN NORTH
LONDON
M. Ruddy1, A.P. Davies2, M.D. Yates1, S. Yates2, S. Balasegaram3, B.
Patel2, S. Lozewicz2, S. Sen4, M. Bahl5, E. James6, M. Lipman7, Y. Drabu2,
J. Watson3, M. Piper8, F. Dronniewski1, H Maguire3, on behalf of a
Londonwide Incident Committee. 1PHLS Mycobacterium Reference Unit,
King’s College Hospital (Dulwich); 2North Middlesex University Hospital
Trust; 3PHLS Communicable Disease Surveillance Centre; 4Barnet, Enfield &
Haringey Health Authority; 5Camden & Islington Health Authority; 6Barnet
& Chase Farm Hospital Trust; 7Royal Free Hospital Trust; 8Department of
Health Prison Policy Unit
Since January 2000 an outbreak of isoniazid mono-resistant
Mycobacterium tuberculosis has been investigated. Typing of
suspected isolates has been performed at the PHLS Mycobacterial Ref-
erence Unit using a new rapid PCR-based method (RAPET), with con-
firmation by RFLP IS6110 typing showing a distinctive 15 band
pattern. Case finding has been performed by initial retrospective and
continuing prospective analysis of isoniazid mono-resistant isolates
from the source and neighbouring hospitals, and all isoniazid mono-
resistant isolates in London from January 1999 onwards, along with
comparison of the fingerprint to RFLP IS6110 databases. The earliest
case detected was a Nigerian student resident in London in 1995.
Epidemiological links were established by questionnaire in face to
face interviews. Outbreak control is coordinated by an Incident Con-
trol Committee at the PHLS Communicable Disease Surveillance Cen-
tre. To date 97 patients’ isolates have demonstrated the RAPET
pattern. Eighty eight microbiologically confirmed cases have been
identified in London, with 14 clinically proven cases in their contacts
and nine epidemiologically linked cases outside London. Contact trac-
ing so far has suggested a higher than predicted transmission rate
(11%). Thirty contacts have been placed on chemoprophylaxis. The
epidemic curve suggests that the peak of the outbreak may not yet
have been reached. A wide range of racial and social groups have
been involved in the outbreak with 17 of the cases associated with
prisons including one prison staff member. The investigation has
revealed the first documented case of transmission in a UK prison.
Nosocomial transmission has occurred involving staff and patients.
The involvement of IVDUs and sex workers along with documented
compliance problems in 38% of cases has made control of the
outbreak difficult.
P154 MISSED DIAGNOSIS OF TUBERCULOSIS IN THE
ACCIDENT AND EMERGENCY DEPARTMENT
M. Bhattacharyya, A. Choudhury, G.E. Packe. Newham Chest Clinic,
Shrewsbury Road, Forest Gate, London E7 8QP, UK
In our district many patients present with illness first to the accident &
emergency department (A&E) at our hospital rather than to primary
care. This is a result of several factors such as poor understanding of
the primary care system in the UK, and poor access to primary care.
The aim of this study was to ascertain how many patients with tubercu-
losis in our district present to the A&E department, and how well they
are diagnosed at presentation.
Of the 243 notified cases of tuberculosis (TB) in Newham during
1999, 121 (50%) patients were seen at A&E prior to notification. Of
these 121 patients, 62 had pulmonary disease; their median age was
32 years (range 1 to 88 years). Fifty one patients attended the A&E
department more than once (total 211 visits). The number of
attendances: number of patients, was as follows: 1 attendance: 70
patients, 2:30, 3:9, 4:8, 5:3, 6:1. Of the 171 visits for which A&E
patient information cards were traced: 143 (84%) were for TB related
episodes, 12 (7%) were episodes unrelated to TB, and 16 (9%) did
not wait after being triaged.
Records for the TB related episodes (143 visits) were divided into
those in whom TB was suspected when seen in the A&E department
(37 visits), and those in whom TB was not suspected (106 visits). All
patients where TB was suspected had one or more symptoms sugges-
tive of the diagnosis (cough, haemoptysis, night sweats, breathless-
ness, lymphadenopathy, and fever). However, in the 106 A&E visits
where TB was not suspected, 61 (58%) cases had one or more symp-
toms suggestive of TB.
Of the 37 visits at which TB was suspected, the number of cases
and the department of the clinician who raised the suspicion were: 29
A&E clinician, five general medicine, two surgical, one gynaecology.
Of the cases that were unsuspected, the majority of cases were seen
only by A&E clinicians. In all cases where presenting symptoms may
Abstract P151
Year Respiratory CNS Other sites Age 0–34 Age 35–74 Age >74 Total
1988 9.55 17.8 7.21 0.42 10.10 36.94 9.26
1989 8.03 42.3 6.9 0.69 8.15 34.95 8.16
1990 7.94 16 5.21 0.69 7.80 29.97 7.49
1991 8.45 8.2 5.48 0.57 7.81 40.6 7.76
1992 7.35 16.85 5.99 0.67 7.61 31.14 7.21
1993 7.14 9.09 6.04 0.71 7.75 30.02 7.14
1994 7.74 13 6.07 0.77 8.39 28.84 7.48
1995 8.56 9.18 5.91 1.03 8.47 32.33 7.97
1996 7.46 12.39 6.37 0.56 7.85 30.87 7.36
1997 6.52 11.02 6.15 0.57 6.96 29.08 6.57
1998 6.36 9.16 6.18 0.89 6.76 30.43 6.44
1999 6.87 4.92 4.47 0.59 6.13 30.68 6.23
2000 5.78 7.45 4.81 0.60 5.64 29.46 5.63
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have suggested TB (98 visits), 19 (19%) patients had a chest x ray
performed and nine (9%) had sputum taken for acid-fast bacilli. Those
patients that were not followed up later presented to A&E or another
hospital department where the correct diagnosis was eventually
made.
Many TB patients attended A&E where the diagnosis was
unsuspected. In our district, with a high incidence of TB, A&E staff
need better education about the diagnosis of TB.
P155 LONDON ACCIDENT AND EMERGENCY (A&E)
DEPARTMENTS: AN OPPORTUNITY TO DIAGNOSE
TUBERCULOSIS (TB) EARLY?
A. Smith, A. Goodburn, A. Story, R. Miller, G. Scott, H. Booth. TB Clinic,
Middlesex Hospital, University College London Hospitals (UCLH), UK
TB is a major health problem in London, accounting for more than
40% of the national total. North Central London Sector has seen the
highest rate of increase in TB since 1998 (155%), and is also the epi-
centre of an ongoing outbreak of isoniazid resistant TB. Early case
finding remains an essential part of TB control.
Aims: (1) To identify the rate of usage of A&E to access healthcare
in our TB patient population. (2) To identify whether A&E attendances
present an opportunity to diagnose TB early.
Methods: TB notifications between the period from January 2001
to March 2002 (15 months), were cross referenced against A&E and
microbiology records for the six month period prior to each
notification.
Results: There were 171 TB notifications during this time. Of these,
48 (28%) patients were seen in A&E a total of 69 times prior to their
diagnosis. Thirty two patients had pulmonary TB (19 smear positive)
and 10 were HIV positive (one previously undiagnosed). Thirty five
patients were admitted from A&E of which 27 were diagnosed as a
direct result of their admission. Four patients were discharged from
A&E with TB clinic follow up. Seventeen (eight admitted) of the 48
patients did not have TB diagnosed or considered at the time of their
A&E attendance(s).
Conclusions: A third of our patients with subsequent TB diagnoses
had attended A&E within the six month period preceding notification.
This may reflect the difficulties that this patient population has in
accessing healthcare by other means. It also serves to emphasise the
key role A&E staff have to play in TB case finding among this popula-
tion.
Thirty five out of 48 patients with TB were admitted, suggesting that
these patients were systemically unwell on presentation, and
emphasising the importance of liaison between acute general medical
and TB services. In 17 out of 48 cases the diagnosis of TB was either
not made or considered, representing a potential missed opportunity
to diagnose TB early.
P156 PERFORMANCE STATUS ON ADMISSION TO
HOSPITAL: A SIMPLE PREDICTOR OF DEATH IN
PATIENTS WITH PULMONARY TUBERCULOSIS IN
SOUTH AFRICA
S. De Valliere1, M. Nthangheni2, R.D. Barker3. 1Department of Medicine,
Medical University of Southern Africa—Polokwane Campus, Pietersburg,
South Africa; 2Statistics and Operations Research, University of the North,
Private Bag X1106, Sovenga 0727, South Africa; 3King’s College Hospi-
tal, Bessemer Road, Camberwell, London, UK
Background: Simple measures are required to identify patients most
at risk of dying from tuberculosis. Performance status has been used in
studies of cancer patients but we are not aware that it has been tested
as a predictor of mortality among patients with tuberculosis.
Methods: During a period of three months all adults (age
>15years) admitted to one of six South African hospitals and put on
anti-tuberculous treatment for suspected or confirmed pulmonary
tuberculosis were eligible. At the time treatment was initiated perform-
ance status was recorded by the doctor or the nurse in charge. The
vital status of the patient (alive or dead) was determined two months
after initiation of treatment (table).
Results: 347 patients were admitted to hospital and started on TB
treatment during the study period. For nine patients performance sta-
tus was not obtained and so analysis has been restricted to the
remaining 338 patients.
Discussion: Performance status at the time of diagnosis appears to
be a powerful predictor of mortality in this population.
Supported by TB Alert.
P157 TUBERCULOSIS AND HIV SEROPREVALENCE IN
LAMBETH, SOUTHWARK AND LEWISHAM, AN AREA
OF SOUTH LONDON
M. Melzer1, A. Warley2, H. Milburn2, D. O’Sullivan3, R.D. Barker4, D.
Shelton5, F. Drobniewski5, G.L. French2. 1Department of Infection and
Tropical Medicine, Northwick Park Hospital, Watford Rd, Harrow,
Middlesex HA1 3UJ; 2Department of Infection and Respiratory Medicine,
Guy’s and St Thomas’ Hospital, Lambeth Palace Rd, London SE1 7GD;
3Lambeth, Southwark and Lewisham Health authority, 1 Lower Marsh St.,
Lambeth, London SE1 7NT; 4Department of Respiratory Medicine, King’s
College Hospital, Denmark Hill, London SE5 9RS; 5Mycobacterium
Reference Unit, Dulwich Hospital, East Dulwich Grove, London SE22 8QF,
UK
Since the mid 1980s the number of cases of TB notified within the UK
has continued to rise although the contribution of HIV to this rise
remains unclear. A 12 month prospective cohort study was conducted
at chest and HIV clinics in four hospitals in Lambeth, Southwark, and
Lewisham (LSL), an area of South London, to determine the proportion
of patients with culture-proven TB infected with HIV. Secondary aims
were to determine the proportion of patients with TB and undiagnosed
HIV at first presentation to chest clinics, to determine the proportion of
patients presenting with TB as an AIDS defining illness (ADI) and to
identify risk factors for co-infection with TB and HIV. In chest clinics,
demographic data and left over blood from patients aged 16 or over
with culture-proven TB was collected, anonymised, and HIV tested. In
HIV clinics, demographic data on patients with TB already known to
be HIV seropositive was also obtained. Twenty one patients (13%,
95% CI 8% to 19%) of 159 with culture-proven TB were infected with
HIV. Four (3%) of 133 patients at first presentation to chest clinics had
undiagnosed HIV; two were subsequently diagnosed. Of the 21
patients with TB and HIV, nine (43%) presented with TB as an ADI.
Patients with TB and HIV were significantly more likely to be aged
between 35–55 years compared to HIV seronegative patients (12/21
(57%) v 38/138 (28%), p=0.006). None of the patients from the
Indian Subcontinent were HIV seropositive (0/21 v 25/138 (18%),
p=0.047). At the present time, universal HIV testing of patients with
culture-proven TB in chest clinics within the UK is unlikely to
significantly reduce the number of patients with undiagnosed HIV.
P158 OUTCOME OF HIV ASSOCIATED TUBERCULOSIS IN
THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY (HAART)
K. Dheda, F. Lampe, M. Lipman, M. Johnson. Department of HIV and
Thoracic Medicine, Royal Free Hospital, & School of Medicine, London, UK
Background: The benefit of HAART on outcome in TB/HIV co-infected
patients is unclear due to concerns about drug adherence, absorption,
Abstract P156
Performance status
alive died
Total n RR 95% CIn % n %
0 109 95% 6 5% 115 1 –
1 58 95% 3 5% 61 0.94 (0.24 to 3.64)
2 74 88% 10 12% 84 2.28 (0.86 to 6.02)
3 20 66% 10 33% 30 6.39 (2.52 to 16.18)
4 23 48% 25 52% 48 9.98 (4.18 to 21.95)
Total 286 84% 54 16% 338
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overlapping toxicities, drug interactions, and paradoxical reactions.
We therefore investigated the effect of HAART on survival in
co-infected patients.
Methods: Ninety two HIV/TB co-infected patients treated at a Lon-
don HIV clinic were retrospectively identified. Patients starting TB
treatment prior to 1 January 1996 (n=36) were compared to those
starting TB treatment after 1 January 1996 (n=56), when HAART was
introduced. HAART was included as a time-updated covariate in a
Cox regression model with adjustment for other prognostic factors.
Results: Compared to patients treated for TB prior to 1996, those
treated during or after 1996 were older (median age 35 v 30), and
were more likely to be women (43% v 17%), Black African (63% v
44%), and in the heterosexual risk group (68% v 47%). Baseline CD4
count tended to be lower for patients in the post-1996 compared to
the pre-1996 group (73% versus 61% <200 /mm3). TB treatment with
Rifabutin was much more common in the post-1996 group (34% v
6%). During a median of 2.6 years of follow up there were 29 deaths.
Three years after initiation of TB treatment, survival was 63% in the
pre-1996 group compared to 79% in the post-1996 group (p=0.19,
log rank test over whole follow up period). This difference in survival
was significant after adjustment for baseline CD4 count (HR for post-
1996 versus pre-1996: 0.42; 95% CI 0.18 to 0.96, p=0.039). In a
Cox model that included HAART use as time-updated variable, and
adjusted for baseline CD4 count, extrapulmonary TB, previous AIDS
and calendar period (pre or post 1996), the use of HAART resulted in
a marked reduction in risk of death (HR: 0.26; 95% CI 0.10 to 0.72,
p=0.009) and explained the effect of calendar period. Initial CD4
count < 200 /mm3 (HR: 3.4; 95% CI 1.3 to 9.3, p=0.015) and a prior
history of AIDS (HR: 2.3; 95% CI 1.1 to 5.1, p=0.032) were also
independently associated with risk of death.
Conclusion: Use of HAART in patients with TB/HIV co-infection
results in a substantial reduction in risk of death.
P159 TUBERCULOSIS: A CHEAP DISEASE?
S. Berkovitz, R. Hurd, M. Mandani, D. Adler, N. Johnson. Whittington
Hospital, London; Camden and Islington Community NHS Trust, UK
Tuberculosis is an increasing problem in some parts of London.
Despite a lack of evidence, it is often regarded as a cheap disease to
treat. To test this hypothesis, we describe the first comprehensive cost
analysis of a dedicated adult tuberculosis service in a busy district
general hospital.
All relevant care data was obtained for patients notified with tuber-
culosis or given chemoprophylaxis in the year 2000, up to their
discharge from hospital care. Computerised information was obtained
from hospital and tuberculosis office databases in addition to paper
based tuberculosis record cards and medical notes. Mean costs for
inpatient (£170 per bed night) and outpatient (£67 per appointment)
episodes were provided by the Trust finance department and specific
drug costs the hospital pharmacy.
Ninety seven patients were notified with tuberculosis and 23
patients given chemoprophylaxis. Mean age at notification was 37
years (median 29, range 13–91). Of the notified patients, 46 were
admitted to hospital at some stage, 11 on two occasions. Mean length
of stay was eight days (median one day, range 1–83). Two patients
died in hospital. Completion rates for therapy were 89%. A summary
of the cost analysis is shown in the table.
Tuberculosis is not a cheap disease to treat. If control of tuberculo-
sis is not taken seriously, it poses a considerable health economic
problem.
P160 TUBERCULOSIS AND HEALTH BELIEFS IN THE
BANGLADESHI COMMUNITY OF EAST LONDON
V. White1, S. Hillier2, J. Moore-Gillon1. 1Depts of Respiratory Medicine;
2Human Science and Medical Ethics, Bart’s and the London School of
Medicine & Dentistry, EC1A 7BE, UK
We investigated the understanding and recognition of symptoms of
TB, any associated stigma, use of alternative practitioners and
attitudes to medication amongst Bangladeshi patients with TB in Tower
Hamlets, east London. Forty three newly diagnosed subjects were
approached and 41 took part. Twenty six were male and 15 female,
aged 20–85 (median 36). 19 had pulmonary and 22 extra
pulmonary TB. Each underwent two interviews, of c.1 h duration, the
first within a few days of diagnosis, the second after 1–3 m treatment.
Interviews were semi-structured, for analysis with NVivo software after
transcription.
Strikingly, only two subjects admitted to knowing that TB could
infect organs other than the lungs. Twenty four of the 41 associated
cough, haemoptysis, and weight loss with TB, but the significance of
fevers and night sweats was largely unrecognised. Most were afraid
to discuss their diagnosis outside their close family, with 31 subjects
believing there was significant stigma associated with TB and five stat-
ing that TB affected a sufferer’s prospects of marriage. While most
(27) expressed no concerns about medication, the others were
unhappy with size and/or number of tablets and duration of
treatment. Only six admitted to pluralistic health practices: while
adhering to standard therapy, they consulted religious leaders and
took herbal remedies.
Seven subjects admitted to being not literate in any language.
Adherence, assessed semi-objectively (including tablet counts and
urine checks) was not related to literacy, proficiency in English, nor
educational attainment, and the least compliant patient was UK
university educated. Fear of TB, the desire for cure and respect for
medical staff were the most commonly expressed reasons for
adherence.
Our findings of lack of awareness of TB symptoms and of substan-
tial stigma must give rise to concerns both about delays in presentation
for medical care and regarding contact tracing. Culturally
appropriate health education initiatives may help address these prob-
lems. We keep in mind, however, that our findings might not
necessarily have been significantly different had we studied UK born
white TB patients.
VLCW is supported by Bart’s Special Trustees and Spitalfields Com-
munity Trust.
P161 NO BOOSTER EFFECT IN BCG IMMUNISED
TUBERCULOSIS CONTACTS UNDERGOING REPEAT
HEAF TESTING
A.R. Martineau, M. Chaudery, J. Jeyanathan, G.E. Packe. Newham Chest
Clinic, Shrewsbury Road, Forest Gate, London E7 8QP, UK
Individuals who undergo repeat tuberculin testing may exhibit increas-
ing reaction size in the absence of new infection. This phenomenon is
known as boosting. Boosting is thought to be commoner in BCG vac-
cinated individuals compared to non-vaccinated individuals.1 BTS
guidelines only advise repeat tuberculin testing in non-BCG
vaccinated TB contacts whose initial tuberculin (Heaf) test is negative.2
We performed a retrospective analysis of TB contacts to establish if
there was an excess of increased Heaf reaction on repeat Heaf testing
in BCG vaccinated individuals. One hundred and forty one TB
contacts, with an initially negative Heaf test (grade 0–1), had repeat
tuberculin testing at our clinic (74 female; age range 18 days to 60
years). Sixteen had neither history of BCG nor BCG scar; 119 had
either (n=19) or both (n=100); six had no recorded details of BCG
Abstract P159 A summary of the cost
analysis
Cost category Cost (£)
Inpatient 126 932
Respiratory outpatient 24 322
Other outpatient 7 362
Surgical procedures 13 862
Radiology 72 605
Medication 26 710
TB nurse service 75 000
Other 6 438
TOTAL 353 231
Cost per patient treated 3 592
Abstract P161
Heaf grade increase
No Heaf grade
increase
Previous BCG 27 92
No previous BCG 7 9
Poster presentations iii93
www.thoraxjnl.com
 group.bmj.com on July 12, 2010 - Published by thorax.bmj.comDownloaded from 
status and were excluded from the analysis. In 34 cases, the grade of
the 2nd Heaf test was unequivocally higher than the grade of the 1st
Heaf test. In the remainder (101 cases) it was not. 27/119 (22.7%)
of those with previous BCG demonstrated an increase in Heaf grade,
compared with 7/16 (43.8%) of those with no evidence of previous
BCG (table).
These results do not support the contention that boosting is more
common in BCG vaccinated subjects.
1. Menzies D. Am J Respir Crit Care Med 1999:159;15–21.
2. Joint Tuberculosis Committee of the British Thoracic Society. Thorax
2000;55:887–901.
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